Session 1: From Discovery to Delivery: Advancing Rare Bone Disease Therapies Across the Entire Innovation Spectrum
● ASBMR/RBDA Pre-Meeting
Symposium
📍 Ballroom C
Introduction From Mechanism to Medicine: The Therapeutic Journey in Rare Bone Disease - Neil Kumar, PhD Leveraging Infrastructure, Capital, and Expertise to Advance Therapies in Rare Disease - Sunitha Malepati, JD Customizing Clinical Trial Design to Rare Disorders - Emil...Introduction
From Mechanism to Medicine: The Therapeutic Journey in Rare Bone Disease - Neil Kumar, PhD
Leveraging Infrastructure, Capital, and Expertise to Advance Therapies in Rare Disease - Sunitha Malepati, JD
Customizing Clinical Trial Design to Rare Disorders - Emil Kakkisread more · Original Link ↗
Yves Sabbagh, PhDStealth mode biotech, Palo Alto, CA, US
Aris EconomidesRegeneron Pharmaceuticals, Inc., USA
Neil Kumar, PhDBridgeBio Pharma, Inc., Palo Alto, CA, US
Sunitha Malepati, JDBuffalo Initiative, USA
Emil KakkisUltragenyx, USA
☆
Thu 10/8 · 9:00 AM - 10:25 AM
Session 1: Unmet Clinical Needs to Diagnose and Treat Bone Quality
● Bone Quality Pre-Meeting
Symposium
📍 Meeting Room 312
Introduction
Revealing Hidden Fragility: The Microstructural and Material Determinants of Bone Quality in Individuals with Type 2 Diabetes - Eve Donnelly, PhD
How Does Aging Affect Bone Quality?Introduction
Revealing Hidden Fragility: The Microstructural and Material Determinants of Bone Quality in Individuals with Type 2 Diabetes - Eve Donnelly, PhD
How Does Aging Affect Bone Quality? A Geroscience Approach - Gustavo Duque, PhD, MD
Metabolic Bone Disease: From Rare to Common - Peter R. Ebeling, MBBS, MD
Quality of Bone Matrix and Toughness Decline with Age in Female C57BL/6N Mice - Emily Daria Berestesky, PhD student
The National Institute on Aging (NIA) supports colonies of mice for investigators to study complications of aging. While bone mass and bone structural quality are known to decrease with advanced age in C57BL/6 (J or N) mice, it is unknown whether the inherent quality of the bone matrix also declines with age, thereby decreasing the fracture resistance of cortical bone. We hypothesized that ultimate stress, post-yield toughness, and crack initiation toughness of cortical bone are lower in aged female mice than in adult female mice because of age-related declines in bone matrix hydration. Upon acclimating and euthanizing 6- and 24-month-old, female C57BL/6N mice from NIA (n=15 per age group), we measured bound water per bone volume (BW) of the right femur using 1 H nuclear magnetic resonance relaxometry. Next, we measured crack initiation toughness (K c,ult ) based on the ultimate force from monotonic, three-point bending tests of right femurs with a micro-notch on the posterior surface at the mid-diaphysis and a linear fracture mechanics determination. Following μCT scans of the left femur to determine cortical volumetric bone and tissue mineral density (Ct.vBMD and Ct.TMD) and (micro)structural parameters, we loaded the hydrated, intact bones to failure in three-point bending to determine ultimate stress and post-yield toughness. Lastly, the right tibiae were flushed of bone marrow, fully demineralized, and then hydrolyzed for fluorescent assays of advanced glycation end-products (fAGEs) and collagen content, and for a high-performance liquid chromatography assay of pentosidine (PE). Mimicking age-related changes in human cortical bone, BW decreased while PE and fAGE levels increased in the bone matrix with the age of the mice (Table). Phenocopying observations from studies of human cortical bone, the mechanical properties decreased with age of the mouse. Unlike human bone, Ct.TMD increased with age, while cortical porosity (Ct.Po) and Ct.vBMD did not vary between the age groups. Being quantifiable by clinical MRI, BW was linearly related to each of the mechanical properties such that BW best predicted the age-related decrease in ultimate stress (Figure). The effect of aging on the mechanical properties of cortical bone in C57BL/6N female is more than just a decline in strength; it involves a loss in the ability to resist post-yield crack formation. This aging model can test treatment strategies or mechanisms that promote water bound to the matrix of bone.read more · Original Link ↗
Angela Man-Wei Cheung, MD, PhDDepartment of Medicine and Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada
David Liu, MDBoston Children's Hospital, USA
Eve Donnelly, PhDCornell University, Ithaca, NY, US; Hospital for Special Surgery, USA
Gustavo Duque, PhD, MDMcGill University, Montreal, QC, CA
Peter R. Ebeling, MBBS, MDMonash University, Clayton, Victoria, Australia
Emily Daria Berestesky, PhD studentVanderbilt University, Nashville, TN, US
Session 2: Mechanometabolic Control of Bone Quality
● Bone Quality Pre-Meeting
Symposium
📍 Meeting Room 312
How the Osteocyte Network Changes as Women Age - Natalie A. Sims, PhD
Osteocytic Calibration of Bone ECM Material Properties - Tamara N.How the Osteocyte Network Changes as Women Age - Natalie A. Sims, PhD
Osteocytic Calibration of Bone ECM Material Properties - Tamara N. Alliston, PhD
Composition and Nanomechanical Properties of Bone Tissues Formed through Modeling- and Remodeling-Based Bone Formation - Yongqiang Vincent Jin, PhD student
Anabolic agents, such as parathyroid hormone (PTH), increase bone mass through both modeling-based bone formation (MBF, formation on quiescent surfaces) and remodeling-based bone formation (RBF, coupled resorption-formation). However, prior studies have focused primarily on the quantity of newly formed bone tissue. This study examined the tissue quality of MBF and RBF to better understand their contributions to fracture resistance. Thirty-two 7-month-old female rats received PTH (20 μg/kg/day) for 3 weeks and sequential fluorochrome injections of green-red-yellow-green at week 0, 1, 2, and 3 (Fig A). Rats were sacrificed at 6, 12, 21, and 30 weeks (n=8/age), yielding tissue ages of 3-6, 9-12, 18-21, and 27-30 weeks (Fig A). Right tibiae were processed and imaged by confocal microscopy with second harmonic generation to distinguish RBF (scalloped cement line, disrupted fiber alignment, Fig BD) from MBF (smooth cement line, Fig CE). Co-localized optical photothermal infrared mapping (Fig F) and nanoindentation (Fig GH) were performed to assess compositional and mechanical properties. Two-way ANOVA showed significant age effects on both properties. Carbonate substitution for phosphate (CO 3 :PO 4 ratio, data not shown) and mineral/matrix ratio (PO 4 :Amide Ⅰ, Fig I) increased with age. Elastic modulus (E, not shown) and hardness (H, Fig J) increased, whereas total work (Ω, Fig K), elastic energy (E el , not shown), dissipated energy (E dis , not shown), and creep (𝛿, Fig L) decreased with age. Heterogeneity (full width at half maximum, FWHM) of Ω (Fig O), E el , E dis , and 𝛿 (Fig P) also decreased with age, while heterogeneity of CO 3 :PO 4 , E, and H (Fig N) was unchanged. Notably, heterogeneity of the mineral/matrix ratio (Fig M) was 13% higher in RBF than MBF.
Age stiffened and strengthened bone but reduced the mean and heterogeneity of energy absorption, recovery, and dissipation, potentially compromising fracture resistance. Energy-related parameters were more age-sensitive than deformation metrics, highlighting their importance in evaluating bone tissue mechanics. Although mean properties were comparable between MBF and RBF, greater heterogeneity of the mineral/matrix ratio in RBF suggested differences in tissue quality and warranted caution in clinical therapies primarily targeting MBF. Overall, these findings advance our understanding of composition - property relationships in MBF versus RBF and highlight the importance of tissue quality beyond quantity.
Citrate Transport Regulates Calcium Distribution, Hydroxyapatite Maturation, and Osteocyte Lacunar Architecture - Naomi Dirckx, PhD
Bone fragility is not fully explained by conventional measures such as bone mineral density (BMD) or microCT-derived structural parameters, highlighting the importance of a better understanding of bone quality at the ultrastructural level. Citrate, a key substrate involved in intracellular energy production, comprises ~5% of the organic bone matrix and is bound to mineral hydroxyapatite in a pattern compatible with a role in regulating crystal growth. We previously showed that loss of the plasma-membrane citrate transporter, Slc13a5 , increased circulating and mineral-associated citrate, with the latter impairing bone strength independent of osteogenic differentiation, bone formation, or mineral apposition rate. However, the precise role of citrate in bone material characteristics remains unclear.
We analyzed femora from 2-month-old male wild-type (WT, n=13) and Slc13a5 - / - (n=12) mice lacking the citrate transporter globally. Quantitative backscattered electron imaging (qBEI) was performed to generate high-resolution calcium maps (1.1 µm) and assess bone mineralization density distribution (BMDD) in cortical and trabecular compartments. Osteocyte lacunae morphology was quantified from binary images (thresholded at 5.2 weight% calcium). Fourier-transform infrared spectroscopy (FTIR) was used to evaluate mineral-to-matrix ratio, collagen crosslinking, mineral crystallinity, and acidic phosphate content.
qBEI revealed expected spatial differences between cortical and trabecular bone but also genotype-specific alterations, including reduced mean and peak calcium content, increased distribution width, and a higher proportion of low-mineralized bone in Slc13a5 - / - mice. FTIR showed no differences in mineral-to-matrix ratio or collagen crosslinking between genotypes. In contrast, Slc13a5 deficiency reduced mineral crystallinity and increased acidic phosphate content in the cortical compartment, consistent with smaller, less mature, and more disordered hydroxyapatite crystals. Intriguingly, mutant osteocyte lacunae exhibited an elongated morphology, indicative of an altered matrix organization.
These findings demonstrate that osteogenic citrate transport regulates bone mineral quality and crystal maturation, providing a structural basis for skeletal fragility that is not captured by conventional measures of bone mass or architecture. Targeting citrate-dependent pathways may represent a novel strategy to improve bone quality in osteoporosis and related disorders.read more · Original Link ↗
Christopher James Panebianco, PhDUniversity Of Pennsylvania, Philadelphia, PA, US
Courtney MazurMassachusetts General Hospital, Boston, MA, US
Natalie A. Sims, PhDSt. Vincent's Institute Of Medical Research, Melbourne, AU; Mary Mackillop Institute for Health Research, Australian Catholic University, Melbourne, VIC Australia, Australia; The University of Melbourne, Department of Medicine at St. Vincent’s Hospital, Fitzroy, Victoria, Australia, Australia
Tamara N. Alliston, PhDNIH - NIAMS, Greenbrae, CA, US
Yongqiang Vincent Jin, PhD studentThe University Of Pennsylvania, Philadelphia, PA, US
Naomi Dirckx, PhDWashington University Of St. Louis, St. Louis, MO, US
☆
Thu 10/8 · 10:45 AM - 12:05 PM
Session 2: The Parathyroid Hormone Pathway: From Emerging Mechanisms to Evolving Therapeutics
● ASBMR/RBDA Pre-Meeting
Symposium
📍 Ballroom C
Engineering PTH Replacement: Molecular, Biologic, and Delivery Innovations in Hypoparathyroidism - Michael Mannstadt, MD
Since the first clinical use of PTH replacement therapy, several novel PTH analogs have been developed, with one agent now approved by the FDA.Engineering PTH Replacement: Molecular, Biologic, and Delivery Innovations in Hypoparathyroidism - Michael Mannstadt, MD
Since the first clinical use of PTH replacement therapy, several novel PTH analogs have been developed, with one agent now approved by the FDA. This presentation will review the scientific rationale underlying these compounds and summarize the currently available clinical and preclinical data.
The Expanding Landscape of PTHR1‑Related Disorders: New Mechanisms and New Diagnoses - Jakob Hoeppner
Beyond GNAS: Evolving Understanding of Epigenetic Disorders in PTH Resistance - Murat Bastepe, MD, PhD
The safety and efficacy of setrusumab in patients <18 years of age with osteogenesis imperfecta: 12-month results of the Phase 3 Orbit and Cosmic trials - Leanne M. Ward
Osteogenesis imperfecta (OI), a rare genetic musculoskeletal disorder, presents with low bone mineral density (BMD), frequent vertebral and non-vertebral fractures, short stature, muscle weakness,and bone pain. Setrusumab (SET) is a fully human, monthly, intravenous (IV) anti-sclerostin mAB being investigated for treating OI.
Two Phase 3 trials investigated treatment with SET in patients (pts) with OI types I, III and IV. Orbit (NCT05125809), a randomized, double-blind, placebo (PBO)-controlled study, enrolled ages 5 to <26 yrs to assess safety and efficacy of SET vs PBO. Cosmic (NCT05768854), a randomized, open-label, active-controlled study, enrolled ages 2 to <7 yrs to compare SET vs IV bisphosphonates (BP). In this 12 month (M) post-hoc analysis of pts <18 yrs of age, we evaluated lumbar spine (LS) BMD z-score (LS-BMDZ), Patient Global Impression of Severity (PGI-S), Pediatric Outcomes Data Collection Instrument (PODCI), Bone Health Index z-score (BHI-Z), and vertebral annualized fracture rate (vAFR). All P- values are nominal.
Neither study achieved its primary endpoint of reduction in AFR; however, in pts <18 years of age, LS-BMDZ, PGI-S, PODCI, and BHI-Z showed significant improvements at M12 in both studies. At M12, least squares mean difference (LSMD) from baseline (SE) in LS-BMDZ was SET 0.70 (0.07) vs PBO −0.26 (0.10, P <0.0001) in Orbit and SET 1.01 (0.22) vs IV-BP 0.32 (0.21, P =0.0116) in Cosmic. At M12, BHI-Z improvements from baseline were statistically significant (LSM [SE] Orbit: SET 0.51 [0.06] vs PBO 0.21 [0.09], P =0.0078; Cosmic: SET 0.43 [0.12] vs IV-BP 0.12 [0.13], P =0.0371). At M12 in Orbit there was statistically significant improvement in PGI-S pain (LSMD −0.37, P =0.0174) and impact on daily activities (LSMD −0.40, P =0.0356); and clinically meaningful improvement in the PODCI sports/physical function domain score vs PBO (LSMD 5.79, P =0.091). Pediatric pts in Orbit (n=135) and Cosmic (n=69) showed numerically lower vAFR of 37% (vAFR, SET 0.21 vs PBO 0.33; P =0.389) and 56% (vAFR, SET 0.14 vs IV-BP 0.33; P =0.083), respectively. Safety data from both studies continued to demonstrate that SET was well-tolerated.
In Orbit and Cosmic, SET was well-tolerated and demonstrated statistically significant improvements in LS-BMDZ and BHI-Z, and numerically lower incident VF rates (by 37 - 56%). In pediatric pts in Orbit, there were statistically significant improvements in daily activities and pain, and meaningful improvements in physical function.read more · Original Link ↗
Emily Germain-Lee, MDUniversity Of Connecticut School Of Medicine/Connecticut Children's Medical Center, USA
Dolores M. Shoback, MDEndocrine Research Unit, San Francisco Veterans Affairs Health Care System, USA
Michael Mannstadt, MDMassachusetts General Hospital Harvard Medical School, Boston, MA, US; Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, USA
Jakob HoeppnerEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US
Murat Bastepe, MD, PhDEndocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, US
Leanne M. WardChildrens Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Ottawa On K1H, ON, Canada
Session 3: Next‑Generation Tools Transforming Rare Bone Disease Research
● ASBMR/RBDA Pre-Meeting
Symposium
📍 Ballroom C
Advancing Novel Genetic Medicine for Fibrodysplasia Ossificans Progressiva - Jae Hyuck Shim, PhD Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder caused by a dominant mutation in the ACVR1 gene (R206H, 97% of cases), leading to debilitating heterotopic ossification...Advancing Novel Genetic Medicine for Fibrodysplasia Ossificans Progressiva - Jae Hyuck Shim, PhD
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder caused by a dominant mutation in the ACVR1 gene (R206H, 97% of cases), leading to debilitating heterotopic ossification (HO) characterized by abnormal bone growth triggered by inflammatory flare-ups.
We have developed disease-modifying, allele-selective small interfering RNA (siRNA) targeting ACVR1 R206H . Allele selectivity is essential as wild-type ACVR1 is crucial for many functions including skeletal homeostasis and development. When conjugated to docosanoic acid (DCA), administration of the fully modified ACVR1 siRNA, either alone or in combination with an siRNA targeting IL1B (a key regulator of inflammation), results in profound reduction of HO using both responsive (post-trauma) and preventative (pre-trauma) intervention strategies in a murine FOP model. Notably, the combination therapy outperforms modulation of either target alone. Furthermore, we have developed the chemical engineering of a new class of lipophilic divalent siRNAs that target both pathways with a single compound, demonstrating superior muscle accumulation and therapeutic efficacy. siRNA treatment inhibits key signaling pathways (e.g. inflammatory , WNT , Notch , Hedgehog , and TGF-β ) , within muscle-resident fibroadipogenic progenitors (FAPs), leading to a significant reduction in cartilage, bone, and connective tissue formation. Collectively, this study establishes a foundation for the development of disease-modifying treatments for FOP and offers a platform for targeting other musculoskeletal disorders involving multi-pathway dysregulation.
AI-Driven Strategies for Discovering and Repurposing Therapies in Rare Diseases - Nicholas Fragola, PhD
From N-of-1 to Platform Therapeutics: A Roadmap for Treating Ultra-Rare Genetic Diseases - Timothy Yu, MD, PhD
From N-of-1 to Platform Therapeutics: A Roadmap for Treating Ultra-Rare Genetic Diseases
Creatine as a Novel Phosphate Regulator - Ignacio Alberto Portales Castillo, MD
Phosphate is a fundamental component of nucleotides, lipids and membranes in cells, and therefore is required for cell survival and proliferation. Changes in cellular metabolism regulate phosphate levels. For instance, glycerol-3-phosphate, a byproduct of glycolysis in the kidneys, stimulates FGF-23 secretion from bone cells. Insulin, on the other hand, suppresses FGF-23 by inactivating the transcription factor forkhead box protein O1 (FOXO1). However, less is known about metabolic regulators of phosphate that act in an FGF-23 independent manner.
We generated a mouse model with the loss-of-function GATM P341L mutation inspired by patients with hypophosphatemic rickets and chronic kidney disease. Homozygous GATM P341L mice (GATM P341L/P341L ) have reduced creatine synthesis, leading to systemic deficiency and in the kidneys, we observed several metabolic changes consistent with adaptation to nutrient deprivation, like activation of FOXO1 and increased levels of autophagy. Interestingly GATM P341L/P341L male mice are hypophosphatemic with inappropriately high urine phosphate excretion despite no signs of proximal tubule injury and normal levels of FGF-23 and PTH(1-84). Expression of Klotho was high by qtPCR and western blot in GATM P341L/P341L male mice, which may explain the lower levels of phosphate.
Creatine supplementation (1% drinking water) for 6 months normalized phosphate levels in GATM P341L/P341L male mice and suppressed Klotho expression in vivo . Using wild-type primary renal cells, we found that creatine exposure increased the expression of the Sodium-dependent phosphate transport protein 2A relative to vehicle treated cells or those treated with rapamycin, an mTOR antagonist associated with hypophosphatemia. Overall, our findings suggest that creatine, as an important metabolic regulator, promotes phosphate reabsorption independent of PTH(1-84) and FGF-23. Given that creatine is readily available and a creatine uptake inhibitor (Ompenaclid) was found to be safe in humans, our findings open the possibility to regulate phosphate levels by varying levels of creatine either systemically or locally, in the kidney.read more · Original Link ↗
Jose Luis MillanSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, US
Roberto Civitelli, MDDepartment of Medicine, Division of Bone and Mineral Diseases. Musculoskeletal Research Center. Washington University School of Medicine, St. Louis, MO USA, USA
Jae Hyuck Shim, PhDUMass Chan Medical School, Worcester, MA-01545, USA
Nicholas Fragola, PhDEvery Cure, Cambridge, MA, US
Timothy Yu, MD, PhDHarvard Medical School, Massachusetts General Hospital, USA
Ignacio Alberto Portales Castillo, MDWashington University St Louis Department of Medicine Division of Bone and Mineral Diseases, USA
☆
Thu 10/8 · 1:00 PM - 2:20 PM
Session 3: Emerging Technologies in Bone Quality Assessment
● Bone Quality Pre-Meeting
Symposium
📍 Meeting Room 312
Cortical Bone Mechanics Technology: A Biomechanical Approach to Assessing Bone Quality - Brian Clark, PhD Evaluating Bone Strength and Fragility Using the Osteoprobe - Simon Yue-Cheong Tang, PhD, MSCI 3D Quantitative Ultrasound Imaging of Bone (3D QUSIB) - Kay Raum,...Cortical Bone Mechanics Technology: A Biomechanical Approach to Assessing Bone Quality - Brian Clark, PhD
Evaluating Bone Strength and Fragility Using the Osteoprobe - Simon Yue-Cheong Tang, PhD, MSCI
3D Quantitative Ultrasound Imaging of Bone (3D QUSIB) - Kay Raum, PhD
Serum Biomarkers - A Biochemical Window into Bone Quality and Fracture - Deepak Vashishth, PhDread more · Original Link ↗
Elizabeth A. Zimmermann, PhDMcgill University, Montreal, QC, CA
Todd L. BredbennerUniversity Of Colorado Colorado Springs, Colorado Springs, CO, US
Brian Clark, PhDOhio University, Athens, OH, US
Simon Yue-Cheong Tang, PhD, MSCIWashington University In St Louis, St Louis, MO, US
Kay Raum, PhDCharité Universitätsmedizin Berlin, Berlin, Brandenburg, DE
Deepak Vashishth, PhDRensselaer Polytechnic Institute, Troy, NY, US
Built for you by(617)-PATRICK, Champion AI speaker
Session 4: It Takes an Ecosystem: The Strategic Partnerships to Unlock Rare Disease Innovation
● ASBMR/RBDA Pre-Meeting
Symposium
📍 Ballroom C
Regulatory Pathways and Patient Voices: An FDA Perspective on Rare Bone Disease Innovation - Amy Rick, JD The Collaboration Imperative: Patients, Innovators, and Industry Working Together for Rare Diseases - Pamela Gavin, MBA Registries as Engines of Discovery and Network...Regulatory Pathways and Patient Voices: An FDA Perspective on Rare Bone Disease Innovation - Amy Rick, JD
The Collaboration Imperative: Patients, Innovators, and Industry Working Together for Rare Diseases - Pamela Gavin, MBA
Registries as Engines of Discovery and Network formation - Natasha Mireille Appelman-Dijkstra, MD PhD
Uniting Voices, Aligning Missions: How Advocacy Leaders Build the Coalitions That Change Rare Disease Trajectories - Deborah Fowler, BAread more · Original Link ↗
Rachel I. Gafni, MDSkeletal Disorders & Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, USA
Neena Nizar, EdDThe Jansen's Foundation, USA
Amy Rick, JDFDA, USA
Pamela Gavin, MBANational Org for Rare Disorders, USA
Natasha Mireille Appelman-Dijkstra, MD PhDLeiden Center For Bone Quality, Leiden, NL
Deborah Fowler, BASoft Bones, USA
☆
Thu 10/8 · 2:45 PM - 4:00 PM
Session 4: Bone Quality Diagnostics
● Bone Quality Pre-Meeting
Symposium
📍 Meeting Room 312
New Ways of Assessing Osteocyte Characteristics in Health and Disease - Markus A. Hartmann, PhD
Genetic Architecture of Bone Quality - Charles R.New Ways of Assessing Osteocyte Characteristics in Health and Disease - Markus A. Hartmann, PhD
Genetic Architecture of Bone Quality - Charles R. Farber, PhD
Pore Water and Bound Water as Predictors of Bone Fragility - Jeffry Nyman, PhD
Long-standing bone microdamage is not repaired during a bisphosphonate drug holiday - Abigail A Coffman, PhD
Bisphosphonates (BPs) are the mainstay for treatment of postmenopausal osteoporosis. However, long-term use of BPs and other antiresorptives is also known to negatively impact bone quality. Sequelae include bone microcrack (µCrk) accumulation and altered matrix composition, leading in some cases to Atypical Femur Fractures. [1] This has led to the idea of a “ drug holiday,” i.e., pausing anti-resorptive treatment to allow renewed remodeling to repair pre-existing µCrks.[2] However, whether remodeling will reactivate after stopping long-term BP use and effectively target long-standing microdamage remains unknown.
METHODS: With IACUC approval, µCrks were induced in ulnar diaphyses of adult SD rats (n=42) by in vivo fatigue loading. [3] Rats were treated with ALN (2.4µg/kg), an experimental BP NE58025 (200 µg/kg) or PBS for 4 months. ALN has good osteoclast inhibitor potency and high mineral binding, thus a long functional half-life in vivo; resorption restarts > a year after stopping ALN. In contrast, 58025 has high potency but low mineral binding, thus a short half-life; resorption restarts about a month after stopping [4], providing a powerful tool to test the underlying concepts of drug. In the Drug holiday group, ulnae were examined 3 mo after stopping BP treatment. µCrks content and secondary osteons were measured. Data are shown as mean ± SD and analyzed by ANOVA with post-hoc testing.
RESULTS: BP caused a marked increase in µCrk number in fatigued ulnae vs baseline fatigue (FAT-Base). In contrast, FAT+PBS (normal remodeling) led to a significant reduction in µCrk content. Drug holiday : Stopping BPs did not increase remodeling or reduce either µCrk number or length in damage-containing cortex. µCrk and osteon data are summarized in Figs 1-3.
DISCUSSION: This study shows that even with a rapidly reversible BP, treatment cessation does not trigger remodeling of long-standing bone microdamage. Recent studies show loss of osteocytes in bone surrounding unremodeled µcracks with BP use. [2,5] Furthermore, osteocyte RANKL expression is triggered by osteocyte apoptosis that is present for only a limited time after µCrk formation [3,5], thus remaining osteocytes near long-standing µCrks would not be expected to activate remodeling. The window to initiate remodeling of pre-existing µCrks may be closed.
REFERENCES: 1)Starr+ Curr Osteoporos Rep 2018; 2) Collins+ Curr Osteoporos Rep 2025; 3)Kennedy+ Bone 2014; 4) Coffman+ JBMR Plus, 2021; 5) Cardoso+ JBMR, 2009read more · Original Link ↗
Noriaki OnoDepartment of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center at Houston (UTHealth Houston) School of Dentistry, USA
Markus A. Hartmann, PhDLudwig Boltzmann Society, Vienna, Vienna, AT
Charles R. Farber, PhDUniversity Of Virginia, Charlottesville, VA, US
Jeffry Nyman, PhDVanderbilt University Medical Center, Nashville, TN, US; Department of Orthopedic Surgery, Vanderbilt Health, Nashville, TN, USA
Abigail A Coffman, PhDDept of Biomedical Engineering, The City College of New York, USA
Session 5: Novel Bone Quality Indicators & Therapeutics
● Bone Quality Pre-Meeting
Symposium
📍 Meeting Room 312
The Gut Microbiome and Age-Related Impairment of Bone Quality - Christopher J. Hernandez, PhD
Is There an Ideal Drug or Drug Target to Improve Bone Quality?The Gut Microbiome and Age-Related Impairment of Bone Quality - Christopher J. Hernandez, PhD
Is There an Ideal Drug or Drug Target to Improve Bone Quality? - Serge Livio Ferrari, MD
Counting Molecules: Ultrasensitive Detection and the Next Generation of Biomarker Panels - Arek V. Melkonian, MD, PhD
Wrap Up & Next Stepsread more · Original Link ↗
Annegreet VlugCentre for Bone Quality, Leiden University Medical Center (LUMC), Leiden, Netherlands
Eric S. OrwollOregon Health & Science University, Portland, OR, US
Christopher J. Hernandez, PhDUniversity Of California, San Francisco, San Francisco, CA, US
Serge Livio Ferrari, MDGeneva University Hospitals And Faculty Of Medicine, Geneva, Switzerland, Geneva, CH
Arek V. Melkonian, MD, PhDBrigham and Women's Hospital, Boston, MA, US; Harvard Medical School, USA; Wyss Institute for Biologically Inspired Engineering, USA
Bone Quality Pre-Meeting Reception & Poster Viewing
● Bone Quality Pre-Meeting
Poster Session
📍 Meeting Room 302/304
Features approximately 94 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Multi-Omics Integration Reveals Regulatory Biomarkers Associated with Bone Mineral Density Variation in Men"; "Disrupted lipid homeostasis underlies bone fragility in diabetes, which is...Features approximately 94 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Multi-Omics Integration Reveals Regulatory Biomarkers Associated with Bone Mineral Density Variation in Men"; "Disrupted lipid homeostasis underlies bone fragility in diabetes, which is corrected by pharmacological activation of the transcription factor LXR"; "Improved Body Composition, Gait Speed, and Personal Care in Older Adults in Aged Care: The Pomerium Study Trial, a 3-Month Multi-Nutrient Supplementation Randomised Controlled Trial"; "Comparative Cardiovascular and Safety Outcomes of Tirzepatide versus Semaglutide in Type 2 Diabetes: A Real-World Propensity-Score-Matched Cohort Study"; "Impact of Phosphocalcic Metabolism on Physical Performance in Adults with XLH: An Argentine Multicenter Study" and 89 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
☆
Thu 10/8 · 5:30 PM - 6:30 PM
Rare Bone Pre-Meeting Reception & Poster Viewing
● ASBMR/RBDA Pre-Meeting
Poster Session
📍 Meeting Room 302/304
Features approximately 86 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Flare-up Dosing with Palovarotene in Non-genetic Heterotopic Ossification"; "3M Syndrome as a Human Model of Growth Plate Failure: Clinical - Molecular Insights into Ubiquitin-Mediated Regulation...Features approximately 86 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Flare-up Dosing with Palovarotene in Non-genetic Heterotopic Ossification"; "3M Syndrome as a Human Model of Growth Plate Failure: Clinical - Molecular Insights into Ubiquitin-Mediated Regulation of Longitudinal Bone Growth"; "Expression Profiles of Frizzled Receptors in Human Osteoclasts and Osteoblasts"; "Recapitulating Dynamic Bone Remodeling on Demineralized Bone Paper to Study Metastatic Cancer Behavior"; "Therapeutic Targeting of Endoplasmic Reticulum Stress with 4-PBA in a Mild (Type I) Model of Osteogenesis Imperfecta" and 81 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
Society Update
Gerald D. Aurbach Lecture - The Ticking DNA Clock: Somatic Expansion of DNA Repeats in Human Disease - Steven McCarroll · Original Link ↗
Emma L. Duncan, FRACP, PhD, MBBS, MRCPKing's College, London, London, GB
Joseph P. Stains, PhDUniversity Of Maryland School Of Medicine, Baltimore, MD, US
Introductory Remarks
Celebrating JBMR 40th Anniversary: Introduction - Rajesh V. Thakker, MD
JBMR: The Beginning and First Decade - John P. Bilezikian, MD, PhD · Original Link ↗
Jennifer J. Westendorf, PhDDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA
Rajesh V. Thakker, MDUniversity of Oxford, United Kingdom
John P. Bilezikian, MD, PhDDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
A short break to stretch, grab a coffee and network with fellow attendees before the next session. · Original Link ↗
☆
Fri 10/9 · 9:45 AM - 10:45 AM
Highlights of the 2026 ASBMR Annual Meeting
● Symposium
Symposium
📍 General Session - Ballroom A & B
Basic Highlights - Fanxin Long
Clinical Highlights - Joy Y. Wu · Original Link ↗
Yumie Rhee, MD, PhDYonsei University College Of Medicine, Seoul, KR; Severance Hospital, Institute of Endocrine Research, Yonsei University College of Medicine, Korea, Republic of (South)
Martina Rauner, PhDMedical Faculty Of The Tu Dresden, Dresden, DE
Fanxin LongThe Children's Hospital Of Philadelphia And The University Of Pennsylvania, Philadelphia, PA, US; The Children's Hospital of Philadelphia, USA
Joy Y. WuStanford University School Of Medicine, Stanford, CA, US
Basic Symposium: Cell Metabolism in the Musculoskeletal System
● Symposium
Symposium
📍 Ballroom C
Chondrocytes & Epigenetics & Mitochondria - Yuuki Imai, PhD
Osteogenic Cells - Mitochondria and B-Oxidation - Ryan C. Riddle
Metabolic Flexibility in Glucose Utilization by Skeletal Progenitors - Steve Stegen, PhD · Original Link ↗
Christa MaesKU Leuven, Leuven, BE
Naomi Dirckx, PhDWashington University Of St. Louis, St. Louis, MO, US
Yuuki Imai, PhDDepartment of Pathophysiology, Ehime University Graduate School of Medicine, Ehime, Japan; Division of Integrative Pathophysiology, Proteo-Science Center, PIAS, Ehime University, Ehime, Japan
Ryan C. RiddleUniversity Of Maryland School Of Medicine, Baltimore, MD, US
Steve Stegen, PhDClinical And Experimental Endocrinology, Ku Leuven, Leuven, BE
☆
Fri 10/9 · 11:00 AM - 12:00 PM
Clinical Symposium: Alkaline Phosphatase Revisited - From Bench to Bedside
● Symposium
Symposium
📍 Meeting Room 302
ALP and Biomineralization: Molecular Mechanisms in Bone Formation and Calcification - Hideo Orimo, MD, PhD There are four human alkaline phosphatase isoenzymes, of which tissue-nonspecific (liver/bone/kidney) type is involved in bone formation, and therefore the talk will focus the tissue-nonspecific...ALP and Biomineralization: Molecular Mechanisms in Bone Formation and Calcification - Hideo Orimo, MD, PhD
There are four human alkaline phosphatase isoenzymes, of which tissue-nonspecific (liver/bone/kidney) type is involved in bone formation, and therefore the talk will focus the tissue-nonspecific alkaline phosphatase. The subjects of the talk are the following:
1. Protein structure of the enzyme.
2. Gene structure and regulation.
3. Physiological roles.
4. The roles in hypophosphatasia and ectopic calcification.
*The fourth subject may be referred briefly.
Deep Dive into ALP: Beyond Routine Laboratory Practice - Juan Carl Pallais, MD, MPH
Alkaline phosphatase is more than a routine laboratory test in bone medicine. This session will explore the biologic role of alkaline phosphatase in biomineralization and connect these concepts to real-world diagnostic interpretation. Attendees will learn about common assay pitfalls and sources of misleading ALP results, while also gaining insight into the clinical spectrum of ALPL-related disease. By the end of the session, participants will have a practical framework for evaluating mineralization disorders and applying these concepts in clinical practice.
Genetic Landscape of ALPL Variants: Comprehensive Overview - Kathryn McCrystal Dahir, MDread more · Original Link ↗
Lothar Seefried, MDUniversity Of Wuerzburg, Orthopedic Center For Musculoskeletal Research, Wuerzburg, DE; University Hospital Wuerzburg, Germany; University of Würzburg, Germany
Eric Thomas Rush, MDAlexion AstraZeneca Rare Disease, Kansas City, MO, US
Hideo Orimo, MD, PhDNippon Medical School, Bunkyo-ku, Tokyo, JP
Juan Carl Pallais, MD, MPHBrigham And Women's Hospital, Boston, MA, US
Kathryn McCrystal Dahir, MDVanderbilt University, USA
☆
Fri 10/9 · 11:00 AM - 12:00 PM
Meet the Professor: Comprehensive Perioperative Bone Care Pathway for Patients with Hyperparathyroidism
● Meet the Professor
Meet the Professor
📍 Meeting Room 309
Comprehensive Perioperative Bone Care Pathways for Patients with Primary Hyperparathyroidism - Bart L. Clarke, M.D. This MTP session will review and discuss management of perioperative bone care for patients with hyperparathyroidism.Comprehensive Perioperative Bone Care Pathways for Patients with Primary Hyperparathyroidism - Bart L. Clarke, M.D.
This MTP session will review and discuss management of perioperative bone care for patients with hyperparathyroidism. This will include mainly patients with primary or tertiary hyperparathyroidism. Patients with these disorders are frequently managed with single or multi-gland removal for primary hyperparathyroidism, or multi-gland removal for tertiary hyperparathyroidism. Issues affecting management include confirmation of diagnosis, imaging to localize parathyroid adenomas or hyperplasia, awareness of previous anterior neck surgery, perioperative calcium and vitamin D intake via diet or supplementation, and long-term management after both successful and unsuccessful surgery. Discussion of management of complications of hyperparathyroidism before and after surgery will be included.
Assessment and Perioperative Management of Patients with CKD Undergoing Parathyroidectomy - Grahame J. Elder, MBBS, PhDread more · Original Link ↗
Bart L. Clarke, M.D.Mayo Clinic College Of Medicine, Rochester, MN, US
Grahame J. Elder, MBBS, PhDDepartment of Renal Medicine, Westmead Hospital, SydneyUniversity of Sydney, Sydney, AU; University of Notre Dame Australia, Australia
☆
Fri 10/9 · 11:00 AM - 12:00 PM
Meet the Professor: Precision Medicine for Osteogenesis Imperfecta: From Molecular Insights to Innovative Therapies
● Meet the Professor
Meet the Professor
📍 Meeting Room 310
Meet the Professor: Precision Medicine for Osteogenesis Imperfecta: From Molecular Insights to Innovative Therapies - Brendan H Lee, MD, PhD Osteogenesis Imperfecta (OI) and more broadly the group of brittle bone disorders have been associated with over 20 distinct genetic...Meet the Professor: Precision Medicine for Osteogenesis Imperfecta: From Molecular Insights to Innovative Therapies - Brendan H Lee, MD, PhD
Osteogenesis Imperfecta (OI) and more broadly the group of brittle bone disorders have been associated with over 20 distinct genetic forms. However, phenotypic expansion and whole genome sequencing has led to ultrarare associations that inform structure function correlations.These have led to insights into the biology of bone formation and homeostasis and opportunities for targeted therapeutics.read more · Original Link ↗
Brendan H Lee, MD, PhDBaylor College Of Medicine, Houston, TX, USA; Baylor College Of Medicine, USA
☆
Fri 10/9 · 11:00 AM - 12:00 PM
Meet the Professor: Provocative Ideas
● Meet the Professor
Meet the Professor
📍 Meeting Room 311
Use of Hormone Replacement Therapy (HRT) and Bone Health - Jane A.Use of Hormone Replacement Therapy (HRT) and Bone Health - Jane A. Cauley, PhD
Use of PTH/PTHrP Analogs to Improve Bone Mass in Patients with Cancer or a History of Cancer - Sabashini Ramchand, MD
Lack of progress on Disease-Modifying Therapies for Osteoarthritis - Chuan-Ju Liu, PhDread more · Original Link ↗
X. Sherry Sherry LiuUniversity Of Pennsylvania, Philadelphia, PA, US
Jane A. Cauley, PhDUniversity Of Pittsburgh, Pittsburgh, PA, US
Sabashini Ramchand, MDCleveland Clinic, USA
Chuan-Ju Liu, PhDYale University School Of Medicine, New Haven, CT, US
☆
Fri 10/9 · 11:00 AM - 12:00 PM
Meet the Professor: Senotherapeutics and Bone: Skeletal Effects of Emerging Anti-Aging Therapies
● Meet the Professor
Meet the Professor
📍 Meeting Room 313
Senotherapeutics and Bone: Skeletal Effects of Emerging Anti-Aging Therapies - Sundeep Khosla, MD
This MTP will discuss current directions in anti-aging therapies, including senolytics, zoledronic acid, GLPR agonists, and others.Senotherapeutics and Bone: Skeletal Effects of Emerging Anti-Aging Therapies - Sundeep Khosla, MD
This MTP will discuss current directions in anti-aging therapies, including senolytics, zoledronic acid, GLPR agonists, and others. The focus will be on the skeletal impact of these therapies, but potential effects on frailty and other co-morbidities will also be included. A brief presentation will provide a general framework leaving most of the time for active discussion.read more · Original Link ↗
Sundeep Khosla, MDMayo Clinic College Of Medicine, Rochester, MN, US
Built for you by(617)-PATRICK, Champion AI speaker
Mechanisms of cachexia-associated wasting - John J. Wysolmerski, MD
Central neural control of skeletal niche adaptation - Erica L.Mechanisms of cachexia-associated wasting - John J. Wysolmerski, MD
Central neural control of skeletal niche adaptation - Erica L. Scheller, DDS, PhD
The skeleton is a dynamic organ whose cellular composition and metabolic activity are subject to continuous regulatory input extending well beyond local biomechanical and paracrine signals. Emerging evidence has established the central nervous system as a critical orchestrator of skeletal homeostasis, coordinating bone remodeling and marrow adiposity through integrated endocrine and peripheral neural pathways. This meet the professor presentation synthesizes current evidence for central and peripheral neural governance of the bone-BMAT axis, highlighting mechanistic insights from rodent models and clinical correlates in conditions of altered central and peripheral neural signaling.read more · Original Link ↗
John J. Wysolmerski, MDYale University, USA
Erica L. Scheller, DDS, PhDWashington University in Saint Louis, Saint Louis, MO, US
☆
Fri 10/9 · 12:30 PM - 1:30 PM
Meet the Professor: Assessing Metabolism in Bone: Methodological Aspect
● Meet the Professor
Meet the Professor
📍 Meeting Room 310
Assessing Metabolism in Bone: Methodological Aspects - Steve Stegen, PhD
Assessing Metabolism in Bone: Methodological Aspects - Ryan C.Assessing Metabolism in Bone: Methodological Aspects - Steve Stegen, PhD
Assessing Metabolism in Bone: Methodological Aspects - Ryan C. Riddle
Assessing Metabolism in Bone: Methodological Aspects - Elizabeth Rendina-Ruedy
The Rendina-Ruedy Lab is focused on developing a comprehensive understanding of how metabolic pathways impact bone health. Bone is an incredibly dynamic tissue that undergoes continuous remodeling involving bone resorbing osteoclasts, bone forming osteoblasts, and mechano-sensing osteocytes. Due to the high energetic demands of this process, targeting metabolic pathways in bone cells is an incredibly provocative tool that can be applied to combat various conditions which lead to increased fracture incidence and/ or complications during fracture repair (i.e., post-menopausal osteoporosis, type 2 diabetes mellitus, and age-related osteoporosis). As such, the Rendina-Ruedy lab has ongoing projects aimed at understanding how bone cells, and cells within the bone marrow niche, store, mobilize, and utilize various metabolic substrates. In addition to understanding how these metabolic pathways impact bone health in a cell-autonomous manner, our lab is particularly interested in how alterations in bone cell bioenergetics modulate whole-body metabolism. In line with this research focus, the lab’s broad goal is to apply their cutting-edge biomedical research to improve the quality of life for patients with musculoskeletal diseases, conditions, and/ or trauma. During this informal session, we aim to discuss current the fields current understanding of bone metabolism, along with challenges, limitations, and perspective approaches.
Assessing Metabolism in Bone: Methodological Aspects - Roman A Eliseevread more · Original Link ↗
Steve Stegen, PhDClinical And Experimental Endocrinology, Ku Leuven, Leuven, BE
Ryan C. RiddleUniversity Of Maryland School Of Medicine, Baltimore, MD, US
Elizabeth Rendina-RuedyDepartment of Nutritional Sciences, College of Allied Health, University of Oklahoma Health Science Campus, Oklahoma City, OK, USA
Roman A EliseevUniversity Of Rochester, Rochester, NY, US; University of Rochester, USA
☆
Fri 10/9 · 12:30 PM - 1:30 PM
Bone 101: Fundamentals of Bone Biology
● Career Development
📍 Meeting Room 311
Bone Cells and Signaling Pathways - Paola Divieti-Pajevic
Hormonal Control of Skeletal Processes - Garyfallia Papaioannou
Tools for Evaluating Bone Mass and Quality - Frank Ko, PhD
Key Mouse Models Used for Bone Research - Josephine T. Tauer · Original Link ↗
Elizabeth A. Zimmermann, PhDMcgill University, Montreal, QC, CA
Lauren Surface, PhDUniversity Of Michigan, Ann Arbor, MI, US
Paola Divieti-PajevicTranslational Dental Medicine, Goldman School of Dental Medicine, Boston University, Boston, MA, USA
Garyfallia PapaioannouMGH, Brookline, MA, US
Frank Ko, PhDRush University, Chicago, IL, US
Josephine T. TauerDepartment of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Austria
☆
Fri 10/9 · 12:30 PM - 1:30 PM
Meet the Professor: Bone Organoids and 3D Models
● Meet the Professor
Meet the Professor
📍 Meeting Room 313
3D models for BMAT/BM interactions - Michaela Ruth Reagan, PhD
3D-printed models mimicking bone microarchitecture - Julie A. Rhodes · Original Link ↗
Michaela Ruth Reagan, PhDMaineHealth Institute for Research, Scarborough, ME, US
Julie A. RhodesVanderbilt University Medical Center, USA
Built for you by(617)-PATRICK, Champion AI speaker
A short break to stretch, grab a coffee and network with fellow attendees before the next session. · Original Link ↗
☆
Fri 10/9 · 1:45 PM - 3:00 PM
Clinical Symposium: Next-Generation Technologies for Bone Assessment
● Symposium
Symposium
📍 Ballroom C
High Resolution Bone Imaging: Current Clinical Applications - Steven K. Boyd, PhD
Artificial Intelligence in Fracture Risk Assessment: Evidence and Perspectives - Namki Hong, MD, PhD
Fracture Liaison Agents - New (Language) Models of Care - Nicholas Fuggle, MBBS, PhD · Original Link ↗
Klaus Engelke, PhDFAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, BY, DE
Claus Christian Glueer, PhDKiel University (Christian Albrechts Universitaet), Kiel, DE
Steven K. Boyd, PhDUniversity Of Calgary, Canmore, AB, CA
Namki Hong, MD, PhDDivision of Endocrinology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Nicholas Fuggle, MBBS, PhDUniversity of Southampton, Southampton, GB
☆
Fri 10/9 · 1:45 PM - 3:00 PM
Bench to Bedside Symposium: Muscle and Bone Interactions
● Symposium
Symposium
📍 General Session - Ballroom A & B
Muscle-Bone Metabolism: The Dynamic Duo in Aging and Exercise - Hanna Taipaleenmaki Breaking the Load Myth: Resistance Training and Muscle Hypertrophy - Stuart Phillips, PhD This talk will cover how the load that is lifted during resistance exercise affects skeletal...Muscle-Bone Metabolism: The Dynamic Duo in Aging and Exercise - Hanna Taipaleenmaki
Breaking the Load Myth: Resistance Training and Muscle Hypertrophy - Stuart Phillips, PhD
This talk will cover how the load that is lifted during resistance exercise affects skeletal muscle hypertrophy and strength gains. Parallels between bone and muscle will also be discussed, focusing on what stimulates bone formation.
Muscle Quality, Aging, and Fracture Risk: Translating Body Composition into Clinical Insight - Peggy M. Cawthon, PhDread more · Original Link ↗
Gustavo Duque, PhD, MDMcGill University, Montreal, QC, CA
Lorenz C. Hofbauer, MDDivision of Endocinology, Diabetes, and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany, Germany
Hanna TaipaleenmakiInsitute of Musculoskeletal Medicine, LMU University Hospital, LMU Munich, Munich, Germany, Germany; University Hospital, LMU Munich, Planegg, DE; Institute of Musculoskeletal Medicine, LMU University Hospital, LMU Munich, Munich, Germany, Germany
Stuart Phillips, PhDMcmaster University, Hamilton, ON, CA
Peggy M. Cawthon, PhDSutter Health Research Institute and University of California San Francisco, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
A short break to stretch, grab a coffee and network with fellow attendees before the next session. · Original Link ↗
☆
Fri 10/9 · 3:15 PM - 4:15 PM
Oral Presentations: Next-Generation Anabolic Approaches to Osteoporosis Treatment
● Oral Abstract Presentations
Oral Abstracts
📍 Ballroom C
A New Intervention for Osteoporosis: Replenishing Key Extracellular Matrix Proteins (e.g.A New Intervention for Osteoporosis: Replenishing Key Extracellular Matrix Proteins (e.g. Cyr61/CCN1) Depleted from Bone During Aging - Xiao-Dong Chen
The purpose of this study is to reverse age-related bone loss by replenishing a key extracellular matrix (ECM) component, Cyr61/CCN1, which is depleted during aging. Cyr61 is a member of the Cell Communication Network protein family and has separate binding domains for insulin-like growth factor binding protein (IGFBP), TGF-β, and BMPs. This protein also tightly binds fibronectin in the ECM and interacts with cells via integrins. Recently, we developed bone-specific Cyr61 knockout mice, driven by the DMP-1 promoter, which display severe bone loss and a reduction in PTH1R expression. We also validated that Cyr61 protein in bone was naturally diminished during aging in mice and marmosets. For this study, we hypothesized that restoration of Cyr61 protein to the aged bone matrix promoted mesenchymal stem cell (MSC) self-renewal, differentiation, and bone formation capacity, resulting in attenuated bone loss. Methods : 20-month-old mice were intravenously (i.v.) injected 3 times at 2-week intervals with varying doses of recombinant (r) Cyr61 (10, 30 or 50µg/animal), suspended in 500µl PBS containing 10µg multi-walled carbon nanotubes (MWCNTs, a bone-targeting vehicle), or PBS alone. On day 28 post-3 rd injection, lumbar vertebrae (L1-3) were harvested for Western blot (Wb) analysis and bone marrow (BM) cells were obtained from left femur and both tibias for colony forming unit (CFU) assay. In addition, right femur and L4-5 were scanned by µCT to quantify changes in bone structure. Results : Based on Wb analysis, Cyr61 was significantly restored to the bone matrix of mice injected with 30µg and 50µg of rCyr61/MWCNT, as compared to PBS alone and 10µg rCyr61/MWCNTs; moreover, presence of Cyr61 was associated with increased expression of PTH1R. Freshly isolated BM cells from mice injected with 30µg and 50µg of rCyr61/MWCNTs contained greater numbers of BM-MSCs, represented by CFU-fibroblasts & -osteoblasts, than mice injected with PBS alone or 10µg rCyr61/MWCNTs. Subsequently, the trabecular architecture of femurs from mice treated with rCyr61/MWCNTs was significantly improved in a dose-dependent manner, as quantified by µCT. Conclusions : Old mice treated with rCyr61/MWCNTs displayed an increase in CFUs, PTH1R, and bone mass in a dose-dependent manner. This study provides a completely new treatment paradigm for osteoporosis by replenishing key ECM components (e.g. Cyr61) depleted during aging, potentially preventing/retarding age-related bone loss.
AAV-mediated delivery of a novel miR-39 as a novel approach to treat osteoporosis - Aijaz Ahmad John Bhat, PhD
Osteoporosis is an aging-associated disease characterized by low bone density and deterioration of bone structure that increases the risk of fractures. Most existing osteoporosis therapies target osteoclasts to inhibit bone resorption, while three FDA-approved anabolic agents (including parathyroid hormone, parathyroid hormone-related protein, and anti-sclerostin antibody) work by promoting osteoblast-mediated bone formation. However, long-term treatment with these drugs shows numerous potential side effects along with waning efficacy. Thus, there is still an unmet need for safe and sustained approaches to treat osteoporosis. Previously, we identified Schnurri-3 (SHN3) as a potent intracellular suppressor of bone formation. Genetic deletion of SHN3 enhances osteogenesis through activation of WNT signaling and protects against bone loss in mouse models of postmenopausal and age-related osteoporosis. However, SHN3 is not readily amenable to pharmacological targeting because it is a large (~250 kDa) intracellular adaptor protein. Therefore, in this study, we sought to identify SHN3-regulated microRNAs in osteoblasts as a potential alternative therapeutic strategy for osteoporosis. Using genome-wide microRNA (miRNA) profiling of wild-type and SHN3-deficient osteoblasts, we identified a novel miRNA nov-miR-39 as a key regulator of the SHN3 pathway in osteoblasts. Recombinant adeno-associated virus (rAAV)-based gene transfer has emerged as a promising therapeutic platform, enabling long-term transgene expression with a favorable safety profile. rAAV9 was identified as the most effective serotype transducing osteoblasts in skeleton and its bone-specific tropism was improved by grafting the bone targeting peptides (DSS 6 ) onto the AAV capsid protein. AAV-mediated overexpression of nov-miR-39 in osteoblasts significantly enhanced osteogenic differentiation and bone-forming activity, whereas inhibition of endogenous nov-miR-39 using its tough decoy markedly attenuated osteogenesis. Moreover, AAV-mediated overexpression of nov-miR-39 robustly reversed bone loss in mouse models of postmenopausal and aging-associated osteoporosis by enhancing osteoblast-mediated bone formation, without detectable adverse effects in non-skeletal tissues. Mechanistically, nov-miR-39 enhances WNT signaling, osteoblastic activity, and bone formation. These findings establish the nov-miR-39 - WNT signaling axis as a promising therapeutic strategy to treat osteoporosis.
Wnt Surrogate Stimulates Bone Formation In Osteoporotic Mouse Models - Syeda N Lamia
Activating Wnt signaling by inhibition of Sclerostin is a proven anabolic therapeutic strategy for osteoporosis. In this study we tested an alternative strategy to activate Wnt signaling in two preclinical models of osteoporosis. We used FL5, a novel antibody-based Wnt surrogate that directly binds to FZD and LRP5 co-receptors thus mimicking the function of endogenous Wnt ligands. We hypothesized that FL5 activates Wnt signaling in bone, increasing bone formation and enhancing low bone mass and strength caused by aging and by WNT1 deficiency in mice.
First, we treated 22-month-old (osteoporotic) female and male C57BL/6 mice (N=50) with 15 or 45 mg/kg FL5 for 4 wks (IP, 3d/wk). Control mice received 45 mg/kg IgG. After 4 wks of FL5 treatment in females, whole-body BMD increased by 20% in the 15 mg/kg group, while 45 mg/kg dose induced a lesser increase (10%). Dynamic histomorphometry showed that 15 mg/kg FL5 stimulated lamellar bone formation on both peri- and endosteal surfaces (4-fold greater than IgG). In L5 vertebra, total BV/TV was 2-fold higher with 15 mg/kg FL5 compared to IgG, resulting in a 3.5-fold increase in ultimate force to failure. Male mice responded similarly, although to a lesser extent. To assess the transcriptional response to FL5, we treated female mice (N=20) for 1 wk and performed bulk RNAseq of bone tissue. 15 mg/kg FL5 elicited a greater transcriptional response than 45 mg/kg, with more differentially expressed genes (5904 vs. 453) and higher fold changes compared to control, suggesting a ‘hook effect’ - at a higher dose, multivalent FL5 molecules compete for receptors and form incomplete bonds. FL5 treatment upregulated osteoblast and osteocyte genes, indicating increased cell number or activity. Wnt target genes Axin2 and Tcf7 were also upregulated by 15 mg/kg FL5 treatment, consistent with activation of canonical Wnt signaling. Next, we tested if FL5 could rescue the early onset osteoporotic (EOOP) phenotype caused by lack of endogenous WNT1 in osteoblasts/osteocytes. We treated 3.5-wk old Ocn-Cre;Wnt1 fl/fl (cKO) and WT mice (N=27) with 5 mg/kg FL5 or IgG for 4 wks. FL5 reduced spontaneous fractures in cKO mice (67 to 17%). Cortical area and ultimate load of femur of FL5-treated cKO mice were equivalent to that of IgG-treated WT, indicating that FL5 effectively reversed Wnt1-related EOOP.
In conclusion, the novel Wnt surrogate FL5 activates Wnt signaling, increases bone formation and rescues two forms of osteoporosis in mice.
A Novel Bispecific Antibody Co-targeting TGF-β and Sclerostin for Osteoporosis Treatment - Ahyoun Choi, PhD
In patients with very high-risk osteoporosis, fracture risk remains substantial and treatment responses are often insufficient despite current therapies, highlighting the need for more effective treatment strategies. Recently we demonstrated that the co-inhibition of TGF-β and sclerostin additively increases bone mass compared to Scl-Ab monotherapy, by providing superior suppression of bone resorption while maintaining comparable anabolic effects. Consequently, we developed a novel bispecific antibody (BsAb) targeting both TGF-β and sclerostin.
The BsAb was engineered using variable regions of romosozumab and fresolimumab, incorporating CrossMab and knobs-into-holes (KiH) structures. Following high-concentration production from Biointron, target affinity was validated via ELISA. To evaluate in vivo efficacy, the BsAb (25mg/kg, x2/week) and Scl-Ab (25mg/kg, x2/week) were administered for four weeks to postnatal week 8 in osteoporosis models, including ovariectomy (OVX) and hindlimb mechanical unloading. Therapeutic outcomes were assessed through micro-CT and serum bone turnover marker analysis.
Affinity assays confirmed that the BsAb maintained high binding potency for both targets, with EC50 values of 5.4 nM for sclerostin and 7.0 nM for TGF-β. Sequential ELISA verified that a single BsAb molecule could simultaneously bind both antigens. In vivo, the BsAb demonstrated superior bone mass recovery in both osteoporosis models compared to Scl-Ab monotherapy. While P1NP levels were modestly lower than those in the Scl-Ab group, the BsAb exhibited significantly more potent inhibition of bone resorption, confirming a robust “dual action” mechanism.
We successfully validated the efficacy of a novel BsAb co-targeting TGF-β and sclerostin as a potent dual action agent. By integrating bone-forming and anti-resorptive properties, this BsAb offers enhanced skeletal protection over conventional monotherapies. Further studies on the long-term safety and optimal clinical dosage are warranted to advance this candidate toward drug development.
Osteoanabolic Actions of Intermittent Parathyroid Hormone (PTH) Require Bone Marrow Adipocyte Lipolysis - Kateryna Nabukhotna, PhD
Parathyroid hormone (PTH, 1-34; teriparatide) is a therapeutic option for severely osteoporotic patients that stimulates bone formation. However, for unknown reasons, a considerable proportion of patients do not respond to PTH therapy, causing added financial burden and delayed treatment. Therefore, continued research is needed to define the molecular mechanisms by which PTH exerts its osteoanabolic effects, and likewise, why some patients do not respond to treatment. Previous research showed that fatty acid metabolism is required for PTH-stimulated bone formation. As such, we have also identified poorly characterized bone marrow adipocytes (BMAdipo) as a potential source of fatty acids within the bone niche. The current project hypothesizes that PTH’s osteoanabolic actions directly involve stimulation of lipolysis in BMAdipo to support enhanced fatty acid oxidation in osteoblasts. We tested this hypothesis by utilizing the novel Flippase-activated Adipoq-Cre (FAC) mouse model crossed with Atgl ( Pnpla2 ) fl/fl mice to selectively block lipolysis in BMAdipo. At 16 weeks of age, female FAC.Atgl fl/fl mice, along with littermate controls (Con), were ovariectomized (OVX) and then allowed to lose bone while expanding marrow adiposity for 6 weeks. Following this time, PTH (100 µg/kg bodyweight) or vehicle control (Veh) were administered daily for 5 days/week for 6 weeks. We discovered that Con OVX mice responded to PTH treatment as evidenced by a significantly higher whole body bone mineral density (BMD) and trabecular bone (bone volume per total volume, BV/TV). Conversely, FAC.Atgl fl/fl OVX mice did not respond to PTH treatment in BMD or trabecular bone, while the cortical bone compartment remained somewhat responsive. To further unravel the molecular mechanism behind this skeletal response, we quantified long chain fatty acids in circulating and bone marrow sera. Unexpectedly, we detected more oleic acid (C18:1) in FAC.Atgl fl/fl OVX-Veh compared to Con OVX-Veh in both serum types. Within the bone marrow space, PTH lowered oleic acid in both Con OVX and FAC.Atgl fl/fl OVX mice. While additional molecular analyses are underway, these data support the tenet that PTH treatment requires fatty acids from BMAdipo to support bone formation. Moreover, these findings offer a novel approach to manage osteoporosis and suggest that responsiveness along with the efficacy of PTH treatment can be regulated by modulation of metabolic processes within the bone niche.read more · Original Link ↗
Teresita Bellido, PhDUniversity Of Arkansas For Medical Sciences, LITTLE ROCK, AR, US
Aline Martin, PhDNorthwestern University, Chicago, IL, US
Xiao-Dong ChenUniversity Of Texas Health Science Center At San Antonio, San Antonio, TX, US; Department of Veterans Affairs, South Texas Veterans Health Care System, USA
Aijaz Ahmad John Bhat, PhDDepartment of Genetic and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA, USA; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA, USA; University Of Massachusetts Chan Medical School, Worcester, Srinagar, IN
Syeda N LamiaWashington University in St. Louis, USA
Ahyoun Choi, PhDSeoul National University, Seoul, KR
Kateryna Nabukhotna, PhDUniversity Of Oklahoma Health Sciences Center, Oklahoma City, OK, US
☆
Fri 10/9 · 3:15 PM - 4:15 PM
Oral Presentations: Sugar, Fat, and Fracture: The GLP-1 Era of Bone Health
● Oral Abstract Presentations
Oral Abstracts
📍 General Session - Ballroom A & B
Unsaturated Bone Marrow Lipids Have Negative Effects on Bone Quality in Individuals with Type 2 Diabetes - Minhao Zhou, Ph.D. Type 2 diabetes (T2D) is an independent risk factor for skeletal fragility.Unsaturated Bone Marrow Lipids Have Negative Effects on Bone Quality in Individuals with Type 2 Diabetes - Minhao Zhou, Ph.D.
Type 2 diabetes (T2D) is an independent risk factor for skeletal fragility. Bone marrow adipose tissue (BMAT), with its unsaturated (unsat) and saturated (sat) components, has been implicated as a regulator of bone health, with unsat BMAT previously associated with positive skeletal outcomes. 1 However, recent cross-sectional studies report conflicting associations between BMAT and bone quality, highlighting the need for longitudinal data. This study aimed to evaluate longitudinal changes in BMAT in relation to bone quality in individuals with and without T2D.
Seventy-eight participants were included: controls ( T2D- ; n =40) and participants with T2D ( T2D+ ; n =38), based on medication history and HbA1c. BMAT composition (total, unsat, sat) and bone quality (density, microarchitecture, and biomechanics) were evaluated for all participants at baseline and 2-year follow-up. BMAT was measured by MRS at L3 and L4 vertebrae. Bone quality was evaluated at the tibia and radius by 1 st -gen HR-pQCT. Longitudinal changes in BMAT and bone quality were assessed using paired parametric/nonparametric tests. Associations between changes (Δ) in BMAT and bone quality were examined. Between-group comparisons were adjusted for demographic differences.
Over 2 years, unsat BMAT increased in both T2D- and T2D+ , while total BMAT remained unchanged. Sat BMAT increased in both groups but did not reach significance in T2D+ (FigA). In T2D+ but not in T2D- , Δunsat BMAT was positively associated with radial ΔTt.vBMD and ΔCt.vBMD but negatively associated with radial Δapparent modulus (FigB). Additionally, Δunsat BMAT was positively associated with tibial Δcortical pore density (r=0.443, p=0.034). No association was found between BMAT and trabecular metrics.
These results show that BMAT composition shifted toward greater unsaturation regardless of T2D status and despite stable total BMAT. Associations between longitudinal changes in BMAT and bone quality differed by T2D status. In T2D+ , increasing unsat BMAT was associated with increased bone density but decreased bone stiffness. Exploratory analyses indicate that this contradiction is due to trabecular microstructure changes that negatively impact bone stiffness but were not significantly associated with BMAT composition changes. This study provides the first longitudinal evaluation of BMAT composition in the context of T2D-related bone changes and suggests a negative impact of unsaturated BMAT on skeletal health.
1.Woods+, JBMR 2022, 37(4)
Serum biomarkers and histomorphometric bone turnover in adults with type 1 diabetes and chronic kidney disease - Clarence Chu, MD
Background: Up to 40% of individuals with type 1 diabetes (T1D), which is generally considered a condition of low bone turnover, eventually develop chronic kidney disease (CKD). Renal osteodystrophy is a heterogeneous condition including high, low, or mixed bone turnover. It is unclear how bone turnover manifests when T1D and diabetic kidney disease coexist. Moreover, it is uncertain how well serum biochemical markers of bone turnover predict histomorphometric turnover determined by gold-standard tetracycline-labeled bone biopsy.
Methods: A skeletal health ancillary study to the PERL trial (allopurinol vs placebo in adults with T1D and moderate diabetic kidney disease) enrolled 97 adults at 7 sites, and 16 of those underwent tetracycline-labeled bone biopsy. Biopsy specimens were interpreted by an experienced bone pathologist for static and dynamic histomorphometry. Serum intact PTH and the kidney function-independent bone turnover markers intact P1NP and TRACP5b were obtained at 3 time points during and post-trial; these were used to calculate time-weighted averages using generalized linear mixed models. Associations between biochemical markers and histomorphometric turnover category (low, normal, high) were analyzed via Wilcoxon rank-sum tests and ANOVA.
Results: The 16 adults who underwent bone biopsy (aged 58±10 y, 50% male, 88% white) had a spectrum of estimated glomerular filtration rate (mean 48, range 26-85 ml/min/1.73 m 2 ) similar to the larger skeletal health cohort. Mean duration of T1D was 44 y, mean HbA1c at biopsy was 6.9%, and 69% had a history of fracture. On bone biopsy, turnover category was 2 low, 5 normal, 8 high, and 1 not evaluable. Serum biomarker levels were largely within normal reference ranges (Figure). Biomarker values were higher in the high histomorphometric turnover category than the combined low/normal histomorphometric turnover categories for P1NP (median 55.6 vs 41.5 ng/mL, p=0.02) and TRACP5b (4.0 vs 2.8 U/L, p=0.03); PTH showed a similar trend but without statistical significance (49.6 vs 38.4 pg/mL, p=0.12).
Conclusion: Among adults with T1D and CKD of varying severity, high bone turnover on bone biopsy was common, challenging the prevailing notion that diabetes is a low turnover state. Serum bone turnover markers were associated with histomorphometric turnover; whether they can aid in distinguishing turnover states requires validation in larger cohorts.
Fracture Risk Among GLP-1 Receptor Agonists and Other Anti-Hyperglycemic Agents: A Compound-Level Analysis in Women ≥50 Years with Type 2 Diabetes - Jawaad Shahid Chaudhry, BS
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes mellitus (T2DM) and improve glycemic control, weight loss, and cardiovascular outcomes. However, their impact on bone health remains unclear, with mixed evidence regarding fracture risk. This study evaluates fracture risk in women ≥50 years with T2DM initiated on GLP-1RAs or dual GLP-1/GIP receptor agonists compared with other antihyperglycemic agents.
A total of 154,740,582 patients on the TriNetX Global Collaborative Network were queried for women ≥50 years with T2DM initiated on SGLT2 inhibitors, DPP-4 inhibitors, GLP-1RAs, dual GLP-1/GIP receptor agonists, sulfonylureas, or thiazolidinediones. Patients on insulin were excluded. Medication exposure required ≥6 prescriptions ≥1 month apart. Cohorts were propensity score matched 1:1 on demographics, comorbidities, and medication use, achieving standardized mean differences <0.1.
The primary outcome was osteoporotic fragility fracture. Outcomes were assessed at 1 year using Kaplan - Meier analysis with hazard ratios (HRs). Outcomes with <10 events were not reported due to data suppression.
Tirzepatide was associated with reduced fracture risk compared to empagliflozin (HR 0.43, 95% CI 0.25 - 0.73; p=0.0013), dapagliflozin (HR 0.41, 95% CI 0.20 - 0.82; p =0.009) and pioglitazone (HR 0.45, 95% CI 0.23 - 0.87; p =0.0147), with no differences versus sitagliptin or glimepiride. Semaglutide demonstrated reduced fracture risk versus empagliflozin (HR 0.50, 95% CI 0.33 - 0.74; p =0.0004), dapagliflozin (HR 0.49, 95% CI 0.29 - 0.82; p =0.0054), pioglitazone (HR 0.39, 95% CI 0.23 - 0.65; p =0.0002), and linagliptin (HR 0.38, 95% CI 0.22 - 0.64; p =0.0002), while sitagliptin approached significance (HR 0.73, 95% CI 0.49-1.09; p=0.1187) and no differences versus sulfonylureas. Dulaglutide showed no significant differences; with empagliflozin approaching significance (HR 0.64, 95% CI 0.37 - 1.12; p =0.12).
Tirzepatide and semaglutide were associated with reduced fracture risk compared with several agents, particularly SGLT2 inhibitors and thiazolidinediones, while dulaglutide showed no differences. These findings contrast with prior literature suggesting neutral or protective effects of SGLT2 inhibitors and highlight variability at the drug level rather than by class. Limitations include lack of data on weight loss and bone mineral density, inability to assess adherence, and potential coding errors. Further prospective studies are warranted.
Fracture risk associated with incretin-based therapies in people living with overweight or obesity: a Bayesian meta-analysis of placebo-controlled randomized trials - Julien Paccou, PhD, MD
Background
Incretin-based therapies, including GLP-1 receptor agonists (GLP-1RAs) and dual/triple agonists, are increasingly prescribed for overweight and obesity and induce substantial weight loss, but their effects on fracture risk remain poorly characterized. Evidence from randomized controlled trials is inconsistent, partly owing to the rarity of fracture events, limited follow-up, and heterogeneity in treatment intensity and magnitude of weight loss. We conducted a systematic review and Bayesian meta-analysis to characterize the heterogeneity of fracture risk associated with incretin-based therapies in people living with overweight or obesity.
Methods
We conducted a systematic review and Bayesian meta-analysis of randomized, double-blind, placebo-controlled trials (RCTs) evaluating incretin-based therapies in adults with overweight or obesity (BMI ≥27 kg/m²). MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to Oct 22, 2025. Eligible trials required a minimum follow-up of 20 weeks and at least 150 participants. All fractures (excluding fingers, toes, and facial/skull) were the primary outcome. Fracture incidence rates were pooled using a Bayesian hierarchical arm-based Poisson model with exposure time as an offset. The protocol was registered with PROSPERO (ID1343484).
Findings
Overall, 39 RCTs were included in the meta-analysis. The 39 trials comprised 56,663 participants, including 30,398 allocated to incretin-based therapies and 26,265 allocated to placebo of whom 29,769 (52.5%) were women. The pooled IRR for fractures was 1.11 (95% CrI 0.75 - 1.72; posterior probability 0.72). Directional signals of higher fracture risk were observed with high-dose compared with standard-dose single agonists (IRR ratio 1.72, 95% CrI 0.62 - 4.97; posterior probability 0.85) and with increasing magnitude of weight loss - each additional 10% reduction associated with an IRR of 1.76 (95% CrI 0.69 - 4.44; posterior probability 0.89) - though credible intervals were wide in both cases. Both signals were reinforced in multivariable meta-regression (Figure).
Interpretation
Fracture risk under incretin-based therapies in people living with overweight or obesity is not uniform, varying consistently with treatment intensity and magnitude of weight loss. These findings support heightened attention to bone health, particularly in those receiving high-intensity regimens or achieving substantial weight reduction.
Semaglutide Use and Risk of Osteoporosis, Osteopenia, and Fracture in Non-Diabetic Postmenopausal Women with Obesity: A Retrospective Cohort Study - Jessica Siguencia, BS
Introduction: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has become increasingly prescribed for chronic weight management in non-diabetic patients with obesity, however its long-term effects on bone health, particularly in postmenopausal women remain unclear. Postmenopausal women have an elevated baseline fracture risk. We hypothesize that semaglutide use would be associated with differences in osteoporosis and osteopenia diagnosis and fracture incidence compared to matched control cohorts over a 5-year follow up period.
Methods: The TriNetX Research Network was queried for non-diabetic women ≥50, the average of onset of menopause, with overweight or obesity. Patients with prior diabetes or bone-modifying therapy were excluded. Two cohorts were constructed: those receiving their first semaglutide prescriptions and matched 1:1 to controls without GLP-1 exposure. Propensity score matching (1:1) yielded 132,197 matched pairs, balanced on age, race,and BMI. Outcomes included osteoporosis, osteoporosis with fracture, osteopenia, femur fracture, and vertebral fracture, assessed at 1-year intervals over 5 years using risk ratio (RR), 95% confidence intervals.
Results: The non-GLP-1 cohort had significantly higher femur fracture risk at all 5 timepoints (Year 1: RR 1.943, 95% CI 1.395 - 2.706; Year 5: RR 1.985, 95% CI 1.620 - 2.431; all p<0.001), with approximately double the fracture incidence throughout. Vertebral fracture risk was also significantly higher in the Non-GLP-1 cohort from year 4-5 (Year 5: RR 1.320, 95% CI 1.185 - 1.470; p<0.001). In contrast, osteoporosis and osteopenia diagnoses were more frequent in semaglutide users across years 1 - 4 (Osteoporosis Year 1: RR 0.716, p<0.001; Osteopenia Year 1: RR 0.681, p<0.001),with rates equalizing by year 5 for both outcomes, a pattern that may indicate earlier detection in the semaglutide group.
Conclusion: In this large propensity-matched cohort of non-diabetic postmenopausal women with obesity, semaglutide use was associated with significantly lower femur and vertebral fracture risk, despite higher rates of osteoporosis and osteopenia diagnosis. Further investigation of GLP-1 receptor agonists on bone outcomes and surveillance patterns, specifically in non-diabetic postmenopausal women with obesity should be considered.read more · Original Link ↗
Ruban Dhaliwal, MD, MPHDepartment of Internal Medicine, The University of Texas Southwestern Medical Center, USA
Elena Gonzalez Rodriguez, PhD, MDUniversity of Lausanne, Switzerland; Interdisciplinary Center for Bone Diseases; Rhumathology Service, Lausanne University Hospital, Switzerland
Minhao Zhou, Ph.D.Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
Clarence Chu, MDDivision of Endocrinology and Metabolism, University of California, San Francisco, San Francisco, CA, USA
Jawaad Shahid Chaudhry, BSPenn State College Of Medicine, Hummelstown, PA, US
Julien Paccou, PhD, MDLille University Hospital, Lille, FR
Jessica Siguencia, BSRenaissance School of Medicine at Stony Brook University, Setauket- East Setauket, NY, US
☆
Fri 10/9 · 3:15 PM - 4:15 PM
Oral Presentations: Skeletal Stem and Progenitor Cell Regulation in Bone Homeostasis and Repair
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 302
Bone marrow adipoprogenitors, not mature adipocytes, primarily regulate bone remodeling and hematopoiesis - Michael Duffy, PhD
Bone marrow mature adipocytes account for 5 - 10% of total adipocytes in adult humans.Bone marrow adipoprogenitors, not mature adipocytes, primarily regulate bone remodeling and hematopoiesis - Michael Duffy, PhD
Bone marrow mature adipocytes account for 5 - 10% of total adipocytes in adult humans. Previous reports suggested their important regulatory roles in bone turnover and hematopoiesis. However, those studies relied on cultured cells or mice with Cre drivers that are also active in adipoprogenitors. To precisely characterize bone marrow adipocytes, we isolated them from human femoral head tissue. Surprisingly, staining the lipid layer of adipocytes revealed numerous CD45+ hematopoietic cells and PDGFA+ stromal cells, indicating that standard adipocyte preparations are highly contaminated. Single-nucleus RNA-sequencing (snRNA-seq) analysis of two samples identified 13 clusters, including adipocytes (871 cells), adipoprogenitors (Adipo-MSCs, 5271), Fibro-MSCs (75), Osteo-MSCs (154), hematopoietic cells (7 subclusters, 12,282), endothelial cells (3788), and VSMCs (1500). Strikingly, osteoclast regulatory factors (e.g., RANKL, CSF1) and hematopoietic niche factors (e.g., CXCL12, KITLG), were highly expressed in Adipo-MSCs but not in mature adipocytes. Pathway analysis showed that transitioning from Adipo-MSCs to adipocytes markedly suppresses pathways for cell communication and vessel morphogenesis while drastically upregulating lipid metabolism. Merging our dataset with peripheral fat pad datasets demonstrated that bone marrow adipocytes are less adipogenic and have more communication with blood cells. We next constructed two mouse lines, Adipoq-CreER DTA, which ablates adipoprogenitors and adipocytes, and Plin1-CreER DTA, which ablates adipocytes only, and analyzed their C1/2 vertebrae because they have a balanced mix of bone marrow hematopoietic cells and adipocytes. Tamoxifen injections in 2-month-old Adipoq-CreER DTA mice (n=5-8) resulted in decreased CD45+ cells (36.4%), larger vessels (2.0-fold in diameter), and increased trabecular bone (1.3-fold in BV/TV), which was driven by a 73.9% increase in osteoblasts and a 57.9% decrease in osteoclasts. Notably, similar treatment did not affect Plin1-CreER DTA mice (n=5). Furthermore, bone marrow recovery at 14 days post 5-FU injection (mimicking chemotherapy) was completely abolished in Adipoq-CreER DTA mice, but not affected in Plin1-CreER DTA mice. In summary, our study profiles the unique transcriptome of bone marrow adipocytes and establishes that bone marrow adipoprogenitors, rather than mature adipocytes, play the predominant role in regulating the bone marrow microenvironment.
CBFβ-INO80 Chromatin Remodeling Preserves Aged Marrow Adipoq<sup>+</sup> Skeletal Progenitors and Bone Repair - Tiannan Huang
Aging impairs bone healing in part through functional exhaustion of skeletal stem and progenitor cells (SSPCs). Marrow Adipoq⁺ lineage cells comprise a subset of late, bipotent SSPCs, as well as adipose-lineage cells with potent paracrine activity, positioning them to influence both marrow-dependent bone repair and periosteal repair responses. However, the epigenetic mechanisms that preserve their reparative function during aging remain poorly understood. Here, we uncover an unexpected epigenetic function of CBFβ, traditionally viewed as a RUNX cofactor, in organizing an INO80-dependent chromatin remodeling program that maintains marrow Adipoq⁺ lineage cell function and bone repair during aging.
CBFβ expression declined with aging in human and mouse marrow Adipoq⁺ lineage cells. In Cbfb f/f ;Adipoq-Cre mice, Cbfb deletion reduced multiple SSPC populations and impaired both drill-hole and fracture repair, indicating defects in marrow-dependent osteogenic repair and periosteal repair responses, respectively. Mechanistically, immunoprecipitation-mass spectrometry, ATAC-seq, and CUT&Tag profiling revealed that CBFβ maintained Adipoq⁺ lineage cell function through INO80-associated chromatin remodeling. Genome-wide profiling showed that CBFβ sustains INO80 complex activity and chromatin accessibility at osteogenic and genome-maintenance loci, whereas CBFβ deficiency induced chromatin closure at these sites. This disrupted two convergent repair programs: (1) suppressed WNT-dependent osteogenic potential in marrow SSPCs; (2) induced genomic instability and cellular senescence, generating an IGFBP7-enriched senescent microenvironment that compromised periosteal SSPC maintenance through inhibiting IGF-AKT signaling, likely via transcortical vascular communication. Importantly, AAV-mediated restoration of CBFβ in aged Adipoq⁺ cells rescued SSPC depletion and improved fracture repair.
Together, these findings redefine CBFβ as an epigenetic guardian of the aged Adipoq⁺ marrow compartment and reveal that genome-wide maintenance of chromatin accessibility by the CBFβ-INO80 axis coordinates osteogenic competence and supportive niche signaling that preserves skeletal progenitor function and bone repair during aging, opening new avenues for restoring skeletal repair in aged individuals.
Multi-modal Transcriptomics reveals site-specific skeletal stem/progenitor cell (SSPC) Dynamics in Abaloparatide-treated fractures - Ashutosh Parajuli, PhD
The PTH1R agonist abaloparatide (ABL) accelerates fracture repair in osteoporosis-related bone fragility. Bone regeneration is mediated by skeletal stem/progenitor cells (SSPCs) recruited from the periosteum, marrow, and surrounding tissues, where they proliferate and differentiate to form the fracture callus. To define how ABL promotes fracture healing, we examined how it engages SSPC subpopulations across callus compartments and timepoints. Unstabilized mid-tibial fractures were generated in 12-week-old male C57BL/6J mice treated with ABL or vehicle (CTRL). Tissue from periosteum (Site 1), fracture gap (Site 2), and marrow (Site 3) was collected at Days 10, 15, and 28 post-fracture and profiled by bulk RNA-seq, Visium spatial transcriptomics (all timepoints), and single-cell RNA-seq (Day 15). Bulk RNA-seq showed that select stem cell markers (e.g., Prrx1, Lepr, Yap1, Cd200, Nes) are normally detected in early callus (Day 10); these markers are undetectable by Day 28 (CTRL) but retained in ABL treated callus. These findings were corroborated by spatial transcriptomics which identified a periosteal-SSPC-like signature at the fracture gap and marrow in ABL at sites where it was not detected in CTRL. Spatial transcriptomics also revealed that site-specific changes in stem cell signatures parallel changes in microdomains (transcriptionally-coherent spatial niches identified by spot clustering) within each of the fracture compartments. An injury-induced fibrogenic (IIFC) microdomain (enriched for Postn, Aspn, Sfrp1, Sfrp2, and Tnmd) is evident early in ABL treated callus (D10) and emerges much later in CTRL callus (D28). To map these changes onto known progenitor identities, scRNA-seq at Day 15 resolved four populations: SSPC-1 (Pdgfra⁺/Prrx1⁺), SSPC-2 (Gli1⁺), CAR cells (Lepr⁺/Cxcl12⁺), and pericytes (Acta2⁺/Rgs5⁺). Accelerated bone healing by ABL at Day 15 is reflected by depletion of SSPC-1 cells at the periosteum and Lepr⁺ CAR cells in the marrow. Concomitantly, ABL expanded both SSPC-1 and SSPC-2 cells in the marrow. Together, these findings indicate that ABL accelerates IIFC microdomain emergence and sustains SSPC signatures in late-stage repair through site-specific compartmental shifts. Thus, ABL/PTH1R activation elicits a compartment-specific cellular response during fracture repair and modulates SSPC dynamics to improve bone healing.
DNMT1 Integrates Aging and Mechanical Unloading Signals to Control BMSC Fate and Skeletal Adaptation - Yangguang Li, MS
Aging and mechanical unloading are major drivers of osteoporosis, yet whether they converge on a shared epigenetic mechanism in BMSCs remains unclear. We identified DNMT1 as a mechanosensitive epigenetic node coupling aging and unloading to BMSC fate and bone formation. DNMT1 protein and global DNA methylation were reduced in BMSCs from aged humans and mice, spaceflight-cultured human BMSCs, and hindlimb-unloaded (HLU) mice. Mesenchymal Dnmt1 deletion using Prx1 -Cre caused 30% trabecular bone loss, and 135% increased marrow adiposity, with reduced BMSC proliferation and osteogenic differentiation and enhanced adipogenesis, thereby phenocopying aging- and unloading-associated skeletal deterioration. Dnmt1 -deficient mice showed attenuated skeletal responses to aging and HLU and impaired anabolic responses to mechanical loading, indicating that DNMT1 is required for skeletal adaptation to mechanical and aging-related stress .
RRBS showed broad DNA hypomethylation after DNMT1 loss, while RNA-seq revealed selective transcriptional remodeling. Integrated methylome - transcriptome analysis identified Igfbp6 and Tmem88 as DNMT1-sensitive targets, whose promoter hypomethylation was associated with transcriptional derepression and suppression of IGF and WNT signaling. Target validation confirmed altered methylation and expression, reduced AKT phosphorylation and active β-catenin, and partial rescue of osteogenic defects by IGF1 supplementation, β-catenin activation, or Igfbp6/Tmem88 knockdown. Upstream, PIEZO1-dependent AKT and CaMKII signaling maintained DNMT1 protein abundance without altering Dnmt1 mRNA; pathway inhibition reduced DNMT1 protein, whereas MG132 partially prevented this effect, supporting proteasome-sensitive post-transcriptional regulation. Aging and unloading were accompanied by reduced PIEZO1 signaling, DNMT1 downregulation, target-gene derepression, and inhibition of WNT/IGF signaling.
Finally, betaine or oral methionine supplementation partially restored trabecular bone mass after HLU. Together, these findings define a PIEZO1 - DNMT1 - WNT/IGF axis that integrates mechanical and aging-related cues to regulate BMSC fate and bone formation, providing a mechanistic and therapeutic framework for unloading- and aging-induced osteoporosis.
Dot1L Histone Methyltransferase Activity Regulates Skeletal Stromal Progenitor Activation and Osteogenic Lineage Competence During Bone Homeostasis and in Response To Injury - Marta Stetsiv, BS, PhD, MD
Disruptor of Telomeric Silencing 1 Like (Dot1L) is the sole histone methyltransferase responsible for H3K79 methylation and is implicated in skeletal progenitor regulation during skeletal development. However, how Dot1L dosage regulates adult bone marrow (BM) skeletal stromal progenitor cells (SSPCs) during homeostasis and in response to injury remains incompletely understood. Our analysis of published and in-house BM stromal scRNA-seq datasets demonstrated Dot1L expression across adult BM SSPC populations, supporting a potential cell-intrinsic role. In adult mice, at steady-state, attenuation of Dot1L gene dosage using Prrx1-Cre resulted in 50% increase in lineage-negative (Lin - ) BM stromal cells, measured by flow cytometry (2.9% to 4.5%) and scRNA‑seq (48.7% to 75.2%). Stromal expansion in Dot1L fl/fl : Prrx1-Cre mice was associated with increased proliferation of Lin - cells, with elevated S-phase entry by flow cytometry (23.6% vs 17.7%) and increased cycling cells by scRNA-seq (23.9% vs 16.2%). Dot1L-deficient BM stromal cells further showed enhanced osteogenic and adipogenic differentiation ex vivo, evidenced by increased Alizarin Red and Oil Red O staining and elevated lineage-associated gene expression. To assess Dot1L function during bone repair, we used pharmacologic inhibition and genetic attenuation of Dot1L activity. Wild type mice were treated with the Dot1L specific inhibitor EPZ-5676, and Dot1L gene dosage was reduced in Dot1L fl/wt : Prrx1-Cre heterozygous mice. scRNA-seq of injured BM revealed stromal expansion in inhibitor-treated mice (3.9%) and Dot1L heterozygous mice (7.8%) compared with controls (0.5%). Pharmacologic inhibition enriched Fibro-MSC populations (27% to 45.7%), whereas genetic attenuation preferentially expanded CXCL12⁺ CAR populations, including Adipo-CAR (29.7% to 43.3%) and Osteo-CAR (24.3% to 35.6%). This divergence reflects context-dependent effects of pharmacologic versus genetic Dot1L attenuation. Importantly, stromal expansion in Dot1L heterozygous mice was accompanied by increased CXCL12 and Osterix immunostaining and increased mineral content seven days post-injury, validating scRNA-seq defined injury-responsive stromal programs. In summary, these data show that loss of Dot1L activity amplifies injury-induced SSPC activation and osteogenesis, identifying Dot1L as a regulator of SSPC activation and osteogenic competence during bone homeostasis and repair.read more · Original Link ↗
Natalie A. Sims, PhDSt. Vincent's Institute Of Medical Research, Melbourne, AU
Meghan E. McGee-Lawrence, PhDMedical College Of Georgia, Augusta University, Augusta, GA, US
Michael Duffy, PhDUniversity Of Pennsylvania, Cherry Hill, NJ, US
Marta Stetsiv, BS, PhD, MDUconn Health, New Britain, CT, US
☆
Fri 10/9 · 3:15 PM - 4:15 PM
Oral Presentations: Greg Mundy Session on Cancer and Bone
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 311
Timing of PD-1/PD-L1 Blockade Determines Skeletal Toxicity and Bone Metastatic Clearance - Rachelle W. Johnson, PhD
Immune checkpoint inhibitors (ICIs) block immunoregulatory proteins, including programmed cell death protein 1 (PD-1) and its ligand (PD-L1).Timing of PD-1/PD-L1 Blockade Determines Skeletal Toxicity and Bone Metastatic Clearance - Rachelle W. Johnson, PhD
Immune checkpoint inhibitors (ICIs) block immunoregulatory proteins, including programmed cell death protein 1 (PD-1) and its ligand (PD-L1). ICIs are used in cancer patients and improve survival for many tumor types but not in patients with bone metastases, and the reason is unknown. To investigate this, we inoculated female C57Bl/6 mice with GFP + E0771 breast cancer cells by intracardiac injection; 3 days later, we began treating with IgG or α-PD-1 for 2 wks to model patients who have bone-disseminated tumor cells when starting ICI therapy. In α-PD-1 treated mice, we observed a reduction in bone mineral density by DXA (by 8%, p=0.04) and ultimate force by 3-point bending (by 19%, p=0.007). Bone metastatic tumor burden was unchanged in α-PD-1 treated mice by flow cytometry, and CD4 + and CD8 + effector T cells were reduced in the bone marrow (by 60-84%, p=0.01-0.005). This suggests that starting ICI therapy after cancer cells arrive in bone does not reduce bone metastasis. Next, to model patients who do not have bone-disseminated tumor cells upon starting ICI therapy, we treated mice with IgG, α-PD-1, or α-PD-L1 for 4 wks and injected E0771 cells as above after 2 wks of treatment. There was no change in trabecular bone volume (BV/TV) with α-PD-1 or α-PD-L1 by µCT at endpoint and bone metastatic tumor burden was reduced by flow cytometry (α-PD-1 by 61%, α-PD-L1 by 52%, p=0.003-0.0005). This suggests giving ICIs before cancer cells disseminate to bone may reduce bone metastasis. Bone marrow CD8 + effector memory T cells also increased (α-PD-1 1.7-fold, α-PD-L1 3.4-fold, p=0.002-0.0009), and depletion of CD4 + or CD8 + T cells prevented α-PD-L1 from reducing bone metastases and dramatically increased tumor burden in bone (p=0.003-0.007), confirming T cells are essential for α-PD-L1 bone metastatic clearance. We next assessed how zoledronic acid (ZA) impacts bone metastasis with ICIs. Using the same model as above with a one-time injection of ZA or PBS, we found that ZA increased trabecular BV/TV with IgG or α-PD-1 treatment, but less so in α-PD-1 treated mice (IgG 7.3-fold, α-PD-1 4.1-fold, p<0.0001). Tumor incidence was reduced by α-PD-1 alone in the PBS treated arm and by ZA in combination with IgG or α-PD-1 (p=0.01-0.004). Bone marrow IFNγ + /CD8 + effector T cells were also reduced by ZA + α-PD-1 vs α-PD-1 alone (by 78%, p=0.008). Our data indicate early administration of ICIs reduces bone metastases and tumor incidence alone and in combination with ZA.
Roles of TUBβ2a and TUBβ3 in Metastatic Properties and Chemotherapy-Induced Bone Loss in Bone Metastatic Breast Cancer - Kayla Monae Gant, PhD Student
Introduction: Bone metastasis (BM) occurs in approximately 70% of patients with advanced breast cancer and is associated with limited therapeutic options and poor survival. Current treatment options include microtubule (MT)-targeting agents like paclitaxel (PTX), which is associated with bone loss. Tubulin β2a (TUBβ2a) and Tubulin β3 (TUBβ3) have been associated with chemoresistance and poor clinical outcomes; however, the specific roles of these isotypes in BM remain poorly defined. We investigated the functions of TUBβ2a and TUBβ3 in BMBC and their potential as therapeutic targets.
Methods : Public RNA-seq datasets were analyzed for tubulin isotype expression and patient survival. IHC assays were performed on matched primary and BM tumor biopsies (n=16) from BC patients. CRISPR/Cas9 gene knockdown (KD) was generated in bone-derived BC MDA-MB-231 cells to target TUBβ2 and TUBβ3. Endosomal distribution was assessed using IF. Wild-type (WT) and TUBβ2a knockout (KO) mice were treated with vehicle or PTX, and bone parameters were evaluated by micro-CT.
Results/Conclusions: IHC revealed elevated TUBβ2a and TUBβ3 expression in BM lesions compared with matched primary tumors, correlating higher expression with reduced patient survival. KD of TUBβ2a or TUBβ3 impaired MT regrowth and reduced M-phase progression. Confocal imaging revealed an enlarged perinuclear cloud of Rab5+/Cav1+ vesicles. Loss of TUBβ2a or TUBβ3 resulted in marked reductions in migration, invasion, and increased adhesion with altered expression of integrins and Talin. RNA-Seq identified enrichment of IL-17-associated cytokine signaling pathway, suggesting coordination between cytoskeletal remodeling and inflammatory and secretory programs. WT mice exhibited greater sensitivity to PTX-induced bone loss, characterized by a reduced BV/TV and trabecular loss. In contrast, KO mice demonstrated a lower reduction in BV/TV after PTX, suggesting partial resistance to chemotherapy-induced bone loss. These findings support a potential role for TUBβ2a in regulating MT-mediated osteoblast function and bone remodeling during chemotherapy. Collectively, these findings identify TUBβ2a and TUBβ3 as previously unrecognized regulators of metastatic properties in breast cancer cells.
Impact: Our study revealed β - tubulin isotype - specific functions as drivers of metastatic progression and supports TUBβ2a and TUBβ3 as potential predictive biomarkers and therapeutic targets for BMBC.
Osteocyte-Driven Vascular Remodeling Primes Bone for Breast Cancer Colonization - Mattie Nester
Established breast cancer (BCa) bone metastases are largely incurable, highlighting the need for earlier intervention. Metastatic dissemination is initiated by primary tumor-driven formation of a pre-metastatic niche (PMN), which facilitates BCa cell trafficking through the organ’s vasculature and subsequent micrometastasis formation. However, how distant tumors condition bone to enable this process remains poorly understood. To investigate PMN formation and early BCa colonization, we developed a model in which orthotopic tumors are surgically resected prior to detectable bone metastasis, followed by intracardial delivery of labeled BCa cells to model hematogenous dissemination to bone. Mice bearing E0771 or MDA-231 primary BCa tumors exhibited increased BCa bone colonization (2.3-fold) within 72h compared to controls, demonstrating functional PMN establishment. To study early bone PMN changes, we performed scRNAseq of osteolineage cells isolated from endosteal bone, a primary site of BCa cell arrival. At this stage, no changes in osteoclasts or bone mass, or major shifts in osteoblastic populations were observed between naïve and PMN mice. However, transcriptional and pathway analysis revealed PMN mice had enrichment in cellular senescence gene sets across osteocytes (Ots), osteo-CAR, and adipo-CAR cells, but not in osteoblasts or pericytes. Among all osteolineage cells, PMN Ots exhibited the most pronounced upregulation for gene sets related to vascular remodeling. Consistent with these findings, bones from PMN mice showed increased p16 + senescent (11.6 vs 3.2%) and Vegfa + Ots (32 vs 10%), and marked vascular remodeling near the endosteum, including a 50% increased vessel number, area, perimeter, and permeability. In vitro , BCa-derived factors upregulated Ot Vegfa mRNA expression (3-fold), and conditioned media from BCa-primed Ots increased angiogenesis (60%) in a VEGFA-dependent manner. BCa-induced Vegfa upregulation in Ots was blunted by senolytics. To directly test the role of Ot-derived VEGFA in PMN formation, we generated mice with conditional deletion of Vegfa by crossing Vegfa fl/fl with Dmp1-8kb-Cre mice (Vegfa cKO ). Vegfa cKO mice bearing E0771 primary BCa tumors exhibited an 80% reduction in BCa bone colonization compared to controls. Collectively, these findings identify Ots as remote sensors of primary tumors that undergo senescence-associated reprogramming to drive VEGFA-dependent vascular remodeling and promote metastatic colonization of bone.
FGF23-KLOTHO Signaling in Myeloma Cells Drives Disease Progression - Aric Anloague, Ph.D., M.S.
Fibroblast growth factor (FGF) 23 is a bone-derived endocrine hormone that regulates phosphate and vitamin D homeostasis through its co-receptor αKlotho (KL) expressed in the kidney. Circulating FGF23 levels are elevated in multiple myeloma (MM) patients, however its role remains incompletely understood. We detected FGF receptor 1 and KL mRNA expression across human and murine MM cell lines, consistent with prior reports in cells from MM patients. To investigate the role of FGF23 signaling in MM, we generated 5TGM1 MM cells with knockdown of the FGF23 co-receptor KL ( KL KD ). In vitro , recombinant (r)FGF23 increased proliferation and upregulated the expression of Cyclin D1 , Heparanase , and Egr1 in control but not in KL KD MM cells. Next, we injected mice intravenously with control or KL KD 5TGM1-GFP MM cells. Mice receiving KL KD MM cells had a 60% reduction in the serum MM tumor biomarker IgG2b and in bone marrow tumor burden (%GFP) compared to mice injected with control cells. Moreover, mice injected with KL KD MM cells showed higher bone mass compared to mice injected with control MM cells. To investigate the mechanisms by which FGF23 stimulates MM cell proliferation and drives tumor growth, we performed bulk RNA sequencing on 5TGM1 MM cells treated with rFGF23. FGF23 upregulated 665 genes and downregulated 922 genes. Gene set enrichment analysis showed activation of gene sets related to cell cycle progression, proliferation, and protein homeostasis, and suppression of apoptotic signaling. To assess the clinical relevance of FGF23 transcriptional changes, we analyzed clinical and gene expression data from newly diagnosed MM patients from the MM Research Foundation CoMMpass registry (708 patients). Expression of 14 top FGF23-regulated genes identified in our dataset ( CHRNG , BSND , NHLRC4 , SMPD3 , KANK1 , MYO1F , OSCAR , TCF20 , ANKDD1A , MOV10L1 , SIDT1 , RAB6B , SLC12A1 , CACNA1I ) was associated with poor overall survival (HR_OS=2.2-0.6; p=10 -7 -10 -2 ). Additionally, KANK1 , MYOF1 , OSCAR , and SIDT1 were upregulated at relapse and correlated with worse progression-free survival in patients treated with bortezomib-based but no other regimens. Collectively, these findings demonstrate that MM cells directly respond to FGF23 via KL, promoting a pro-proliferative and pro-survival transcriptional program that enhances tumor growth, therapeutic resistance, and bone disease. These results highlight tumor niche FGF23 signaling as a potential therapeutic target in MM.
Osteosarcoma hijacks a bone stress-signaling axis to build a suppressive tumor microenvironment, reversed by host-myeloid STING activation - Elizabeth Young
Background: Osteosarcoma is a developmentally timed pediatric bone cancer, with incidence tracking the adolescent growth spurt. Despite arising in a developmentally active niche, metastatic survival remains ~20% and immunotherapy has not improved outcomes. We propose that osteosarcoma hijacks a bone stress-signaling axis between osteoblast-lineage cells and marrow myeloid cells to build a suppressive tumor microenvironment (TME), and that this axis is therapeutically targetable through host myeloid cells.
Methods: We measured baseline cytokine secretion from a panel of patient-derived xenograft (PDX) osteosarcoma cell lines and assessed macrophage polarization using bone marrow-derived macrophage (BMDM) co-cultures. STING agonism was tested in vivo using diABZI in orthotopic K7M2.1 tumors with intact or CRISPR-deleted tumor STING. Macrophage versus tumor STING dependence was dissected using a 2×2 genetic co-culture design. Single-cell RNA-seq was performed at 2 hours post-treatment to characterize the early response. T cell requirements were assessed by CD8 depletion during primary treatment and CD4/CD8 depletion at rechallenge. A STING activation signature derived from STING-treated PDX lines was applied to patient bulk and single-cell RNA-seq cohorts.
Results: Osteosarcoma PDX lines constitutively secrete IL-6, CCL2, CCL5, M-CSF, and CXCL10, driving an MHCII⁻CD206⁺ suppressive macrophage phenotype reversible by STING activation. In vivo, diABZI drove tumor regression independent of tumor STING, with response requiring macrophage STING. Single-cell analyses revealed myeloid cells initiate the IFN response within 2 hours, with rapid tumor necrosis by 48 hours. CD8 T cells were required for primary clearance; either CD4 or CD8 sufficed for durable memory. In patients, a STING activation signature was prognostic (HR 0.13) and enriched in host immune cells, not tumor cells.
Conclusions: Osteosarcoma builds its suppressive TME by co-opting an osteoblast-myeloid stress-signaling axis. STING agonism reverses this through host myeloid IFN signaling, with downstream T cell-mediated clearance and durable memory. The host-myeloid STING signature is prognostic in patients, supporting clinical translation through myeloid-directed combination strategies.read more · Original Link ↗
Jesus Delgado-Calle, PhD1
Theresa A. Guise, MD2
Rachelle W. Johnson, PhD3
Kayla Monae Gant, PhD Student4
Mattie Nester1
Aric Anloague, Ph.D., M.S.5,6,7
Elizabeth Young8, (1)University Of Arkansas For Medical Sciences, Little Rock, AR, US(2)Md Anderson Cancer Center, Houston, TX, US(3)Vanderbilt University Medical Center, Nashville, TN, US(4)Rush University, Chicago, IL, US(5)Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, USA(6)Wintrop P. Rockefellar Cancer Institute, University of Arkansas for Medical Sciences, USA(7)University of Arkansas for Medical Sciences, USA(8)UCSF, USA
☆
Fri 10/9 · 3:15 PM - 4:15 PM
Oral Presentations: Heterotopic Ossification and Pathologic Bone Formation
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 312
Periosteal Ossification: Redefining the Cellular Sources of Heterotopic Bone in FOP - Loreilys Mejías Rivera Mutations in the BMP type I receptor ACVR1 /ALK2 ( ACVR1 R206H/+ ) cause the rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP), in which bone...Periosteal Ossification: Redefining the Cellular Sources of Heterotopic Bone in FOP - Loreilys Mejías Rivera
Mutations in the BMP type I receptor ACVR1 /ALK2 ( ACVR1 R206H/+ ) cause the rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP), in which bone forms in soft connective tissues such as skeletal muscle. Pdgfrα+ fibro/adipogenic progenitors (FAPs) are recognized as key contributors to heterotopic ossification (HO) after muscle injury in FOP. However, PDGFRα expression is not restricted to FAPs, but also occurs in stromal cells of the periosteum (PSCs), a thin, dense connective tissue (fibrous and cambium layers) that envelops bones, but has not previously been explored as a potential source of HO progenitor cells in the context of FOP. To further investigate the role of Acvr1 R206H/+ Pdgfrα-lineage cells in ectopic bone formation, we used FOP mouse models with either global expression of the Acvr1 R206H mutation or expression restricted to Pdgfrα+ cells. We evaluated muscle injury (cardiotoxin)-induced HO progression using micro-computed tomography, histology stains, and immunofluorescence. In global- Acvr1 R206H/+ mice, we discovered that expression of the Acvr1 R206H mutation induced periosteal thickening by 5-7 days post-injury (dpi). Periosteal thickening was observed in bones both proximal and distal to sites of skeletal muscle injury, concurrent with HO formation. The expanded Acvr1 R206H/+ periosteum progressed to endochondral ossification between 7 and 14dpi, forming heterotopic bone continuous with the endogenous skeleton. This periosteum-associated HO infiltrated the surrounding muscle. To further define the cellular mechanism driving periosteal-HO in FOP and determine whether mutant Pdgfrα-lineage periosteal cells are sufficient to promote the observed periosteal response, we examined Pdgfrα- Acvr1 R206H/+ mice. In response to muscle injury, these mice developed robust HO in the vicinity of injured muscle by 5 dpi, along with significantly increased periosteal thickness relative to controls. This periosteal expansion was driven by a significant increase in periosteal cambium layer thickness, a hallmark of fracture repair. Consistent with this, lineage tracing confirms the expansion of Pdgfrα+ cells in periosteal-associated HO. Periosteal expansion in Pdgfrα- Acvr1 R206H/+ mice occurred both locally and systemically. Together, these findings provide new cellular perspectives on Pdgfrα+ HO progenitors in FOP and establish a foundation for understanding interactions between skeletal muscle and periosteal cells in the context of BMP/Acvr1 signaling.
Age-dependent Progression of Heterotopic Ossification and Transcriptional Responses in Fibrodysplasia Ossificans Progressiva - Nadine Z. Großmann
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disease characterized by heterotopic ossification (HO) driven by activating ACVR1 mutations. Although disease onset and severity vary with age, the impact of age on HO formation and underlying mechanisms remain unclear. This study aimed to examine how age influences the HO volume and kinetics, and gene expression in an inducible FOP mouse model.
Juvenile (1.5 months), young adult (4 months), and adult (10 months) WT- Acvr1 +/+ FOP- Acvr1 R206H/+ mice received Cardiotoxin (CTX) injections into the gastrocnemius muscle to induce injury. HO formation was assessed by ex vivo and longitudinal in vivo microCT. Histological stains (H&E, Alcian Blue, Orange G) were utilized to assess tissue morphology, chondrogenesis, and mineralization. RNA-Sequencing (RNA-Seq) of injured gastroc muscle was conducted at 3, 7, and 21 days post-injury (dpi) to evaluate age-dependent gene expression patterns.
Juvenile FOP- Acvr1 R206H/+ developed significantly greater mineralized HO volume at 21 dpi compared to older groups, with earlier onset (10 vs. 14 dpi in young adults). HO was additionally detected in the contralateral, uninjured hindlimbs exclusively in juveniles. At 7 dpi, juveniles exhibited hypertrophic chondrocytes , whereas older mice showed predominantly fibroproliferative tissue, which is characteristic of a pre-endochondral HO stage, indicating delayed or impaired chondrogenesis. RNA-Seq revealed dynamic, timepoint-specific gene expression patterns in juveniles, with significant enrichment of pathways related to extracellular matrix (ECM) organization, TGFβ signaling, and endochondral ossification. Compared to young adults, juveniles showed enhanced activation of regeneration, BMP signaling and robust upregulation of ECM and cartilage-associated genes, responses that were all attenuated in young adults.
To conclude, age is a critical determinant of HO formation in FOP. Juvenile mice display earlier onset and greater HO volumes, accompanied by a pronounced pro-chondrogenic and pro-regenerative transcriptional response. These findings highlight age-dependent differences in disease initiation and progression and identify potential molecular pathways for age-specific treatment options.
Inhibition of MNK1/2-eIF4E Signaling Alleviates Pain and Reduces Heterotopic Ossification - Monisha Mittal, MS
Traumatic musculoskeletal injuries frequently result in chronic pain and aberrant healing, including heterotopic ossification (HO), the formation of ectopic bone in soft tissues. Sensory neural signaling has emerged as a key regulator of HO. Using single-cell RNA sequencing (scRNA-seq) of HO tissue and innervating dorsal root ganglia (DRG), we identified increased expression of mitogen-activated protein kinase-interacting kinases 1/2 (MNK1/2) and their downstream target, eukaryotic initiation factor 4E (eIF4E) in DRGs post-injury. Here, we identify and functionally test the role of the MNK1/2-eIF4E signaling axis in linking pain signaling to pathological bone formation using genetic mouse models and human tissues.
HO was induced in 10-week-old C57BL/6J mice using combined burn and Achilles tenotomy (BT), producing HO over 9 weeks. scRNA-seq was performed on the DRG innervating the HO site, identified via retrograde tracing, at days 0, 7, and 21 post-injury. We also conducted differential pathway and cell-cell communication analyses on scRNA-seq data from the HO site and DRG at corresponding time points. To assess pathway inhibition, we used eIF4E S209A mutant mice expressing a non-phosphorylatable eIF4E variant. HO formation, signaling, and mechanical sensitivity were evaluated using micro-CT, immunostaining, proteomics, and behavioral analyses.
scRNA-seq with retrograde tracing identified increased MNK1/2 expression in HO tissue and innervating DRG post-injury, validated by immunostaining and RNAscope. eIF4E S209A mice showed reduced pain sensitivity, accelerated recovery, and decreased HO volume (Fig.1A-D). This HO reduction was associated with diminished ECM/crosslinking and Hedgehog signaling. Trajectory analysis indicates that loss of eIF4E S209 phosphorylation redirects MPCs toward adipogenesis, limiting osteogenesis, with proteomics and BODIPY confirming increased lipid metabolism in eIF4E S209A mice (Fig.1E-J). To expand the translational relevance of these findings, we next cultured human DRG neurons. In human DRG neurons, NGF increased neurite outgrowth and eIF4E Ser209 phosphorylation, supporting MNK1/2-eIF4E as a key neuroregulatory pathway.
MNK1/2-eIF4E inhibition attenuates trauma-induced HO and associated pain, highlighting MNK1/2 - eIF4E as a promising dual-action therapeutic target for trauma-related morbidity. Activation of this pathway in human neurons underscores its translational relevance as a potential therapeutic target.
An O‑GlcNAc Rheostat on YAP Tunes Mesenchymal Progenitor Cell Fate in Heterotopic Ossification - Heeseog Kang, Ph.D.
Heterotopic ossification (HO) is a frequent complication of trauma, burns, or joint replacement in which mesenchymal progenitor cells (MPCs) adopt an aberrant osteogenic fate. However, the metabolic mechanisms linking injury signals to aberrant MPC fate remain unclear. To address this gap, we used a clinically relevant burn/tenotomy mouse model to examine how injury reprograms MPCs. Using spatial transcriptomics, scRNA-Seq, metabolomics, and functional assays, we found that injury increases glutamine flux through the hexosamine biosynthetic pathway (HBP). This nutrient-sensitive pathway produces UDP-GlcNAc, the substrate required for protein O-GlcNAcylation. Functional studies showed that O-GlcNAc cycling promotes osteogenic differentiation. Pharmacological and genetic inhibitions of O-GlcNAc transferase (OGT) or the HBP reduced osteogenesis and decreased HO formation in vivo , whereas inhibition of O-GlcNAcase (OGA) enhanced mineralization. scRNA-Seq of HO site tissue demonstrated coordinated upregulation of HBP enzymes and YAP‑positive MPCs, indicating that metabolic activation and YAP signaling are tightly coupled during HO progression. Mass spectrometry of HO site tissue identified a previously unrecognized O-GlcNAc site on YAP at Ser378 adjacent to the C-terminal phosphodegron. CRISPR knock-in MPC clones encoding S378A (O-GlcNAc-null) or S378C (persistent O-GlcNAc) alleles revealed Ser378 as a bidirectional rheostat that redistributes YAP/TEAD output between proteasomal degradation and cytoplasmic sequestration. YAP(S378A) increased phosphodegron priming phosphorylation and ubiquitination, reduced canonical YAP/TEAD output, yet enhanced osteogenic differentiation. In contrast, YAP(S378C) promoted cytoplasmic sequestration, increased canonical YAP/TEAD output, and increased cell spreading and mechanically reinforced stromal state with suppressed osteogenesis. Notably, cell spreading and traction were inversely correlated with osteogenic commitment, indicating that YAP Ser378 states uncouple MPC osteogenic fate from canonical YAP/TEAD output. Collectively, these findings define an injury-induced HBP/O-GlcNAc axis that promotes osteogenic programming and identify YAP Ser378 as an internal rheostat that determines how this metabolic input is translated into osteogenic fate and can counteract its pro-osteogenic effects. Targeting the YAP site-specific regulatory mechanism may provide therapeutic strategies to prevent HO and enhance bone formation.
From Tissue Repair to Heterotopic Ossification: The Degree of Somatosensory Innervation Dictates Outcomes After Injury - Sam Bae, BS
Tendon injuries remain a major clinical challenge, with trauma frequently leading to prolonged recovery and incomplete functional restoration. Somatosensory innervation has emerged as an active regulator of early tendon repair, with nerve growth factor (NGF)-tropomyosin receptor kinase A (TrkA) signaling modulating tendon cell proliferation, neurovascularization, and mesenchymal differentiation. Yet, approaches to utilize the potential of this pathway in a therapeutic context remain underdeveloped, and the dose-dependent consequences of TrkA agonism on repair versus pathological ossification are undefined. We investigated whether local pharmacological TrkA activation via gambogic amide (GA), a selective small-molecule agonist, enhances tendon regeneration or induces heterotopic ossification (HO) in a murine injury model.
Twelve-week-old male C57BL/6J mice (n=5 per group) underwent Achilles tendon punch biopsy with daily local injections of vehicle, low-dose GA (1 mg/kg), or high-dose GA (2 mg/kg) from 24 hours before injury through 2 weeks post-injury. Tissue-level outcomes were assessed by Safranin O staining and immunofluorescence of somatosensory nerve fibers (TUBB3), osteochondrogenic marker SOX9, and tenogenic marker tenomodulin (TNMD). At the single-cell level, scRNA-seq profiled 9,458 cells across uninjured tendon, day-14 repair, and HO conditions, with mesenchymal lineage trajectories and differential pathway analysis performed using CytoTRACE2 and Seurat.
Low-dose GA promoted tenogenic repair, with a 33% increase in TUBB3-positive innervation and 3-fold upregulation of TNMD (Fig. 1a). In contrast, high-dose GA drove a 10-fold increase in Safranin O-positive cartilaginous area, a 55% increase in innervation, and 7-fold upregulation of SOX9 with no significant TNMD change, consistent with HO (Fig. 1a). scRNA-seq confirmed dose-dependent divergence in progenitor fate, with osteogenic mesenchymal cells expanding from 46 in uninjured tendon to 595 in HO (Fig. 1b), alongside enrichment of osteogenic and chondrogenic pathways, while the day-14 repair conditions showed predominant tenogenic and proliferative pathway activation (Fig. 1c).
These findings define a therapeutic dosing window for TrkA agonism and establish that calibrated neurotrophic signaling is essential to promote tendon regeneration while preventing pathological ossification, positioning NGF-TrkA as a tractable target for musculoskeletal repair.read more · Original Link ↗
Mona Al Mukaddam, MD, MS1
Daniel S. Perrien, PhD2
Loreilys Mejías Rivera1,3,4
Nadine Z. Großmann5,6,7,8
Monisha Mittal, MS9
Heeseog Kang, Ph.D.10
Sam Bae11, (1)University Of Pennsylvania, Philadelphia, PA, US(2)Emory University, Atlanta, GA, US(3)Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, USA(4)The Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, USA(5)Institute of Chemistry and Biochemistry, Freie Universität Berlin, Germany(6)Berlin School for Regenerative Therapies, Charité Universitätsmedizin, Berlin, Germany(7)The Center for Research in FOP and Related Disorders, University of Pennsylvania, USA(8)Department of Orthopaedic Surgery, University of Pennsylvania, USA(9)UT Southwestern Medical Center, Dallas, TX, US(10)University Of Texas Southwestern, Dallas, TX, US(11)Johns Hopkins University School of Medicine, Baltimore, MD, US
Built for you by(617)-PATRICK, Champion AI speaker
Microbiome, Inflammation and Bone Loss: What Have we Learnt From Animal and Human Studies - Roberto Pacifici, MD Metabolic Pathways in Inflammation-Induced Ectopic Bone Formation - Chase Pagani, PhD KMT9 safeguards periodontal homeostasis by suppressing retrotransposon-induced cellular senescence - Shuang...Microbiome, Inflammation and Bone Loss: What Have we Learnt From Animal and Human Studies - Roberto Pacifici, MD
Metabolic Pathways in Inflammation-Induced Ectopic Bone Formation - Chase Pagani, PhD
KMT9 safeguards periodontal homeostasis by suppressing retrotransposon-induced cellular senescence - Shuang Jiang, DDS
Purpose : Primarily residing in heterochromatin, retrotransposons (RTs) exhibit dynamic expression patterns that orchestrate development but can drive degenerative diseases upon non-selective reactivation. Tissue regeneration, characterized by rapid cell proliferation and heterochromatin remodeling, creates a vulnerable window for RT dysregulation that requires tight epigenetic coordination. Here, we observed that dynamic expression of histone methyltransferase KMT9 closely mirrors RT activities during periodontal tissue regeneration. This study aimed to explore its role in safeguarding periodontal homeostasis.
Methods : We first performed transcriptomic profiling and immunohistochemical analysis on human periodontal tissues to define the relationship between RT and periodontitis, which also led to the identification of KMT9 as the potential regulator. Subsequently, we used genetic mouse models to characterize the effects of KMT9 deficiency on mucosal inflammation and alveolar bone resorption in a ligature-induced periodontitis model. We then applied RNA-seq, ChIP-seq, immunoblotting, and qPCR to dissect the molecular mechanisms and evaluate cGAS-STING pathway activation. Finally, we utilized extracellular vesicle (EV) transfer assays to validate the cell-to-cell propagation. We further extended this mechanism to a DSS-induced colitis model to test its generalizability.
Results : Transcriptomic analysis identified global RT reactivation, especially LINE subclass, and KMT9 downregulation as concurrent pathological signatures of human periodontitis. KMT9 deficiency under physiological conditions triggered premature tissue senescence and stem cell exhaustion, characterized by the upregulation of p16, p21 and SA-β-gal. Upon induction of experimental periodontitis, these baseline defects in tissue homeostasis manifested as significantly exacerbated mucosal inflammation and alveolar bone resorption. Mechanistically, KMT9 directly silences LINE-1 elements; its loss leads to the cytoplasmic accumulation of RT-derived DNA, which engages the cGAS-STING innate immune pathway to drive senescence. We also found the phenotype transmissible to neighboring cells via EVs. Notably, this pathological phenotype was recapitulated in the colitis model.
Conclusion : Our findings establish KMT9 as a conserved epigenetic regulator that promotes tissue repair and regeneration by silencing LINE-1 to suppress cGAS-STING-mediated cellular senescence.
Protective Neutrophil Subpopulation Reduces Inflammatory Arthritis-Related Bone Loss in Mice - Ryan MacLeod, MD, PhD
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural changes in bone structure. Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that is most known to affect synovial joints, but it is also associated with significant comorbidities. Approximately one-third of post-menopausal RA patients have osteoporosis with a 2-fold increase in frequency of osteoporosis when compared to the general population. Disease duration and seropositivity for anti-cyclic citrullinated peptide (anti-CCP) antibody and rheumatoid factor are associated with reduced bone mass in patients with RA, independent of glucocorticoid exposure, arthritis severity, estrogen status or other traditional risk factors of osteoporosis. Although multiple immune cells contribute to RA pathogenesis, neutrophils drive immune dysregulation and tissue destruction through the release of proteases, cytokines, and reactive oxygen species. Using single-cell RNA sequencing to analyze immune cells isolated from inflamed joints in mice, our lab has identified a novel subpopulation of neutrophils defined by Cd177 and Cd56 expression - herein referred to as Neu Res . Adoptive transfer of Neu Res significantly reduced inflammation and mitigate d articular bone erosion in the collagen-induced arthritis (CIA) model. Micro-computed tomography (micro-CT) analysis of L4 vertebrae and femurs isolated from these mice indicates that inflammatory arthritis-induced bone loss is ameliorated in Neu Res -treated mice compared to vehicle control. We developed a novel tamoxifen-inducible CD177-Cre mouse that when crossed with Rosa DTA mice results in a model of inducible ablation of CD177+ cells (Neu Res ), as shown in Figure 1a-b . CIA-induced Neu Res ablation mice exhibit a markedly worsened phenotype with elevated markers of inflammation and tissue damage in the joint microenvironment when compared to controls. Similarly, micro-CT analysis shows significant worsening of bone mass in the L4 vertebrae in Neu Res -ablation mice ( Figure 1c ). Taken together, these results underscore the protective role of this novel neutrophil subpopulation not only on reduction of local joint damage in inflammatory arthritis, but also systemic inflammatory bone loss associated with these conditions. Whether Neu Res have important roles in resolving inflammation and promoting tissue regeneration in other inflammatory conditions remains to be determined.read more · Original Link ↗
Hiroshi TakayanagiDepartment of Microbiology and Immunology, Institute for Immunological Sciences, University of Rochester, USA; Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Japan
Mary Beth HumphreyUniversity Of Oklahoma Health Sciences Center, Oklahoma City, OK, US
Roberto Pacifici, MDDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, USA
Chase Pagani, PhDUniversity of Texas Southwestern Medical Center, Dallas, TX, US
Shuang Jiang, DDSSichuan University, Chengdu, CN
Ryan MacLeod, MD, PhDYale University, Hamden, CT, US
☆
Fri 10/9 · 4:30 PM - 5:30 PM
ASBMR / ECTS Clinical Debate: This house believes that a T-score threshold of -2.5 should remain the standard criterion for managing osteoporosis
● Symposium
Symposium
📍 General Session - Ballroom A & B
Introductions and Voting ASBMR: For the Motion - Michael R McClung, MD ECTS: Against the Motion - Elizabeth Martha Winter ASBMR: For the Motion - Ghada El-Hajj Fuleihan, MD, MPH, FRCP ECTS: Against the Motion - Richard Eastell, MD Question...Introductions and Voting
ASBMR: For the Motion - Michael R McClung, MD
ECTS: Against the Motion - Elizabeth Martha Winter
ASBMR: For the Motion - Ghada El-Hajj Fuleihan, MD, MPH, FRCP
ECTS: Against the Motion - Richard Eastell, MD
Question and Answer
Restatements
Summary and Votingread more · Original Link ↗
Emma L. Duncan, FRACP, PhD, MBBS, MRCPKing's College, London, London, GB
Features approximately 207 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Baseline Characteristics in Part 1 of the ongoing ANDECAL Study, a two-part Phase 2/3 Study of andecaliximab (anti-matrix metalloproteinase-9 mAb) in participants with...Features approximately 207 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Baseline Characteristics in Part 1 of the ongoing ANDECAL Study, a two-part Phase 2/3 Study of andecaliximab (anti-matrix metalloproteinase-9 mAb) in participants with Fibrodysplasia Ossificans Progressiva (FOP)"; "The Association Between Glycemic Status and Bone Health in US Adults Aged 50 Years and Older-Results from the National Health and Nutrition Examination Survey (NHANES)."; "Bone Microarchitecture by Mode of PTH Replacement in Chronic Hypoparathyroidism: HR-pQCT Findings from the SHINE Cohort"; "Hypophosphatasia: Genotype/Phenotype Characterization of 272 Parents of 184 Affected Children"; "Chronic Hypoparathyroidism in the US: Prevalence and Incidence From 2018 to 2024, With Baseline Clinical Characteristics" and 202 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
ASBMR News
Esteemed Awards Presentations
Louis V. Avioli Lecture - Calcium and Phosphate Physiology: Translating Findings to the Clinic - Michael T Collins, MD · Original Link ↗
Emma L. Duncan, FRACP, PhD, MBBS, MRCPKing's College, London, London, GB
Joseph P. Stains, PhDUniversity Of Maryland School Of Medicine, Baltimore, MD, US
Michael T Collins, MDNational Institutes of Health, USA
Introductory Remarks
JBMR: The Second Decade (Part 1) - Marc Drezner, MD
JBMR: The Second Decade (Part 2) - John A. Eisman, FRACP, PhD, MBBS · Original Link ↗
Eileen M. ShorePenn Institute for Regenerative Medicine, Musculoskeletal Program, Perelman School of Medicine, University of Pennsylvania, USA
Marc Drezner, MDUW School of Medicine, USA
John A. Eisman, FRACP, PhD, MBBSGarvan Institute Of Medical Research, USA
☆
Sat 10/10 · 9:45 AM - 10:15 AM
Coffee Break in Discovery Hall
● General
📍 Discovery Hall - Exhibit Hall C & D
Coffee and light refreshments in the Discovery Hall, with time to network between sessions. · Original Link ↗
☆
Sat 10/10 · 9:45 AM - 10:15 AM
Rapid Fire Presentations - Saturday
● Oral Abstract Presentations
Oral Abstracts
📍 Product Theater, Discovery Hall - Exhibit Hall C & D
NPR2 Gain-Of-Function of Variants Drive Increased Skeletal Growth But Causes Tibial Curvature in Mice - Kalyan Nannuru
Skeletal growth occurs via a highly organized process of chondrocyte proliferation and hypertrophy in growth plate cartilage.NPR2 Gain-Of-Function of Variants Drive Increased Skeletal Growth But Causes Tibial Curvature in Mice - Kalyan Nannuru
Skeletal growth occurs via a highly organized process of chondrocyte proliferation and hypertrophy in growth plate cartilage. Natriuretic peptide receptor (NPR) signaling through NPR2 plays a crucial role in endochondral bone growth by promoting proliferation of chondrocytes and their hypertrophic differentiation. NPR2 is activated by its preferred ligand, C-type natriuretic peptide (CNP), which is produced by chondrocytes in growth plates and drives downstream signaling events, including production of cyclic guanosine monophosphate (cGMP). NPR2 signaling exerts its growth-promoting effects by inhibiting FGFR3 signaling, a negative regulator of endochondral bone growth. Previous studies identified gain-of-function mutations in the NPR2 gene associated with increased skeletal growth and height and valgus deformities of hip knee and ankle joints resulting in epiphyseal chondrodysplasia, Miura type.
We analyzed large-scale human exome sequence data to identify novel NPR2 variants that have a large effect size on height. We discovered novel ultra-rare NPR2 variants associated with increased height in the general population. These putative gain-of-function (GoF) variants localize in all three domains of NPR2. These variants can be classified into two types based on the mechanism: those that are hyper-responsive to CNP, and those that have higher basal (ligand-independent) activity but are resistant to further activation by CNP. To assess the magnitude of phenotype with variants with different modes of action (MOA) in a homogeneous genetic background, ligand hypersensitive NPR2 variants R655C, R562Q and constitutively active, ligand resistant NPR2 variants V883M and Y808C were modeled in mice. Skeletal phenotyping of these mutant mice revealed that, irrespective of their mechanism of action in activating NPR2 signaling, these variants promote skeletal growth . However, this accelerated bone growth in NPR2 gain of function variants comes at a cost, as it results in adverse effects such as tibial deformity. These results verify the crucial role of NPR signaling in promoting endochondral bone growth but also highlight the importance of identifying a safe yet efficacious level of NPR2 activation for developing therapeutic strategies to promote skeletal growth. These results indicate that maximal NPR2 signaling is not desirable; instead, a balanced activation of NPR2 is key for achieving therapeutic efficacy while minimizing adverse effects.
Dynamic Regulation of Reactive Oxygen Species in the Osteogenic Microenvironment Promotes Bone Regeneration in Infectious Osteomyelitis - Longxiang Shen
The treatment of infectious osteomyelitis faces a temporal paradox: the initial infection phase requires a burst of high-concentration reactive oxygen species (ROS) to disrupt dense biofilms and eradicate bacteria; however, during the subsequent tissue repair phase, excessive ROS accumulation triggers severe oxidative stress, causing osteoprogenitor apoptosis, impaired bone formation, and ultimately non-union. To address this shifting demand, we propose an osteoimmunomodulatory strategy utilizing an ultrasound-controlled nanoplatform to dynamically reprogram ROS levels, seamlessly transitioning from infection eradication to tissue regeneration. The core units are indocyanine green/glutathione-derived carbon dots (IG-CDs). These IG-CDs possess an integrated bidirectional regulatory capability: generating cytotoxic ROS under low-intensity ultrasound (US), while inherently scavenging excessive ROS in their resting state. To achieve spatiotemporal control, we utilized the sulfhydryl groups on the IG-CDs' surface to crosslink with thiolated sodium alginate, constructing a ROS-responsive hydrogel via dynamic disulfide bonds. This established a physician-controlled cascade release mechanism. In vitro, US triggered initial ROS generation from surface IG-CDs, which cleaved local disulfide networks, accelerating the release of deep IG-CDs and creating an amplified ROS burst that eradicated MRSA biofilms. Following bacterial clearance, our focus shifted to osteogenic niche normalization. Once US ceased, released IG-CDs exerted their intrinsic antioxidative effect, restoring redox balance. Cellular assays revealed this dynamic ROS clearance promoted macrophage polarization toward the M2 phenotype, reducing inflammatory cytokines and rescuing osteoblasts from ROS-induced apoptosis. In a rat MRSA-infected tibial defect model, in situ hydrogel application followed by intermittent US successfully controlled deep infection. Crucially, Micro-CT and histological analyses at 8 weeks post-operation demonstrated that dynamically rescuing the osteogenic niche significantly accelerated woven bone maturation and lamellar bone deposition. This was evidenced by remarkably enhanced bone volume fraction (BV/TV) and improved trabecular architecture compared to antibiotic monotherapy. Conclusively, dynamic ROS regulation using this ultrasound-controlled platform effectively rescues the osteogenic niche, offering a promising sequential therapy for infectious osteomyelitis.
To Amputate or Not Amputate? A Retrospective Cohort Study Evaluating Complications following Amputation for Chronic Tibial and Fibular Osteomyelitis - Kelan Queenan
AIM: Chronic osteomyelitis is a severe bone infection often requiring surgical intervention when antibiotic therapy is insufficient. Amputation carries significant morbidity and mortality, yet research evaluating complications in this population remains limited. This study determined the five-year risk of delayed wound healing, sepsis, bacteremia, mortality, and long-term antibiotic and opioid use among patients with chronic osteomyelitis of the tibia or fibula who underwent lower extremity amputation compared to those who did not.
METHODS: Using CPT and ICD-10 codes, we queried the TriNetX Global Collaborative Network on April 1, 2026 for patients with chronic osteomyelitis of the tibia or fibula between March 2006 and March 2026. Patients were stratified into two cohorts: those who underwent lower extremity amputation and those who did not. Patients with periprosthetic tibial fractures were excluded. 1:1 propensity score matching controlled for age, sex, race, type 2 diabetes mellitus, HIV, nicotine dependence, primary malignant neoplasm, and lower leg fracture. Five-year outcomes were analyzed with exclusion of patients with outcomes prior to amputation. Risk difference, risk ratio, and Kaplan-Meier analyses were performed; p<0.05 was significant.
RESULTS: After matching, each cohort included 2,821 patients. Amputation was associated with significantly higher risk of delayed wound healing, sepsis, and mortality (all p<0.05). Long-term antibiotic use was significantly higher in non-amputation patients (p<0.001). No significant differences were observed in opioid use or bacteremia. Kaplan-Meier analysis showed lower five-year survival in the amputation group (62.58 vs. 70.56%; log-rank χ²=17.82, p<0.001). Amputation was associated with increased mortality hazard (HR 1.27; 95% CI: 1.14 - 1.42, p<0.001).
CONCLUSIONS: Amputation for chronic tibial or fibular osteomyelitis was associated with higher risks of delayed wound healing, sepsis, and mortality, but lower long-term antibiotic use. These findings highlight the complex risk - benefit profile of lower extremity amputation and underscore the importance of careful patient selection, shared decision-making, and perioperative risk stratification.
Gut microbiome alterations in proton pump inhibitor users and their associations with impaired musculoskeletal health and fracture risk - Marina Vilar Geraldi
Proton pump inhibitors (PPIs) are widely prescribed, particularly among older adults, and long-term use has been associated with increased fracture risk and alterations in gut microbiome composition. However, the interplay between PPI use, the gut microbiome, and skeletal health remains unclear. We analyzed data from 2,114 community-dwelling women aged 75 - 80 years from the SUPERB cohort (308 PPI current users; median follow-up: 7.9 years). Gut microbiome composition was profiled using fecal shotgun metagenomics. Associations between PPI use and incident fractures and injurious falls were assessed using Cox proportional hazards models and multivariable linear regression adjusted for age, BMI, smoking, alcohol intake, education level, use of statins, metformin, glucocorticoids and osteoporosis medications, Charlson comorbidity index, and previous fractures. PPI use was associated with increased risk of any incident fracture (HR 1.30, 95% CI 1.07-1.57), vertebral fractures (HR 1.50, 95% CI 1.11-2.01), and injurious falls (HR 1.33, 95% CI 1.09-1.63). PPI users had poorer physical function, as reflected by slower walking speed, fewer chair-stand repetitions, longer timed up-and-go, and lower grip strength, as well as lower HRpQCT assessed tibial trabecular volumetric BMD. Microbiome profiling showed reduced richness and Shannon diversity, as well as taxonomic and functional shifts in PPI users. We identified 48 species associated with PPI use, of which 58% showed consistent associations in an independent cohort of 1,822 middle-aged adults. Taxa enriched in PPI users included oral and small intestinal bacteria (e.g., Streptococcus , Actinomyces , Rothia mucilaginosa , Bifidobacterium dentium ) that were significantly associated with fracture risk, injurious falls, and adverse musculoskeletal traits, and were identified as potential mediators of these outcomes after adjustment for multiple comparisons (Figure 1). These results suggest that PPI use is associated with impaired musculoskeletal health and increased fracture risk in older women, and point to gut microbiome alterations as a potential contributing factor.read more · Original Link ↗
Kalyan NannuruRegeneron Pharmaceuticals Inc, Tarrytown, NY, US
Longxiang Shen上海交通大学医学院附属第六人民医院, Shanghai, CN
Kelan QueenanPenn State College of Medicine, USA
Marina Vilar GeraldiUniversity Of Gothenburg, Mölndal, SE
Clinical Symposium: Phosphate Dynamics: From Basics to Bone Disorders
● Symposium
Symposium
📍 Ballroom C
Phosphate-Sensing Mechanisms and Functions of Phosphate as a First Messenger - Yuichi Takashi, M.D., Ph.D. Fibroblast growth factor 23 (FGF23) is a hormone that plays a central role in maintaining phosphate homeostasis.Phosphate-Sensing Mechanisms and Functions of Phosphate as a First Messenger - Yuichi Takashi, M.D., Ph.D.
Fibroblast growth factor 23 (FGF23) is a hormone that plays a central role in maintaining phosphate homeostasis. However, the mechanism by which bone, the primary site of FGF23 production and secretion, senses changes in blood phosphate levels and regulates FGF23 production has long remained elusive. We have identified fibroblast growth factor receptor 1 (FGFR1) as a phosphate-sensing receptor in bone. In this symposium, we will discuss recent advances in our understanding of the skeletal phosphate-sensing mechanism and the emerging concept of phosphate as a first messenger.
FGF23-Driven Rare Bone Disease: Treatment Advances - Kelly Lauter Roszko
Regulators of FGF23 in CKD: Phosphate, Iron/EPO, and Systemic Consequences - Erica L Clinkenbeard, PhD
As kidney is a key mineral metabolism regulator, reduced function during chronic kidney disease (CKD) disrupts mineral homeostasis including alterations in FGF23. This talk with discuss regulation of FGF23 during CKD and the systemic consequences of pathological elevations of this phosphaturic hormone.read more · Original Link ↗
Heide Siggelkow, MD; PhDUniversity Medicine Of Goettingen,Research and Development Department of Trauma, Orthopedics and Reconstructive Surgery, Göttingen, NDS, DE
Elena Tsourdi, MDCenter for Healthy Aging, Technische Universität Dresden, Dresden, Germany
Yuichi Takashi, M.D., Ph.D.Fukuoka University, Japan
Kelly Lauter RoszkoNational Institutes of Health (NIH), USA
Erica L Clinkenbeard, PhDIndiana University School Of Medicine, Indianapolis, IN, US; Indiana University, USA
☆
Sat 10/10 · 10:15 AM - 11:15 AM
Basic Symposium: Novel Factors Driving Bone Metastasis
● Symposium
Symposium
📍 Meeting Room 302
Osterix+ Osteolineage Cells Are a Source of Tumor-Promoting myCAFs in Breast Cancer - Giulia Furesi, PhD Osteolineage-Derived CAFs Reshape the Bone Metastatic Niche - Jennifer Zarrer Permissive Niches in Breast Cancer Bone Metastasis: Mechanisms and Therapeutic Opportunities - Igor L...Osterix+ Osteolineage Cells Are a Source of Tumor-Promoting myCAFs in Breast Cancer - Giulia Furesi, PhD
Osteolineage-Derived CAFs Reshape the Bone Metastatic Niche - Jennifer Zarrer
Permissive Niches in Breast Cancer Bone Metastasis: Mechanisms and Therapeutic Opportunities - Igor L Bado, PhDread more · Original Link ↗
Roberta Faccio, PhDDepartment of Orthopaedic Surgery, Washington University School of Medicine in St. Louis, USA
Rachelle W. Johnson, PhDVanderbilt University Medical Center, Nashville, TN, US
Giulia Furesi, PhDWashington University in St. Louis, School of Medicine, Clayton, MO, US
Jennifer ZarrerInstitute of Musculoskeletal Medicine, LMU University Hospital, LMU Munich, Germany; Musculoskeletal University Center Munich, LMU University Hospital, LMU Munich, Germany
Igor L Bado, PhDIcahn School of Medicine, New York, NY, US
☆
Sat 10/10 · 10:15 AM - 11:15 AM
Meet the Professor: Bone Health in Cancer Care: Managing Skeletal-Related Events and Treatment-Induced Bone Loss (Can Anabolic Agents be Used?)
● Meet the Professor
Meet the Professor
📍 Meeting Room 309
Bone Health in Cancer Care: Managing Skeletal-Related Events and Treatment-Induced Bone Loss (Can Anabolic Agents be Used?) - Azeez Farooki, MD
Cancer treatment may cause bone loss and bone fragility.Bone Health in Cancer Care: Managing Skeletal-Related Events and Treatment-Induced Bone Loss (Can Anabolic Agents be Used?) - Azeez Farooki, MD
Cancer treatment may cause bone loss and bone fragility. In the setting of advanced cancer in the bone, cancer can cause skeletal related events such as pathologic fractures. This talk will explore adjuvant and antifracture data with antiresorptives in postmenopausal breast cancer. Also, the limited data on anabolic bone therapies in cancer will also be discussed. The provocative question of whether anabolic agents may be used in this vulnerable population will be discussed. The presenter's pilot data from a study of romosozumab in active myeloma will be discussed.read more · Original Link ↗
Azeez Farooki, MDMemorial Sloan Kettering Cancer Center, New York, NY, US
☆
Sat 10/10 · 10:15 AM - 11:15 AM
Meet the Professor: Provocative Ideas
● Meet the Professor
Meet the Professor
📍 Meeting Room 310
GLP-1 Agonists and Bone Health - Anne L. Schafer, MD
Are Multimorbidities Interchangeable - Gordon L.GLP-1 Agonists and Bone Health - Anne L. Schafer, MD
Are Multimorbidities Interchangeable - Gordon L. Klein, MD
This presentation will describe how conditions set by the development of Osteoporosis can create Atherosclerosis, and how Atherosclerosis can exacerbate bone loss, illustrating the relationship between two comorbid conditions of aging. The talk may also include studies exploring the mechanistic relationship between osteoporosis and Alzheimer's disease, another comorbidity of aging (if time permits).read more · Original Link ↗
Naomi Dirckx, PhDWashington University Of St. Louis, St. Louis, MO, US
Elena Ambrogini, PhD, MDCentral Arkansas Va Healthcare System, Univ Of Arkansas For Medical Sciences, Little Rock, AR, US
Anne L. Schafer, MDUniversity Of California, San Francisco and The San Francisco Veterans Affairs Health Care System, San Francisco, CA, US
Gordon L. Klein, MDUniversity Of Texas Medical Branch, Dickinson, TX, US
☆
Sat 10/10 · 10:15 AM - 11:15 AM
Meet the Professor: Bone Health and Diabetes: From Pathophysiology to Clinical Management
● Meet the Professor
Meet the Professor
📍 Meeting Room 311
Bone Health and Diabetes: From Pathophysiology to Clinical Management - Nicola Napoli, MD, PhD
Bone Health and Diabetes: From Pathophysiology to Clinical Management - Tatiane Vilaca, MD, PhD · Original Link ↗
Nicola Napoli, MD, PhDDepartment of Medicine and Surgery, Research Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Italy
Tatiane Vilaca, MD, PhDUniversity Of Sheffield, SHEFFIELD, GB
☆
Sat 10/10 · 10:15 AM - 11:15 AM
From Scientific Innovation to Clinical Impact: The Next Generation of Osteoporosis Therapies
● Symposium
Symposium
📍 Meeting Room 312
TBD - Willard Dere, MD, FACP
TBD - Art Santora, PhD, MD · Original Link ↗
Willard Dere, MD, FACPAngitia Incorporated Limited, USA
Art Santora, PhD, MDRutgers Rwj Medical School, USA
☆
Sat 10/10 · 10:15 AM - 11:15 AM
Meet the Professor: Anabolics in Action
● Meet the Professor
Meet the Professor
📍 Meeting Room 313
Emerging use of Osteoanabolics in Difficult to Manage Glucocorticoid-Induced Osteoporosis - Ken G. Saag, MD
Which Anabolic, for Which Patient? PTH Analogues vs Romosozumab - Gregory A. Clines, PhD, MD · Original Link ↗
Ken G. Saag, MDThe University Of Alabama At Birmingham, Birmingham, AL, US
Gregory A. Clines, PhD, MDUniversity Of Michigan, Ann Arbor, MI, US
Built for you by(617)-PATRICK, Champion AI speaker
Oral Presentations: Hormonal Networks Governing Bone and Phosphate Physiology
● Oral Abstract Presentations
Oral Abstracts
📍 Ballroom C
FGF23 produced from sinusoidal endothelial cells controls hematopoiesis, adipose mass, and bone quality in anemic mice - Jackie A.FGF23 produced from sinusoidal endothelial cells controls hematopoiesis, adipose mass, and bone quality in anemic mice - Jackie A. Fretz, PhD
Elevation of plasma fibroblast growth factor 23 (FGF23), a phosphaturic hormone canonically produced by osteocytes, occurs in iron deficiency and β-thalassemia. Previously, we found that bone marrow (BM) sinusoidal endothelial cells (SEC) upregulate Fgf23 during chronic iron deficiency anemia ( Tmprss6 -/- ) and β-thalassemic (Hbb th3/+ ) mice, during acute phlebotomy-induced anemia, and following EPO injection. Here we elucidate physiological consequences of Fgf23 disruption in SEC of normal and anemic mice. To define the effects of Fgf23 disruption in SEC of normal and anemic mice we utilized conditional knock-out of Fgf23 in SEC ( Fgf23 SEC-CKO) using 2 different Stabillin-2 ( Stab2) Cre drivers with recombinase activity in SEC of liver, spleen, lymph node, and BM. Using the Stab2-iCreF2 driver, Fgf23 SEC-CKO fully blocked the induction of total plasma FGF23 by EPO. Study of Stab2-iCreF2 Hbb th3/+ pups was precluded by an apparent Cre-incompatibility, suggested by their marked underrepresentation at birth, independent of Fgf23 genotype. Using the Stab2-iCreF3 driver, which confers Cre activity in SEC but not hematopoietic cells or their progeny, Fgf23 SEC-CKO produced mild changes in baseline hematological parameters of heathy mice. Fgf23 SEC-CKO decreased baseline plasma total FGF23, blunted its elevation after EPO injection, and delayed recovery of hemoglobin levels after large-volume phlebotomy. In genetic anemia models (both Tmprss6 -/- and Hbb th3/+ mice), Fgf23 SEC-CKO blunted plasma total FGF23 elevation, caused mild changes in hematological parameters, and prevented anemia-related reductions in body weight. Intriguingly, Fgf23 SEC-CKO reversed the reduction in white adipose tissue mass in Tmprss6 -/- animals, with a similar trend present in Hbb th3/+ mice. Skeletal growth, defined by femoral and tibial length, was normalized in the Hbb th3/+ Fgf23 SEC-CKO model, but both anemia models displayed improvements in bone quality, increased osteoblast number, and elevated osteoid. A trend for reductions in osteoclast numbers was also observed in Fgf23 SEC-CKOs. Together these data demonstrate that in healthy mice, SEC-derived FGF23 contributes significantly to plasma total FGF23 elevation after EPO injection and to hematological recovery during stress erythropoiesis. In Hbb th3/+ and Tmprss6 -/- mice, SEC-derived FGF23 contributes to FGF23 plasma elevation, and facilitates pathological reductions in body mass and anemic bone loss.
N-terminal FGF23 Peptide Is Sufficient to Correct Bone and Mineral Metabolism in Fgf23 Null Mice - Eduardo Duque, PhD, MD
Background : Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that controls phosphate homeostasis and circulates either as intact hormone or as cleaved N- (Nter-FGF23) and C-terminal (Nter-FGF23) derived peptides. While Cter-FGF23 regulates hepcidin and iron metabolism during inflammation, the biological activity of Nter-FGF23 is unknown. Methods : To define its function, we generated mice overexpressing Nter-Fgf23 in osteocytes and examined renal, mineral, and skeletal phenotypes at 7 weeks in WT, Fgf 23 KO (KO), Nter- Fgf 23 Dmp1-cTg (TG) and Fgf 23 KO /Nter- Fgf 23 Dmp1-cTg (CPD). We measured biochemical markers of mineral metabolism and performed 3D micro-CT analysis, “bulk” RNA sequencing and proteomics in kidneys to identify genes and molecular pathways altered by Nter-FGF23. Results: As expected, KO mice displayed growth retardation, absent FGF23, hyperphosphatemia, elevated calcitriol, and shortened lifespan. Strikingly, Nter-FGF23 overexpression in KO mice restored survival and reestablished growth (76% increase in body weight and 10% in tail length in CPD vs. KO mice). Nter-FGF23 also reduced calcitriol (−30% vs. KO) and renal phosphate reabsorption, increasing phosphaturia and lowering serum phosphate (+92% and −70%, respectively, in CPD vs. KO mice), despite the absence of intact FGF23 and suppression of PTH. Renal transcriptomic and proteomic profiling revealed a coordinated Nter-FGF23 regulatory program targeting tubular function, oxidative stress, and mineral handling, including regulation of Slc26a1 , Slc22a5 , Sod1 , Nt5e , and Alpl . Functionally, these changes translated into near-complete resolution of nephrocalcinosis in CPD mice. In parallel, Nter-FGF23 rescued skeletal defects in KO mice, normalizing trabecular architecture (3-fold increase in BV/TV), bone mineral density (+16%), and cortical porosity (−58%). Conclusion : Together, these findings identify Nter-FGF23 as an active endocrine peptide that reproduces core FGF23 functions in the kidney, driving phosphate excretion and protecting against ectopic calcifications. This work challenges the view that FGF23 cleavage is inactivating and instead establishes it as a mechanism generating biologically active peptides with distinct, tissue-directed actions.
The Transcription Factor ETV1 Mediates Reciprocal FGF23 and PTH Regulation of the Vitamin D 24-Hydroxylase (CYP24A1) - Emmanuel Solis
Purpose: Calcitriol (1,25D) is tightly regulated in the kidney by FGF23, PTH, and 1,25D, and can be markedly disturbed in diseases involving these hormones. FGF23 and 1,25D enhance, whereas PTH suppresses, the 1,25D catabolic enzyme CYP24A1, with exact reciprocal control of anabolic CYP27B1. However, the identity of the FGF23-activated transcription factors (TFs) controlling CYP24A1 are unknown.
Methods: We performed 10X Multiome on kidneys from mice temporally injected with FGF23 to isolate tubule-segment specific transcriptional reprogramming at the single-cell level. Co-injections of FGF23 and PTH, and dietary challenges in WT and DOX-inducible Pax8-Cre/flox-ETV1 mice tested regulatory function with parallel FGF23, 1,25D, and PTH-mimetic treatments in vitro.
Results: 10X Multiomics revealed FGF23 increased the TF Etv1 mRNA specifically in kidney PTS1-2 cells, co-localizing with Cyp24a1 ; KL-KO mice had completely suppressed Etv1 . Nuclear ETV1 accumulation occurred in megalin-positive PT cells with FGF23 delivery to WT mice as determined by IF, whereas PTH rapidly reduced ETV1 in isolated nuclei. In HEK-mKL cells, endogenous ETV1 mRNA was potently induced by combined FGF23 and 1,25D treatment, and ETV1 protein by FGF23, but 1,25D alone had no effect. However, coimmunoprecipitation showed stabilized ETV1-VDR complexes only in the presence of 1,25D. Overexpression of ETV1 cDNA increased CYP24A1 (4-6 fold; p<0.01) in HEK-mKL and RPTEC cells, and ETV1 shRNA blocked FGF23 increases in CYP24A1. Further, a PTH mimetic SIK inhibitor (SIKi) ablated FGF23-mediated ETV1 protein expression, which was rescued by a proteasomal inhibitor. To evaluate loss of ETV1 in vivo, Pax8-Cre/flox-ETV1 mice were challenged with 1) FGF23 injections and 2) a high phosphate diet. The conditional mice were resistant to FGF23-mediated Cyp24a1 mRNA increases, and during hyperphosphatemia had increased plasma FGF23 but lower PTH compared to controls.
Conclusion: In summary, ETV1 is a PT-specific TF activated by FGF23 that interacts with VDR and increases Cyp24a1 . In contrast, PTH and SIKi reduced ETV1, thus identifying the reciprocal regulatory transcriptional network. Loss of kidney ETV1 disrupted CYP24A1 expression and systemically enhanced and reduced plasma FGF23 and PTH, respectively. Thus, ETV1 is a novel PT component directing balanced control of key enzymes regulating 1,25D, opening new connections for strategies critically needed for vitamin D- and FGF23-related disorders.
ETV1 unifies genomic endocrine regulation of vitamin D metabolism by FGF23 and PTH - Eileen Sember
Kidney-produced active vitamin D 3 (1,25(OH) 2 D 3 , 1,25D) controls serum levels of calcium and phosphate. 1,25D is made by the CYP27B1 enzyme and is degraded by the CYP24A1 enzyme. Both enzymes are regulated through endocrine signaling in the kidney by parathyroid hormone (PTH) (activates Cyp27b1 and suppresses Cyp24a1 ) and fibroblast growth factor 23 (FGF23) and 1,25D itself (both suppress Cyp27b1 and activate Cyp24a1 ). Genomic actions of PTH and 1,25D are known to act through CREB and VDR respectively, however; the mechanism of PTH suppression of Cyp24a1 and genomic control by FGF23 have remained a critical knowledge gap. To identify this factor(s), we examined kidney expression data to identify transcription factors (TFs), and performed ChIP-seq in vivo . In vitro, we tested the TF gene expression and actions by FGF23, 1,25D, and PTH signaling. We found the E twenty-six (ETS) family member ETV1 bound to the genome at kidney-specific genomic enhancers for Cyp24a1 after FGF23 treatment in the mouse kidney. Genome-wide, >80% of FGF23-stimulated ETV1 genomic binding overlapped with 1,25D-induced VDR binding. In vivo , FGF23+1,25D cotreatment synergistically upregulated Cyp24a1 , and ETV1 co-immunoprecipitated VDR, positioning ETV1 as a novel VDR interacting protein. In vitro , Cyp24a1 gene expression revealed an mRNA increase from 4- to 50-fold with FGF23 and 1,25D individually to >400-fold in combination. ETV1 bound to the Etv1 gene promoter as well, driving its own production which was eliminated by mutation of ETS binding sites (EBS) in vitro . Mutation of an EBS in the Cyp24a1 promoter also prevented the activation of Cyp24a1 in vitro by FGF23 and opposed the synergistic increase (1,25D+FGF23). Surprisingly, when mice were treated with PTH, ETV1 was completely removed from Cyp24a1 enhancers even with FGF23 pre-treatment. In fact, ETV1 genome-wide binding was reduced from 4,790 to 22 sites, a remarkable depletion. These activities were corroborated in vitro as reporters revealed that inducing the PTH pathway via SIK inhibition reduces Cyp24a1 activation. Taken together, our data position ETV1 as a dynamic partner that controls FGF23-mediated Cyp24a1 in partnership with 1,25D-induced VDR. Strikingly, ETV1 was also involved in PTH-mediated suppression of Cyp24a1 . These studies help answer a long-standing mechanistic question of FGF23 genomic actions in kidney and point to ETV1 as being at the nexus of PTH and FGF23 signaling that controls vitamin D endocrinology.
Restoration of parathyroid hormone receptor (PTH1R) localization to the primary cilium reverses the impaired osteocyte mechanosensitivity in diabetes mellitus - Joan Pizarro Gomez, PhD
The anabolic response in vivo or the anti-apoptotic effects in vitro of mechanical stimulation are impaired in diabetic mice (DM) or in osteocytic cells exposed to high glucose (HG), respectively. In addition, mice lacking the PTH receptor (PTH1R) in osteocytes and osteoblasts exhibit a decreased response to loading suggesting the requirement of the PTH1R in the skeletal response to mechanical stimuli. We investigated herein the potential role of the PTH1R in the defective mechanotransduction in DM/HG. We found that mechanical stimulation by fluid flow (FF) of cultured MLO-Y4 osteocytic cells induces the translocation of the PTH1R to the primary cilium, organelle that functions as mechanosensory center. In control medium, 60% of cells transfected with GFP-PTH1R exhibited receptor localization throughout the entire extension of the cilium in response to FF vs 32% in static conditions, assessed by confocal microscopy. In contrast, in HG medium, only 33% of cells exhibited PTH1R ciliary localization in response to FF vs 35% in static conditions. The Synovial Sarcoma X breakpoint-interacting protein 2 ( Ssx2ip) gene encodes a protein critical for targeting proteins to the cilium. Quantitative PCR revealed that cultured osteocytic cells and ex vivo bone organ explants exposed to HG exhibited lower expression vs control of genes encoding primary cilium components, including Ssx2ip (27% and 65% reduction, respectively). The expression of Ssx2ip was also lower in bones from diabetic mice (high fat diet+STZ) vs control, as quantified by bulk RNAseq analysis. Moreover, Gene Ontology mapping (GO) revealed a reduction in diabetic bones in Wnt and Hedgehog signaling pathways, critical for cell responses to mechanical cues. Further, single cell RNAseq analysis revealed reduced expression of Ssx2ip and other ciliary genes and lower number of Wnt and Hedgehog-related GOs in the osteocyte and osteoblast clusters in bones from diabetic vs control mice. Lastly, PTH1R ciliary localization and the survival effects induced by FF, which were lost in HG, were restored partially and completely, respectively, in cells transfected with Ssx2ip. These results are consistent with the notion that HG and DM impair mechanotransduction by downregulating ciliary genes and inhibiting PTH1R ciliary localization. Further, these findings demonstrate that restoring Ssx2ip- mediated PTH1R localization to the cilium is sufficient to correct mechanical responsiveness of bone cells in the frame of DM.read more · Original Link ↗
Lauren Surface, PhDUniversity Of Michigan, Ann Arbor, MI, US
Victoria E. DeMambro, PhD, MSMaineHealth Institute For Research, Scarborough, ME, US; MaineHealth Institute for Research, USA
Jackie A. Fretz, PhDYale School Of Medicine, Naugatuck, CT, US
Eduardo Duque, PhD, MDNorthwestern University, Chicago, IL, US
Emmanuel SolisIndiana University, Indianapolis, IN, US
Eileen SemberUniversity of Wisconsin-Madison, Department of Food and Nutritional Sciences, USA
Joan Pizarro Gomez, PhDDepartment of Basic Medical Sciences, School of Medicine, Universidad San Pablo- CEU, CEU Universities, Campus Monteprincipe, Alcorcón, Madrid, Spain, Spain; Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
☆
Sat 10/10 · 11:30 AM - 12:30 PM
Oral Presentations: Smarter Fracture Risk Prediction: AI and Biomarkers Across Populations
● Oral Abstract Presentations
Oral Abstracts
📍 General Session - Ballroom A & B
Hematological Markers and Fracture Risk Independent of Bone Mineral Density: Evidence from the UK Biobank - Jeonghoon Ha, PhD, MD
Purpose Accumulating evidence suggests that hematological parameters may be associated with fracture risk; however, large-scale longitudinal data remain limited.Hematological Markers and Fracture Risk Independent of Bone Mineral Density: Evidence from the UK Biobank - Jeonghoon Ha, PhD, MD
Purpose Accumulating evidence suggests that hematological parameters may be associated with fracture risk; however, large-scale longitudinal data remain limited. It also remains unclear whether these associations are mediated by bone mineral density (BMD) or reflect independent biological mechanisms. We aimed to investigate the association between diverse hematological markers and incident fracture risk and to assess the mediating role of BMD.
Methods We analyzed 418,959 participants from the UK Biobank without prior fracture history (median follow-up, 13.2 years). Hematological markers, including red cell distribution width (RDW), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR), were evaluated alongside clinical conditions such as anemia, immune thrombocytopenia (ITP), and essential thrombocythemia (ET). Multivariable Cox proportional hazards models with penalized splines were used to assess associations. Mediation analyses using DXA-derived BMD (n=36,549) were performed to estimate indirect effects through bone density.
Results During follow-up, 16,466 incident fractures (3.9%) occurred. In fully adjusted models, higher RDW (HR 1.046, 95% CI 1.031 - 1.062), MCV (1.065, 1.048 - 1.083), NLR (1.031, 1.020 - 1.041), and MLR (1.012, 1.005 - 1.020) were independently associated with increased fracture risk (all P<0.001). Clinical diagnoses of anemia (HR 1.155, 95% CI 1.086 - 1.228), ITP (1.122, 1.015 - 1.240), and ET (1.242, 1.039 - 1.485) were also associated with higher fracture incidence. Mediation analyses indicated no evidence that the significant associations between hematological markers and fracture risk were mediated by BMD.
Conclusions Hematological markers independently predict fracture risk, irrespective of BMD. These findings suggest that systemic inflammation, altered erythropoiesis, and hematopoietic dysregulation contribute to skeletal fragility through mechanisms not captured by bone mass alone.
Associations of Circulating Inflammatory Markers with Bone Microarchitecture in Older Men: Findings from the MrOS Study - Malak Faraj, PhD
Chronic low-grade inflammation has been associated with an increased risk of fracture, possibly by influencing bone microarchitecture. However, evidence regarding inflammatory markers and bone microarchitecture in men is limited. We therefore examined the cross-sectional associations between circulating inflammatory markers and bone microarchitecture in older men. Analysis included 875 men (mean age, 84.3 ± 4.0 years) from the Year 14 Osteoporotic Fractures in Men (MrOS) study exam who underwent high-resolution peripheral quantitative computed tomog (HR-pQCT) scanning at the distal radius and distal tibia. Circulating levels of C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, and IL-17A were measured. Inflammatory markers were analyzed individually and as a composite index based on the number of elevated cytokines. Linear regression models adjusted for age, race, BMI, limb length, clinical site, eGFR, and diabetes were used to evaluate associations between inflammatory markers and HR-pQCT parameters. Higher circulating levels of TNF-α, IL-6, and IL-17A were each associated with lower cortical vBMD (TNF-α: distal radius p=0.005, distal tibia p=0.0003; IL-6: distal tibia p=0.042; IL-17A: distal tibia p= 0.07 [trend]), whereas higher CRP levels were associated with greater failure load (distal radius p=0.01), cortical thickness (distal tibia p=0.01), and cortical area (distal radius p=0.02, distal tibia p=0.005). Moreover, the composite inflammatory index including all five markers did not show significant associations with HR-pQCT parameters. However, when CRP was excluded from the index, men with one elevated inflammatory marker, compared with men without any elevated cytokines, had lower failure load at the distal radius (p=0.03) and lower cortical vBMD, cortical thickness, and cortical area at both the distal radius (Ct.BMD: p=0.002; Ct.Th: p=0.002; Ct.Ar: p=0.001) and tibia (Ct.BMD: p=0.01; Ct.Th: p=0.02; Ct.Ar: p=0.007). Men with > 2 elevated inflammatory markers, compared with men without any elevated cytokines, had lower cortical vBMD at both the distal radius (p=0.01) and tibia (p=0.0004), but higher trabecular thickness at the distal tibia (p=0.02). In conclusion, these findings suggest that systemic inflammation, assessed by cytokines but not CRP, is associated with impaired cortical bone microarchitecture in older men.
Clinically Interpretable Predictors of Imminent Subsequent Fractures in a Deep-Learning Prediction Model - Huy Gia Nguyen, PhD
The inherent “black-box” nature of machine- and deep-learning models, despite their strong predictive performance, limits clinical adoption. Clinicians require interpretable predictions that can support individualised treatment decisions. This study aimed to quantify and characterise the relative importance of predictors in a deep-learning algorithm for imminent subsequent fracture risk, supporting clinical interpretability and potential deployment within electronic health records.
We developed a DeepHit prediction model for subsequent fractures using administrative health data from a statewide population-based cohort of 280,686 adults in New South Wales, Australia. Participants had sustained an incident fracture requiring hospital or emergency admission between January 2005 and January 2017, were born on or before 1955, and were followed until January 2019. Predictors included age, index fracture site, prior fractures or falls, and 1,805 ICD-10 codes mapped to 60 predefined chronic disease groups related to fracture and mortality risk. SHapley Additive exPlanations (SHAP) were used to quantify each predictor’s contribution across possible predictor subsets.
Over a median follow-up of 2.0 years (IQR, 1.6-2.0), 7,002 men and 21,167 women were admitted with a subsequent fracture, corresponding to incidence rates of 53.3 (95% CI, 52.1-54.6) and 64.8 (64.0-65.7) per 1,000 person-years, respectively. The model showed strong discrimination and calibration for 1- and 2-year subsequent fracture risk, with minimal prediction bias and C-indices of up to 0.81 for hip fracture and 0.75 for any subsequent fracture. Age at index fracture was the dominant predictor, accounting for 20% of predictive contribution for any subsequent fracture in men and up to 34% for hip fracture in women. Index fracture site was also influential, contributing 8-14% of overall model performance. Key comorbidity contributors included lung disease, dementia, urinary tract infections or incontinence, drug- or alcohol-related disorders, and eye and neurological conditions.
This study identified clinically meaningful predictors of imminent subsequent fracture. It demonstrates that explainable deep-learning models can achieve accurate prediction while improving transparency, supporting targeted secondary fracture prevention.
A Novel Deep Learning Application to Predict High-risk Fracture Patients for Imminent Non-Fracture Re-Hospitalizations - Jacqueline R. Center, MD, PhD
Early identification of patients at high risk of adverse outcomes after fracture is essential for optimizing post-fracture care. We developed and validated a deep learning model to predict the imminent risk of non-fracture (NF) re-hospitalization following a fragility fracture using administrative data.
This statewide, whole-of-population retrospective cohort study included 280,686 adults in New South Wales, Australia, born on or before 1/1/1955, who sustained an incident fracture between 2005 and 2017 and were followed through 2022. Fractures and comorbidities associated with fracture risk and mortality were identified using ICD-10 codes recorded within 5 years pre-fracture. The primary outcome was substantive NF re-hospitalizations, defined as ≥24-hour episodes of care occurring ≥7 days post-fracture. A DeepHit neural network model was used to estimate 1- and 2-year risks of NF re-hospitalization, accommodating high-dimensional predictors, nonlinear relationships, and competing risks of subsequent fracture and death. Predictors included age, fracture sites, prior falls or fractures, and 1,870 individual ICD-10 codes for 65 predefined comorbidities. Data were randomly partitioned into training (70%), validation (10%), and hold-out testing (20%) sets.
Over a median follow-up of 1.5 years (IQR: 0.4 - 2.00), 39,742 men and 76,963 women experienced ≥1 NF re-hospitalization, yielding the incidence of 42.7 (95% CI: 42.2-43.1) and 30.7 (30.4-30.9) re-hospitalizations/100 person-years, respectively. Leading reasons for re-hospitalization included cardiovascular (heart disease 6.2%, ischemic heart disease 3.7%, and cerebrovascular disease 2.7%), respiratory disorders (influenza/pneumonia 4.0%, chronic lower respiratory diseases 3.5%), malignancies (5.8%), and arthropathies (5.6%). Competing event rates for subsequent fracture and mortality rates were 4.4 (95% CI: 4.3-4.6) and 10.0 (9.8-10.2)/100 person-years in men, and 5.6 (5.5-5.7) and 6.1 (6.0-6.2)/100 person-years in women, respectively. The model showed good discrimination [C-index: 0.77 (95% CI: 0.76 - 0.78) in men; 0.75 (0.75 - 0.76) in women] with modest overestimation of absolute risk (bias~ -0.02). A calculator was developed to estimate individualized risk predictions, supporting clinical implementation (Figure).
Our model accurately identified patients at imminent risk of NF re-hospitalization using administrative data, suggesting its potential for automated risk stratification within the healthcare system.
Racial and Ethnic Differences in Clinical Indications for Osteoporosis Treatment in U.S. Women: A Population-Based Cohort Study - Adele Carty, PhD, MSc
Purpose: Osteoporotic fractures affect ~1 in 3 women aged ≥50 years, yet osteoporosis remains undertreated. Osteoporosis treatment indications include prior fracture, bone mineral density (BMD) T-scores, and fracture risk prediction by FRAX (US-FRAX being adjusted for race and ethnicity). We examined differences in osteoporosis treatment indication in a large, racially and ethnically diverse cohort of women.
Methods: This retrospective cohort study included 374,287 women aged ≥50 years in the Kaiser Permanente Southern California health care system (2007-2022) with a complete FRAX questionnaire at index dual x-ray absorptiometry (DXA) scan and ≥12 months of continuous health plan enrollment prior to index DXA. Women were hierarchically classified into mutually exclusive groups by osteoporosis treatment indications: (I) prior fracture, (II) BMD T-score ≤-2.5, or (III) FRAX treatment thresholds (hip ≥3% or major osteoporotic fracture ≥20%). Distribution of treatment indication was examined overall and by group, stratified by age and self-reported race and ethnicity.
Results: Mean age was 66.3 years (SD=8.1); 49.4% were White, 25.8% Hispanic, 13.5% Asian, and 11.3% Black. Overall, 32.1% (n=120,241) of women met indications for osteoporosis treatment: 37.6%, 30.8%, 28.3% and 18.3% of White, Asian, Hispanic, and Black women, respectively. Prevalence of treatment indication increased with age from 21.1% (50-59 years) to 55.7% (≥70 years). The leading indicator for treatment was BMD T-score ≤-2.5 (42.3%), followed by FRAX thresholds (30.7%) and prior fracture (27.0%) (Figure 1). Among those meeting treatment indications, FRAX thresholds were most common among White women (39.8%), compared to Black, Asian, and Hispanic women (p<0.01). BMD T-score ≤-2.5 was the leading treatment indication among Asian (66.6%), Hispanic (53.1%), and Black (43.7%) women. A smaller proportion of Asian women had treatment indication for prior fracture (15.8%) compared to Hispanic, Black, and White women (all >27.0%; p<0.01). The leading indicator for treatment varied by age: prior fracture for ages 50-59 (54.3%), BMD T-score ≤-2.5 for 60-69 (52.8%), and FRAX thresholds for ≥70 years (44.8%).
Conclusions: Nearly one-third of women aged ≥50 years met osteoporosis treatment indications, varying by race, ethnicity and age. The differences in pathways to clinical treatment qualification across groups may inform development of more equitable screening and treatment recommendations.read more · Original Link ↗
Muhammad Kassim JavaidUniversity Of Oxford, Oxford, GB
Tony M. Keaveny, PhDO.N. Diagnostics, Berkeley, CA, USA
Jeonghoon Ha, PhD, MDStanford University School of Medicine, USA; The Catholic University Of Korea, Seoul, KR
Malak Faraj, PhDCampus Bio-Medico University Of Rome, Rome, IT
Jacqueline R. Center, MD, PhDGarvan Institute of Medical Research, Australia
Adele Carty, PhD, MScEndocrinology Division, Department of Medicine, Mass General Brigham, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
☆
Sat 10/10 · 11:30 AM - 12:30 PM
Oral Presentations: Molecular Regulation of Osteoblast Function and Bone Formation
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 302
Bmp and Activin Membrane-Bound Inhibitor (Bambi), a Novel PTH Target Gene in Osteocytes, is Required for Dendrite formation and for Cortical Bone Integrity and Skeletal Homeostasis in Mice - Kalpana Patel, PhD Intermittent PTH induces an anabolic response of the...Bmp and Activin Membrane-Bound Inhibitor (Bambi), a Novel PTH Target Gene in Osteocytes, is Required for Dendrite formation and for Cortical Bone Integrity and Skeletal Homeostasis in Mice - Kalpana Patel, PhD
Intermittent PTH induces an anabolic response of the skeleton. Bulk RNAseq of highly enriched osteocytes (Ocyte) from PTH-treated OVX mice revealed that BMP and Activin Membrane-Bound Inhibitor (Bambi), a TGF-β type I decoy receptor that inhibits TGF-β and favors Wnt signaling, was markedly increased. scRNAseq databases further revealed that Bambi expression is relatively restricted to Ocyte, but its role in Ocyte biology and skeletal homeostasis remains unexplored.
Bambi is expressed in Ocyte cell lines (OmGFP66 and Ocy454) and upregulated by PTH. Bambi knockdown (Bambi-KD) in OmGFP66 cells increased Sost and Rankl (Tnfsf11) expression, reduced active β-catenin, and enhanced pSmad2 levels, confirming altered Wnt and TGF-β signaling. Moreover, Bambi KD decreased Ocyte dendrite formation and reduced Sp7 and Osteocrin expression. Importantly, PTH induced not a decrease but a significant increase in Sost expression in KD cells, with no impact on the increase in Tnfsf11 .
Bulk RNA-seq of Bambi KD OmGFP66 cells revealed significant alterations. As expected Bambi KD downregulated Wnt target genes ( Sfrp4, Axin2, Dkk 1) and upregulated TGF-β/BMP-responsive genes ( Id1 - 3, Smad6, Msx2 ). Ocyte marker genes ( Phex, Dmp1, Pdpn, Rankl, Fgf23 ) were also altered by Bambi KD. Consistent with the decreased dendrites, dendrite-associated genes ( Netrin1, Sema3a, Sp7, Fgf2, Profilin, Lpars ) and peri-lacunar remodelling (PLR) genes ( Mmp2, Mmp13, Mmp14, Ctsk, Acp5 ) were significantly altered in Bambi KD.
To assess the role of Bambi in vivo , we generated 10 kb Dmp1-Cre: Bambi-flox mice. In KO mice, uCT at 8 and 12 weeks showed a significant reduction in BV/TV in tibia and vertebrae. Consistent with uCT, Bambi KO had low bone formation and increased osteoclasts. Silver staining of tibia sections revealed a reduction in Ocyte lacunar area and dendrite number per cell, confirming our in vitro findings. BSEM analysis showed increased cortical bone porosity, associated with enhanced cortical remodeling.
In conclusion, Bambi is an essential PTH target gene in Ocyte, required for PTH to downregulate Sost and for dendrite formation. In contrast, Bambi is not required for PTH-induced Tnfsf11 expression. Deletion of Bambi in Ocyte in vivo leads to low bone mass and increased cortical remodeling and porosity, indicating a critical role of this decoy-receptor in skeletal homeostasis. Ongoing studies are evaluating the effects of Ocyte Bambi KO in the skeletal response to PTH treatment.
SLC22A17 Is Required for Lipocalin-2-Mediated Suppression of Wnt/β-Catenin Signaling in Bone - Vivek S. Khanal, PhD
Lipocalin-2 (LCN2), a secreted factor, regulates systemic metabolism through endocrine signaling via MC4R; however, whether LCN2 exerts local functions within bone has been elusive. We recently identified a bone-intrinsic role for LCN2, where its deletion in late osteoblasts and osteocytes (9.6kb Dmp1-Cre + ; Lcn2 fl/fl , i.e., Lcn2 ΔDmp1 ) increases bone mass without altering systemic energy balance. Mechanistically, loss of LCN2 enhances osteoblast number and activity, accompanied by reduced intracellular iron and lipid peroxidation and activation of Wnt/β-catenin signaling, indicating that LCN2 acts as a negative regulator of bone formation. However, the receptor that mediates LCN2’s local effects in bone, independent of MC4R, remains unknown. In this study, we tested the hypothesis that SLC22A17, a high-affinity LCN2 receptor expressed in osteoblast-lineage cells, mediates LCN2’s inhibitory effects on bone formation.
To determine whether SLC22A17 mediates LCN2’s inhibitory effects on osteoblast-lineage cells, we first evaluated its role, in vitro, in OCY454 osteocyte-like cells treated with recombinant LCN2. LCN2 increased oxidative stress, lipid peroxidation, and reduced Wnt/β-catenin signaling in OCY454 cells. These effects were ablated by silencing Slc22a17 . This indicates that SLC22A17 is required for LCN2-mediated suppression of osteoblast-lineage cell activity. To test the role of SLC22A17 in regulating bone mass in vivo , we generated mice with haploinsufficiency of Slc22a17 in Dmp1-expressing osteoblasts and osteocytes (9.6kb Dmp1-Cre + ; Slc22a17 fl/+ , i.e., Slc22a17 D Dmp1/+ ). Micro-CT analysis revealed that Slc22a17 D Dmp1/+ mice have increased trabecular bone volume, trabecular thickness, and bone mineral density compared to control littermates. Similarly, cortical bone area, cortical thickness, and bone mineral density were increased in Slc22a17 D Dmp1/+ mice. Notably, the skeletal phenotype of Slc22a17 D Dmp1/+ mice mirrors that of Lcn2 ΔDmp1 mice.
Together, these findings identify SLC22A17 as a downstream receptor of LCN2 in bone and support an LCN2 - SLC22A17 axis that regulates bone mass through modulation of Wnt/β-catenin signaling. Our work also highlights that LCN2 engages distinct receptors to mediate systemic and bone-specific effects, and given its diverse systemic functions, SLC22A17 enables us to selectively modulate LCN2’s impact on bone without broadly disrupting its endocrine metabolic actions.
11β-HSD1 Regulates Osteoblast Proliferation and Bone Remodeling Through Modulation of Wnt/β-Catenin Signaling - Husam Bensreti, PhD
Age-related bone loss may be influenced by age-associated increases in circulating glucocorticoids (GCs). In bone, local GC availability is enhanced by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1; gene name Hsd11b1), which regenerates active GCs. The contribution of local GC activation to osteoblast function and skeletal remodeling remains incompletely understood, although 11β-HSD1 expression increases with age in bone. Here, we investigated whether osteoprogenitor-specific deletion of Hsd11b1, which decreases intracellular GC availability in bone cells, regulates osteoblast proliferation through modulation of Wnt/β-catenin signaling. Bone marrow stromal cell (BMSC)-derived osteoblasts from adult-onset bone-targeted Hsd11b1 knockout mice (Hsd11b1-CKO OSX ) exhibited significantly increased proliferation compared to WT controls, including following treatment with 11-dehydrocorticosterone (11-DHC), which requires 11β-HSD1-mediated activation, or dexamethasone, which is already active (p Genotype = 0.016). This proliferative advantage was not observed in osteoblasts isolated from 21-month-old mice (p Genotype = 0.139). Because Wnt signaling is a key regulator of osteoblast proliferation, we next evaluated Wnt/β-catenin signaling pathways. Expression of Wnt ligands was unchanged between genotypes (p > 0.05); however, the Wnt inhibitor Dkk1 was significantly reduced in Hsd11b1-CKO OSX osteoblasts (p = 0.007), while β-catenin expression was significantly increased (p = 0.037). Furthermore, BMSC-derived osteoblasts exhibited increased nuclear localization of β-catenin in Hsd11b1-CKO OSX , even following 11-DHC treatment, consistent with enhanced Wnt/β-catenin transcriptional activity. Adult-onset Hsd11b1 deletion increased trabecular BV/TV and improved skeletal microarchitecture with aging. Interestingly, young Hsd11b1-CKO OSX mice also exhibited compartment-specific cortical remodeling characterized by increased osteoclast activity and increased periostin (POSN)-positive periosteal cells, suggesting activation of compensatory periosteal remodeling pathways. Collectively, these findings identify 11β-HSD1-mediated glucocorticoid activation as a suppressor of osteoblast Wnt/β-catenin signaling and a potential therapeutic target for skeletal aging.
Glucose Oxidation in Mitochondria is Dispensable for Bone Formation - Jasmin Koehnken Sawall, PhD
The metabolic processes that govern osteoblasts - the primary cells responsible for forming bone - are still not fully understood. Our previous studies of osteoblasts in vitro indicated that glucose is predominantly converted to lactate in the cytosol with minimal contribution to TCA metabolism. However, a potential role of glucose oxidation in the mitochondria of osteoblasts has not been examined in vivo. The mitochondrial pyruvate carrier (MPC), a heterodimeric complex composed of protein subunits Mpc1 and Mpc2, is mainly responsible for transporting pyruvate from the cytosol into the mitochondrial matrix for the TCA cycle. Alternatively, the glutamic pyruvate transaminase GPT2 may convert alanine back to pyruvate in the mitochondria after alanine is first produced from pyruvate in the cytosol and then transported into the mitochondrial matrix. Here, we sought to genetically block pyruvate entry into the mitochondria by conditionally deleting both Mpc2 and Gpt2 with Prx1-cre in the embryonic limb mesenchyme of the mouse. The double conditional knockout mice appeared normal both at and after birth. Cellular bioenergetic assays confirmed that pyruvate oxidation was blocked in the bone marrow stromal cells of the mutant mice. Unexpectedly, the double deletion significantly increased trabecular bone mass in both males and females at 8 weeks of age. This phenotype persisted in the females at 22 weeks of age with an additional significant increase in cortical bone mass. Dynamic histomorphometry by double labeling at 8 weeks of age showed a significant increase in mineralizing surface over bone surface, indicating more active osteoblasts in the mutants, independent of sex. Moreover, the trabecular bone formation rate normalized to tissue area was significantly increased in the mutant females, indicating an overall increase in bone formation. On the other hand, TRAP staining revealed no effect on bone resorption by the deletions in either sex. Together, these findings suggest that glucose and pyruvate oxidation in the mitochondria is dispensable for osteoblast development and bone formation in vivo.
Fra2/AP-1 in B Cells Is a Key Regulator of Osteoblastogenesis in Bone Remodeling - Flora Nguemedjio Foko Takile
B cells emerge as key regulators of bone homeostasis through the RANKL/OPG axis and the release of pro-inflammatory cytokines and antibodies that promote bone loss. We previously reported that the Activator Protein-1 (AP-1) transcription factor complex regulates bone homeostasis and B cell development through its Fos family members. Specifically, Fosl1 (Fra1) expression in B cells restricts autoantibody-mediated autoimmune bone loss, but loss of Fosl2 (Fra2) markedly reduces bone marrow and splenic B cells in mice. However, the impact of Fra2 expression in B cells on bone homeostasis has not yet been elucidated. To study B cell-specific effects on bone homeostasis, we generated Fra2ΔBcell knockout mice by crossing Fra2fl mice to mb1cre mice. µ-CT analysis revealed higher bone volume per total volume (p=0.006) and increased osteoblast numbers per total area (P=0.0245) than wild-type controls. In vitro, conditioned medium from Fra2ΔBcell LPS/IL7-stimulated B cells promoted mesenchymal stem cell proliferation and differentiation into osteoblasts more effectively than conditioned medium from WT control cells. Consistently Single-cell RNA sequencing of bone marrow cells analysis, using the CytoTRACE2 tool, indicated that Fra2ΔBcell MSCs are skewed toward osteogenic differentiation. In addition, Fra2ΔBcell mice depicted higher serum osteocalcin (P=0.0086) and osteopontin (P=0.0265) levels compared to wild-type mice. To define how Fra2 in B cells mediates this effect, we performed ChIP-seq in WT B220⁺ B cells. Hereby we identified Dkk1, a Wnt/β-catenin inhibitor, as a potential Fra2 target. Accordingly, Dkk1 levels were significantly reduced in Fra2ΔBcell B-cell-conditioned medium and in the serum of Fra2ΔBcell mice. In accordance with our Fra2ΔBcell mouse model, Dkk1ΔBcell mice with B cell-specific Dkk1 deletion were established and showed increased bone volume BV/TV (P=0.0035) due to increased osteoblast numbers N.OB/B.Pm (P=0.0088). Moreover, conditioned medium from Dkk1ΔBcell induced more efficiently MSC proliferation and osteoblast differentiation compared to wild-type conditioned B-cell medium. In conclusion, Fra2 deletion in B cells enhances osteoblastogenesis by reducing Dkk1 expression, a Wnt-β-catenin inhibitor promoting the transcription of genes essential for osteoprogenitor precursor cells' differentiation. This suggests that the Fra2 - Dkk1 axis in B cells may serve as a novel therapeutic target for bone-loss diseases, including osteoporosis.read more · Original Link ↗
Francesca Gori, PhDHarvard School Of Dental Medicine, Boston, MA, US
Frank Ko, PhDRush University, Chicago, IL, US
Kalpana Patel, PhDDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, BOSTON, MA, US
Vivek S. Khanal, PhDUams, Little Rock, AR, US
Husam Bensreti, PhDDepartment of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, GA, USA
Jasmin Koehnken Sawall, PhDThe Children's Hospital Of Philadelphia, Philadelphia, PA, US
Flora Nguemedjio Foko TakileFreidrich Alexander University/Uniklinikum Erlangen, Erlangen, DE
☆
Sat 10/10 · 11:30 AM - 12:30 PM
Oral Presentations: Pathway-Targeted Approaches to Skeletal Dysplasia
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 311
Mitochondrial dysfunction plays a key role in premature musculoskeletal aging in hypochondroplasia mouse model - Chantal Fayad, PhD student
Hypochondroplasia (HCH) is a mild rhizomelic dwarfism caused by FGFR3 gain-of-function mutations.Mitochondrial dysfunction plays a key role in premature musculoskeletal aging in hypochondroplasia mouse model - Chantal Fayad, PhD student
Hypochondroplasia (HCH) is a mild rhizomelic dwarfism caused by FGFR3 gain-of-function mutations. To decipher the effect of FGFR3 on the musculoskeletal system during aging, we studied the Fgfr3 N534K/+ mouse model at various time points. In particular, we evaluated articular cartilage (AC) and subchondral bone (SB) by thickness measurements, collagen fibers quantification, and we assessed bones by microCT and proteomics. The skeletal muscle was also examined by grip test, RT-qPCR and immunofluorescence.
Fgfr3 N534K/+ showed a decrease in AC thickness and thick collagen fibers in the medial tibial plateau compared to Fgfr3 +/+ mice. They also had higher BMD, BV/TV and trabecular number in the SB consistent with a sclerotic bone phenotype in the medial part suggesting an increase in SB remodeling and revealing osteoarthritis-like changes in mutants.
Furthermore, Fgfr3 N534K/+ mice exhibited reduced muscle force, reduced fibers cross sectional area and increased shape factor index compared to Fgfr3 +/+ mice, suggesting that the muscle is structurally and functionally altered. TRIM63 expression was significantly reduced indicating disrupted protein turnover, which may contribute to compromised muscle homeostasis.
Finally, microCT of femurs showed increased cortical TMD & BV/TV and decreased trabecular BMD & BV/TV in Fgfr3 N534K/+ compared to Fgfr3 +/+ in old mice. Bone parameters were more severely disrupted in Fgfr3 N534K/+ , indicating enhanced bone fragility and osteoporosis.
To further understand this bone defect, we performed proteomics of the cortical bone from 3 to 24 months. Interestingly, our analyses revealed strong Fgfr3 mutation-specific disruption of mitochondrial pathways, particularly oxidative phosphorylation and the TCA cycle. These pathways showed unexpectedly high functional centrality relative to their physical interactions, suggesting that the mutation is pushing the metabolic machinery to an extreme functional state to maintain network coordination. Consequently, mutants exhibited an early activity spike of mitochondrial pathways which accelerated their physiological aging trajectory relative to wild-type.
In conclusion, our findings indicate that the Fgfr3 gain-of-function mutation impairs mitochondrial metabolic pathways and disrupts musculoskeletal homeostasis. Here, we identified for the first time a key role of mitochondria in cortical bone of Fgfr3 N534K/+ mice which provide a potential mechanism for the premature aging in hypochondroplasia.
Prenatal Treatment with Dabogratinib Increases Both Long Bones and Size of the Foramen Magnum and Delays Premature Fusion of Synchondroses in a Mouse Model Mimicking Achondroplasia - Jacqueline Starrett, PhD
Objectives: Achondroplasia (ACH) is a multi-system condition which results in disproportionate short stature, functional challenges and serious medical complications. Infants with ACH have an increased risk for death related to critical foramen magnum stenosis, which has been detected as early as the third trimester. An autosomal dominant mutation in Fibroblast Growth Factor Receptor 3 (FGFR3) causes ACH. FGFR3 gain-of-function mutations impair endochondral bone formation by disrupting both chondrogenesis and osteogenesis. Dabogratinib (formerly TYRA-300), a selective oral FGFR3 inhibitor, recently demonstrated improved growth when treated from 1 day old for 15 days in the Fgfr3 Y367C/+ mouse model which mimics the phenotype of ACH. While these results represent promising therapeutic potential, the current study addresses whether additional improvement could result from initiating treatment before birth.
Methods: Dabogratinib was administered daily at a 2.7 mg/kg dose in pregnant mice from embryonic day 14.5 through birth, which models the third trimester in mice, then administered to Fgfr3 Y367C/+ neonates at a 1.2 mg/kg dose from 1 day after birth for 15 days.
Results: Dabogratinib treatment of Fgfr3 Y367C/+ mice resulted in a 37.4% increase in the length of the tibias and 26.3% increase in the femurs, compared with vehicle-treated Fgfr3 Y367C/+ mice. The increase in long bone size is greater when mice are treated in utero, confirming that dabogratinib crosses the placental barrier. Importantly, mCT analyses showed a significant effect of dabogratinib treatment on the area of the foramen magnum (+35.1%) and synchondroses. Analysis of the intraoccipital synchondrosis anterior revealed that while vehicle-treated mice had prematurely fused synchondroses, dabogratinib treatment resulted in open intraoccipital synchondroses (10/11 mice). We also observed reduced premature fusion of the spheno-occipital synchondroses.
Conclusions: This study demonstrates that inhibiting FGFR3 prenatally can further increase bone growth in Fgfr3 Y367C/+ mice. Most importantly, prenatal plus postnatal treatment resulted in a greater increase in the area of the foramen magnum and opening of the synchondroses compared to postnatal treatment alone. Dabogratinib is currently being evaluated in a Phase 2 trial in children ages 3-10 with ACH, BEACH301 (NCT06842355). These results suggest that earlier treatment may positively impact foramen magnum stenosis in infants with ACH.
Appendicular and cranial base skeletal defects in Achondroplasia are ameliorated by treatment with a retinoid drug as revealed in a mouse model - Christina Mundy, PhD
Achondroplasia (ACH), a most common form of human dwarfism, is due to gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3). The disease affects the appendicular skeleton most visibly but also deranges the axial skeleton with lordosis and causes substandard growth of the cranial base, with potentially severe consequences. FGFR3 is normally expressed in growth plate chondrocytes where it limits proliferation and maturation and thereby reduces the overall rates of skeletal growth. The greater signaling output by mutant FGFR3 (FGFR3 ACH ) further reduces those processes, leading to dwarfism. In previous studies, we reported that the normal functioning of the growth plate and the consequent rates of skeletal growth are promoted by retinoic acid receptors (RARs), acting as ligand-deficient transcriptional repressors. Here, we asked if retinoid antagonists capable of enhancing such beneficial RAR transcriptional repression may counterbalance the deleterious effects of FGFR3 ACH and permit normal skeletal growth. Compound mice bearing an inducible knock-in Fgfr3 ACH mutation and Acan CreER allele active in chondrocytes were given tamoxifen at postnatal day 10 (P10). Mice were then administered retinoid antagonist drugs or vehicle three times/week. Imaging, histochemical and molecular analyses of the appendicular skeleton and long bone growth plates over time revealed that the drug treatment was able to counter the pathogenic effects of FGFR3 ACH . It preserved the growth plate’s zonal structure and the expression of Pthlh , Apoe , Ihh , Gli1/2/3 and Col10a1 in appropriate zones as well as the normal long bone lengthening and increases of body weight over time, compared to mutant mice receiving vehicle. Importantly, the drug treatment preserved also the structure and activity of growth plate synchondroses in the cranial base, preventing the emergence of ectopic bone bridges and premature closure. Blood tests showed that the drug treatment was safe throughout the experimental periods tested. In sum, our study reveals that the retinoid antagonist drugs protect against the ravages of FGFR3 ACH in both the appendicular and craniofacial skeleton. The drugs may be superior to the current FDA-approved treatments for ACH with recombinant C-type natriuretic peptide (CNP) analogs that partially and only address appendicular skeletal defects. The retinoid drugs may thus represent a novel, comprehensively effective and easy-to-administer treatment for ACH.
PTH1R agonist treatment improves growth plate architecture and promotes skeletal growth in Achondroplasia model mice - Prem Swaroop Yadav, PhD
Achondroplasia (ACH), the most common genetic form of human dwarfism (1 in 20,000-30,000 live births), is caused by activating mutations in FGFR3 that suppress chondrocyte proliferation and accelerate their differentiation through enhanced MAPK/ERK signaling. Constitutive FGFR3 activity also suppresses expression of PTH-related peptide (PTHrP) and parathyroid hormone 1 receptor (PTH1R) in growth plates, thus further limiting the pro-proliferative actions of PTHrP/PTH1R signaling in chondrocytes and thereby accelerating growth plate closure. Vosoritide, a C-type natriuretic peptide (CNP) analog, is currently the only approved therapy for ACH, and acts via the natriuretic peptide receptor (NPR) to attenuate enhanced MAPK/ERK signaling and thereby improve longitudinal growth. The projected final adult heights of most vosoritide-treated individuals, however, remain well below those of healthy controls, which highlights the need for improved therapeutic strategies.
Here, we tested whether intermittent activation of PTH1R signaling by daily s.c. injection of a potent PTH agonist analog, (palmitoyl(p)M-PTH(1-11) [pM-PTH(1-11); at 50 nmol/kg/day], could improve growth defects in ACH model mice. The Fgfr3 G374R/+ (ACH/+) mice were generated by introducing the G374R mutation, equivalent to human G380R, into one mouse Fgfr3 allele of humanized PTH1R mice via the Cas9-based iGONAD procedure. ACH/+ mice were significantly smaller than wild-type (WT) littermates (7.1 ± 0.5 g vs. 18.2 ± 1.0 g at 30 d of age) and exhibited skeletal defects characteristic of ACH.
Daily injection of pM-PTH(1-11) increased the body weight of ACH/+ mice (12.2 ± 1.2 g vs. 6.9 ± 1.4 g at 30 d of age), improved tail and long bone length, and normalized closure of the cranial sutures, as compared to vehicle-treated ACH littermates. Daily pM-PTH(1-11) injections did not induce hypercalcemia or other obvious adverse effects. Histological analyses of growth plates in pM-PTH(1-11)-treated ACH/+ mice revealed marked expansion of the Col2-positive proliferative zone, expanded Col10-positive hypertrophic layers, delayed growth plate closure, and normalized osteopenia, as compared to the growth plates in vehicle-treated ACH/+ controls.
The data overall provide strong support for the use of a PTH1R agonist as a strategy to normalize skeletal growth in ACH. Ongoing studies are assessing whether combined PTH1R agonist and vosoritide treatment can yield additive improvements in skeletal growth in ACH.
An orally available small-molecule inverse agonist to reduce constitutive activity of PTH1R mutants that cause Jansen’s metaphyseal chondrodysplasia - Jakob Hoeppner
Jansen’s metaphyseal chondrodysplasia (JMC) is a rare, skeletal dysplasia caused by constitutively active mutations in the PTH/PTHrP receptor, PTH1R. Patients typically present with severe growth-plate abnormalities, short stature, hypercalcemia, hypophosphatemia, suppressed PTH levels, and hypercalciuria. No therapy is currently available for JMC. Peptide-based PTH1R inverse agonists suppress constitutive signaling of JMC-PTH1R mutants in vitro and partially correct mineral ion and skeletal abnormalities in JMC mouse models; however, these peptide ligands require high-dose parenteral administration, which limits their therapeutic utility. There is thus a need for an orally available PTH1R inverse agonist.
Here, we show that a previously reported small-molecule PTH1R antagonist, DS69910557 (DS699), functions as a potent inverse agonist at JMC-PTH1R mutants in vitro and in vivo. In HEK293 cells, DS699 suppressed constitutive cAMP signaling by JMC-PTH1R mutants with a potency comparable to that of a peptide inverse agonist. DS699 showed no inhibitory activity at related G protein-coupled receptors, including PTH2R, indicating high selectivity. Pharmacological assays in vitro and in silico docking supported an allosteric mode of PTH1R inhibition.
To assess translational efficacy in vivo, we administered DS699 to humanized JMC model mice expressing the T410R-PTH1R JMC allele. Single-dose subcutaneous injection or oral gavage reduced elevated blood ionized calcium levels in these animals, and in parallel, de-suppressed endogenous PTH levels. In longer-term studies, DS699 treatment improved the grossly abnormal growth-plate morphology of T410R-PTH1R mice. These results indicate efficacy on both mineral ion abnormalities as well as skeletal defects.
Collectively, these findings identify DS699 as an orally active small-molecule inverse agonist at constitutively active PTH1R mutants and support its further development as a candidate therapeutic for JMC.read more · Original Link ↗
Ivo Kalajzic, PhD, MDUniversity Of Connecticut School of Dental Medicine, Farmington, CT, US
Roy Morello, PhDUniversity Of Arkansas For Medical Sciences, Little Rock, AR, US
Chantal Fayad, PhD studentUMR 1163, Imagine Institute, Université Paris Cité, Paris, France
Jacqueline Starrett, PhDTyra Biosciences, Carlsbad, CA, US
Christina Mundy, PhDChildren's Hospital of Philadelphia, USA
Prem Swaroop Yadav, PhDHarvard Medical School/Mass General Brigham, Belmont, MA, US
Jakob HoeppnerEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US
☆
Sat 10/10 · 11:30 AM - 12:30 PM
Oral Presentations: Osteoclasts at the Interface of Skeletal and Hematopoietic Regulation
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 312
Bone Resorptive Microenvironment Fosters Macrophage-Hematopoietic Stem Cell Interactions That Safeguard Red Blood Cell Regeneration - Ryan Adapathya
Severe inflammatory stress (e.g. radiation/chemotherapy) compromises hematopoietic stem cell (HSC) regeneration and leads to symptoms including anemia and thrombocytopenia.Bone Resorptive Microenvironment Fosters Macrophage-Hematopoietic Stem Cell Interactions That Safeguard Red Blood Cell Regeneration - Ryan Adapathya
Severe inflammatory stress (e.g. radiation/chemotherapy) compromises hematopoietic stem cell (HSC) regeneration and leads to symptoms including anemia and thrombocytopenia. Understanding regulatory mechanisms that safeguard HSCs is critical to ensure proper hematopoiesis under inflammatory stress.
Using intravital tracking of bone remodeling and an HSC reporter mouse model ( Mds1 GFP ;Flt3 cre ), we found that HSCs are not uniformly compromised under systemic inflammation (LPS, 1.4 mg/kg). HSCs harvested from marrow cavities undergoing local bone resorptive (RE) activity have unexpectedly superior regeneration. Intravital tracking also revealed a subset of macrophages (MΦ) frequently retrieving cellular cargos from HSCs in RE cavities, followed by HSC division. Functionally, HSCs exhibited asymmetric division patterns following these interactions, in contrast with the general notion that an inflammatory microenvironment drives symmetric division and HSC exhaustion.
Mechanistically, in vivo antibody staining confirmed surface expression of calreticulin and MHC-I on HSCs that interacted with MΦ, consistent with interactions identified in zebrafish models, termed “grooming” that promotes HSC clonality. Via flow cytometry, we found that the CD206 + /CD74 + MΦ subset is the primary population that performs grooming. Single cell sequencing revealed autocrine IL-10 signaling enriched in the RE-resident CD206 + /CD74 + MΦ. Deleting IL-10 from MΦ ( Csf1r cre ; Il10 fl/+ ) disrupted formation of “phagocytic cups” required for grooming interactions. The CD206 + /CD74 + MΦ subset and grooming interactions, however, were considerably reduced by chemotherapy (cyclophosphamide, 200 mg/kg) and anti-bone resorptive zoledronate (ZOL) (1.2 µg/mouse).
On the translational perspective, inducing grooming using high throughput screened compound DL-PPMP (.02 mg/kg) promoted expansion of erythroid-biased progenitors while maintaining the HSC pool. Complete blood count analyses showed that single-dose DL-PPMP administered after high-dose (6 Gy) radiation mitigated anemia in mice. Notably, ZOL, commonly given after radiation or chemotherapy to prevent bone loss, blunted red blood cell regeneration and counteracted the beneficial effects of DL-PPMP.
All together, we showed that the bone resorptive microenvironment fosters MΦ-HSC interactions that safeguard red blood cell regeneration. These findings provide targetable candidates to protect hematopoiesis under severe inflammatory stress.
Physiological bone remodeling shapes a non-uniform inflammatory landscape of marrow macrophages that regulates <em>Tet2<sup>+/-</sup></em> mediated clonal blood disorders - Kevin Lee
Myelodysplastic syndromes (MDS) are driven by hematopoietic stem cells harboring leukemia-associated mutations (e.g. TET2 ) that expand in the bone marrow. Understanding the mechanisms that regulate expansion of mutant clones is critical to restrain disease progression.
Several prior studies have revealed that the spatial organization of hematopoietic cells in the bone marrow impacts clonal behaviors, but the underlying mechanisms are unclear. To answer this question, we have recently developed intravital imaging methodologies to track the development of the mutant clones ( Tet2 +/- ) with bone remodeling. With this technique, we showed that mutant clonal burden fluctuates with the bone remodeling process. We visualized compartmentalized expansion (hotspot) of mutants in bone resorptive cavities (RE) but retained as singlets (coldspot) in cavities that were non-resorptive (NR). Spatially resolved single-cell transcriptomic profiling and functional assessment revealed that physiological bone remodeling influences CD206 + macrophages (MΦs) plasticity and cytokine secretion. Specifically, Cd206 + MΦs excrete higher IL-1b in response to danger signals released from bone resorption (hydroxyapatite, Ca 2+ ). Notably, MΦs in the non-resorptive marrow cavities are inherently anti-inflammatory, with low antigen presentation even under high-dose IFN-γ stimulation (100ug/mouse). Mechanistically, this is mediated by IL-10 and the Il-10 deficiency in MΦs/dendritic cells ( Csf1r-cre; IL10 fl/+ ) reduced the coldspots and aggravated Tet2 expansion. Inhibition of bone remodeling with zoledronate decreased clonal burden and mitigated cytopenia during disease progression.
As failure in hypomethylating agent (HMA) treatment is a major bottleneck to improve MDS prognosis, we next examined whether physiological bone remodeling serves as protective niches to support growth of residual mutant clones after HMA treatment. Leveraging the same model, preliminary data showed a rebound in Tet2 +/- clonal burden as soon as 4-days post withdrawal of 5-Azacitidine (60ug/mouse QDx5). Notably, this increase coincided with an overblown increase in RE cavities.
All together, these results reveal that physiological bone remodeling shapes a non-uniform inflammatory landscape of macrophages that direct Tet2 +/- clonal expansion. Elucidation of the microenvironment in a residual disease scenario will illuminate mechanisms in the bone-bone marrow interface involved in mutant clonal persistence after therapy.
Targeting SRPK1 brakes energy metabolism of osteoclasts by regulating alternative splicing - Qingliang Ma, MD
Purpose: Excessive osteoclast-mediated bone resorption is a crucial cause of osteoporosis, yet the role of alternative splicing (AS) in osteoclastogenesis remain unclear. This study aimed to identify key AS regulators in osteoclasts and elucidate the underlying mechanisms.
Methods: Integrative bioinformatic screening of osteoporotic patient bone tissues and RANKL-stimulated transcriptomes was performed to identify the vital AS regulator in osteoclastogenesis. Myeloid-specific Srpk1 conditional knockout mice were generated to evaluate bone phenotype. Phosphoproteomics and proteomics were conducted to characterize the crucial pathways regulated by SRPK1. LACE-seq and RNA-seq were integrated to determine the downstream AS events, which was further confirmed by RIP, EMSA, PCR, and mini-gene assays. In vitro osteoclastogenesis, mitochondrial function assays, and OVX mouse models were employed to evaluate the effects of targeting SRPK1 in regulating energy metabolism, osteoclast differentiation, and OVX-induced bone loss.
Results: Osteoclasts exhibited active AS with exon skipping as the dominant type. The expression of SRPK1 was up-regulated during osteoclastogenesis. Srpk1 cKO mice displayed increased trabecular bone mass, improved microarchitecture, and reduced osteoclast numbers. Phosphoproteomics demonstrated targeting SRPK1 mainly affected RNA splicing pathways, with serine/arginine-rich splicing factor 5 (SRSF5) emerging as the primary downstream phospho-substrate. Proteomic profiling further demonstrated SRPK1 inhibition downregulates proteins enriched in oxidative phosphorylation (OXPHOS) pathways, leading to reduced ATP production. LACE-seq and transcriptomics identified Opa1 as the vital downstream target of the SRPK1-SRSF5 axis. SRPK1-mediated phosphorylation of SRSF5 facilitates exon 4b skipping of Opa1 , maintaining an appropriate S-OPA1/L-OPA1 ratio. Loss of SRPK1 increases exon 4b retention, elevates S-OPA1 levels, and attenuates mitochondria fusion, which impairs mitochondrial OXPHOS, thereby suppressing energy metabolism and osteoclastogenesis. Pharmacological SRPK1 inhibition rescued OVX-induced bone loss, improved trabecular parameters, and decreased osteoclast numbers.
Conclusion: By combining conditional gene knockout mice and multi-omics approaches, this study elucidated that SRPK1-SRSF5- Opa1 axis couples AS to mitochondrial energetics in osteoclastogenesis. Targeting SRPK1 represents a promising therapeutic strategy for osteoporosis.
Intermittent parathyroid hormone employs osteoclast-dependent mechanisms to drive osteogenesis from Ebf3-expressing skeletal progenitor cells - Byron S K Chan, PhD
Background : Bone marrow Cxcl12-abundant reticular (CAR) cells, marked by Early B-cell Factor 3 (Ebf3) expression, give rise to osteoblasts. Our prior lineage tracing studies showed that intermittent PTH (iPTH) stimulates Ebf3-lineage cell recruitment to bone surfaces and osteoblastic differentiation. The cell-intrinsic and extrinsic mechanisms underlying this event and whether they operate in human CAR cells are unknown. Here, we study the mechanisms by which iPTH promotes CAR cells to differentiate into osteoblasts and establish this progenitor source as an essential mediator of bone anabolism.
Methods : 10-week-old Ebf3-CreERT2;tdTomato (tdT) mice received tamoxifen to label Ebf3+ cells and their progeny, and then were treated with vehicle, OPG-Fc (5mg/kg/week), PTH 1-34 (100µg/kg/day), or combination for 10 days. Tamoxifen-treated Ebf3-CreERT2;tdT and Ebf3-CreERT2;Sp7f/f;tdT mice received vehicle or PTH for 4 weeks to assess the effects of Sp7 deletion from Ebf3-lineage cells. Tibia and femur were isolated for histological tdT+ cell quantification and microCT. Pooled long bones underwent serial digestion, tdT+ stromal cells were characterized by flow cytometry and sorted for 10X scRNA-seq and in vitro migration assay. Bone marrow aspirates from postmenopausal women receiving teriparatide for 3 months were processed for scRNA-seq and integrated with a naïve human bone marrow atlas.
Results : OPG-Fc cotreatment blocked iPTH-stimulated tdT+ cell recruitment to bone surfaces and osteoblastic differentiation without impairing iPTH-induced 6C3+tdT+ subset expansion by flow cytometry. scRNA-seq revealed that PTH ± OPG-Fc downregulated CAR cell genes Ebf1 and Foxc1 , while TGFß-responsive genes ( Snai1, Pmepa1, Plod2, Tgm2) were increased by PTH and blunted by OPG-Fc. TGFß1 and osteoclast-conditioned medium induced greater tdT+ cell migration than controls. In teriparatide-treated human CAR cells, CXCL12, KITLG, EBF3, and FOXC1 expression were lower, while TGFß-responsive genes ( SERPINE1, CCN2, FN1, PLOD2) were higher versus atlas CAR cells. Sp7 deletion in Ebf3-lineage cells blocked iPTH-induced increases in serum P1NP and CTX and trabecular bone mass gains in both the secondary and primary spongiosa.
Conclusions : iPTH-driven osteogenesis from CAR cells requires osteoclasts and may be mediated by TGFß-responsiveness. PTH transcriptomic effects on murine CAR cells are conserved in human CAR cells. CAR cells are essential contributors to iPTH-induced bone anabolism.
Angiogenin-Mediated Mitochondrial Biogenesis Is Required for Osteoclast Fusion - Ke Shen, MD
Cell - cell fusion is a critical step in osteoclastogenesis, enabling formation of multinucleated osteoclasts required for normal bone remodeling. This fusion is energy intensive and requires increased mitochondrial biogenesis to supply ATP; however, how mitochondrial biogenesis is regulated during osteoclast fusion remains poorly understood. Here, we identify angiogenin (ANG), a member of the RNase A superfamily, as an essential mitoribosome biogenesis regulator during osteoclast fusion. Deletion of Ang ( Ang−/− ) markedly reduced mitochondrial activity and mature osteoclasts formation in vitro , and resulted in a dramatic high-bone-mass phenotype in vivo . Motivated by scRNA-seq and structural analyses implicating ANG in mitochondrial biogenesis, we examined the dynamic changes of subcellular distribution and found that ANG translocated to mitochondria upon fusion initiation. To assess the consequence of ANG loss on mitochondrial activity, Seahorse assay was performed and showed reduced mitochondrial respiration in Ang−/− cells compared to Ang+/+ cells during fusion. To elucidate the molecular basis of the respiration phenotype, we found that ANG deficiency specifically impaired the expression of mitochondrial DNA-encoded subunits, with a global elevation in all the rRNA-precursor ends in Ang−/− cells during fusion, suggesting an accumulation of the unprocessed rRNA precursors. We then reintroduced ANG into Ang−/− cells and found that wild-type ANG, but not ribonuclease-defective mutant, restored mitochondrial biogenesis and osteoclastogenesis, suggesting that the ribonuclease activity of ANG is required for mitochondrial RNA (mtRNA) processing. We mapped ANG-mediated cleavage sites by performing a transcriptome-wide parallel analysis of RNA ends (PARE-seq). The results revealed that ANG cleaves the tRNA 3’-end bordering rRNAs in pre-mtRNA, releasing rRNAs to initiate mitoribosome assembly and drive mitochondrial biogenesis for fusion. Given osteoclast-mediated callus resorption is required for fracture healing, we examined whether ANG deficiency leads to abnormal healing using a drill-hole model. Osteoclast number and activity markedly decreased at the healing sites, along with excessive accumulation of enlarged woven bone in Ang−/− versus Ang+/+ mice. Our findings identify ANG as a mtRNA processing enzyme essential for mitoribosome biogenesis during osteoclast fusion, a process required for proper bone remodeling during bone homeostasis and fracture healing.read more · Original Link ↗
Ritu Chakravarti, PhDUniversity of Kentucky, Lexington, KY, US; Associate Professor, USA
Megan Weivoda, PhDMayo Clinic, Rochester, MN, US
Ryan AdapathyaDepartment of Pharmacology and Physiology, University of Rochester Medical Center, USA
Kevin LeeUniversity of Rochester, Rochester, NY, US
Qingliang Ma, MDQilu Hospital of Shandong University, Jinan, CN
Byron S K Chan, PhDMassachusetts General Hospital, Boston, MA, US
Ke Shen, MDJohns Hopkins University, Baltimore, MD, US
Built for you by(617)-PATRICK, Champion AI speaker
A short break to stretch, grab a coffee and network with fellow attendees before the next session. · Original Link ↗
☆
Sat 10/10 · 12:45 PM - 2:00 PM
Industry-Supported Symposium: Bone Beyond Density: Evidence on Quality and Strength in Postmenopausal Women with Osteoporosis (Non-CME Event)
● Industry Session
Industry Session
📍 Ballroom C
An industry-supported educational symposium held alongside the main ASBMR program. · Original Link ↗
☆
Sat 10/10 · 12:45 PM - 2:00 PM
Industry-Supported Symposium: Beat the Clock: Can You Recognize, Diagnose, and Treat Fibrodysplasia Ossificans Progressiva Early
● Industry Session
Industry Session
📍 Meeting Room 210
An industry-supported educational symposium held alongside the main ASBMR program. · Original Link ↗
☆
Sat 10/10 · 12:45 PM - 2:00 PM
Industry-Supported Symposium: Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies
● Industry Session
Industry Session
📍 Meeting Room 304
An industry-supported educational symposium held alongside the main ASBMR program. · Original Link ↗
☆
Sat 10/10 · 12:45 PM - 2:00 PM
Industry-Supported Symposium: Advancing Care in X-Linked Hypophosphatemia: Applying Newly Published International Treatment Guidelines
● Industry Session
Industry Session
📍 Meeting Room 306
An industry-supported educational symposium held alongside the main ASBMR program. · Original Link ↗
☆
Sat 10/10 · 12:45 PM - 1:45 PM
Meet the Professor: Novel Insights into Mechanosensing
● Meet the Professor
Meet the Professor
📍 Meeting Room 309
Osteocyte fluidics: implications for cell mechanobiology and bone fragility - Alessandra Carriero, PhD
The periosteum in bone mechanotransduction: from mechanical cues to cortical bone formation - Jinhu Xiong · Original Link ↗
Alessandra Carriero, PhDThe City College Of New York, New York, NY, US
Jinhu XiongUniv Of Arkansas For Medical Sciences, Little Rock, AR, US
☆
Sat 10/10 · 12:45 PM - 1:45 PM
Meet the Professors: The Future of Skeletal Regeneration
● Meet the Professor
Meet the Professor
📍 Meeting Room 310
Mammalian Digit Tip Regeneration - Connor Dolan, PhD Role of Erythrocytes in Skeletal Regeneration - Annemarie Lang, PhD, DVM Role of the Inflammatory Response in Bone Regeneration - Jennifer Simkin, PhD Role of TGF Beta Signaling in Bone Loss and...Mammalian Digit Tip Regeneration - Connor Dolan, PhD
Role of Erythrocytes in Skeletal Regeneration - Annemarie Lang, PhD, DVM
Role of the Inflammatory Response in Bone Regeneration - Jennifer Simkin, PhD
Role of TGF Beta Signaling in Bone Loss and Fracture Repair - David E. Maridas, PhD
Panel Q & Aread more · Original Link ↗
Jialiang Wang, PhDUT Southwestern Medical Center, Dallas, MA, US
Connor Dolan, PhDArizona State University, Tempe, AZ, US
Annemarie Lang, PhD, DVMUniversity Of Michigan, Ann Arbor, MI, US
Jennifer Simkin, PhDUniversity of Kentucky, Lexington, KY, US
David E. Maridas, PhDAugusta University, Augusta, GA, US
☆
Sat 10/10 · 12:45 PM - 1:45 PM
Meet the Professor: Senescence in the Skeleton
● Meet the Professor
Meet the Professor
📍 Meeting Room 311
The Aging Landscape by scRNAseq of Mesenchymal Lineage Cells in Mouse Bone - Maria Jose S. Almeida, PhD
Senolytic Treatment Improves Responsiveness to Mechanical Loading in the Skeleton of Aged Mice - Alexander G. Robling · Original Link ↗
Maria Jose S. Almeida, PhDUniversity of Arkansas for Medical Sciences, Little Rock, AR, US
Alexander G. RoblingIndiana University, Indianapolis, IN, US
☆
Sat 10/10 · 12:45 PM - 1:45 PM
Multiverse of Science Careers: Pathways in Research, Medicine, Industry, and Advocacy
● Career Development
Career Development
📍 Meeting Room 312
Rare Disease Non-Profit Director - Tracy Hart, B.S.Rare Disease Non-Profit Director - Tracy Hart, B.S.
Medical Science Liaison - Maria Barr, PharmD
Medical Science Liaison - Amel Dudakovic
Medical Science Liaison - Brian Sciari, PhD
Pharma - Senior Scientist - Michael Friedman, PhD
Biotech - Yves Sabbagh, PhD
Education Research - John Drazan, PhD
NIH Program Officer - Kristy Nicks, PhD
Clinician Scientist - Benjamin Levi, MD
Research Compliance - Curtis Van Slyck
Journal Editor - Sejal Vyas, PhD
Consultant/Program Management - Kunle Demuren, PhD
Patent Law - John Spangenberger, JD
Patent Law - Amanda caradona, JD
Small Pharma/Regulatory Affairs - Ricardo Dent, MDread more · Original Link ↗
Tracy Hart, B.S.1
Maria Barr, PharmD2
Amel Dudakovic3
Brian Sciari, PhD4
Michael Friedman, PhD5
Yves Sabbagh, PhD6
John Drazan, PhD7
Kristy Nicks, PhD8
Benjamin Levi, MD9
Curtis Van Slyck10
Sejal Vyas, PhD11
Kunle Demuren, PhD12
John Spangenberger, JD13
Amanda caradona, JD13
Ricardo Dent, MD14, (1)Osteogenesis Imperfecta Foundation, USA(2)Alexion, USA(3)Amgen, USA(4)Amgen Pharmaceuticals, USA(5)Merck, USA(6)Stealth mode biotech, Palo Alto, CA, US(7)Fairfield University, USA(8)National Institutes of Health, USA(9)Center for Organogenesis, Regeneration, and Trauma, Department of Surgery, University of Texas Southwestern, Dallas, Texas, USA(10)Northeastern University, USA(11)Cell Press, USA(12)Priovant Therapeutics, USA(13)Lando & Anastasi, LLP, USA(14)Angitia Biopharmaceuticals (Angitia Incorporated Limited), Guangzhou, China, and Westlake Village, CA, USA, USA
☆
Sat 10/10 · 12:45 PM - 1:45 PM
Meet the Professor: New Tools to Perform Histomorphometry
● Meet the Professor
Meet the Professor
📍 Meeting Room 313
New Tools to Perform Histomorphometry - Thomas Levin Andersen, PhD
In this Meet-the-Professor session, attendees will learn about advanced applications of histomorphometric principles for defining the functions of osteoblasts, reversal cells (osteoprogenitors), and osteoclasts across different skeletal compartments.New Tools to Perform Histomorphometry - Thomas Levin Andersen, PhD
In this Meet-the-Professor session, attendees will learn about advanced applications of histomorphometric principles for defining the functions of osteoblasts, reversal cells (osteoprogenitors), and osteoclasts across different skeletal compartments. The session will cover the quantification of the bone remodeling process, bone structural unit (BSU) composition, various modes of bone formation (RBF, MBF, and oRBF), and RNA-based histomorphometry.
In addition, we will introduce the newly established Rodent Open Science Skeletal Archive (ROSSA), which aims to preserve and share data from rodent skeletal phenotyping studies within the bone research community. The archive includes data from Dual-Energy X-ray Absorptiometry (DEXA), Microcomputed Tomography (µCT), bone histomorphometry, mechanical strength testing, and biomarker assays conducted on serum, plasma, and urine samples.
New Tools to Perform Histomorphometry - Peter Maye, PhDread more · Original Link ↗
Thomas Levin Andersen, PhDUniversity Of Southern Denmark, Odense, DK
Peter Maye, PhDUConn Health, Farmington, CT, US
☆
Sat 10/10 · 12:45 PM - 1:30 PM
Industry Expert Session: Beyond the Bone in HPP: Understanding the Multisystemic Impact of Low ALP Activity
● Industry Session
Industry Session
📍 Product Theater, Discovery Hall - Exhibit Hall C & D
An industry-sponsored expert session held in the Discovery Hall exhibit area. · Original Link ↗
Built for you by(617)-PATRICK, Champion AI speaker
Features approximately 95 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Adult patients with hypophosphatasia treated with Asfotase Alfa in real-world practice."; "Bone Marrow Adiposity in Bone Biopsies from Chronic Kidney Disease Patients Differs...Features approximately 95 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Adult patients with hypophosphatasia treated with Asfotase Alfa in real-world practice."; "Bone Marrow Adiposity in Bone Biopsies from Chronic Kidney Disease Patients Differs across Different TMV Phenotypes"; "Artificial Intelligence - Enabled Analysis of the Published Literature Reveals Greater ALPL Genetic Burden in Adults with Hypophosphatasia and Atypical Femoral Fractures"; "Physical Activity and Response to Romosozumab in Premenopausal Women with Idiopathic Osteoporosis (PremenIOP)"; "Zoledronic acid administered during hospitalization for vertebral compression fracture (VCF) augmentation therapy is associated with a reduced risk of subsequent new VCFs" and 90 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
☆
Sat 10/10 · 2:00 PM - 3:30 PM
Poster Session I
● Poster Session
Poster Session
📍 Discovery Hall - Exhibit Hall C & D
Features approximately 410 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Baseline Characteristics in Part 1 of the ongoing ANDECAL Study, a two-part Phase 2/3 Study of andecaliximab (anti-matrix metalloproteinase-9 mAb) in participants with...Features approximately 410 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Baseline Characteristics in Part 1 of the ongoing ANDECAL Study, a two-part Phase 2/3 Study of andecaliximab (anti-matrix metalloproteinase-9 mAb) in participants with Fibrodysplasia Ossificans Progressiva (FOP)"; "Bone Microarchitecture by Mode of PTH Replacement in Chronic Hypoparathyroidism: HR-pQCT Findings from the SHINE Cohort"; "Chronic Hypoparathyroidism in the US: Prevalence and Incidence From 2018 to 2024, With Baseline Clinical Characteristics"; "CD24 Protects Senescent BMSCs From Macrophage-Mediated Phagocytosis"; "3 and 12 Month Changes in Hip Bone Strength During Romosozumab Treatment in Women with Postmenopausal Osteoporosis: A Real-World Study" and 405 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
☆
Sat 10/10 · 2:00 PM - 2:45 PM
Industry Expert Session: Patient and HCP Perspectives: A Treatment for Hypoparathyroidism
● Industry Session
Industry Session
📍 Product Theater, Discovery Hall - Exhibit Hall C & D
An industry-sponsored expert session held in the Discovery Hall exhibit area. · Original Link ↗
A short break to stretch, grab a coffee and network with fellow attendees before the next session. · Original Link ↗
☆
Sat 10/10 · 3:45 PM - 4:45 PM
Oral Presentations: Spatial Bone Marrow Microarchitecture
● Oral Abstract Presentations
Oral Abstracts
📍 Ballroom C
High-Resolution Spatial Transcriptomics Reveals Distinct Cellular Niches and Aging Remodeling in Murine Femoral Bone Marrow - Lutian Yao, MD
Background: Defining the spatial organization of bone marrow cells is important for understanding bone remodeling and skeletal aging.High-Resolution Spatial Transcriptomics Reveals Distinct Cellular Niches and Aging Remodeling in Murine Femoral Bone Marrow - Lutian Yao, MD
Background: Defining the spatial organization of bone marrow cells is important for understanding bone remodeling and skeletal aging. However, spatial transcriptomic analysis of mineralized bone remains challenging because decalcification can damage RNA and tissue architecture. Here, we established an optimized workflow and applied it to young and aged murine femora.
Methods: Femora from 3- and 20-month-old mice were rapidly decalcified with Morse solution and analyzed using the 10x Visium HD platform. Nuclear feature-based cell segmentation was performed. Spatial regions were manually defined by anatomical distance, including endosteal/trabecular surfaces, peri-endosteal/peri-trabecular areas, far-from-bone regions, and peri-vessel regions. In total, 45,467 cells from four femora were analyzed. Twenty-one clusters were identified, and cell identities were assigned by integrative deconvolution with single-cell RNA-seq references.
Results: We identified osteoblasts, osteo-CAR cells, osteoclasts, and diverse hematopoietic populations. These cells showed clear spatial specificity. Bone-associated cells were enriched along endosteal, trabecular, peri-endosteal, and peri-trabecular regions, whereas immune and blood cells were mainly located in far-from-bone and peri-vessel regions. Myeloid progenitors preferentially localized to bone-associated niches, while mature neutrophils and monocytes were enriched farther from bone surfaces. MALP/marrow adiposity-related cells accumulated in peri-endosteal, peri-trabecular, and peri-vessel areas. Osteo-CAR cells and osteoblasts displayed polarized distribution along bone surfaces. Pathway analysis indicated PTH- and Wnt-responsive programs in osteo-CAR cells. Integration with single-cell RNA-seq data further showed osteogenic features in osteo-CAR cells after PTH treatment, supporting their potential role as a bone-anabolic progenitor-like population. Aging was associated with reduced osteoblast abundance, relative preservation of osteo-CAR cells, and increased marrow adiposity-related cells and plasma cells.
Conclusions: We established a high-resolution spatial transcriptomic workflow for mineralized bone and defined distinct femoral marrow niches. These findings reveal spatial compartmentalization of bone-associated and hematopoietic cells, identify aging-associated niche remodeling, and suggest that osteo-CAR cells may contribute to bone surface anabolic responses through PTH/Wnt-associated osteogenic potential.
Spatial Deconvolution of the Bone Microenvironment and Inflammatory Niches using a Transcriptomic-Driven Segmentation and Cell Simulation Approach - Visanu Wanchai
High-resolution spatial transcriptomics via the Visium HD platform enables cellular-level insights, but its accuracy remains heavily dependent on cell segmentation. Standard analysis pipelines rely on H&E imaging, which often underperforms in mineralized tissues where nuclear staining is lost or obscured. While multi-modal tools exist, they frequently fail to resolve complex skeletal morphologies, such as multinucleated osteoclasts. To address these limitations, we developed Transcript-signal ENrichment and Grouping Unit (TENGU), a computational framework employing transcriptome-guided deconvolution and cell simulation for high-fidelity spatial reconstruction. We applied TENGU to our in-house Visium HD datasets of S. aureus -infected mouse femurs, effectively capturing the intricate cytoarchitecture of the infected bone. TENGU successfully identified large, multinucleated osteoclasts (20 - 250 µm) at active resorption sites and identified osteocytes within the mineralized cortical matrix. Within areas of reactive bone formation on the periosteum, we detected a diverse cellular landscape including chondrocytes, osteoblasts, pre-osteoblasts, and a cell population expressing high levels of Postn , designated Osteo-X. To demonstrate the ability of TENGU to provide biological insights, we utilized TENGU’s spatially aware cell-cell communication feature to visualize targeted ligand-receptor interactions within distinct pathological niches. In the reactive bone formation area, TENGU resolved a tight spatial signaling hub of essential skeletal development (e.g., Tgfb - Tgfbr2/1 ), localized specifically to Osteo-X cells at the outer edge of the structure. This suggests that Tgfb autocrine or paracrine signaling is a critical driver of Osteo-X function during involucrum formation. We also examined the heavily infiltrated marrow cavity, where TENGU mapped the pro-inflammatory and osteoclastogenic factors (e.g., Il1a/b - Il1r1/2 ). This revealed a distinct spatial architecture of immune-stromal crosstalk between recruited myeloid populations (e.g., neutrophils and monocytes/macrophages) and the endosteal microenvironment, contrasting with the structurally confined TGF-β signaling in the periosteum. Together, these results demonstrate that TENGU effectively decodes the functional micro-anatomy of osteoimmunological inflammation, providing a foundation for developing niche-specific therapeutic interventions that may help resolve persistent inflammation in chronic osteomyelitis.
Single Cell Spatial Transcriptomics Maps Region-Specific Diversity of Human Skeletal Stem Cells - Kun Chen, PhD, MD
Adult tissue maintenance and regeneration depend on resident stem cells, whose dysfunction contributes to degenerative conditions such as aging. Bone-forming stem cells in patient fracture calluses functionally decline with age, which has been linked to shifts in stem cell subtype distribution toward a fibro-stromal state. However, the molecular basis remains unclear. Here, we combined scRNA-seq and spatial transcriptomics to map human skeletal stem cell (hSSC) diversity, niche-specific distributions and age-associated functional changes during repair. hSSCs (CD45 - CD235a - TIE2 - CD31 - CD146 - PDPN + CD73 + CD164 + ) were isolated from periosteal and growth plate regions of fetal long bones for scRNA-seq. Spatial transcriptomics was performed on 5 µm fixed frozen sections of a 20-week fetal phalange and 4 adult fracture samples using NanoString CosMx SMI with a 1,000-gene panel. Combined analyses revealed region-specific differences in hSSC populations, while long bone hSSCs shared common marker expression across the tissue. Using CosMx data with CellCharter, we identified five distinct cell communities corresponding to known anatomical regions of developing long bones. We estimated hSSC localization by identifying SOX9+PDGFRA+ cells in the CosMx dataset. Most SOX9+PDGFRA+ cells were found in the growth plate and periosteum, and to a lesser extent in the metaphysis, but were absent from bone marrow, suggesting they are distinct from bone marrow stromal cells. Consistent with site-specific bone formation, growth plate SOX9+PDGFRA+ cells expressed markers of endochondral ossification, whereas periosteal SOX9+PDGFRA+ cells were enriched for intramembranous ossification genes. Ligand-receptor analysis supported region-specific molecular signatures and interactions, validating the anatomical specificity of hSSC subpopulations. Fracture sample analysis using Google’s Antigravity suggested an age-associated shift in hSSC subtypes accompanied by a decrease in STAT3 signaling and increased inflammatory signatures in stem cells as well as greater myeloid/osteoclast numbers in immediate cell neighborhoods, indicating a functional drift of SSCs during repair with aging. These findings highlight the anatomical specificity, transcriptomic heterogeneity and age-associated remodeling of hSSCs across skeletal sites. Defining region-specific hSSC diversity and niche interactions may inform skeletal aging, disease progression and therapies for degenerative bone diseases.
Intravital Imaging of Connexin 43 (Cx43)-regulated Calcium Network Topology Reveals Immune-Modulatory Loci and Regulates Bone Homeostasis in the Bone Marrow - Cih-Li Hong, DVM, PhD student
Intercellular communications through calcium signaling orchestrates coordinated cell functions across tissues. Bone marrow stromal cells (BMSCs) form a network in the marrow and secrete cytokines essential for regulating hematopoiesis. Yet, the coordination and heterogeneity of the interconnected BMSC network remain unclear.
We developed an intravital calcium imaging platform using LepR-cre; Salsa6f mice, in which tdTomato and a calcium flux indicator (GCaMP6f) are expressed in BMSC lineages. We identified a subset of BMSCs that communicate as a network via intercellular calcium waves (ICWs). The ICWs are provoked by acute inflammatory challenges (lipopolysaccharide, LPS, 1.4 mg/kg) but interrupted by the gap junction inhibitor Carbenoxolone (1.5 mg/mouse, topical). scRNA sequencing analyses suggest that the BMSC subset enriched for Ca 2+ axis is abundant in Ccl2 and Rankl (Receptor Activator of Nuclear Factor B Ligand), key regulators of bone remodeling through osteoclastogenesis. Functional validations using intravital tracking confirmed that ICW initiation led to aggregation of CCR2 + leukocytes 2 h post-ICW, forming “hot spots” within the systemic inflammatory landscape. In addition, the amplitude of ICWs exhibits circadian oscillations that align with the rhythms of RANKL and pro-inflammatory cytokine production, and are spatially localized to marrow cavities with local bone resorptive activities. These results suggested spatially and temporally heterogenous immune responses and bone remodeling in response to systemic inflammation.
To determine causality, we next generated triple transgenic LepR-cre; Cx43 -floxed ; Salsa6f mice. Functionally, Cx43 deficiency reduced ICWs and led to a more diffused CCR2 cell distribution compared to the localized hot spots observed in WT mice under inflammation. Mice with Cx43 -deficiency in stromal cells also had reduced bone mass, suggesting the role of the BMSC network in coupling bone resorption and formation. Notably, similar CCR2 + cell distribution and interrupted ICWs were observed in aged mice following LPS challenge, suggesting that targeting BMSC network integrity may help regulate immune responses and bone homeostasis during aging.
Together, our intravital imaging toolbox uncovered a BMSC subset that coordinates through ICWs in spatiotemporally controlled manner. The network forms immune-modulatory loci and regulates bone homeostasis, potentially contributing to bone and hematopoietic decline during aging.
Dysbiosis of the Aged Gut Drives Myeloid Bias by Altering the Skeletal Stem Cell Niche - Kelly Weldon, PhD student
Deterioration of the musculoskeletal system is a primary driver of age-related morbidity and immune dysfunction. In the bone, skeletal stem cells (SSCs) act as master regulators of skeletal integrity and the bone marrow (BM) hematopoietic niche. While the gut microbiome (GM) is a known modulator of host physiology, the causal mechanisms linking gut-derived signals to the stem cells controlling the BM niche remain obscure. Our preliminary studies established that GM depletion via antibiotic ablation in aged mice rejuvenated SSC function, evidenced by enhanced osteogenic activity and a significant increase in SSC recruitment following fracture injury. Building on these observations, we investigated how the aged, dysbiotic GM actively impairs the SSC-controlled hematopoietic niche and skeletal integrity in vivo . Aged (24-month) male C57BL/6 mice underwent five weeks of GM depletion via broad-spectrum antibiotics in drinking water. Aged SSC functionality was further evaluated via in vivo ossicle-forming capacity through renal capsule transplantation. To track the systemic effects of changes to the hematopoietic niche, longitudinal peripheral blood flow cytometry and end-point BM immunophenotyping of progenitor populations were performed. Single-cell RNA sequencing (scRNA-seq) characterized the transcriptional landscape of the niche, while hematopoietic reconstitution studies differentiated between cell-intrinsic and niche-driven alterations. In vivo , SSCs from aged, GM-depleted mice demonstrated superior mineralized ossicle formation compared to age-matched controls. We also observed a significant shift in circulating hematopoietic lineage composition, reversing age-related myeloid bias to reach a restored, balanced lymphoid-to-myeloid ratio by week 5. This shift toward the lymphoid lineage was mirrored in endpoint BM populations. Analysis of scRNA-seq data identified a distinct expansion of B-cell progenitors with upregulated markers of youthful lymphoid activity, including Ebf1 , Il7r , and Rag1/2 . Reconstitution studies suggested these effects were driven by niche-specific alterations, identifying the SSC lineage as the primary responder to gut dysbiosis. These data demonstrate that the aged niche can be functionally rejuvenated through microbiome modulation, identifying SSCs as central mediators of a gut-bone-immune axis that governs immune niche remodeling and lymphoid lineage development.read more · Original Link ↗
Robert Tower, PhDUniversity Of Texas Southwestern Medical Center, IRVING, TX, US
Mohamed G. Hassan, DDS, PhD, MSWashington University In St. Louis, St. Louis, MO, US
Lutian Yao, MDThe First Hospital Of China Medical University, Shenyang, PA, CN
Visanu WanchaiCenter for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, USA; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, USA
Kun Chen, PhD, MDUc Davis, West Sacramento, CA, US
Cih-Li Hong, DVM, PhD studentUniversity Of Rochester, Rochester, NY, US
Kelly Weldon, PhD studentUniversity Of California, Davis, Sacramento, CA, US
☆
Sat 10/10 · 3:45 PM - 4:45 PM
Oral Presentations: John H. Carstens Memorial Session
● Oral Abstract Presentations
Oral Abstracts
📍 General Session - Ballroom A & B
The Effects of 3-Months of Romosozumab Followed By 21-Months of Denosumab Versus 12-Months of Romosozumab Followed By 12-Months of Denosumab on BMD in Postmenopausal Osteoporotic Women: The LIDA-Extension Study - Benjamin Z.The Effects of 3-Months of Romosozumab Followed By 21-Months of Denosumab Versus 12-Months of Romosozumab Followed By 12-Months of Denosumab on BMD in Postmenopausal Osteoporotic Women: The LIDA-Extension Study - Benjamin Z. Leder, MD
Romosozumab is a dual-acting osteoporosis drug that rapidly increases bone mineral density (BMD) and reduces fractures, though its anabolic effects are short-lived. Romosozumab's use may also be limited by high cost, monthly injection burden, and possible cardiovascular (CV) risk. In the LIDA RCT of postmenopausal osteoporotic woman, 3 months of romosozumab followed by 9 months of denosumab was similarly effective as 12 months of romosozumab in improving hip BMD (primary endpoint) as well as other anatomic sites. This report presents results from a 12-month extension in which all participants received an additional year of denosumab.
Methods : In the LIDA-Extension trial, postmenopausal women at high fracture risk received standard doses of either 3 months of romosozumab followed by 21 months of denosumab (3M-ROMO) or 12 months of romosozumab followed by 12 months of denosumab (12M-ROMO). BMD by DXA and bone turnover markers were measured at 0, 3, 6, 12, and 24 months.
Results : Extension study enrollment included 41 of the original 47 LIDA participants (87%). All participants completed the final visit (22 in 3M-ROMO, 19 in 12M-ROMO). Baseline characteristics were similar between groups (mean age 69.7 yrs). At 24 months, total hip BMD increased by 6.9 ± 2.9% in the 3M-ROMO group and 8.3 ± 3.9% in the 12M-ROMO group (p=0.099). Femoral neck BMD rose by 5.9 ± 5.7% in the 3M-ROMO group and 8.5 ± 7.6% in the 12M-ROMO group (p=0.228). Lumbar spine BMD increased by 13.6 ± 5.5% in the 3M-ROMO group and 18.0 ± 6.7% in the 12M-ROMO group (p=0.026). Distal radius BMD increased by 1.3 ± 3.0% in 3M-ROMO group but decreased in the 12M-ROMO group ( -1.0% ± 2.8%, p=0.018).
Summary : In postmenopausal women at high fracture risk, hip and femoral neck BMD gains did not differ significantly between groups, though they were numerically greater with 12 months of romosozumab. Spine BMD gains were significantly greater with the 12-month regimen, while distal radius gains favored the 3-month regimen. Overall, over 2 years, a shorter romosozumab course achieved substantial and generally comparable skeletal benefits with site-specific differences. This approach may reduce treatment burden, cost, and possibly CV risk, supporting its consideration in shared decision-making for selected patients. Further studies should evaluate other alternative strategies, including short re-treatment courses.
Premenopausal women with idiopathic osteoporosis have continued BMD increases with sequential romosozumab-denosumab therapy - Lauren Kelly Lynch, PhD, MD
Premenopausal women with idiopathic osteoporosis (PremenIOP) have marked deficits in bone density and microstructure, as well as a variable remodeling rate. We have previously reported the effects of romosozumab (ROMO), an antisclerostin antibody with osteoanabolic and antiresorptive effects, for PremenIOP: In 29 PremenIOP, 12M of ROMO led to BMD increases (mean ± SD) of 15.0 ± 10.2% at the lumbar spine (LS), 5.3 ± 4.5% at the total hip (TH), and 5.4 ± 7.1% at the femoral neck (FN) (all p<0.001). All 29 women had significant increases (>0.022 g/cm 2 ) in LS BMD, and there were thus no nonresponders.
After completion of 12M of ROMO, the study’s 2-year sequential treatment design included a second year on denosumab (DMAB) 60mg SC q6M for 12M, followed by transition to clinical care for further antiresorptive treatment. Herein we report results for BMD and TBS, assessed q6M in the 26 participants who completed the 2-year sequence of ROMO-DMAB. These participants were aged 38 ± 7 years, with mean of 4 ± 2 adult fractures, 62% with vertebral fractures, and mean baseline BMD Z scores of -2.4 ± 1.0 at LS, -1.7 ± 0.8 at TH, -1.9 ± 0.9 at FN, and -0.3 ± 0.2 at the distal 1/3 radius (DR).
In Year 2 on DMAB following ROMO, BMD increased by a further 3.3 ± 2.6% at the LS (p<0.001), 1.5 ± 2.3% at the TH (p=0.002), and 3.3 ± 2.6% at the FN (p=0.007) (all mean ± SD; paired t-tests). There was no significant additional change in DR BMD or TBS. Over the 24M ROMO-DMAB sequence, BMD increased by 18.5 ± 11.7% at the LS (p<0.001), 7.0 ± 6.6% at the TH (p<0.001), and 8.6 ± 10.3% at the FN (p<0.001), and there was no significant change at the DR (p=0.95) (FIGURE). TBS increased by 3.4 ± 5.4% (p=0.002). One participant had a clinical fracture (maxillary fracture with mechanical fall after 4M DMAB). There were no new clinical or morphometric vertebral fractures. At the completion of both the DMAB portion only and the combined ROMO-DMAB sequence, there was no difference in response between those with a pregnancy and lactation osteoporosis (PLO) presentation (n=15) and those without PLO.
In summary, these results demonstrate that DMAB leads to continued gains in BMD in PremenIOP completing ROMO. This proof-of-concept study suggests there are benefits of sequential therapy in this severely affected group of young women with osteoporosis.
Pretreatment High Bone Turnover Phenotype Is Associated With Greater Bone Mineral Density Gains During 5-Year Denosumab Treatment - Koji Ishikawa, PhD
Purpose
To investigate the association between pretreatment bone turnover phenotype and bone mineral density (BMD) response during 5-year denosumab (Dmab) treatment in patients with primary osteoporosis.
Methods
This retrospective study included patients with primary osteoporosis treated with Dmab. Bone turnover markers (BTMs) including tartrate-resistant acid phosphatase 5b (TRACP-5b) and total serum procollagen type I N propeptide (PINP) were obtained prior to Dmab initiation. Bone turnover phenotype was quantified with Turnover Index (TI), defined as the sum of standardized log-transformed PINP and TRACP-5b values. We classified patients into 3 TI groups by quartiles: High turnover (highest quartile, group H), Intermediate (2nd and 3rd quartiles, group I), and Low turnover (lowest quartile, group L). Lumbar spine and total hip BMD were assessed by dual-energy X-ray Absorptiometry (DXA) every 6 months after Dmab initiation. We compared the percent change of BMD and absolute change of T-score by spline-based multivariable linear mixed-effects models among the TI groups up to 5 years.
Results
We included 291 patients treated with Dmab (Group H, n=70; Group I, n=148; Group L, n=73), of whom 122 reached 5-year follow-up. All available longitudinal measurements were analyzed. Baseline age, BMI, fragility fracture history, and BMD did not differ significantly among groups, whereas prior osteoporosis treatment differed significantly (p<0.001). After adjustment for age, sex, BMI, eGFR, prior osteoporosis treatment, and vitamin D use, TI group was significantly associated with longitudinal changes in lumbar spine BMD and T-score. At 5 years, model-estimated lumbar spine BMD gains from baseline were 21.8% (95% CI, 17.8 to 25.8) in Group H, 17.5% (95% CI, 15.0 to 20.0) in Group I, and 12.4% (95% CI, 9.4 to 15.5) in Group L (Fig.). At the total hip, 5-year BMD gains were 9.9%, 7.2%, and 1.8% in Groups H, I, and L, respectively (p < .001). This graded association was consistent in sensitivity analyses restricted to treatment-naïve patients and patients with complete 5-year follow-up, suggesting robustness to prior therapy imbalance and incomplete follow-up.
Conclusion
Pretreatment BTM phenotype was associated with BMD improvement during 5-year Dmab treatment. Low-turnover patients showed attenuated BMD gains over 5 years, suggesting that baseline bone turnover status may help characterize heterogeneity in skeletal response to Dmab.
Integrated Effects of Vitamin D, Omega-3 Fatty Acids, and Exercise on Bone and Muscle Health in Generally Healthy Older Adults: Results from the DO-HEALTH Trial - Heike Annette Bischoff-Ferrari
Background: Vitamin D, omega-3 fatty acids, and exercise are low-cost, scalable interventions to promote healthy musculoskeletal aging, yet their combined effects on bone and muscle remain uncertain. We therefore conducted an integrated evaluation of skeletal and muscle outcomes in the DO-HEALTH randomized trial.
Methods: DO-HEALTH was a 3-year, multicenter, randomized, placebo-controlled 2×2×2 factorial trial in generally healthy and active adults aged ≥70 years from 5 European countries (Switzerland, Germany, France, Austria, Portugal). Participants received vitamin D3 (2000 IU/day), omega-3s (1 g/day), and/or a simple home exercise program (SHEP; 3 times/week). Outcomes included vertebral and nonvertebral fractures, bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers, physical performance (SPPB, grip strength), muscle mass, sarcopenia, and Fried-based physical frailty.
Results: Among 2,157 randomized participants (mean age 74.9 years; 61.7% women), 1,900 (88%) completed follow-up (mean 2.99 years). Exercise reduced vertebral fracture incidence in women (IRR 0.52, 95% CI 0.28-0.98), vertebral fracture progression overall (IRR 0.34, 95% CI 0.16-0.75), and sclerostin levels (Δ adjusted mean -1.56 pmol/L, 95% CI -2.54 to -0.58). Vitamin D3 modestly improved total hip BMD (Δ adjusted mean 0.0035 g/cm², 95% CI 0.0011-0.0059). Omega-3s reduced falls by 10% (IRR 0.90, 95% CI 0.81-1.00). No intervention improved muscle outcomes. The combination of all 3 interventions reduced incident pre-frailty in an additive way (OR 0.61, 95% CI 0.38-0.98).
Conclusions: In generally healthy older adults, the DO-HEALTH public health interventions delivered modest but clinically relevant and complementary benefits across domains of musculoskeletal aging. Vitamin D3 modestly preserved hip BMD, omega-3s reduced falls, and exercise lowered vertebral fracture incidence and progression plus reduced sclerostin levels. The combination of all three interventions also had additive benefits on the prevention of pre-frailty. Thus, despite small benefits, together, these safe, affordable, scalable strategies may yield meaningful population-level gains in musculoskeletal health when broadly implemented.
Comparative Risk of Osteonecrosis of the Jaw With SERMs, Bisphosphonates and Denosumab in Osteoporosis: A Nationwide Target Trial Emulation Study - Kyoung Jin Kim, PhD
Purpose: Osteonecrosis of the jaw (ONJ) is an uncommon but serious adverse event associated with antiresorptive therapy. Although ONJ risk is lower in osteoporosis care than in oncology settings, concern about this outcome can influence treatment decisions. Direct head-to-head comparisons among selective estrogen receptor modulators (SERMs), bisphosphonates (BPs), and denosumab are limited. We estimated comparative ONJ risk across these drug classes using a nationwide target trial emulation with three causal contrasts. Methods: Using the Korean National Health Insurance Service database, we identified 177,693 adults aged ≥50 years with osteoporosis (ICD-10 M80 - M82) who newly initiated SERMs (n=13,249), BPs (n=156,448), or denosumab (n=7,996) between July 2016 and December 2021. Patients with end-stage renal disease, prior cancer, prior ONJ, or anabolic agent use were excluded. Follow-up continued through December 2023. Incident ONJ was identified using ICD-10 codes M87.1 or K10.2. Inverse probability of treatment weighting balanced baseline covariates (all standardized mean differences <0.10). We estimated three causal contrasts: per-protocol (PP; primary; censored at switching or discontinuation), intention-to-treat (ITT; 365-day carry-forward), and time-varying (TV) as-treated exposure, accounting for switching and re-initiation. Results: In the PP analysis, 63 ONJ events occurred. Compared with BPs, adjusted hazard ratios (aHRs) were 0.89 (95% CI, 0.28 - 2.89) for denosumab and 0.21 (95% CI, 0.03 - 1.51) for SERMs. In the ITT analysis, 70 ONJ events occurred; aHRs were 0.80 (95% CI, 0.25 - 2.58) and 0.56 (95% CI, 0.18 - 1.81), respectively. In the TV analysis, 163 ONJ events occurred; aHRs were 1.48 (95% CI, 0.97 - 2.26) for denosumab and 0.45 (95% CI, 0.21 - 0.94) for SERMs. Absolute PP incidence rates were 3.75, 3.57, and 0.81 per 10,000 person-years for BPs, denosumab, and SERMs, respectively. Conclusions: Among patients treated for osteoporosis, ONJ occurred rarely across all treatment groups. Denosumab was not associated with higher ONJ risk than BPs in the PP and ITT analyses. The numerically higher denosumab estimate in the TV analysis suggests that switching, re-initiation, and cumulative treatment history can influence risk estimation. SERMs showed lower ONJ risk estimates, although event counts were limited. To our knowledge, this is the first nationwide study to compare SERMs, BPs, and denosumab for ONJ using target trial emulation.read more · Original Link ↗
Suzanne Nicole Morin, MD, MSMcgill University, Montreal, QC, CA
Atthakorn Jarusriwanna, MDFaculty of Medicine, Naresuan University, Phitsanulok, Thailand
Benjamin Z. Leder, MDMassachusetts General Hospital Harvard Medical School, Boston, MA, US
Lauren Kelly Lynch, PhD, MDDivision of Endocrinology, Department of Medicine, Columbia University, New York, USA
Koji Ishikawa, PhDDuke University, Chapel Hill, NC, US
Heike Annette Bischoff-FerrariUniversity of Basel, Dept. of Geriatrics and Dept. of Acute Aging Medicine FELIX PLATTER, Basel, Switzerland, Switzerland; Swiss Campus for Healthy Longevity at the University of Basel, Basel, Switzerland, Switzerland
Kyoung Jin Kim, PhDDivision of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Korea, Republic of (South)
☆
Sat 10/10 · 3:45 PM - 4:45 PM
Oral Presentations: Advances in Osteocyte Biology: Mechanotransduction, Metabolism, and Matrix Regulation
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 302
Mechano-metabolic axis involves mitochondrial responses via BMP/Smad regulatory effect on cyclophilin D - Roman A Eliseev
Mechanical stimulation is fundamental for anabolism in various tissues including bone.Mechano-metabolic axis involves mitochondrial responses via BMP/Smad regulatory effect on cyclophilin D - Roman A Eliseev
Mechanical stimulation is fundamental for anabolism in various tissues including bone. Importantly, mechanical stimulation has been shown to induce reprogramming of cell metabolism likely in order to adjust it to increased anabolism. The signal transduction within this mechano-metabolic axis is incompletely understood. Aiming to delineate such signal transduction, we exposed osteoprogenitors to fluid shear stress (FSS) and assessed cell signaling and bioenergetics. BMP/Smad pathway is known to be activated by mechanical stress and we indeed detected its activation by FSS. We previously reported that BMP downregulates cyclophilin D (CypD), an opener of the mitochondrial permeability transition pore (MPTP). Downregulation of CypD/MPTP improves mitochondrial inner membrane integrity and therefore oxidative function. We found that in FSS-stimulated cells, CypD was indeed downregulated and mitochondrial oxidative function activated in BMP-dependent manner. Meanwhile, osteogenic effect of FSS was dependent on CypD downregulation and mitochondrial responses. On the other hand, publicly available data from NASA indicate that osteoprogenitors under microgravity, a proxy of unloading, present with higher CypD expression when compared to cells exposed to cells on earth. Not surprisingly, microgravity is known to cause mitochondrial dysfunction in humans and mice, presenting with a metabolomic signature consistent with premature aging and oxidative stress.
To confirm our in vitro results in vivo , we optimized a novel model of tooth extraction-mediated unloading of craniofacial bones in mice. Tooth extraction and subsequent unloading led to bone loss and upregulation of CypD in the affected cranial bones. Osteoblast-specific deletion of CypD protected against unloading-mediated bone loss while CypD re-expression in these mice restored bone loss. In sum, we here present new evidence that mechano-metabolic axis in osteogenic cells involves BMP/Smad-mediated downregulation of CypD and CypD-dependent mitochondrial responses. Such regulation is important for osteoanabolic effect of mechanical stimulation. Our data also suggest that targeting CypD can be an effective strategy to prevent bone loss caused by unloading due to immobility, space flight, or tooth extraction.
Interrogating the Impact of Sclerostin Monoclonal Antibody Treatment on Osteocyte Mechanosensitivity <em>In Vivo</em> - Andi Sarai Garcia-Ortiz, MS
Sclerostin monoclonal antibody (Scl-mAb) promotes bone formation by enhancing anabolic Wnt signaling 1,2 . This effect diminishes over time in a dose-dependent manner 3 , implying adaptation in the bone mechanosensor, osteocytes. However, it is not clear whether Scl-mAb interacts with osteocytes and/or directly impacts their mechanosensitivity. Our lab uses intravital two-photon (2P) microscopy to study osteocyte mechanotransduction in vivo 4 . Here, we use this approach to test the hypothesis that Scl-mAb reaches the osteocyte microenvironment and alters their mechanosensitivity in mice in vivo .
We used local 10uL sub-q injection of Alexa Fluor tagged Scl-mAb to observe antibody penetration into the lacuno-canalicular system (LCS) of the mouse third metatarsal (MT3) in vivo (R&D Systems, n=1). To assess the impact of Scl-mAb on osteocyte mechanotransduction, we used mice with osteocyte targeted DMP1-Cre driven GCaMP6f expression (16-18wk, M/F). Single dose Scl-mAb acute treatment groups received a 10uL sub-q bolus over the MT3 with 30min incubation (Regeneron), followed by in vivo sine loading (1000με, 1 Hz, 5 bouts, n=10-19/group). Long-term treatment groups received Scl-mAb IP at 50 mg/kg once a week for either 3 or 5 weeks, followed by in vivo loading (250με-3000με, 1 Hz, n=10-19/group) two days after final injection. We measured percentage of responding cells, response magnitude, and 2D morphology in ImageJ (NIH) and MATLAB (MathWorks), with statistics performed in GraphPad Prism.
Scl-mAb penetrated the LCS, implying direct interaction with osteocytes (A). Scl-mAb increased osteocyte Ca²⁺ signaling acutely, with effects on signaling intensity waning by 1 hour (B-C). After long-term Scl-mAb osteocyte elongation and enlargement occurred, indicating morphological adaptation as early as 3wks (D). The long-term Scl-mAb groups’ Ca²⁺ signaling and magnitude of response were indistinguishable from naïve controls (E-F).
Our findings show Scl-mAb penetrates the LCS, supporting a paradigm whereby Scl-mAb directly impacts osteocyte mechanobiology. Changes to osteocyte structure and Ca²⁺ signaling suggest adaptation and may explain attenuation of Scl-mAb effects over time. Differences in cell morphology may reflect distinct mechanisms by which osteocytes adapt to the enhanced Wnt signaling induced by Scl-mAb.
References: 1) Robling+ (2009) Crit Rev Eukary Gene Expr ; 2) Kramer+ (2010) Mol Cell Biol ; 3) Li+ (2014) Endocrin; 4) Lewis+ (2023) Jove
Disuse Increases Cancellous and Cortical Bone Responses to Mechanical Loading by Enhancing Lacunocanalicular Fluid Dynamics - Haisheng Yang, PhD
Introduction: Disuse conditions - including microgravity, prolonged bed rest, sedentary lifestyles, and limb immobilization - induce severe bone loss, a pathology potentially treatable through mechanical loading (e.g., exercise or vibration). However, how disuse alters bone tissue's response to mechanical stimuli and the underlying mechanobiological mechanisms remain poorly understood. Given that osteocytes, positioned within the fluid-filled microenvironment of the lacunocanalicular network (LCN), serve as the primary mechanosensors and regulators of bone remodeling, we hypothesized that disuse would influence cancellous and cortical bone responses to mechanical loading by altering lacunocanalicular fluid dynamics.
Methods: Axial compressive tibial loading was applied on tail-suspended and ground control female mice of 7-month-old. Micro-CT was used to assess loading-induced changes in cortical and trabecular bone mass and morphology of the tibiae. Confocal imaging was utilized to measure LCN structures. A multiscale computational model from whole bone to LCN level was established to characterize fluid dynamic microenvironments (flow velocity and shear forces) within the LCN under mechanical loading. RNA-seq and RT-qPCR were employed to detect gene expression and signaling pathways.
Results: At the macroscopic level, the tibiae of suspended mice exhibited enhanced responsiveness to the identical mechanical load, with more pronounced increases in metaphyseal trabecular bone volume fraction (normal: 29%, disuse: 90%) and diaphyseal cortical bone area fraction (normal: 15%, disuse: 18%). At the cellular level, disuse led to a significant increase in lacunar volume (normal: 342±125 μm 3 , disuse: 383±146 μm 3 ; p<0.001) with a more spherical shape, resulting in greater fluid shear stresses under the same mechanical loading. At the molecular level, disuse-reloaded mouse skeletons showed a significant enrichment of signaling pathways related to the fluid shear stress (e.g., Wnt, PI3K-AKT, FAK).
Conclusion: Disuse increases cancellous and cortical bone responses to mechanical loading by enhancing lacunocanalicular fluid dynamics and promoting activation of mechanosensitive signaling pathways. These findings advance our mechanistic understanding of bone mechanoadaptation, particularly under disuse conditions.
MeSo-Cre: A new Cre-driver line employing a permissive 2-promoter/2-recombinase strategy to target Cre to the osteocyte population with high fidelity - Alexander G. Robling
Several Cre driver lines have been developed to achieve osteocyte (OCY)-selective recombination of loxP sites in floxed murine models. These lines (e,g., Dmp1-Cre, Sost-Cre) exhibit strong and reliable expression in OCYs, but off-target recombination has been noted for each. We sought to develop a new Cre driver line for studying OCY biology in floxed mice - one that exhibits greater selectivity for OCYs with negligible off-target expression. Rather than relying on yet another OCY-enriched single promoter to drive Cre, a 2-promoter (Mepe and Sost) approach was explored, where expression of both promoters in the same cell would be necessary to induce Cre activity. Both of these genes have strong expression in OCYs, but their non-OCY (off-target) expression patterns do not overlap substantially, which we surmised might reduce/prevent non-OCY Cre expression. To this end, two independent recombinase-expressing mouse lines were generated, using the endogenous Mepe and Sost genes (3’UTR knockin approach) to drive expression. Two independent recombination systems were used - Dre-Rox and Cre-Lox - in the same mouse to narrow expression of Cre to OCYs. Mepe-Dre mice were generated by knocking a 2A-Dre cassette into the Mepe 3’UTR, and Dre-gated Sost-Cre mice were generated by knocking a 2A-roxP-stop-roxP-Cre cassette into the Sost 3’ UTR. These Me pe-2A.Dre and So st-2A.RSR.Cre mice were intercrossed (hereafter “MeSo-Cre”) and tested for OCY-selective loxP recombination efficiency and off-target activity. Inclusion of the Cre-reporter allele Ai9 revealed strong MeSo-Cre-driven recombination of the OCY population in all skeletal elements examined, including the cranial vault, mandible, femur, and spine. Close to 100% of OCYs exhibited a positive tdTomato (tdT) signal regardless of bone envelope (cortical, trabecular). Adjacent tissues in the bone cryosections (muscle, tendon, cartilage, marrow, periosteum, IV disk) were examined but no tdT signal was detected. Further, liver, spleen, kidney, intestine, heart, bladder, and cerebrum were sectioned from Meso-Cre positive+Ai9 mice but no tdT-positive cells were detected. Bone mass (DXA) was not affected in MeSo-Cre mice, compared to wild-type littermates, suggesting the 3’UTR knockin strategy had minimal disruptive effect on endogenous host gene function. In summary, the MeSo-Cre driver exhibits high fidelity to the OCY population and expands our toolbox for selectively targeting OCYs in floxed mouse models of skeletal disease.
ENPP1 is a direct SP7-regulated target in osteocytes and bone extracellular matrix mineralization - Jialiang Wang, PhD
Osteocytes are central regulators of bone homeostasis and key sources of mineral-regulatory factors, yet how they fine-tune local phosphate-pyrophosphate balance within the extracellular matrix (ECM) remains incompletely understood. SP7 is a transcription factor with a well-established role in osteoblast differentiation and a recently recognized, essential function in the osteoblast-to-osteocyte transition. A homozygous SP7 pathogenic variant ( c.946C>T; R316C ) causes r ecessive osteogenesis imperfecta (OI) marked by fragility fractures and skeletal deformities. Building on our prior work, we show that SP7 controls osteocyte-specific transcriptional programs governing matrix mineralization and reveal therapeutically relevant pathways in mineralization disorders.
We generated Sp7 R342C mice, corresponding to the human R316C mutation, which recapitulate key OI features. Increased osteoid and delayed mineralization in mutant mice indicate mineralization defects arising during the osteoblast-to-osteocyte transition. We identified Enpp1, a key enzyme in pyrophosphate (PPi) synthesis, as a potential target whose expression is suppressed by Sp7. Enpp1 is upregulated in R342C osteocytes, especially in females (Fig. 1A). ChIP-seq in Ocy454 cells reveals a strong Sp7-bound, osteocyte-specific enhancer within the Enpp1 locus, and ChIP-qPCR confirms robust binding at this enhancer by wild-type Sp7 but markedly reduced binding by the mutant protein. Female mutants display elevated plasma PPi, whereas males do not (Fig. 1B), indicating sexual dimorphism. qBEI and Raman analyses show reduced cortical and trabecular matrix calcium deposition, lower mineral-to-matrix ratio, and enlarged osteocyte lacunae in mutants. These findings suggest that the R342C mutation impairs ECM mineralization via osteocytic Enpp1 upregulation and PPi accumulation. In our pilot study, treatment of female mutants with an Enpp1 inhibitor result in decreased PPi, increased trabecular bone mineral density, and improved bone bending resistance. Together, these results identify ENPP1 as a direct SP7 target and support PPi inhibition as a strategy to restore mineralization and bone strength.
Investigation of the regulatory role of the SP7-ENPP1 axis in osteocytes and bone ECM mineralization addresses a critical gap in our understanding of how osteocytes actively orchestrate local mineral homeostasis and defines an osteocyte-specific mechanism linking transcriptional control to matrix mineralization.read more · Original Link ↗
Lilian I. Plotkin, PhDIndiana University School Of Medicine, Indianapolis, IN, US
Anika Shimonty, PhDBrigham & Women's Hospital, Harvard Medical School, Boston, MA, US
Roman A EliseevUniversity Of Rochester, Rochester, NY, US
Andi Sarai Garcia-Ortiz, MSCornell University, USA
Haisheng Yang, PhDBeijing University Of Technology, Beijing, CN
Alexander G. RoblingIndiana University, Indianapolis, IN, US
Jialiang Wang, PhDUT Southwestern Medical Center, Dallas, MA, US
☆
Sat 10/10 · 3:45 PM - 4:45 PM
Oral Presentations: Tackling Fibrous Dysplasia: From FGF Signaling to Real-World Therapy
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 311
Raman Spectroscopy Identifies Consistent And Marked Extracellular Matrix Abnormalities In Fibrous Dysplasia Lesions - Lucie Levaillant Background: Fibrous dysplasia (FD) is a rare mosaic bone disorder caused by activating GNAS mutations, leading to replacement of normal bone marrow by fibro-osseous...Raman Spectroscopy Identifies Consistent And Marked Extracellular Matrix Abnormalities In Fibrous Dysplasia Lesions - Lucie Levaillant
Background: Fibrous dysplasia (FD) is a rare mosaic bone disorder caused by activating GNAS mutations, leading to replacement of normal bone marrow by fibro-osseous tissue and impaired bone quality. Diagnosis may be challenging in small or isolated lesions. Raman spectroscopy enables non-destructive molecular characterization of bone extracellular matrix components and may provide objective biomarkers of matrix alterations in FD.
Objective: To identify specific extracellular matrix abnormalities in human FD lesions using Raman spectroscopy and to evaluate their potential diagnostic value.
Methods: In this single-centre retrospective study, decalcified, paraffin-embedded specimens were examined using a confocal Raman microspectrometer (785 nm excitation). Spectra were processed to remove fluorescence and paraffin contributions. Five physicochemical parameters were quantified: enzymatic collagen cross-linking (~1670/~1690 cm⁻¹), collagen secondary structure (~1670/~1640 cm⁻¹), non-enzymatic cross-linking (pentosidine, ~1495/~1450 cm⁻¹; and carboxymetyllysine ~1150/~1450), hydroxyproline content (~872/~854 cm⁻¹), and glycosaminoglycan content (~1380/~1245 cm⁻¹). Results were expressed as mean ratio relative to healthy controls.
Results: Surgical samples from 13 patients with histologically confirmed FD (mean age 15.4 ± 13.9 years; 77% male) were analysed. Five patients had polyostotic FD with confirmed GNAS variants, including two with McCune - Albright syndrome. All assessed parameters differed significantly between FD lesions and controls. In particular, FD samples showed increased enzymatic collagen cross-linking and reduced pentosidine content (both p < 0.001), with complete separation between groups. Alterations were also observed in collagen secondary structure, hydroxyproline content, and glycosaminoglycan content. No significant differences were detected based on disease form (monostotic vs. polyostotic/McCune-Albright syndrome), sex, or recent fracture.
Conclusion: Raman spectroscopy identifies consistent and marked extracellular matrix abnormalities in human FD lesions, particularly in enzymatic collagen cross-linking and pentosidine content. These findings support the presence of matrix quality alterations in FD and suggest that Raman-based signatures may assist in the differential diagnosis of challenging cases.
Repression of FGF Signaling as a Potent Therapeutic Strategy for Fibrous Dysplasia - Rinna Kanai, PhD Student
Fibrous dysplasia (FD) is a challenging bone disorder in which the bone marrow is replaced by fibro-osseous tissues containing immature bones. It can occur as monostotic or polyostotic lesions throughout the skeleton. Patients with polyostotic FD often present bone pain, deformities, and fractures, and craniofacial FD may lead to neurological symptoms due to nerve compression. Currently, treatment options are limited to surgical interventions and symptomatic management of bone pain. Medical therapies for FD remain an unmet medical need. In this study, we aimed to identify the therapeutic target pathways for FD. First, we generated a novel mouse model (R26R-GNAS R201H ) that conditionally expresses an FD-associated GNAS mutant in a Cre-dependent manner. FD-like lesions were observed in the long bones of Lepr-Cre;R26R-GNAS R201H mice following bone marrow ablation surgery. In contrast, Trps1-Cre;R26R-GNAS R201H mice spontaneously developed FD-like lesions in their long bones after 3 months of age. Next, we performed spatial transcriptome analysis of FD-like lesions in Lepr-Cre;R26R-GNAS R201H mice and human long bone FD specimens to identify commonly activated signaling pathways. This analysis revealed the activation of the FGF signaling pathway in both mouse and human samples. Based on these findings, we administered an FGF receptor inhibitor to the FD model mice to evaluate its therapeutic potential. In Lepr-Cre;R26R-GNAS R201H mice, the treatment at disease onset partially suppressed the progression of FD lesions. Similar results were observed in Trps1-Cre;R26R-GNAS R201H mice. Notably, no significant adverse effect was observed in either treatment groups. Given that the FGF receptor inhibitor used in this study has already been evaluated in clinical trials for other human diseases, it will be a promising candidate for drug repositioning in FD. These findings may contribute to the development of novel preventive and therapeutic strategies for the rare skeletal disorder.
A Phase 2 trial of Denosumab for Prevention of Skeletal Disease Progression in Children with Fibrous Dysplasia - Vivian MacDonald
OBJECTIVES: Fibrous dysplasia (FD) is a mosaic disorder associated with fractures, pain, and deformities. Bone lesions appear in early childhood and expand during skeletal growth, reaching final disease burden in adulthood. Evidence supports that the pro-osteoclastic factor RANKL plays a pivotal role in FD pathogenesis, and that the RANKL inhibitor denosumab reduces lesional activity in adults. However, it is unknown if denosumab can prevent FD expansion in children. Additionally, pediatric trials have been limited by post-treatment rebound, resulting in life-threatening hypercalcemia in patients with open growth plates. This study evaluated the safety and efficacy of denosumab to prevent FD lesion progression in children.
METHODS:15 children (age 5-14) were treated with denosumab for 48-weeks followed by a 28-week post-discontinuation monitoring period. Doses ranged from 0.25-0.7 mg/kg monthly. The primary endpoint was change in FD progression over 48 weeks compared to untreated historical controls. All patients received oral calcium +/- calcitriol while on-treatment, and received zoledronate at weeks 4 and 8 post-denosumab discontinuation.
RESULTS:Denosumab was associated with a marked decline in Skeletal Burden Score (median -7.54 units/year, IQR-9.35 to -1.73), in contrast to controls who showed a increase of 2.12 units/year (IQR 0.81 to 2.88), p<0.0001. Bone turnover markers were elevated at baseline and declined post-treatment: CTX -74.8% (50.7-83.0%, p<0.0001), P1NP -78.4% (64.9-85.8%, p<0.0001), alkaline phosphatase -63.3% (58.3-76.5%, p<0.0001). While on denosumab, 8 patients developed mild asymptomatic calcium disturbances (8 with hypocalcemia and 4 with hypercalcemia), which resolved with changes in oral supplements. Post-discontinuation, 4 patients developed mild asymptomatic hypercalcemia (10.5-11 mg/dL), which resolved with small interval doses of denosumab. At the end of the post-discontinuation monitoring period, bone turnover markers returned to pre-treatment baseline. All treatment-related adverse events were mild, and none resulted in treatment or trial withdrawal.
CONCLUSIONS:Denosumab treatment in children with FD was well-tolerated and associated with reduced skeletal progression compared to historical controls. Denosumab was safely discontinued without clinically significant disturbances in calcium. Results from this trial support that denosumab is a safe and effective treatment strategy to prevent FD lesion progression in children.
Identifying Novel Therapies for Fibrous Dysplasia of the Bone Using a Transcriptomics-Based Computational Drug Repurposing Strategy - Jeayoung Park, MD
Fibrous dysplasia/McCune-Albright Syndrome (FD/MAS) is a somatic, mosaic genetic disease caused by missense mutations in GNAS leading to constitutive activation of the G s -GPCR signaling pathway and resulting in a debilitating skeletal dysplasia. Our prior data and those of others showed that inhibiting the G s signaling pathway could be a viable strategy for reducing FD lesion growth in mice. However, direct targeting of the mutant G s α by small molecules has been elusive, with small molecules showing significant toxicity or poor selectivity. Transcriptomics-based computational drug repurposing, where potential drugs are screened to identify candidates that may “reverse” a gene expression pattern in a disease, holds promise for finding molecules that may target downstream pathways that contribute to the fibrotic pathology seen in FD.
We performed a drug repurposing analysis using gene expression sequencing data from 4 human FD bone samples. We compared profiles from FD stromal, endothelial, and perivascular cells with transcriptomic profiles of multiple drug databases, generating a Kolmogorov-Smirnov statistic ranging from -1 to 1 based on the degree of reversal. We identified several drug classes predicted to have a high gene reversal score. We selected drugs with established safety data for in vitro validation. To better mimic the heterozygosity of GNAS mutations in FD lesions, we used a CRISPR-Cas9 editing strategy to introduce the GNAS R201H mutation into a wildtype human induced pluripotent stem cell (hiPSC) line. We also developed a lentivirus-transduced primary mesenchymal stem cell (MSC) line that expressed GNAS R201H . Using the hiPSC line, we found that several of our candidates could significantly reduce the expression of marker genes highly expressed in FD (DDX5, KAT6B, IRS1; p<0.05) and increase expression of under-expressed genes (ATF3, DNAJB1, RGS16; p<0.05) that we identified in FD. In the GNAS R201H MSCs (N=3), we identified two drug candidates that could decrease intracellular cAMP levels as measured by immunofluorescence (32 vs 3 a.u.; p<0.05). Our findings show that a combined computational/ in vitro strategy holds promise for identifying novel compounds that may reverse the abnormal gene expression patterns found in FD bone, separate from direct GNAS targeting. Further studies are needed to understand how these pathways intersect with the GNAS signaling cascade and whether these therapeutic strategies reduce FD lesion formation in vivo .
Burosumab In The Treatment Of Fgf-23 Induced Hypophosphatemia In Fibrous Dysplasia Of Bone - A Real-World Study In 11 Patients - Roland Chapurlat, MD, PhD
Background: Fibrous dysplasia of bone (FD) may be associated with FGF23-mediated renal phosphate wasting, contributing to chronic hypophosphatemia, osteomalacia, bone pain, deformities, and fractures. Burosumab, an anti-FGF23 monoclonal antibody, is approved for X-linked hypophosphatemia and tumor-induced osteomalacia and a recent phase 2 study has shown promising results in FD.
Objective: To describe the biochemical response to burosumab in patients with FD complicated by renal phosphate wasting.
Methods: We conducted an observational longitudinal analysis of 11 patients treated with burosumab, initiated at 0.4 mg/kg, for FD-associated renal phosphate wasting. Serum phosphate, TmP/GFR, calcium, alkaline phosphatase (ALP), CTX, P1NP were collected at baseline and follow-up. We analyzed using patient-level median values within two windows: early follow-up (M0-M6) and later follow-up (≥M12). Continuous variables are reported as median [IQR]. Paired changes from baseline were assessed using Wilcoxon signed-rank tests.
Results: At burosumab initiation, median age was 14 years and median body weight was 42 kg [36 - 56]. Baseline serum phosphate was low (0.95 mmol/L [0.74 - 1.02]) and median TmP/GFR was 0.72 mmol/L [0.64 - 0.92], consistent with renal phosphate wasting. Serum phosphate increased rapidly after treatment initiation. At day 15, median serum phosphate increased from 0.95 to 1.42 mmol/L, corresponding to a median paired increase of +0.49 mmol/L (n=9, p=0.014). This increase was maintained at month 3 (+0.48 mmol/L; n=7, p=0.035) and month 9 (+0.26 mmol/L; n=6, p=0.036). Serum calcium remained stable, without hypercalcemia signal. Importantly, ALP decreased substantially during follow-up, supporting improvement in mineralization. Median ALP was 701 UI/L [432 - 846.5] at baseline. In paired window-based analyses, ALP decreased to 451.5 UI/L before M6, corresponding to a median relative reduction of 28.6% (n=8, p=0.030). This reduction appeared to persist from month 12 onward, with a median ALP of 489 UI/L and a median relative reduction of 30.2% versus baseline (n=5, p=0.059). No further significant change was observed between early and later follow-up (p=0.787).
Conclusion: In this small observational cohort, burosumab was associated with rapid correction of hypophosphatemia and a marked reduction in ALP, providing biochemical evidence consistent with improvement of osteomalacia in FD-associated FGF23-mediated phosphate wasting.read more · Original Link ↗
Michael J. Econs, MDIndiana University School Of Medicine, Indianapolis, IN, US
Demetrios Thomas Braddock, MDYale University, NEW HAVEN, CT, US
Lucie LevaillantUniv Angers, Inserm U1083, UMR CNRS 6015, MitoVasc, CarMe Team, SFR ICAT, F-49000 Angers, France; Department of Pediatric Endocrinology and Diabetology, University Hospital of Angers, Endo-ERN Center for Rare Endocrine Conditions, 49933 Angers Cedex 9, France
Rinna Kanai, PhD StudentThe University Of Osaka, Suita, JP
Vivian MacDonaldNational Institutes Of Health, Bethesda, MD, US
Jeayoung Park, MDEndocrine Research Unit, San Francisco Veterans Affairs Health Sciences Center, USA; Division of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, USA
Roland Chapurlat, MD, PhDRheumatology Department, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; INSERM UMR 1033, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, 69437 Lyon, France
☆
Sat 10/10 · 3:45 PM - 4:45 PM
Oral Presentations: The Systemic Disease - Bone Interface
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 312
Trabecular Bone Score In Children With Duchenne Muscular Dystrophy: TBS Osteo Advanced For Pediatrics (Version 4) - Anna N.H. Walstra, PhD Student
Purpose : Duchenne Muscular Dystrophy (DMD) is associated with progressive muscle loss, skeletal deterioration, and elevated fracture risk.Trabecular Bone Score In Children With Duchenne Muscular Dystrophy: TBS Osteo Advanced For Pediatrics (Version 4) - Anna N.H. Walstra, PhD Student
Purpose : Duchenne Muscular Dystrophy (DMD) is associated with progressive muscle loss, skeletal deterioration, and elevated fracture risk. Bone mineral density (BMD) alone may not fully capture any disease- and glucocorticoid-related changes in bone microarchitecture. Trabecular bone score (TBS), a validated index of DXA-derived bone microarchitecture, may provide complementary skeletal insight. This study evaluated TBS Z-scores in a cohort of boys with DMD relative to age-matched normative data and assessed associations with disease severity and fracture.
Methods : Male patients with DMD undergoing lumbar spine DXA were included in TBS Osteo Advanced (Version 4) for Pediatric analysis (age 5 - 20 years). TBS Z-scores were derived from an age-matched reference population. Correlation between TBS Z-score and disease stage (2: Early ambulatory; 3: Late ambulatory; 4: Early non-ambulatory; 5: Late non-ambulatory) was assessed; between stage differences were evaluated by Kruskal-Wallis with Dunn post-hoc testing. Fracture burden was categorized as ≥2 or ≥3 long bone fractures, and spine fractures, aligned to Pediatric ISCD guidelines. TBS was compared for those meeting versus not meeting each fracture burden threshold.
Results: There were 242 DXA scans from 71 boys with DMD in the cohort (median age 12.7±3.5 years; 71% White). TBS Z-scores in boys with DMD were significantly lower than reference values ( - 0.94±1.33; p<0.001). Over one fifth (23.1%) had a Z-score of ≤ - 2.0, with a further 23.1% from - 2.0 and - 1.0. In boys with complete disease stage data (n=38), TBS Z-scores correlated with disease stage (ρ= - 0.35, p <0.001), with progressive decline (stage 2: - 0.25 [IQR - 1.21, 0.66]; stage 3: - 0.50 [ - 2.03, - 0.22]; stage 4: - 1.36 [ - 1.94, - 0.16]; stage 5: - 1.58 [ - 2.67, - 0.49]). Between-stage differences were significant (Figure A). In those with available fracture data (n=22), TBS was significantly lower in those with ≥2 fractures (median difference - 0.70, p=0.005) and ≥3 fractures (median difference - 0.66, p=0.008). For spine fractures, the median TBS difference was - 0.59, not reaching significance (p=0.129).
Conclusions: Boys with DMD demonstrate degraded trabecular microarchitecture, with TBS Z-scores declining across disease stages, and markedly lower values in those with higher fracture burden. These findings support TBS as a complementary DXA-derived measure that, alongside BMD, may better characterize the presence and severity of skeletal involvement in DMD.
Development of a Fracture Prediction Model for Patients Aging with HIV - Evelyn Hsieh, MD, PhD
Fragility fractures are a critical outcome for people aging with HIV (PAH). Studies demonstrate higher prevalence, incidence, and earlier onset than for individuals without HIV. Prediction models for the general population underestimate risk in this group. We aimed to develop predictive models for fracture risk that better capture risk among men and women aging with HIV.
We combined data from two electronic health record-based cohorts: 1) the Veterans Aging Cohort Study, a national cohort of all individuals diagnosed with HIV receiving care within the Veterans Health Administration; and 2) Yale New Haven Healthcare System. PAH (≥50 years of age) from VACS were followed from 01/01/2011-12/31/2020, and those from YNHH from 1/1/2015-12/31/2023. Fragility fracture outcomes at the spine, hip/femur, wrist/forearm, and shoulder/upper arm were identified using validated ICD9 and ICD10 codes. From an initial pool of 29 candidate variables, we used multivariable logistic regression to select 15 predictors that were then reduced to 10 based on statistical criteria and feedback from HIV providers. This feedback motivated two adaptations to our original model: 1) the optional inclusion of race, and 2) the presentation of both one-year and three-year models to provide short-term and medium-term risk prediction.
The cohort included 35,389 individuals contributing 239,053 person-years of data (83,217 three-year person-intervals). Mean age of the cohort was 57.7±7.0 years, 5.4% female, 55.8% non-white race. Mean CD4 + count was 553.6±334.7 cells/mm 3 and over 70% had an undetectable viral load. Over the follow up period, 2,355 incident fractures occurred in the 1-year dataset, and 2,134 fractures occurred in the 3-year dataset. The one-year and three-year models with race for females (Table 1A) exhibited good discrimination [AUC (95%CI) = 73.7 (72.6-74.8) and 78.4 (76.6-80.1), respectively] and consistently good calibration. The models for males (Table 1B) also exhibited good discrimination [AUC (95%CI) = 74.2 (73.9-74.6) and 73.2 (72.6-73.8), respectively] and consistently good calibration. The models without race consistently showed underprediction among Whites, and overprediction among non-Whites.
Based upon rigorous statistical analysis and provider input, we present a new risk prediction model for fragility fracture that is robust and uniquely optimized for the care of PAH. Future studies will evaluate how FRAC-HIV can best be integrated into clinical practice.
Target-Trial Emulation Identifies ARB/Statin Protective Signals and Clinically Interpretable Fracture-Risk Signals in Osteoporosis - Jianing Liu
Purpose: Fractures remain common despite osteoporosis therapies yet approved non-osteoporosis medications prescribed to older adults have not been systematically evaluated for fracture prevention using target-trial emulation. We conducted a high-throughput target-trial emulation screen of 1,222 marketed drugs to identify drug-class signals associated with 2-year incident osteoporotic fracture.
Methods: MarketScan Medicare Supplemental claims (2016 - 2022) identified adults ≥65 years with osteoporosis, no prior osteoporotic fracture, ≥12 months pre-index enrollment, and 730-day follow-up. For each drug, confirmed new users were landmarked at the 1st qualifying dispensing (≥2 fills ≥30 days apart) and compared with active-comparator initiators not indicated for osteoporosis. Baseline diagnoses were mapped to 552 clinical categories for propensity-score estimation. Stabilized inverse-probability weights, trimmed at 1st/99th percentiles, estimated absolute 2-year RDs. Each drug underwent 100 active-comparator emulations; drugs were screened only if <2% of covariates had post-weighting standardized mean difference >0.20. Benjamini-Hochberg false-discovery-rate correction was applied.
Results: Among ~547,000 older adults with osteoporosis, 1,222 drugs were screened; 238 met cohort-size criteria, 48 achieved covariate balance, 39 remained after excluding primarily over-the-counter drugs, and 18 met FDR<0.05. Results are expressed as mean RDs with 95% empirical intervals (EIs) across emulations. Eleven drugs were associated with lower fracture risk, led by losartan (RD, - 2.4 percentage points [95% EI, - 2.8 to - 1.9]), valsartan ( - 2.4; - 3.0 to - 1.7), pravastatin ( - 2.4; - 2.8 to - 1.9), and rosuvastatin ( - 2.2; - 2.7 to - 1.5); signals clustered in angiotensin receptor blockers and statins. Seven drugs were associated with a higher risk, led by tramadol (+3.2; +2.7 to +3.7), alprazolam (+2.5; +1.9 to +3.1), and cyclobenzaprine (+2.2; +1.6 to +2.8), aligning with fall-risk pharmacology.
Conclusion: This comparator-robust screen identified coherent ARB/statin signals associated with lower 2-year fracture risk and interpretable safety signals for sedating analgesics, anxiolytics, and muscle relaxants. These findings prioritize ARBs/statins for independent validation and show how target-trial emulation can accelerate fracture-focused drug repurposing.
Fracture Risk and Post-Fracture Mortality with Chronic Proton Pump Inhibitor Use: Findings from the OSIRIS Nationwide Study - Cecile Philippoteaux, MD, PharmD, PhD
Background: Chronic proton pump inhibitors (PPI) use has been associated with increased fracture risk, though findings remain inconsistent due to residual confounding. Data on post-fracture mortality in this setting remain unexplored.
Objectives: To assess PPI-associated risk of major osteoporotic fracture (MOF), post-fracture mortality, and heterogeneity by age and sex.
Methods: OSIRIS is a retrospective cohort study using the French National Administrative Claims Database, from 2014 to 2023. Adults aged 40 years or older newly initiating PPI (2014-2016) and meeting a chronic exposure definition (more than 180 cumulative days within year 1) were matched 1:1 to non-exposed individuals by propensity score on age, sex, comorbidities, osteoporosis causes, PPI indications, and co-medications. MOF (hip, vertebra, humerus, wrist) were analyzed using cause-specific Cox models with death as a competing event. A sensitivity analysis restricted to individuals with 720 or more cumulative days was performed. Post-fracture mortality and sex-stratified analyses with formal interaction testing were performed for MOF overall, hip, and vertebral fractures.
Results: The matched cohort included 1,398,522 individuals (mean age 66.1 years; 49.5% women; mean follow-up 8.75 years). PPI use was associated with increased MOF risk at all sites (Figure 1A), strongest for vertebrae (HR 1.46, 95% CI 1.42-1.50), consistent in sensitivity analyses. Among individuals younger than 80 years, HRs were 1.32 (95% CI 1.26-1.38) at 50-59 years, 1.27 (95% CI 1.23-1.31) at 60-69 years, and 1.22 (95% CI 1.19-1.26) at 70-79 years. Women showed higher fracture risk than men for MOF (HR 1.34 vs 1.26, p<0.001) and hip fracture (HR 1.37 vs 1.24, p<0.001). Among 84,316 individuals with MOF, post-fracture mortality did not differ by PPI exposure (HR 1.01, 95% CI 0.99-1.03). Exploratory sex-stratified analyses revealed no association in women (HR 0.99, 95% CI 0.97-1.01) but a borderline excess in men (HR 1.04, 95% CI 1.00-1.07), with a significant interaction by sex (p=0.040) (Figure 1B).
Conclusions: In this large cohort of nearly 1.4 million patients, chronic PPI use was associated with a substantial and early increase in fracture risk at all MOF sites, stronger for vertebrae, with marked heterogeneity by age and sex. Post-fracture mortality was not increased overall. These results provide granularity to identifying most-at-risk patients in the context of PPI use.
Mapping disease trajectories preceding hip fracture: a population-based analysis from Hong Kong and the United Kingdom - Ching-Lung Cheung, PhD
Background
Hip fracture is associated with high mortality rate, yet the evolution of chronic diseases preceding fracture remains poorly characterized. We aimed to map disease prevalence and quantify hip fracture risk over time compared with matched controls.
Methods
We conducted a matched case-control study using Hong Kong’s territory‑wide real-world data from an electronic health record database (CDARS) as discovery cohort, with validation in UK Biobank (UKB). Incident hip fracture cases from 2010 - 2019 were matched with up to five controls by age, sex, and calendar time via incidence density sampling. We examined 202 chronic diseases (defined using ICD codes) and estimated odds ratios (ORs) for hip fracture each year before fracture using conditional logistic regression.
Results
We included 56,008 cases and 274,044 controls in CDARS (mean age 82.1 years; 67.2% women) and 5,604 cases and 28,018 controls in UKB (mean age 62.5 years; 66.8% women). At 5 years pre-fracture, 33 diseases across multiple organ systems were associated with hip fracture after Bonferroni correction in both cohorts. Strongest associations were observed for alcoholic liver disease (CDARS: OR 3.15, 95% CI 2.48 - 4.01; UKB: 4.55, 2.64 - 7.85), chronic kidney disease (CDARS: 2.00, 1.86 - 2.14; UKB: 3.57, 2.14 - 5.97), diabetic eye disease (CDARS: 1.91, 1.79 - 2.05; UKB: 2.44, 1.84 - 3.24), and lupus erythematosus (CDARS: 1.90, 1.75 - 2.06; UKB: 3.26, 1.82 - 5.85). Case-control prevalence differences widened approaching the index date for most conditions.
Conclusion
Diverse chronic diseases are associated with hip fracture years before onset, with accelerating prevalence in the near‑term. These findings suggest that hip fracture may be a consequence of multi-organ failure and highlight potential windows for earlier prevention.read more · Original Link ↗
Roland Chapurlat, MD, PhDINSERM UMR 1033, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, 69437 Lyon, France
Tayyab Sami Khan, MDDivision Of Endocrinology, Department Of Medicine, Western University, London, ON, CA; Osteoporosis and Bone Disease Program, St. Joseph's Health Care London, Canada
Anna N.H. Walstra, PhD StudentMedimaps, Geneva, Geneva, CH
Evelyn Hsieh, MD, PhDYale School of Medicine, Section of Rheumatology, Allergy and Immunology, New Haven, CT, USA; Yale School Of Medicine, WESTPORT, CT, US
Jianing LiuThe Ohio State University, Dublin, OH, US
Cecile Philippoteaux, MD, PharmD, PhDLille University, Lille University Hospital, ULR 2694 - METRICS, Rheumatology dept, F-59000 Lille, France
Ching-Lung Cheung, PhDThe University Of Hong Kong, Hong Kong, HK
Built for you by(617)-PATRICK, Champion AI speaker
Public Outreach Session: An Owner’s Manual for the Skeleton: Protecting Your Bones Through Movement, Medicine, and Menopause
● Symposium
Symposium
📍 Meeting Room 210
Talking to Your Physician About Bone Health - Eric S. Orwoll
Exercise and Bone Health - Lora M. Giangregorio, PhD
Menopause - Joy Tsai, MD · Original Link ↗
Mary L. Bouxsein, PhDBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, US
Tamara N. Alliston, PhDNIH - NIAMS, Greenbrae, CA, US
Eric S. OrwollOregon Health & Science University, Portland, OR, US
Lora M. Giangregorio, PhDUniversity Of Waterloo, Waterloo, ON, CA
Joy Tsai, MDMassachusetts General Hospital, Boston, MA, US
☆
Sat 10/10 · 5:00 PM - 6:00 PM
International Meetup for Latin America: Fostering New Connections
● Symposium
Symposium
📍 Meeting Room 309
Introductory Remarks Bringing Local Science to the Global Stage - Vanesa CARLA Longobardi, MD Regional Abstracts at the Annual Meeting - Marise Lazaretti-Castro Examples of Regional Collaboration with Global Impact - Jose Francisco Torres Naranjo, MD, MPH Meet the Region:...Introductory Remarks
Bringing Local Science to the Global Stage - Vanesa CARLA Longobardi, MD
Regional Abstracts at the Annual Meeting - Marise Lazaretti-Castro
Examples of Regional Collaboration with Global Impact - Jose Francisco Torres Naranjo, MD, MPH
Meet the Region: Getting to Know Each Other's Work & Closing Remarksread more · Original Link ↗
Pablo Florenzano, MDPontificia Universidad Catolica De Chile, Santiago, CT, CL
Maria Belen Zanchetta, MDIdim, Universidad Del Salvador, Buenos Aires, AR
Vanesa CARLA Longobardi, MDIdim, CABA, AR
Marise Lazaretti-CastroDivision of Endocrinology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
Jose Francisco Torres Naranjo, MD, MPHCentro de Investigación Ósea y de la Composición Corporal, CIO, Mexico
☆
Sat 10/10 · 5:00 PM - 6:00 PM
International Meetup: Exploring Global Research in Bone Science - Fostering New Connections with the Africa, Middle East, and India Regions
● Symposium
Symposium
📍 Meeting Room 310
Introductory Remarks Autoimmune AADC Inhibition and Zinc Metalloenzyme Deficiency: Dual Drivers of Refractory Osteoporosis - Asma Aljaberi Osteoporosis in Young Adults and Associated factors - Asma Arabi, MD <em>The Role of dlx5a and dlx6a in Regulating Bone Mineral Density and...Introductory Remarks
Autoimmune AADC Inhibition and Zinc Metalloenzyme Deficiency: Dual Drivers of Refractory Osteoporosis - Asma Aljaberi
Osteoporosis in Young Adults and Associated factors - Asma Arabi, MD
<em>The Role of dlx5a and dlx6a in Regulating Bone Mineral Density and Developmental Homeostasis: Insights from Zebrafish Models</em> - Lital Ashtamkar Matok, PhD
<em>Bone Quality in Acromegaly: An HR-pQCT-Based Case-Control Study</em> - Shivendra Verma, MD
Panel Discussion
Question and Answerread more · Original Link ↗
Kate A. Ward, PhDUniversity Of Southampton, Southampton, GB
Amna N. Khan, MDPerelman School of Medicine at University Of Pennsylvania And Corporal Michael J. Crescenz VA Medical Center, Wynnewood, PA, US
Arwa Elsheikh, MBBSUniversity Of Colorado, Denver, CO, US
Asma AljaberiSheikh Tahnoon Bin Mohammed Medical City, Al Ain, AE
Asma Arabi, MDCalcium Metabolism And Osteoporosis Program, American University Of Beirut, Beirut, LB
Lital Ashtamkar Matok, PhDBar-Ilan University, Dalton, IL
Shivendra Verma, MDSanjay Gandhi Post Graduate Institute Of Medical Sciences, Lucknow, IN
☆
Sat 10/10 · 5:00 PM - 6:00 PM
Meet the NIH
● Career Development
Career Development
📍 Meeting Room 312
Meet the NIH - NIAMS - Kristy Nicks, PhD Meet the NIH - NIAMS - Isaah Vincent Meet the NIH - NIAMS - Raj Srinath Meet the NIH - NIAMS - Faye Chen Meet the NIH - CSR - Amber...Meet the NIH - NIAMS - Kristy Nicks, PhD
Meet the NIH - NIAMS - Isaah Vincent
Meet the NIH - NIAMS - Raj Srinath
Meet the NIH - NIAMS - Faye Chen
Meet the NIH - CSR - Amber Collins
Meet the NIH - CSR - Vanessa D. Sherk, PhD
Meet the NIH - NIA - Lyndon Joseph
Meet the NIH - NIA - John Williamsread more · Original Link ↗
Kristy Nicks, PhD
Isaah Vincent
Raj Srinath
Faye Chen
Amber Collins
Vanessa D. Sherk, PhD
Lyndon Joseph
John WilliamsNational Institutes of Health, USA
☆
Sat 10/10 · 5:00 PM - 6:00 PM
International Meetup: Exploring Global Research in Bone Science - Fostering New Connections with the Asia Pacific Regions
● Symposium
Symposium
📍 Meeting Room 313
Improved Body Composition, Gait Speed, and Personal Care in Older Adults in Aged Care: The Pomerium Study Trial - Ahmed Al Saedi Differential Skeletal Response to Parathyroidectomy Across Biochemical Phenotypes of Primary Hyperparathyroidism - Sung Joon Cho Stepwise Crystal Formation...Improved Body Composition, Gait Speed, and Personal Care in Older Adults in Aged Care: The Pomerium Study Trial - Ahmed Al Saedi
Differential Skeletal Response to Parathyroidectomy Across Biochemical Phenotypes of Primary Hyperparathyroidism - Sung Joon Cho
Stepwise Crystal Formation Shapes a Hydroxyapatite-Dissolving Macrophage in Vascular Calcification - Kazuma Sato, PhD student, MS
Hepatic Steatosis and Fibrosis Are Independently Associated with Sarcopenia: Insights from the New Hong Kong Cardiovascular Risk Factor Prevalence Study (N-CRISPS) - David Lui, MDread more · Original Link ↗
Christian GirgisDepartment of Endocrinology, Royal North Shore Hospital, Australia
Serk In Park, DDS, PhDKorea University College Of Medicine, Seoul, TN, KR
Yoon-Sok (MARTIN) ChungDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
Shinsuke Ohba, D.D.S., Ph.D.Department of Tissue and Developmental Biology, Graduate School of Dentistry, The University of Osaka, Japan
Ahmed Al SaediDivision of Endocrinology, Boston Children's Hospital, USA
Sung Joon ChoCatholic Kwandong University College Of Medicine, Incheon, KR
Kazuma Sato, PhD student, MSThe University Of Osaka, Suita, JP
David Lui, MDThe University of Hong Kong, Hong Kong, Hong Kong, CN
Plenary Symposium: Incretins and Musculoskeletal Health
● Symposium
Plenary
📍 General Session - Ballroom A & B
ASBMR News Esteemed Awards Presentations GLP-1 and GIP Therapies: Physiology, Mechanisms, and Clinical Relevance - Morten Frost Frost, PhD Bone and Muscle Effects of GLP-1 Receptor Agonists - Guillaume Mabilleau Bone Protection During Medical and Surgical Weight Loss - Kristen...ASBMR News
Esteemed Awards Presentations
GLP-1 and GIP Therapies: Physiology, Mechanisms, and Clinical Relevance - Morten Frost Frost, PhD
Bone and Muscle Effects of GLP-1 Receptor Agonists - Guillaume Mabilleau
Bone Protection During Medical and Surgical Weight Loss - Kristen Marie Beavers, PhD
While intentional weight loss delivers benefits for metabolic and cardiovascular health, it can often come with an unintended side effect: accelerated bone loss and increased fracture risk. This is particularly true during rapid weight loss achieved through bariatric surgery or incretin memetic medications. In this 20-minute session, Dr. Kristen M. Beavers will explore the underlying mechanisms driving bone loss during significant weight reduction. She will also translate the latest clinical evidence into actionable strategies, discussing the role of targeted exercise modalities, nutritional optimization (including protein and calcium supplementation), and potential pharmacological interventions.read more · Original Link ↗
Julien Paccou, PhD, MDLille University Hospital, Lille, FR
Anne L. Schafer, MDUniversity Of California, San Francisco and The San Francisco Veterans Affairs Health Care System, San Francisco, CA, US
Morten Frost Frost, PhDOdense University Hospital, Odense, DK
Guillaume MabilleauUniversity Of Angers, Angers, FR
Kristen Marie Beavers, PhDWake Forest University School of Medicine, USA
Introductory Remarks
JBMR: The Third Decade (Part 1) - Thomas L. Clemens
JBMR: The Third Decade (Part 2) - Juliet Compston, MD · Original Link ↗
René St-Arnaud, PhDShriners Hospital For Children - Canada And Mcgill University, Montreal, QC, CA
Thomas L. ClemensJohns Hopkins University, USA
Juliet Compston, MDUniversity Of Cambridge School Of Clinical Medicine, United Kingdom
☆
Sun 10/11 · 9:45 AM - 10:15 AM
Coffee Break in Discovery Hall
● General
📍 Discovery Hall - Exhibit Hall C & D
Coffee and light refreshments in the Discovery Hall, with time to network between sessions. · Original Link ↗
☆
Sun 10/11 · 9:45 AM - 10:15 AM
Rapid Fire Presentations - Sunday
● Oral Abstract Presentations
Oral Abstracts
📍 Product Theater, Discovery Hall - Exhibit Hall C & D
Data-Driven Clustering Reveals Potential Genetic Subtypes of Osteoporosis with Varying Effects on Fracture Risk - Nipith Charoenngam, MD
Bone mineral density (BMD) is a polygenic trait and a strong predictor of fracture risk.Data-Driven Clustering Reveals Potential Genetic Subtypes of Osteoporosis with Varying Effects on Fracture Risk - Nipith Charoenngam, MD
Bone mineral density (BMD) is a polygenic trait and a strong predictor of fracture risk. Because BMD-associated loci act through diverse biological pathways, we aimed to determine whether clusters of these loci, reflecting genetic subtypes of osteoporosis driven by distinct pathways, differentially influence fracture risk.
We clustered independent BMD-associated loci and examined their associations with 10-year fracture risk in an independent cohort. We applied a Bayesian non-negative matrix factorization (bNMF) pipeline to cluster independent loci from a European-ancestry GEFOS lumbar spine and femoral neck DXA-BMD genome-wide association study (GWAS) meta-analysis (N=157,441) based on their patterns of association with 94 traits. Among European-ancestry participants aged >55 years in the Mass General Brigham Biobank (MGBB), we generated a total polygenic score (PS) reflecting individual burden of BMD-lowering alleles and cluster-specific partitioned polygenic scores (pPS). We tested their associations with 10-year incident hip fracture and major osteoporotic fracture (MOF), ascertained from coded diagnoses.
Using bNMF, we identified 9 clusters of BMD loci representing different pathways, including Low Body Mass , Calcium Metabolism , Bone Marrow Adiposity , Hematopoiesis , Decreased Height , Increased Height , Kidney-Uric , Lipid-Glucose and Sex Hormone-Binding Globulin . In the MGBB analysis (N=28,603, Mean±SD age: 67.1±7.9 years, 48.2% female, total follow-up 284,534 person-year, 931 hip fracture cases, 2,828 MOF cases), those in the highest quartile of total PS had a higher 10-year risk of hip fracture (aHR 1.54, 95%CI 1.27 - 1.86) and MOF (aHR 1.45, 95%CI 1.30 - 1.61) than those in the lowest quartile, after adjustment for age and sex ( Figure A ). Associations between cluster-specific pPS and MOF risk varied across clusters and were generally proportional to their impact on lowering BMD ( Figure B ), with the Increased Height cluster showing the strongest association with fracture risk. Notably, the Decreased Height clusters showed strong association with BMD but relatively weaker association with fracture risk. These findings suggest that genetically determined reductions in BMD may not uniformly confer fracture risk.
In summary, we identified potential genetic subtypes of osteoporosis that represent heterogeneous biological pathways and have varying effects on fracture risk, which may help explain inter-individual variation in the BMD-fracture association.
Neural Crest-Specific Evc2 Disruption Models TMJ Development and Maintenance and Reveals a Regionally Distinct, Hedgehog-Regulated Progenitor Cell Population with Colony-Forming Capacity - Rafael Correia Cavalcante
The temporomandibular joint (TMJ), essential for jaw movement, is prone to osteoarthritis (OA), affecting approximately 12 million adults in the United States. Here, we introduce a novel genetic mouse model based on a neural crest-specific Evc2/Limbin conditional knockout ( Evc2;Wnt1Cre ) to investigate TMJ development, maintenance, and the effects of mechanical loading. Disruption of Evc2 in neural crest-derived cells led to morphological alterations in TMJ cartilage and predisposed joint components to degenerative changes resembling those observed in human TMJ-OA. Notably, condylar defects were associated with distinctive histological changes, including alterations in cartilage, bone, stem cells, and an augmented polymorphic layer. Gene expression analysis revealed increased inflammatory and OA markers, and modifying chow hardness directly influenced the severity of joint degeneration. Building upon our initial findings with the Evc2;Wnt1Cre pre-clinical mice model, we subsequently employed the Evc2 fl/fl ;Gli1Cre strategy to disrupt Evc2 in presumptive TMJ-derived progenitor cell populations to investigate their regenerative potential and the role of Hedgehog (HH) signaling. Wild-type TMJ-derived cells exhibited multipotency, differentiating into osteogenic and chondrogenic lineages. Cells isolated from the anterior TMJ showed greater colony-forming capacity and pronounced regional heterogeneity. Using FACS to sort TMJ-derived cells from Gli1Cre ERT ;TdTomato reporter mice, we found that all colonies were composed exclusively of TdTomato-positive Gli1 -expressing progenitors. Gli1 -expressing, slow-cycling cells were specifically localized to the enthesis and ligament attachment sites and expanded throughout the condyle. Disruption of Evc2 in Gli1 + cells paradoxically upregulated the expression of Gli1 and mechanosensors ( Yap, Wwtr1, Piezo1 ) in the condyle. Colony formation assays on isolated mutant cells revealed robust colony expansion, likely driven by increased transit amplifying cells (TACs); however, we believe that terminal differentiation is impaired in the absence of Evc2 . These findings reveal critical roles for HH singling in regulating TMJ progenitor cell dynamics, joint homeostasis, and responses to mechanical load, and identify a novel progenitor cell niche within the TMJ enthesis. Targeted manipulation of cell signaling, and mechanical environments may inform novel strategies for TMJ-OA repair and therapy.
<em>In vivo</em> base editing partially rescues bone dysplasia in a mouse model of Hutchinson-Gilford Progeria Syndrome - Wayne A. Cabral, PhD
Hutchinson-Gilford Progeria Syndrome (HGPS) is a premature aging disorder affecting tissues of mesenchymal origin. Most patients harbor a c.1824C>T/p.G608= variant, commonly described as G608G, in exon 11 of LMNA that leads to aberrant splicing and production of the toxic progerin protein. In addition to cardiovascular, dermal, and adipose tissue deterioration, HGPS mouse models also develop progressive bone dysplasia that occurs in patients. Here we characterize the efficacy of in vivo mutation correction with an adenine base editor (ABE) to rescue structural and functional defects in HGPS transgenic murine bone tissue. Treatment of double-copy transgenic osteoblast cultures with a lentiviral-delivered CRISPR-Cas9 ABE achieved nearly 40% gene correction in vitro , resulting in significant reduction of progerin transcripts and protein, in the absence of selective agents. Furthermore, gene correction improved progeroid osteoblasts’ capacity to deposit and mineralize extracellular matrix compared to untreated cultures. In vivo , a single intravenous dose of AAV9-delivered ABE corrected the mutation, achieving ~14%, ~22%, ~10% and <1% correction in bone by six months of age when administered at P3, P14, 1 and 4 months of age, respectively. Partially rescued bone structural and physical parameters were observed in P14-treated mice with concomitant normalization of gene transcriptional programs and intracellular signaling pathways involved in bone remodeling. This work demonstrates in vivo delivery of a locus-specific DNA base editor to bone tissue, delineates the timing of treatment required for maximum efficacy, and suggests that this system might be tailored for application to other monogenic bone disorders.
Mechanoregulation of Fetal Skeletal Development by Maternal Exercise - Christopher James Panebianco, PhD
Fetal movements exert mechanical forces that shape the developing skeleton. Conditions that impair fetal movement, termed “fetal akinesia”, can cause debilitating skeletal defects ( e.g., joint contractures, impaired bone development). 1 Maternal exercise during gestation can rescue skeletal development in the “muscle-less” Splotch-delayed mouse model of fetal akinesia. 2 Here, we aim to identify the mechanisms by which maternal exercise regulates skeletal development in the muscular dysgenesis ( mdg/mdg ) mouse, which has non-contractile skeletal muscle. 3
Pregnant dams began daily exercise at E13.5, which coincides with the onset of fetal movements and the early stages of endochondral ossification. 4 At E16.5, forelimbs were harvested for optical projection tomography and single-cell RNA-sequencing (scRNA-seq).
Maternal exercise rescued joint and bone morphogenesis defects in mdg/mdg fetuses (Fig A-B). Strikingly, maternal exercise also prevented disuse associated resorption of the deltoid tuberosity, an established hallmark of mechanoregulated morphogenesis (Fig C). 5 Using scRNA-seq to determine potential mechanisms, we captured high-quality transcriptomes from 263,309 cells and categorized them into 12 clusters. The connective tissue cluster had relatively fewer cells in mdg/mdg conditions (Fig D-E), coinciding with previous results. 6 To elucidate how mechanosensitive connective tissues respond to mutation and exercise, we conducted differential gene expression testing and Gene Ontology (GO) analysis. At the cluster-level, we found GO terms for development and growth, demonstrating how mutation and exercise impact deltoid tuberosity morphogenesis (Fig F). We next used iterative clustering to identify enthesis cells (Fig G). Within the enthesis subcluster, mdg/mdg Sham cells upregulated growth factor signaling inhibitors ( e.g., Sfrp2, Igfbp3 ) and downregulated growth factor signaling activators ( e.g., Wtip1, Ryk, Smad4, Akt1 , Fig H).
Together, these findings indicate that maternal exercise rescues fetal akinesia-induced skeletal disorders and suggest a mechanism involving Hippo, Wnt, Tgfβ, and/or PI3/Akt signaling. These findings motivate using maternal exercise as a platform for studying in utero developmental mechanobiology and as a potential therapeutic intervention for fetal akinesia.
Ref [1] Nowlan+ Eur Cell Mater 2015 [2] Panebianco+ FASEB J 2025 [3] Pai+ Dev Biol 1965 [4] Suzue+ Neurosci Lett 1996 [5] Blitz+ Dev Cell 2009 [6] Tsinman+ J Orthop Res 2023
Identification of Disease-Driving Cellular States and Therapeutic Opportunities from Multi-Tissue Single-Cell Atlas of Human Knee Osteoarthritis - Rajnikant Dilip Raut, PhD
Purpose: Osteoarthritis (OA) is a progressive whole-joint disease and a major cause of chronic pain and disability worldwide. Current treatments remain largely symptomatic because the cellular mechanisms driving disease progression across joint tissues are poorly understood. This study generated the first integrated multi-tissue single-cell RNA sequencing (scRNA-seq) atlas of the human OA knee to identify disease-driving cellular states, inflammatory mechanisms, and therapeutic targets.
Methods: scRNA-seq datasets from 53 human knee tissues, including cartilage, synovium, meniscus, and subchondral bone from non-OA and OA specimens, were analyzed using Seurat, SingleR, and celldex. Tissue stem cell (TSC), immune, stromal, and chondrocyte populations were characterized, and disease-associated transcriptional programs linked to inflammation, fibrosis, pain signaling, and osteogenesis were identified. Cell-cell communication analyses using CellChat and NicheNet defined coordinated signaling pathways contributing to OA progression.
Results: OA tissues showed extensive cellular remodeling. Healthy synovium and meniscus contained regenerative TSC populations expressing SDF1, SOX9, CD146, PDGFRB, and CD105, whereas these populations were markedly depleted in OA, suggesting impaired endogenous repair. OA tissues demonstrated expansion of NT5E-positive osteogenic TSC populations associated with pathological ossification and subchondral bone remodeling. OA cartilage was enriched with MMP13- and RUNX2-expressing chondrocytes and fibroblast-like chondrocytes linked to matrix degradation and fibrosis. Inflammatory macrophages expressing IL1B, IL6, NOS2, TNF, and P2RX7 were significantly expanded in OA tissues, identifying inflammatory and nociceptive pathways associated with pain and disease progression. Cell-cell communication analyses revealed coordinated cross-tissue signaling networks promoting inflammatory macrophage activation and osteogenic differentiation.
Conclusion: This study establishes the first comprehensive multi-tissue single-cell atlas of the human OA knee and identifies inflammatory, fibrotic, osteogenic, and regenerative cellular programs driving OA progression. These findings highlight potential targets for precision medicine, regenerative therapies, and disease-modifying OA interventions.read more · Original Link ↗
Nipith Charoenngam, MDEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, USA
Rafael Correia CavalcanteUniversity Of Michigan, Ann Arbor, MI, US
Wayne A. Cabral, PhDCenter for Precision Health Research, NHGRI, NIH, USA
Christopher James Panebianco, PhDUniversity Of Pennsylvania, Philadelphia, PA, US
Rajnikant Dilip Raut, PhDBoston University, BOSTON, MA, US
Sequencing Matters: Strategic Treatment Planning for Optimal Outcomes - Benjamin Z. Leder, MD
Rethinking Zoledronate: When, How, and for Whom? - Bente L.Sequencing Matters: Strategic Treatment Planning for Optimal Outcomes - Benjamin Z. Leder, MD
Rethinking Zoledronate: When, How, and for Whom? - Bente L. Langdahl, DSc., PhD, MD
The Denosumab Dilemma: Unresolved Questions Regarding Management Strategies for Denosumab Discontinuation - Adi Cohen, MD, MSread more · Original Link ↗
Yumie Rhee, MD, PhDYonsei University College Of Medicine, Seoul, KR
Elaine W. YuMassachusetts General Hospital, Boston, MA, US
Benjamin Z. Leder, MDMassachusetts General Hospital Harvard Medical School, Boston, MA, US
Bente L. Langdahl, DSc., PhD, MDAarhus University Hospital, Aarhus N, DK
Adi Cohen, MD, MSVagelos College of Physicians & Surgeons, Columbia University, USA
☆
Sun 10/11 · 10:15 AM - 11:15 AM
Basic Symposium: New Roles of the FGF23-HIF/Oxygen Axis in Bone
● Symposium
Symposium
📍 Meeting Room 302
Iron/FGF-23/Erythroid HSC Mobilization - Valentin David
Erythroid Precursors Regulate Local Oxygen Tension and Repair Outcomes in the Bone Marrow Niche - Annemarie Lang, PhD, DVM
HIFs and Bone/Bone Marrow - Colleen Wu, PhD · Original Link ↗
Martina Rauner, PhDMedical Faculty Of The Tu Dresden, Dresden, DE
Kenneth White, PhDIndiana University School of Medicine, USA
Valentin DavidNorthwestern University, Feinberg School Of Medicine, Chicago, IL, US
Annemarie Lang, PhD, DVMUniversity Of Michigan, Ann Arbor, MI, US
Colleen Wu, PhDDuke University, Durham, NC, US
☆
Sun 10/11 · 10:15 AM - 11:15 AM
Meet the Professor: Newly Defined Causes of Osteomalacia & Appropriate Clinical Management
● Meet the Professor
Meet the Professor
📍 Meeting Room 309
Newly Defined Causes of Osteomalacia & Appropriate Clinical Management - Nobuaki Ito, MD, PhD
Acquired FGF23-related hypophosphatemic osteomalacia has long been considered to be caused predominantly by tumor-induced osteomalacia (TIO).Newly Defined Causes of Osteomalacia & Appropriate Clinical Management - Nobuaki Ito, MD, PhD
Acquired FGF23-related hypophosphatemic osteomalacia has long been considered to be caused predominantly by tumor-induced osteomalacia (TIO). However, it has become increasingly clear that this disorder encompasses a much broader spectrum of etiologies. These include intravenous iron-induced hypophosphatemia, alcohol-associated disease, hypophosphatemia associated with neurofibromatosis type 1, and cases occurring in patients with advanced malignancies such as prostate or lung cancer. More recently, our group identified a novel autoimmune form of the disease caused by autoantibodies against PHEX, which we termed autoimmune osteomalacia .
In this lecture, I will discuss a practical and efficient diagnostic approach for distinguishing among the diverse causes of acquired FGF23-related hypophosphatemic osteomalacia. I will also review the optimal management and treatment strategies tailored to each underlying etiology.
Osteomalacia: A Fresh Look at a Familiar Disorder - Suzanne M. Jan de Beurread more · Original Link ↗
Nobuaki Ito, MD, PhDDivision of Therapeutic Development for Intractable Bone Diseases, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan
Suzanne M. Jan de BeurUniversity of Virginia, USA
☆
Sun 10/11 · 10:15 AM - 11:15 AM
Meet the Professor: Public Omics Data: Find It, Analyze It, Reuse It
● Meet the Professor
Meet the Professor
📍 Meeting Room 310
Public Omics Data: Find It, Analyze It, Reuse It - Struan F.A. Grant, PhD
This session will introduce practical public-domain omics resources and ready-to-use analytical tools relevant to bone research.Public Omics Data: Find It, Analyze It, Reuse It - Struan F.A. Grant, PhD
This session will introduce practical public-domain omics resources and ready-to-use analytical tools relevant to bone research. The goal is to help clinicians and investigators better understand where to find these data and how to begin using them effectively. Attendees will gain an accessible and practical framework for applying omics resources in their own work.
Omics data for all - Where to find public domain data and the tools already built for you to use in your analyses - Cheryl L. Ackert-Bicknell, PhD
Advances in high-throughput "omics" technologies have transformed skeletal biology research, generating extensive public datasets. However, a general perception is that meaningful analyses require costly experiments, specialized expertise, and advanced programming skills often deters researchers. This is particularly true for those early in their careers, where is concerns with engaging with such powerful approaches. This session aims to break down those barriers by outlining the wealth of high quality genomic, transcriptomic, epigenomic and proteomic data that already exists in the public domain. Indeed, such rich datasets are largely freely available and can be engaged to aid novel bone-related queries.
We will provide a practical tour of key repositories relevant to musculoskeletal research, including the Gene Expression Omnibus, the Musculoskeletal Knowledge Portal, GTEx, the GWAS Catalog, ENCODE and single-cell atlases. We will outline the specific types of skeletal and cellular data each of these resources contain. Importantly, the session will then introduce a suite of user-friendly, point-and-click tools that require little or no coding experience. This will enable attendees to interrogate these datasets, from differential expression and pathway enrichment analyses to exploration of genetic associations and cell type-specific expression. Furthermore, we will also share our perspective from the other side i.e. as data generators, outlining how we deposit our own datasets into such public repositories so that attendees can learn how to both use and contribute to these powerful shared resources.
After completion of the session, attendees will be equipped with a robust starting toolkit, a curated list of trusted resources, and a sense of how to independently incorporate publicly available omics data into their research programs, regardless of prior computational experience or laboratory budget.read more · Original Link ↗
Struan F.A. Grant, PhDChildren's Hospital Of Philadelphia / University Of Pennsylvania, Swarthmore, PA, US
Cheryl L. Ackert-Bicknell, PhDUniversity Of Colorado, Aurora, CO, US
☆
Sun 10/11 · 10:15 AM - 11:15 AM
Meet the Professor: Clinical Management of X-linked Hypophosphatamic Rickets: Optimizing Care Across Lifespan
● Meet the Professor
Meet the Professor
📍 Meeting Room 313
Clinical Management of X-linked Hypophosphatamic Rickets: Optimizing Care Across Lifespan - Thomas O. Carpenter, MD
Clinical Management of X-linked Hypophosphatamic Rickets: Optimizing Care Across Lifespan - Aliya Khan, MD, FRCPC, FACP, FACE · Original Link ↗
Thomas O. Carpenter, MDYale University School Of Medicine, New Haven, CT, US
Aliya Khan, MD, FRCPC, FACP, FACEDivision of Endocrinology and Metabolism, McMaster University, Hamilton, Canada
Built for you by(617)-PATRICK, Champion AI speaker
Oral Presentations: Cancer and Bone Tumor - Immune - Bone Interactions in Disease Progression and Therapy
● Oral Abstract Presentations
Oral Abstracts
📍 Ballroom C
Denosumab Discontinuation in Breast Cancer Survivors - Monica Fornier, MD
Purpose: Denosumab (Dmab) is widely used to reduce bone loss, as well as improve breast cancer (BC) outcome, in BC patients on endocrine therapy with aromatase inhibitors (AI).Denosumab Discontinuation in Breast Cancer Survivors - Monica Fornier, MD
Purpose: Denosumab (Dmab) is widely used to reduce bone loss, as well as improve breast cancer (BC) outcome, in BC patients on endocrine therapy with aromatase inhibitors (AI). When patients stop AI, Dmab is typically discontinued as well. Dmab rebound phenomenon, a well-documented rapid bone loss after Dmab discontinuation, has been reported in the osteoporosis population. This is likely due to activation of osteoclasts. Less is known in regard to BC patients with normal bone density (BMD) or osteopenia, who initiated Dmab while on therapy with AI, to prevent bone loss and ameliorate outcome. We hypothesized that these patients may be at lower risk from rebound bone loss, when they discontinue both Dmab and bone-damaging AI.
Methods: In an ongoing prospective clinical trial, we aim to determine the impact of Dmab discontinuation on BMD, bone turnover markers, and circulating osteoclast precursor cells (OPCs) in BC patients with either osteopenia or normal bone density, who received at least two doses of Dmab (60 mg) and then stopped it, at Memorial Sloan Kettering Cancer Center.
Results: So far, 19 patients have been accrued. Mean age is 67.66 +/- 9.97. All patients were treated with an AI. Mean duration of dmab was 4.62 years,equivalent to 9 cycles. Baseline BMD was measured by DEXA analysis prior to last Dmab dose. 75% of patients had osteopenia and 25% had normal BMD. We observed an accelerated decline in BMD after Dmab discontinuation in 75% of patients at both the lumbar spine and total hip, regardless of baseline BMD, at 12 months after the last Dmab dose. Lumbar spine T-score and total hip T-score were decreased by 0.415 and 0.425, respectively. Bone-specific alkaline phosphatase and C-terminal telopeptide of type 1 collagen increased at 9 months by 9.3 mcg/L and 876.6 pg/ml, respectively, compared to baseline. Circulating OCPs increased to levels comparable to those observed in patients with osteoporosis, following Dmab withdrawal. No fractures have been reported.
Conclusions: Although this is a small cohort, findings suggest that bone turnover markers and circulating OCPs increase, and bone loss may occur after discontinuing Dmab, even in patients with osteopenia or normal BMD. Accrual is ongoing.
Anti-RANKL Enriches for Immunosuppressive Bone Marrow Myeloid Populations in Breast Cancer Bone Metastases - Jailyn Smith
Breast cancer cells often metastasize to bone, where they increase bone resorption that fuels tumor growth through release of bone-derived growth factors. Denosumab is a humanized monoclonal antibody that binds to receptor activator of nuclear factor-κB ligand (RANKL) to inhibit osteoclast-mediated bone resorption and is increasingly used to prevent and manage skeletal-related events in patients with bone metastases. Previous studies show that RANKL blockade reduces bone metastases in mice, and denosumab increases bone-metastasis-free survival in breast cancer patients. Denosumab is thought to reduce breast cancer bone metastasis by reducing osteoclast maturation, but a recent preclinical study revealed that RANKL blockade decreases primary tumor growth and infiltration of immunosuppressive cells, such as CD4 + and CD8 + T regulatory cells. The impact of RANKL blockade on the bone-tumor-immune microenvironment has not been investigated in an immunocompetent breast cancer bone metastasis model. Thus, we treated female 6-wk BALB/c mice with α-RANKL (murine equivalent of denosumab) or IgG for 2 weeks (100µg 3x/wk), then inoculated 4T1 murine breast cancer cells by intracardiac injection, continuing treatment to sacrifice. Histomorphometric analysis revealed that α-RANKL reduced tumor burden in the bone (by 90%, p<0.05) and osteoclast number and surface (by 100%, p<0.005-0.05). Serum ELISA analysis revealed that α-RANKL decreased CTX-1 (by 99%, p<0.05) but did not affect P1NP. Surprisingly, flow cytometry revealed that α-RANKL did not alter CD4 + or CD8 + T cell populations in bone marrow but increased immunosuppressive myeloid populations, including F4/80 + /CD11c lo /CD68 + /CD206 + M2-like macrophages and Ly6G + /Ly6C lo /PDL1 + and Ly6G + /Ly6C lo /PDL1 + /F4/80 + myeloid-derived suppressor cell (MDSC)/tumor-associated neutrophil (TAN)-like cells (by 1.64-2.39-fold, p<0.01). We next assessed whether α-RANKL directly acts on breast cancer cells, which we confirmed express RANK mRNA ( Tnfrsf11a ) and protein. Treatment with α-RANKL significantly decreased pERK/ERK protein (by 25.8%, p<0.005) in 4T1 cells; however, there was no change in 4T1 cell counts after in vitro treatment with α-RANKL, suggesting minimal direct effects of α-RANKL on breast cancer cells. These data together suggest that while α-RANKL reduces osteoclast activity and breast cancer bone metastasis, it may increase immunosuppressive myeloid cells in the bone marrow.
Bone-Derived TGF-β Promotes Anaplastic Thyroid Cancer Bone Metastases: Therapeutic Effects of Zoledronate and Bone-Targeted TGF-β Inhibition on ATC-Bone-Immune Microenvironment - Shiyu Yuan, PhD
Anaplastic thyroid cancer (ATC) patients often develop osteolytic bone metastases, which are associated with shorter survival and poor response to treatment (kinase inhibitors ± immunotherapy). The mechanism of ATC bone metastases remains unknown. We established the first syngeneic model of ATC bone metastases by intratibial inoculation of murine ATC cells into C57BL/6J mice. This model exhibited osteolytic lesions, elevated plasma TGF-β1, and activated TGF-β/Smad signaling in tumors. As TGF-β released from bone matrix due to osteolytic lesions can impact tumor progression, we hypothesized that ATC promotes bone destruction and acquires resistance to therapy in response to bone-derived TGF-β.
To test whether blocking TGF-β release inhibits ATC bone metastases, mice were treated with osteoclastic bone resorption inhibitor zoledronate (ZA) or DPBS after tumor inoculation. Bones were assessed by X-ray and µCT. Tumor burden, osteoclasts, and p-Smad2 were evaluated by histomorphometry. Immune profiling was performed by CyTOF. Compared with DPBS, ZA-treated mice showed decreased osteolytic lesions (9.2 vs 2.9 mm², **p<0.01), reduced tumor burden (53% vs 32%,**), fewer osteoclasts at the tumor-bone interface (10 vs 4 cells/mm,**), decreased plasma TGF-β1, and reduced nuclear p-Smad2 in tumors. ZA also reshaped the immune microenvironment toward a less immunosuppressive state, with increased M1 macrophages (2% vs 16%, p<0.05) and decreased PD-L1+ M2 macrophages (49% vs 0.9%, p<0.001) (Fig.1A). Since ZA may inhibit release of other bone matrix-derived factors, we next tested direct TGF-β blockade using the systemic TGF-β neutralizing antibody 1D11. Unexpectedly, 1D11 did not alter tumor growth, bone destruction, or immune cell composition compared with isotype controls. We therefore tested bone-targeted TGF-β inhibition using 1D11-alendronate (1D11-ALN), in which alendronate served as a bone-homing moiety due to its high affinity for hydroxyapatite rather than as an osteoclastic inhibitor. Strikingly, 1D11-ALN reduced tumor burden and bone destruction (Fig. 1B), decreased osteoclast number, and reduced nuclear p-Smad2 in tumors compared with 1D11 or isotype controls.
In conclusion, bone-derived TGF-β promotes ATC bone metastases and induces an immunosuppressive bone microenvironment. Targeted TGF-β blockade within bone is required for therapeutic efficacy. Combination therapies with ZA or bone-targeted TGF-β inhibitors may improve treatment for ATC bone metastases.
CART Therapy is Associated with Altered Bone Microarchitecture in Multiple Myeloma - Anders Narum
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy, and although chimeric antigen receptor (CAR) T-cell therapy has transformed treatment, its effects on bone health remain uncharacterized. Immune-activating therapies such as checkpoint inhibitors have been linked to inflammatory bone loss, raising concerns that CART may exert similar effects on the skeleton.
To address this, we leveraged longitudinal bone biopsies collected through a Phase II safety run-in cohort (N=6) of NCT06940297, testing whether senolytic therapy (dasatinib+quercetin; D+Q) modulates CART efficacy or toxicity. MM patients eligible for cilta-cel CART received D+Q for 2 days prior to lymphodepletion and monthly for 3-months post-CART infusion. Bone biopsies and aspirates were collected on baseline and Day (D) 1, 30, 60, 90, and 180 post-CART. Peripheral blood (PB) collected on D14 was used to quantify CART expansion. Bone biopsies were evaluated by µCT. Bone marrow (BM) and PB cells were profiled by flow cytometry. Clinical response was assessed by BM clonal plasma cell minimal residual disease (MRD) analysis and PET imaging.
Five patients achieved BM MRD/PET negativity, and one achieved only BM MRD negativity. 60% of biopsies were evaluable by µCT, with the higher quality biopsies obtained at later timepoints. Baseline and D1 biopsies showed substantial heterogeneity and fragmentation across patients, consistent with lytic lesions. BV/TV at D30 (N=3), D90 (N=5), and D180 (N=2) were 26.3%±6.0, 18.4%±8.4, and 18.0%±4.1, respectively, with parallel declines in TbS, TbN, and TbTh. Among patients with paired later-timepoints (N=4), non-parametric, paired analysis revealed trends (p=0.125) for decreased BV/TV, TbS, and TbN and an increase in TbSp.
A notable pattern emerged when these outcomes were compared to CART kinetics. A higher ratio of CD8:CD4 CART cells at D14, as well as higher CD8:CD4 area-under-the-curve ratio, was associated with lower BV/TV, TbS, TbN, and increased TbSp at D90 (p=0.08). No associations were observed with CD8 or CD4 CART levels alone, suggesting that imbalanced, CD8-dominant CART activation may contribute to bone loss.
These findings provide the first preliminary longitudinal evidence that CART therapy may influence bone microarchitecture in MM and that specific immune activation patterns may underlie bone deterioration. As CART moves earlier in treatment, evaluation of its skeletal effects and potential protective strategies will be essential.
Fracture Risk Associated with Immune Checkpoint Inhibitor Therapy: A Population-Based Matched Cohort Analysis Using Administrative Health Data - Carrie Ye, FRCP
Background: Immune checkpoint inhibitors (ICIs) improve survival in patients with cancer by activating antitumor immune responses. However, prolonged immune activation may adversely affect bone, potentially increasing the risk of osteoporosis and fractures. We evaluated fracture risk among ICI users compared with matched controls using administrative health data.
Methods: We conducted a retrospective population-based matched cohort study using the Alberta Cancer Registry linked to provincial healthcare databases. Individuals who received ICI therapy were matched 1:1 to non-ICI users based on age, sex, cancer type and cancer stage. The index date was ICI initiation for ICI users and the pseudoindex date in matched controls was assigned using the lag time from cancer diagnosis to ICI initiation, with landmark analysis built into the matching criteria (survival to pseudoindex date). Fractures occurring after the index date were identified using international classification of diseases (ICD) code-based case definitions. Incidence rates ratios (IRRs) were calculated per 1000 person-years. Multivariable Cox regression models were used to estimate hazard ratios (aHRs) for incident fracture from ICI exposure after adjusting for multiple covariates and accounting for the competing risk of death.
Results: 4,868 of 6,220 ICI users were matched to a control for a total cohort size of 9,736 individuals with cancer (mean age 65 years, 56% male, 48% lung cancer). Incidence rate ratios were 1.66 (95% CI 1.34, 2.07) for any fracture and 1.72 (95% CI 1.36, 2.18) for major osteoporotic fracture (MOF, comprising fractures of the hip, forearm, vertebrae and humerus) in the first year after index date and 2.00 (95% CI 1.46, 2.75) and 2.16 (95% 1.53, 3.07), respectively, in the second year after index date. In the Cox regression model, ICI users had an elevated aHR of 1.81 (95% CI 1.45 - 2.26, p<.001) for any fracture and aHR 1.89 for MOF (95% CI 1.49 - 2.39, p<.001).
Conclusion: In this population-based matched cohort among cancer patients, ICI therapy was associated with a significantly increased risk of any incident fracture and MOF, even after accounting for multiple covariates and competing mortality. Clinicians and patients should consider fracture risk when discussing the risks and benefits of ICI therapy and appropriate bone health screening and fracture prevention measures should be considered.read more · Original Link ↗
Serk In Park, DDS, PhDKorea University College Of Medicine, Seoul, TN, KR
Cyrille B. Confavreux, MD, PhDCRCL Inserm 1052 CNRS 5286 - Universite Claude Bernard Lyon 1, Chaponost, France
Monica Fornier, MDMemorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA
Jailyn SmithVanderbilt University, USA
Shiyu Yuan, PhDDepartment of Endocrine Neoplasia and Hormonal Disorders, the University of Texas M. D. Anderson Cancer Center, USA
Anders NarumMayo Clinic, USA
Carrie Ye, FRCPUniversity Of Alberta, Edmonton, AB, CA; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
☆
Sun 10/11 · 11:30 AM - 12:30 PM
Oral Presentations: Calcium Homeostasis Disorders: Phase 3 Breakthroughs and Precision-Driven Care
● Oral Abstract Presentations
Oral Abstracts
📍 General Session - Ballroom A & B
Genotype-First Approach to Estimate the Prevalence and Characterize the Phenotypic Spectrum of Familial Hypocalciuric Hypercalcemia Type 1 - Nipith Charoenngam, MD Familial hypocalciuric hypercalcemia type 1 (FHH1), caused by inactivating CASR variants , is characterized by lifelong hypercalcemia and hypocalciuria...Genotype-First Approach to Estimate the Prevalence and Characterize the Phenotypic Spectrum of Familial Hypocalciuric Hypercalcemia Type 1 - Nipith Charoenngam, MD
Familial hypocalciuric hypercalcemia type 1 (FHH1), caused by inactivating CASR variants , is characterized by lifelong hypercalcemia and hypocalciuria that should be distinguished from primary hyperparathyroidism as their management differs substantially. Prior reports have suggested additional manifestations (i.e., pancreatitis, chondrocalcinosis), but epidemiologic evidence is limited.
Using a genotype-first analysis of UK Biobank (UKB) whole-exome/whole-genome sequencing linked to health records, we estimated the prevalence and characterized the phenotypic spectrum of FHH1 due to inactivating CASR variants. Candidate variants were drawn from the CASRdb, which aggregates variants reported in the literature and ClinVar/LOVD, and were supplemented with additional variants predicted to be high-impact. Variants were classified as FHH1-associated if designated in ClinVar as pathogenic/likely pathogenic (P/LP) or, for non-P/LP variants, determined to have a high probability of causing FHH1 based on variant curation criteria that considered predicted loss-of-function status, allele frequency data, and mean carrier serum total calcium in UKB. We compared biochemical phenotypes with those of the remaining UKB population and performed covariate-adjusted PheWAS across ICD-10 diagnoses and quantitative traits.
Among 454,787 exomes and 490,640 genomes, 162 individuals carried FHH1-causing variants (33.0/100,000). Mean serum calcium was higher in FHH1 than in the remaining UKB population (10.4±0.6 vs 9.5±0.4 mg/dL; p=1.2×10 -72 ) but overlapped from approximately 9.2 - 9.4 mg/dL upward ( Figure ). PheWAS signals were dominated by calcium/parathyroid-related diagnoses and traits; we found no differences in pancreatitis or diabetes-related outcomes between FHH1 individuals and the remaining UKB population. Serum phosphate was modestly lower in FHH1 individuals (3.3±0.5 vs 3.6±0.5 mg/dL; p=6.7×10 -17 ), and the rate of serum phosphate <3.0 mg/dL was higher among FHH1 individuals (27% vs 12%; p=1.7×10 -9 ). In gnomAD v4.1, the estimated prevalence (SE) of FHH1 was 31.2(2.0)/100,000 overall and varied by ancestry, ranging from 46.6(12.5)/100,000 in the Admixed American group to 13.5(9.6)/100,000 in the Ashkenazi Jewish group. Taken together, these data indicate that FHH1 appears to be more common than previously appreciated and is characterized by variable degrees of hypercalcemia, modest hypophosphatemia, and no additional traits in UKB.
Encaleret Restores Mineral Homeostasis And Increases Bone Turnover In Autosomal Dominant Hypocalcemia Type 1 (ADH1): 24-Week Results From Phase 3 CALIBRATE Trial - Erik Imel
Autosomal dominant hypocalcemia type 1 (ADH1), due to gain-of-function variants in the calcium-sensing receptor gene ( CASR ), manifests as low parathyroid hormone (PTH), hypocalcemia, hypercalciuria, hyperphosphatemia, hypomagnesemia, and low bone turnover. Standard of care (SoC) treatment with calcium and active vitamin D worsens hypercalciuria and can lead to renal morbidity. Encaleret, an investigational, oral, negative allosteric modulator of the CaSR, normalized mean albumin-corrected blood calcium (cCa) and 24-hour urine calcium excretion in a Phase 2b study of ADH1.
CALIBRATE ( NCT05680818) is a global, Phase 3, randomized, controlled, open-label trial of encaleret for ADH1. After screening, a SoC optimization period, and a 4-week SoC dose maintenance period, participants were randomized 2:1 to receive encaleret or continue SoC for 24-weeks (W24). Those randomized to encaleret stopped SoC prior to encaleret initiation; the encaleret dose was titrated to achieve target cCa (8.3-10.7 mg/dL).
Sixty-seven participants (16-76y, 52% female) were randomized, and 66 completed W24. Only 4% of encaleret treated patients required ongoing SoC. From baseline to W24, encaleret stimulated intact PTH secretion to ≥ lower limit of normal in 91% of participants (vs SoC: 0%) and normalized 24-hour urinary calcium (80% vs 38%), serum cCa (88% vs 29%), phosphate (91% vs 52%), and magnesium (91% vs 76%).
From baseline to W24, bone turnover markers increased in the encaleret-treated group, as indicated by increases in the proportion of participants above the age- and sex-specific normal range for P1NP from 2.2% to 71% (vs 9.1% to 0% with SoC) and CTx from 0 to 40% (vs 0% to 0% with SoC). Over the same period, mean DXA bone mineral density (BMD) Z-scores decreased in the encaleret-treated group at the lumbar spine, femoral neck, and total hip, with no change at total body or 1/3 distal radius; whereas mean BMD Z-scores in SoC participants were similar across all sites. Encaleret was generally well-tolerated.
Encaleret-mediated increases in PTH resulted in increased bone turnover and reduced BMD at selected sites, with mean BMD Z-scores remaining above the population mean. These findings support the efficacy of encaleret in reversing the underlying pathophysiology of ADH1. Longitudinal monitoring will be important to characterize long-term skeletal health.
Participant-Reported Changes in Symptoms and Treatment Experience with Encaleret in Autosomal Dominant Hypocalcemia Type 1: 24-Week Findings From the Phase 3 CALIBRATE Trial - Steven Wai Ing, MD
Background : Autosomal dominant hypocalcemia type 1 (ADH1) is a rare condition and genetic form of hypoparathyroidism. In the phase 3, randomized CALIBRATE trial (NCT05680818), treatment with encaleret, an oral calcilytic, led to significant biochemical improvements vs standard of care (SoC; calcium supplementation and/or active vitamin D) in participants with ADH1. Here, we report participant-reported symptom changes for encaleret and SoC groups in CALIBRATE.
Methods : In CALIBRATE, doses of encaleret and SoC were titrated to achieve target albumin ‑ corrected calcium levels over 20 weeks, followed by a 4-week maintenance period. Participants completed semi-structured exit interviews with trained interviewers at weeks 24 - 26 or within 2 weeks of the early exit visit. Interviews explored changes in spontaneously reported symptoms (with probing of nine common ADH1 symptoms) and treatment satisfaction during the trial. Interview transcripts were reviewed and coded using a coding framework to identify key concepts. Changes in symptoms and ADH1-related impacts on daily functioning were summarized using descriptive statistics.
Results : Exit interviews were completed by 45 of 67 participants; 42 occurred within the 2-week post-trial window (encaleret, n=31; SoC, n=11). At exit interview, the mean (SD) age of the 42 participants included in the analysis was 42.5 (14.8) years and time since diagnosis was 19.7 (16.2) years; 64% were female; 62% enrolled in the US. All participants who received encaleret reported improvements in ≥1 ADH1 symptom vs 45.5% with SoC. Improvements in symptoms (regardless of reported symptom presence at baseline) were more common with encaleret vs SoC: fatigue (61.3% vs 27.3%), muscle cramps (58.1% vs 36.4%), muscle spasms (58.1% vs 18.2%), tingling (51.6% vs 9.1%) and brain fog (48.4% vs 9.1%). No symptoms had higher improvement rates with SoC than encaleret. Improvements in ADH1-related impacts on daily functioning were more frequently reported with encaleret vs SoC, including mood/emotion (61.3% vs 27.3%), physical activities (45.2% vs 9.1%), daily life (35.5% vs 18.2%) and work life (35.5% vs 9.1%).
Conclusions : A greater proportion of participants receiving encaleret vs SoC reported improvements in key symptoms, such as fatigue and neuromuscular symptoms, and in daily functioning, such as work life and daily life. These patient experience insights into symptom and impact improvements complement the trial’s biochemical endpoint results.
Balanced Effects of Eneboparatide on Skeletal Parameters: Results From a Phase 3, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Eneboparatide in Adults With Chronic Hypoparathyroidism (CALYPSO) - Aliya Aziz Khan, MD
Purpose: Assess the effect on bone of daily eneboparatide (ENB), a novel parathyroid hormone 1 receptor agonist, in a phase 3, randomized, double-blind, parallel, placebo-controlled, 24-week (W) trial, followed by a 28W open-label extension in adults with chronic hypoparathyroidism (HypoPT) (NCT05778071, funded by Alexion).
Methods: 202 adults aged 18-80 with chronic HypoPT were randomized 2:1 to ENB or placebo (PBO). After optimization of conventional therapy (oral calcium and active vitamin D), patients received a daily subcutaneous injection of ENB or PBO. Conventional therapy was incrementally reduced, and titration of ENB was permitted except during W20-24. The primary endpoint was the proportion of patients achieving independence from conventional therapy while sustaining normal serum calcium in W20-24. Bone analysis parameters included change in serum procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide (CTX) bone turnover markers, bone mineral density (BMD), Z-score, T-score, and trabecular bone score (TBS) assessed by dual-energy x-ray absorptiometry in all patients and in the low BMD/osteoporosis (OP) at baseline (BL) subgroup (n=38).
Results: At W24, primary and key secondary endpoints met statistical significance (data previously presented). More patients receiving ENB met the primary endpoint vs PBO (31% [41/132] vs 6% [4/68] [ P <0.0001]). At W24, CTX and P1NP increased concordantly from BL but stayed within age- and sex-specific reference ranges with ENB treatment (195.2 ng/L and 49.54 ng/L) vs PBO (11.3 ng/L and 4.43 ng/L), and in patients with low BMD/OP at BL (ENB: 237.8 ng/L and 54.75 ng/L vs PBO: 17.7 ng/L and 10.76 ng/L, respectively), smaller but continued increases within reference ranges occurred through W52. No clinically significant decreases in mean BMD T-scores and Z-scores were observed at W24 or W52 (Figure) across 4 assessed bone sites in patients treated with ENB, including those with low BMD/OP at BL. Mean TBS levels remained stable in ENB-treated adults over 52Ws, including those with low BMD/OP at BL. Overall, ENB was well tolerated through W52. Mild-to-moderate hypocalcemia was the most frequently reported adverse event through W52 (ENB: 52/132, PBO: 41/68 [W24]; ENB/ENB: 49/124, PBO/ENB: 35/63 [W52]).
Conclusions: ENB given over 52Ws resumes balanced bone turnover without reducing BMD in adults, including those with low BMD/OP, and shows an acceptable safety profile consistent with previous reports.
Long-Term Effects of Palopegteriparatide on BMD and TBS in Adults With Chronic Hypoparathyroidism: Pooled Results From the PaTH Forward and PaTHway Trials - Aliya Aziz Khan, MD
Purpose : The PaTH Forward and PaTHway clin i cal trials have demonstrated the safety and efficacy of palopegteriparatide in the treatment of adults with chronic hypoparathyroidism for up to 5 years . This analysis report s long-term changes in bone mineral density (BMD) o bserved in the combined cohorts of these trials .
Methods: D ata were analyzed post-hoc from the phase 2 PaTH Forward and phase 3 PaTHway trials, comprising randomized, double-blind, placebo-controlled periods through Weeks 4 and 26 and open-label extension (OLE) periods through Weeks 266 and 182, respectively. Bone mass and microarchitecture were assessed through longitudinal assessment of BMD by DXA and t rabecular bone score (TBS ) . TBS assessments were perform ed using 2 distinct versions of the TBS iNsight algorithm . Safety assessments included treatment-emergent adverse events (TEAEs).
Results: At baseline, participants (N=139) had a me dian (range) duration of hypoparathyroidism of 9 (1-56) years an d a mean (SD) age of 49 (12) years; 80% were female (of which 35% were postmenopausal) . Of the 129 participants who completed their respective trials, 123 (95%) were independent from therapeutic doses of calcium ( required ≤ 600 mg elemental calcium per day) , 127 ( 98% ) were independent from active vitamin D , and 114 ( 88% ) were normocalcemic . Mean BMD T- and Z-scores declined from elevated baseline levels and stayed within normal ran g e s through the OLE periods of the trials . Lower baseline BMD T- and Z-scores were generally associated with smaller declines in BMD over time . Longitudinal changes in DXA BMD values were consistent with those observed in TBS and TBS Z-scores. Mean TBS Z-score s remained above zero for premenopausal and postmenopausal women through Week 266 . As with BMD changes, t he magnitude of change in TBS Z-scores over time was generally smaller among participants with lower baseline TBS Z-scores. Adverse events of fractures were uncommon and deemed unrelated to palopegteriparatide . Two participants (1.4%) had vertebral fracture events.
Conclusion s: Chronic h ypoparathyroidism was associated with elevated baseline BMD and TBS for participants in the PaTH Forward and PaTHway trials. Treatment with palopegteriparatide led to early normalization of these values, which was subsequently sustained for the duration of the trials. These data suggest that, over a 5 - year period, palopegteripar a tide normalized bone mass and microarchitecture consistent with age- and sex-matched norms .read more · Original Link ↗
Deborah E. Sellmeyer, MDStanford University, School Of Medicine, Palo Alto, CA, US
Harald Jueppner, MDMassachusetts General Hospital, Boston, MA, US
Nipith Charoenngam, MDDepartment of Medicine, Harvard Medical School, Boston, MA, USA, USA; Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, USA
Erik ImelIndiana University School Of Medicine, Indianapolis, IN, US
Steven Wai Ing, MDThe Ohio State University Wexner Medical Center, Columbus, OH, US
Aliya Aziz Khan, MDDivision of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada
☆
Sun 10/11 · 11:30 AM - 12:30 PM
Oral Presentations: Cellular and Bioengineering Approaches to Bone Repair
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 302
CXCL9 Neutralization Enhances Aged Fracture Repair and Rebalances CXCL12 Signaling in the Periosteal Niche - Matthew Daniel Wan, BS, PhD Student
Fragility fractures increase with aging in part due to dysfunction of the periosteal niche that initiates skeletal repair.CXCL9 Neutralization Enhances Aged Fracture Repair and Rebalances CXCL12 Signaling in the Periosteal Niche - Matthew Daniel Wan, BS, PhD Student
Fragility fractures increase with aging in part due to dysfunction of the periosteal niche that initiates skeletal repair. This niche is regulated by chemokines that coordinate skeletal stem/progenitor cell (SSPC) activation and lineage progression during fracture healing. CXCL12 is a well‑established pro-repair chemokine; yet how aging-associated inflammatory chemokines alter CXCL12‑dependent periosteal programs remains poorly defined. Based on its reported anti-osteogenic activity, we hypothesized that CXCL9 is an aging-biased inhibitory chemokine that disrupts reparative periosteal signaling and is therapeutically targetable. Bilateral femoral fractures were generated in young (4 months) and aged (24 months) male mice. Periosteal cells from intact femurs and day-3 fractured femurs were FACS sorted (CD45−Ter119−) for scRNA seq with emphasis on Prrx1+ mesenchymal progenitors. scRNA seq identified Cxcl9 as an aging‑enriched chemokine expressed in intact periosteal SSPCs prior to injury, a finding validated by flow cytometry. Following fracture, young mice showed expansion of cycling progenitors, whereas aged mice exhibited elevated senescence signatures and disrupted differentiation trajectories, consistent with delayed healing at day 14 post-injury. Surprisingly, aging increased Cxcl12 expression following fracture, with elevated systemic CXCL12 confirmed by serum analysis, suggesting a compensatory but spatially or functionally dysregulated chemokine response. In contrast, expression of inflammatory cytokines including Tnf and Ifng was unchanged. In vitro, CXCL9 exposure (100 ng/mL, 10 days) suppressed osteogenic gene expression in bone marrow stromal cells. To test therapeutic relevance, aged mice received anti-CXCL9 neutralizing antibody or IgG control (10 mg/kg i.p. on days 1, 3, 6, 9, and 12 post fracture). CXCL9 neutralization enhanced callus formation, increased Osterix+ cells, and improved healing outcomes at day 14. Notably, while improving repair, CXCL9 inhibition was accompanied by reduced serum CXCL12 levels, without altering TNF, or VEGF, supporting a chemokine-selective mechanism. These findings indicate that impaired fracture repair with aging reflects CXCL9-driven disruption of periosteal chemokine signaling rather than generalized inflammation. Targeting CXCL9 restores chemokine balance and represents a tractable strategy to rejuvenate bone healing in aged individuals.
Muscle-derived CX3CL1 promotes bone repair through CX3CR1-expressing osteoprogenitors - Koji Ishikawa, PhD
Fractures with muscle defects often heal poorly, suggesting that injured muscle signals are important for effective bone repair. However, how adjacent muscle regulates bone regeneration remains poorly understood. To identify pro-regenerative muscle signals, we examined factors that are induced in muscle after bone injury and could contribute to repair. This strategy led us to identify CX3CL1 as a strong candidate. Although CX3CL1 is known to recruit CX3CR1 expressing immune cells, its role in musculoskeletal injury repair remains unclear. Using a femoral drill hole bone injury model, we found that Cx3cl1 expression was robustly induced in adjacent muscle, increasing approximately 20 fold, while bone, skin, and other major organs showed little or no induction. Notably, this muscle CX3CL1 response was reduced by 60 to 70% with aging ( Fig. A ). We further identified CD31⁺ endothelial cells in adjacent muscle as a major local source of CX3CL1 ( Fig. B ).
We next examined which cells within the bone repair niche respond to muscle-derived CX3CL1. We found that osteoblast progenitors, including PDGFRα⁺ cells (CD45 - Ter119 - CD31 - PDGFRα + ), express CX3CR1, the receptor for CX3CL1, during repair. These progenitors also showed robust osteoblastogenesis when stimulated with recombinant CX3CL1 in vitro . Lineage tracing using Col1a1 Cre ;tdTomato;Cx3cr1 GFP/WT and Pdgfr α CreER ;tdTomato;Cx3cr1 GFP/WT reporter mice, in which tdTomato labels Col1a1 + osteoblast-lineage or Pdgfrα + stromal progenitor - derived cells, revealed that tdTomato⁺ Cx3cr1 ⁺ double-expressing cells accumulate at the injury site during repair.
Having identified CX3CR1-expressing osteoprogenitors as a potential target of muscle-derived CX3CL1, we next tested whether CX3CL1 is required for bone repair in vivo. To define its role, we used complementary deletion strategies, including inducible global Cx3cl1 deletion, local adenoviral Cre mediated deletion in Cx3cl1 flox/flox mice, and endothelial-specific deletion using Cdh5 Cre ; Cx3cl1 flox/flox mice. Across these models, loss of CX3CL1 impaired bone repair ( Fig. C ). Moreover, local recombinant CX3CL1 treatment in aged mice increased PDGFRα⁺CX3CR1⁺ osteoprogenitor accumulation at the injury site and improved bone repair.
Together, these data support a model in which muscle-derived CX3CL1 promotes bone repair through CX3CR1-expressing osteoprogenitors, positioning CX3CL1 as a key regulator of muscle-to-bone communication during bone regeneration.
Macrophage YAP/TAZ Signaling Mediates Mechanoregulation of Bone Fracture Repair - Georgios Kotsaris
Bone fracture healing is governed by coordinated mechanical and immune signals, yet how immune cells sense and translate mechanical cues to regulate repair remains unclear 1,2 . Macrophages are central regulators of inflammation throughout all stages of bone healing and dynamically respond to changes in their mechanical environment 3,4 .
Here, we investigated the role of YAP/TAZ mechanotransduction in macrophage-mediated bone regeneration. Using macrophage-specific YAP/TAZ knockout (LysM-Cre) mice and a stabilized femoral osteotomy model with controlled mechanical loading of the regenerating tissue, we assessed fracture repair under stiff and compliant fixation. At 70 days post-fracture, wild-type animals exhibited complete regeneration with restoration of the marrow cavity under compliant fixation, whereas YAP/TAZ-deficient animals showed impaired healing, including non-unions and disorganized tissue formation, despite the deletion being restricted to myeloid cells (Fig. A). In wild-type animals, compliant fixation promoted greater callus formation than stiff fixation at early time points. In contrast, YAP/TAZ-deficient animals displayed reduced sensitivity to mechanical cues, resulting in altered bone formation at 14 days post-fracture (Fig. B). These findings indicate that macrophage YAP/TAZ signaling is required to translate mechanical inputs into appropriate regenerative outcomes. To define the underlying mechanisms, we performed single-cell RNA sequencing at day 7 post-fracture under compliant conditions. Loss of YAP/TAZ reduced inflammatory macrophage and monocyte populations (Fig. C), accompanied by decreased expression of pro-inflammatory cytokines. YAP/TAZ-deficient macrophages showed a 40% reduction in bacterial particle uptake in vitro. In addition, we identified a macrophage-associated population expressing ECM remodeling genes, and confirmed their presence in in vitro cultures, suggesting a direct role of these cells in shaping the stromal environment during repair (Fig. D).
Collectively, these findings establish YAP/TAZ as key regulators of macrophage mechanosensitivity that integrate mechanical and inflammatory signals to orchestrate bone regeneration. Disruption of this pathway uncouples mechanical loading from effective repair, highlighting macrophages as critical mechanotransducers and potential therapeutic targets in fracture healing.
Ref: 1. Collins, Dev. Cell , 2024; 2. Kegelman, JBMR , 2020; 3. Meli, Sc. Adv. , 2020, 4. Lang, NPJ , 2025
An Implantable Biobattery for In Situ Critical-Sized Bone Regeneration via Chemical-to-Biological Energy Conversion - Duoyi Zhao
Critical-sized bone defects face healing challenges due to insufficient local bioenergy, a condition further exacerbated in the aged state. This study reports an in situ implantable, fully absorbable magnesium‒zinc biobattery that directly converts chemical energy into a stable, biocompatible electric field (EF) for bone regeneration. The biobattery integrates Mg‒Zn electrodes within a calcium sulfate-modified 3D-printed poly(lactic‒glycolic acid) (PLGA) scaffold and delivers a stable 0.4 V for over 6 weeks, generating mild EF. In supracondylar femoral critical defect models of young rats, the biobattery significantly overcame energy deficiency barriers to regeneration, achieved full bone formation, and increased the bone volume fraction. Surprisingly, the energy conversion strategy also demonstrated promising bone-forming potential in the aged rat critical-sized bone defect model, further validating the feasibility of energy supplementation. The biobattery also demonstrated efficacy and safety in both young and aged goat models with critical-size defects, showcasing robust bone regeneration capacity without systemic toxicity. The results underscore its translational potential, given the greater anatomical and pathophysiological relevance of large animal models to humans. Mechanistic study revealed the biobattery influenced the activation of calcium ion channels by consuming chemical energy to generate localized EF. Calcium influx increased mitochondrial biogenesis, cristae remodeling, and intracellular ATP production, which promoted the proliferation, migration, and osteogenic differentiation of the progenitor cells in the bone formation process. This work pioneers a new paradigm for in situ chemical - bioenergy conversion, providing a potent, clinically translatable solution for next-generation bone graft substitutes.
Targeting ACLY-Mediated Fatty Infiltration with Hydrogel Microneedles Promotes Tendon-Bone Healing After Rotator Cuff Injury - Mingjie Ma
Objective: Fatty infiltration (FI) following rotator cuff injury often leads to surgical failure. This study aimed to investigate the clinical impact of FI on the bone quality of the humerus greater tuberosity (GT), identify key metabolic regulatory targets via single-cell sequencing, and evaluate the therapeutic efficacy of targeted hydrogel microneedles loaded with a metabolic inhibitor in promoting tendon-to-bone healing and protecting local bone mass.
Methods: Clinical Analysis: Sixty patients with rotator cuff tears were categorized by FI degree. GT cortical thickness and bone mineral density (BMD) were analyzed using CT-based software. Mechanism Identification: Single-cell RNA sequencing (scRNA-seq) was performed on a mouse rotator cuff injury model. GSEA, GSVA, CellChat, and scMetabolism analyses were utilized to identify FI-related hubs. Targets were validated via immunofluorescence in mice following systemic inhibitor administration. Microneedle Intervention: Targeted peptide-anchored hydrogel microneedles loaded with the identified inhibitor were developed and implanted at the tendon suture site in mice. Tendon-bone healing and bone protection were evaluated 30 days post-surgery via Micro-CT, biomechanical testing, and histological staining.
Results: Clinical data demonstrated that the degrees of FI and tear size are independent risk factors for GT bone quality decline (P < 0.05), showing a significant negative correlation. Multidimensional scRNA-seq analysis identified ATP-citrate lyase (ACLY) as the core metabolic target regulating FI. In mice, systemic ACLY inhibition significantly reduced local adipocytes. In the intervention study, the ACLY inhibitor-loaded microneedle group exhibited superior tendon-to-bone integration compared to the modeling-only group. Micro-CT confirmed significantly improved GT bone mass and architecture. Histological assessments revealed a dense fibrocartilage interface, reduced osteoclast activity, and suppressed FI in the treatment group. Furthermore, biomechanical strength was significantly enhanced (P < 0.05).
Conclusion: Fatty infiltration post-rotator cuff injury significantly compromises GT bone quality, with ACLY acting as a key molecular driver. Targeted delivery of ACLY inhibitors via hydrogel microneedles effectively reverses local FI, preserves bone mass, and promotes high-quality tendon-bone healing. This strategy offers a novel translational approach to prevent fixation failure in rotator cuff repair.read more · Original Link ↗
Mimi Sammarco, PhDMayo Clinic, Rochester, MN, US
Sanja Novak, PhDUniversity of Arkansas for Medical Sciences (UAMS), Little Rock, AR, US
Matthew Daniel Wan, BS, PhD StudentUConn Health, Bloomfield, CT, US; Department of Orthopaedics, UConn Health, USA
Koji Ishikawa, PhDDuke University, Chapel Hill, NC, US
Georgios KotsarisUniversity Of Pennsylvania, Philadelphia, PA, US
Mingjie MaDepartment of Orthopaedics, the First Hospital of China Medical University, China
☆
Sun 10/11 · 11:30 AM - 12:30 PM
Oral Presentations: ASBMR/OARSI Oral Presentation: Molecular Mechanisms of Osteoarthritis Development.
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 311
Osteocyte Parvalbumin Mediates Mechanotransduction to Attenuate Osteoarthritis - Jiansen Su, MD, PhD Student
Osteoarthritis is a leading cause of disability in the elderly, characterized by aberrant subchondral bone remodeling preceding cartilage degeneration.Osteocyte Parvalbumin Mediates Mechanotransduction to Attenuate Osteoarthritis - Jiansen Su, MD, PhD Student
Osteoarthritis is a leading cause of disability in the elderly, characterized by aberrant subchondral bone remodeling preceding cartilage degeneration. Osteocytes, the primary bone mechanosensors, mediate this process, but the molecular mechanisms linking excessive mechanical loading to osteocyte dysfunction remain unclear. This study investigates the role of osteocytic parvalbumin (Pvalb), a calcium-binding protein, in mechanical overload-induced osteoarthritis.
Tibial plateau specimens from TKA patients were analyzed in high-stress (medial) and low-stress (lateral) regions. Osteocyte-specific Pvalb conditional knockout mice were generated and underwent destabilization of the medial meniscus (DMM) surgery. Motor function, pain, cartilage degeneration and subchondral bone remodeling were evaluated by behavioral tests, histology, IHC and micro-CT. In vitro, primary osteocytes and MLO-Y4 cells were subjected to cyclic tensile strain. Molecular mechanisms were explored using transcriptomics, western blot, IF, Co-IP, luciferase and ChIP assays. A bone-targeted liposome system delivered recombinant Pvalb for therapeutic testing.
Pvalb expression was significantly reduced in osteocytes from high-stress subchondral bone in both patients and DMM mice, correlating with intracellular calcium overload. Osteocyte-specific Pvalb deletion markedly accelerated DMM-induced osteoarthritis, causing severe cartilage degeneration, subchondral bone loss, osteoclast activation, motor deficits and pain. In vitro, >20% mechanical strain downregulated Pvalb, leading to osteocyte apoptosis and enhanced osteoclast differentiation. Mechanistically, Pvalb chelates calcium and competes with CaMKIV for calmodulin binding, inhibiting CaMKIV phosphorylation and nuclear translocation. This blocks CREB phosphorylation at Ser114 and binding to the RANKL intronic enhancer, suppressing RANKL transcription. Bone-targeted Pvalb delivery significantly reduced subchondral bone remodeling, cartilage degeneration and functional deficits in DMM mice.
This study identifies a novel osteocyte mechanotransduction pathway in osteoarthritis. Excessive mechanical loading downregulates osteocytic Pvalb, activating the Ca²⁺-calmodulin-CaMKIV-CREB-RANKL axis to drive pathological osteocyte-osteoclast crosstalk and subchondral bone remodeling. These findings establish Pvalb as a promising early biomarker and therapeutic target, with bone-targeted Pvalb delivery offering a novel early intervention strategy.
GNL3 Maintains Nucleolar−Chromatin Integrity to Suppress ERV−driven Innate Immune Activation in Osteoarthritis - Yaguang Zhao
Osteoarthritis (OA) is a degenerative joint disease lacking disease-modifying therapies, and the mechanisms linking genetic risk to cartilage degeneration remain poorly defined. A genome-wide association study identified a coding variant in GNL3 (rs11177), yet its functional role in OA pathogenesis is unknown. Here, we identify GNL3 as a critical regulator of nucleolar integrity, chromatin organization, and innate immune activation in articular chondrocytes. The OA-associated R39Q mutation increases GNL3 protein stability by reducing ubiquitination but paradoxically promotes cellular senescence, indicating functional impairment. In vivo , chondrocyte-specific deletion of Gnl3 accelerates both destabilization of the medial meniscus (DMM)-induced and age-associated OA, characterized by cartilage loss, osteophyte formation, and increased catabolic and hypertrophic marker expression. In contrast, Gnl3 overexpression protects against OA progression, thereby establishing a bidirectional role for GNL3 in maintaining joint homeostasis (Fig. 1A). Mechanistically, Gnl3 loss induces nucleolar stress (Fig. 1B) and disruption of nucleolus-associated domains (NADs) (Fig. 1C), leading to derepression of transposable elements, particularly endogenous retroviruses (ERVs) (Fig. 1D). Transcriptomic profiling revealed robust activation of interferon and senescence-associated pathways, accompanied by global ERV upregulation. Reactivated ERVs generate cytosolic nucleic acids that engage cGAS - STING and RIG-I - MAVS signaling, resulting in TBK1 activation, interferon-stimulated gene expression, and senescence. Consistently, ERV activation, interferon signaling, and senescence markers were elevated in Gnl3 -deficient cartilage in vivo and in primary chondrocytes following Ade-Cre - mediated deletion (Fig. 1E). Collectively, these findings define a nucleolar - chromatin - innate immunity axis in OA, whereby GNL3 maintains heterochromatin organization to suppress ERV-driven inflammatory signaling. Disruption of this pathway promotes interferon-mediated senescence and accelerates OA progression, suggesting that targeting ERV-driven innate immune activation may represent a therapeutic strategy for osteoarthritis. Because nucleolar stress leads to widespread cellular degeneration, other mechanisms contributing to GNL3 KO-induced OA warrant further exploration.
LOXL2 as a master regulator of inflammation, cartilage homeostasis, and pain in knee and TMJ osteoarthritis - Manish V Bais, PhD
Purpose: Osteoarthritis (OA) of the temporomandibular joint (TMJ) and knee features progressive cartilage degeneration, inflammation, and chronic pain, yet disease‑modifying therapies are lacking. We identified lysyl oxidase‑like 2 (LOXL2) as a regulator of joint homeostasis and a candidate therapeutic target. This study defines mechanisms by which LOXL2 modulates OA inflammatory and nociceptive pathways to inform translation.
Methods: Experimental models included cartilage‑specific inducible Loxl2 knockout mice, post‑traumatic knee OA (PTOA) models, primary goat chondrocytes, LOXL2 overexpression, and intra‑articular delivery. Readouts included bulk and single‑cell RNA‑seq with ligand - receptor analysis, histology, immunostaining, mitochondrial function and apoptosis, macrophage phenotyping, biomechanical testing, treadmill endurance, and mechanical allodynia.
Results: Cartilage‑specific LOXL2 loss produced OA‑like pathology in TMJ and knee, which decreased aggrecan/proteoglycan content, increased MMP13 and ADAMTS4/5, mitochondrial dysfunction, and elevated chondrocyte apoptosis. Bulk transcriptomics showed activation of inflammatory programs including NF‑κB signaling, leukocyte activation, osteoclast differentiation, and cytokine‑mediated matrix remodeling. Single‑cell RNA‑seq revealed expansion of inflammatory macrophage and neutrophil populations, loss of chondrocyte populations, and emergence of nociceptive and osteogenic transcriptional signatures. Ligand receptor analysis identified Oncostatin M (OSM) signaling as a central inflammatory axis where myeloid‑derived OSM engages OSMR/IL6ST/LIFR on chondrocytes to activate NF‑κB and catabolic pathways. LOXL2 gain‑of‑function (overexpression or intra‑articular delivery) suppressed inflammatory signaling, reduced OSM receptor expression, preserved matrix integrity, and protected chondrocytes from IL‑1β‑induced apoptosis. LOXL2 treatment validated decreased M1 macrophage infiltration, restored biomechanical performance, improved treadmill endurance, and reduced mechanical allodynia in the OA model.
Conclusions: LOXL2 is a master suppressor of inflammatory and nociceptive pathways in TMJ and knee OA. Augmenting LOXL2 activity preserves cartilage matrix, limits myeloid‑driven inflammatory signaling, particularly the OSM-OSMR axis, and improves functional and pain outcomes in PTOA models. These data support the translational potential of LOXL2 as a disease‑modifying therapy for TMJ and knee osteoarthritis.
Targeted degradation of Nav1.7 by PROTAC attenuates cartilage degeneration and pain in osteoarthritis - Wenyu Fu, PhD
Osteoarthritis (OA) is the most prevalent age-associated joint disease and a leading cause of chronic pain and disability, yet no available therapy effectively halts cartilage degeneration while simultaneously alleviating OA-associated pain. We recently identified the voltage-gated sodium channel Nav1.7, previously considered a neuron-specific pain channel, as a critical regulator of chondrocyte biology and OA progression in addition to its established role in nociception. Genetic studies support a cell type - specific model in which chondrocyte-expressed Nav1.7 drives cartilage degeneration, whereas dorsal root ganglion (DRG) neuron - expressed Nav1.7 mediates pain perception. Importantly, pharmacological inhibition of Nav1.7 attenuates both structural joint damage and OA-associated pain, establishing Nav1.7 as a unique dual-action therapeutic target. However, direct Nav1.7 inhibitors have shown limited clinical success due to insufficient target engagement, suboptimal selectivity, and dose-limiting adverse effects.
To overcome these limitations, we developed a targeted protein degradation strategy to eliminate Nav1.7 rather than transiently inhibit its activity. Using a cellular thermal shift assay (CETSA) - ELISA - based screening platform, we identified P2026 as a small-molecule binder of the Nav1.7 C-terminal domain and subsequently generated P2026-based proteolysis-targeting chimeras (PROTACs). P2026-based PROTAC induced robust, dose-dependent degradation of full-length Nav1.7 in both neuronal cells and chondrocytes, whereas P2026 alone had no effect. PROTAC treatment reduced endogenous Nav1.7 protein levels in mouse neurons and human chondrocytes, and significantly suppressed Nav1.7 channel currents in stable Nav1.7-expressing HEK cells.
Functionally, Nav1.7 degradation enhanced expression of anabolic markers and suppressed inflammatory cytokine - induced catabolism in human and murine chondrocytes. In ex vivo human OA cartilage explants, P2026-based PROTAC preserved proteoglycan content and reduced Nav1.7 protein levels. In the mouse DMM OA model, intra-articular administration of P2026-based PROTAC weekly produced dose-dependent benefits, with medium and high doses significantly reducing cartilage loss and alleviating OA-associated pain behaviors.
Together, these findings demonstrate that targeted Nav1.7 degradation represents a novel disease-modifying therapeutic strategy for OA, capable of simultaneously preventing joint degeneration and reducing pain.
Dysregulation of Chondrocyte-mediated Endochondral Ossification Contributes to The Developmental Osteopetrosis Bone Phenotype in <em>Lrrk1</em> Knockout Mice. - Anakha Udayakumar
Osteopetrosis is marked by increased bone density due to defect in osteoclast function. Bone strength is compromised in osteopetrosis patients with increased fracture risk despite the high bone mass. We and others have previously shown that patients with mutations in leucine rich repeat kinase I gene ( Lrrk1 ) displayed osteosclerotic metaphyseal dysplasia with multiple fractures of the long bones. To understand LRRK1 functions in bone, we generated mice with targeted knockout of (KO) of Lrrk1 and found that adult Lrrk1 KO mice also exhibited osteopetrosis and defective osteoclast function phenotypes. Since long bone development occurs via endochondral ossification in which mineralized and unmineralized cartilage template is subsequently degraded and replaced by bone matrix and since Lrrk1 is also expressed highly in chondrocytes, we evaluated if the osteopetrosis phenotype in Lrrk1 KO mice is due to developmental defect in chondrocyte mediated endochondral ossification. At E18.5, bone marrow space of the femoral metaphysis of the Lrrk1 KO mice contained massive amounts of un-resorbed mineralized cartilage while no mineralized bone or cartilage is present in the same region of the wild type (WT) mice. At E18.5 and 3 weeks of age, toluidine blue and alizarin red staining revealed evidence for the presence of massive amounts of cartilage that is mineralized in the marrow space of long bones of Lrrk1 KO mice. The height of safranin O-stained region was 3-fold greater (P<0.01) in the primary spongiosa of proximal tibia of 3-week-old Lrrk1 KO mice compared to WT mice. IHC studies revealed evidence for the presence of significant amounts of COL10 (cartilage marker) in the bone marrow of distal femur of 7-day-od Lrrk1 KO mice. In Lrrk1 KO mice, trabecular BV/TV measured by microCT was increased by 5.5-fold (P<0.0001) at the distal femur at 3-weeks of age and by 6.7- and 14.4-fold, respectively (both P<0.001), in the distal femur and proximal tibia at 4-weeks of age compared to WT mice. Bone strength measurements by 3-point bending in the proximal tibia revealed that maximal load was reduced by 55% in the Lrrk1 KO mice (P<0.01) compared to WT mice. Based on these data, we conclude that KO of Lrrk1 gene disrupts endochondral ossification during embryonic and postnatal development resulting in the accumulation of mineralized cartilage that is not fully replaced by bone resulting in mechanically weaker bone.read more · Original Link ↗
Nancy E. Lane, MDUniversity Of California, Davis Medical Center, Hillsborough, CA, US
Samantha Weaver, PhDUniversity Of Wisconsin-Madison, Madison, WI, US
Jiansen Su, MD, PhD StudentShanghai Sixth People's Hospital, Shanghai, CN
Yaguang ZhaoVan Andel Institute, Grand Rapids, MI, US
Manish V Bais, PhDBoston University Henry M. Goldman School Of Dental Medicine, Boston, MA, US
Wenyu Fu, PhDYale University, Bethany, CT, USA
Anakha UdayakumarLoma Linda Veterans Association For Research And Education, San Bernardino, CA, US; Department of Basic Sciences, Loma Linda University, USA
☆
Sun 10/11 · 11:30 AM - 12:30 PM
Oral Presentations: Genetic Prediction and Stratification of Fracture Risk
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 312
Personalized fracture risk assessment with a focus on hip and vertebral fractures: validation of the HiVe fracture risk score in men from the MrOs study cohort - Claus Christian Glueer, PhD
Fracture risk assessment is dominated by studies in women.Personalized fracture risk assessment with a focus on hip and vertebral fractures: validation of the HiVe fracture risk score in men from the MrOs study cohort - Claus Christian Glueer, PhD
Fracture risk assessment is dominated by studies in women. Using data from the MrOS study we evaluated the performance of the new Hip & Vertebrae Fracture Risk Score (HiVe) in men. Different from other risk calculators, HiVe calculates the 3-year risk of incident hip fractures or vertebral fractures (iHForVF), including radiologic VFs graded by Genant SQ. Risk is derived from age, areal bone mineral density of the total hip (aBMD ht ) by DXA, and the person's two strongest clinical risk factors (cRFs) selected from a list of 31 cRFs identified by the DVO Osteoporosis Guideline Group from an evidence based review of 2267 publications. Age associated iHForVF base risk was derived from MrOS participants who had none of the DVO cRFs (superhealthy individuals). Fracture risk was modelled by logistic regression analysis. As benchmark, the four standard FRAX models were chosen.
Base risk showed strong age related increase of HFs, doubling every 4.4 yrs, and VF dominating for most of the age range, doubling only every 20 years. iHForVF was 3% at age 65, 13% at age 90. In MrOS, 23 of the 31 DVO cRFs were known for 5994 men, aged 64-100 (mean 73.7). HiVe predicted iHForVF (n=289 during 4.6 years) with AUC=0.721, significantly better (p<0.003) than FRAX HIPwtBMD (AUC=0.664) as strongest of the four FRAX models.
For clinical interpretation, risk was assessed across 4 bands ( DVO guideline s) (band1(0-3%): no treatment (tx), band2(3-5%): consider tx, band3(5-10%): recommend tx, band4(≥10%): recommend bone anabolic tx) (table) . The standard HiVe model showed 6 times higher true fracture rates in band4 vs band1, but overestimation at higher risks. This could be resolved by recalibration, with two different models: separate modeling of iHFs and iVFs (HiVe-sep), and age interaction modeling (HiVe-ageint). In those models, 1 out of 8 men in band4 suffered an iHForVF within 3 years, 7-8x more frequently vs band1. FRAX models, recalibrated to predict iHForVFs, failed to classify men at very high risk (band4) and had poorer discrimination (only 2-4x more fractures in band3 vs band1.
In conclusion, clinically motivated emphasis on hip and vertebral fracture, a refined individualized cRF assessment, shorter 3-year risk assessment period (more relevant for elderly patients, stronger gradients) all contributed to HiVe's strong performance, validating HiVe in the MrOS population for individualized risk assessment as basis for treatment recommendations including bone anabolic treatment.
Increased Gluteofemoral Fat Elevates Fracture Risk through Bone Mineral Density Reduction in Two-sample Mendelian Randomization Study - Sung Hye Kong, PhD, MD
The relationship between obesity and bone health is complex and often contradictory, partly due to the distinct metabolic roles of regional fat depots. This study investigated the causal effects of body mass index (BMI)-adjusted body fat distribution - specifically visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (ASAT), and gluteofemoral adipose tissue (GFAT) - on bone mineral density (BMD), osteoporosis, and fracture risk.
A two-sample Mendelian randomization (MR) study was performed using UK Biobank-derived genetic instruments for BMI-adjusted VAT, ASAT, and GFAT from genome-wide association study (GWAS). Outcome data for BMD, osteoporosis, and fracture were obtained from the Genetic Factors for Osteoporosis Study (GEFOS), the Million Veteran Program (MVP), and FinnGen. The inverse variance-weighted (IVW) method was used as the primary estimator, with MR-Egger, weighted median (WM), weighted mode (WMode), and MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) as sensitivity analyses. Two-step MR mediation analysis evaluated BMD as a mediator of fat depots - fracture effects.
BMI-adjusted GFAT showed consistent inverse associations with BMD across multiple skeletal sites, including the lumbar spine ( β = − 0.169, P <0.001), femoral neck ( β = − 0.108, P =0.001), and forearm ( β = − 0.224, P <0.001), supported by all sensitivity analyses. In contrast, ASAT and VAT were associated with lumbar spine BMD only ( β = − 0.149, P =0.002 for ASAT; β =0.152, P =0.035 for VAT), with inconsistent sensitivity results suggesting heterogeneous pleiotropy. GFAT was associated with elevated osteoporosis risk (odds ratio (OR) 1.12 [95% confidence interval (CI): 1.02 - 1.23]) and fracture risk at lumbar spine/pelvis (OR 1.14 [1.02 - 1.27]) and shoulder/upper arm (OR 1.11 [1.03 - 1.20]). Two-step mediation analysis confirmed BMD as a significant mediator of the effect of GFAT on fracture risk, at both lumbar spine/pelvis ( β =0.131, P =0.020) and shoulder/arm ( β =0.102, P =0.008) sites. Neither ASAT nor VAT showed significant associations with osteoporosis or fracture.
These findings indicate that fat distribution, beyond total adiposity, may be a key determinant of bone health. GFAT was causally associated with lower BMD and greater risks of osteoporosis and fracture, ASAT and VAT had no significant effect on these outcomes. These findings highlight the clinical relevance of fat depot - specific evaluation in the assessment of osteoporosis and fracture susceptibility.
Genetic Clustering of Bone Mineral Density Loci Reveals Heterogeneous Mechanistic Pathways Associated with Osteoporosis - Nipith Charoenngam, MD
Genome-wide association studies (GWAS) have established bone mineral density (BMD) as a highly polygenic trait, yet the mechanisms underlying most genetic loci remain unclear. To organize BMD loci into a more meaningful biological framework and identify potential mediators, we clustered these loci according to their shared genetic associations with other phenotypes.
We extracted genome-wide significant, independent lead variants for lumbar spine and femoral neck BMD from a European-ancestry GEFOS DXA-BMD meta-analysis (N=157,441). These loci were aligned with GWAS summary statistics for a broad range of traits (i.e., body composition, laboratory measures). We then constructed a 374-variant×94-trait association matrix and applied Bayesian non-negative matrix factorization (bNMF) to derive clusters of BMD loci. To identify candidate mechanisms, we performed epigenomic annotations for noncoding variants and generated cluster-specific partitioned polygenic scores for association testing with phenotypes in multi-ancestry samples from the UK Biobank (N=486,757) and Mass General Brigham Biobank (N=64,154).
Using bNMF, we identified 9 clusters of BMD loci, with all variants aligned to the BMD-lowering allele. These clusters capture loci with shared patterns of association with phenotypes ( Table ). For example, the Low Body Mass cluster (19 loci) was associated with lower lean and fat mass and included obesity-protective loci mapped to MC4R and FTO , suggesting a pathway mediated by decreased body mass. The Calcium Metabolism cluster (6 loci) was associated with higher serum calcium and lower phosphate, with the top two loci mapped to enhancer elements interacting with the CASR promoter and other loci mapped to DGKD and CNNM4 , consistent with a calcium-parathyroid related pathway. The Bone Marrow Adiposity cluster (23 loci) was associated with increased bone marrow fat fraction and mapped to genes including CYP3A7 , CYP19A1 , ESR1 , CCDC170 , WNT4 and WNT5B , forming a pathway related to estrogen metabolism and noncanonical WNT signaling that may influence mesenchymal differentiation toward adipocytes versus osteoblasts. The Hematopoiesis cluster (16 loci) was associated with increased blood counts and multiple inflammatory cytokines.
In summary, our data-driven clustering approach identified 9 clusters of genetic loci that suggest heterogeneous physiological processes controlling BMD, highlighting pathways related to adiposity, calcium, estrogen, inflammation and others.
Polygenic Risk and Ancestry-Specific Genetic Effects Drive Hip Bone Mineral Density Prediction - Martha Isabel Gonzalez Ramirez
Low hip bone mineral density (BMD), a key predictor of fracture risk, is highly heritable, yet most genetic models predicting BMD do not capture ancestry-dependent genetic effects. In addition, the gut microbiome may influence bone metabolism by modulating immune function, nutrient absorption, and metabolite production, such as short-chain fatty acids. Here, we evaluated whether modeling genotype × ancestry interactions, together with microbiome features, improves hip BMD prediction.
We analyzed 6,732 individuals (aged 19 - 86; 46% female; 41% African American, 58% Caucasian) from the Louisiana Osteoporosis Study, with whole-genome sequencing (WGS) data, including a subset of 1,794 with shotgun metagenomic sequencing (MGS). We first built two models in parallel: a clinical covariate model and a Polygenic Risk Score (PRS) model based on Genome-Wide Association Analysis (GWAS)-identified SNPs. Their predictions were combined in a stacked framework, which was then extended using elastic net to include selected SNPs and genotype × principal component interactions to capture ancestry-aware genetic effects, and further expanded to include microbiome features and genotype × microbiome interactions. Models were tuned and tested via a nested five-fold cross-validation. Performance was assessed using the coefficient of determination (R²).
The ancestry-aware model achieved the highest performance (R² = 0.505 in the full dataset; 0.312 in the subset with both WGS and MGS), followed by the combined model based on clinical covariate and PRS predictions (0.476; 0.315) and PRS alone (0.416; 0.279), while the clinical covariates explained the least variance (0.259; 0.215). While PRS captured the dominant genetic signal, SNP × ancestry interactions revealed ancestry-dependent effects. Despite the polygenic nature of BMD, accurate prediction was achieved with a sparse set of predictors (126 in the full dataset and 30 in the subset), selected from thousands of features. In contrast, microbiome features did not improve performance (R² = 0.308).
These results indicate that BMD prediction is primarily driven by genetic factors, with additional contributions from ancestry-dependent genetic effects, and support the scalability of this framework to larger admixed populations for improved ancestry-aware risk stratification.
Multi-Omic Dissection of Fragility Fractures Identifies Systemic Aging Signatures and Novel Ancestry-Specific Targets <sup data-turn-source-index="1"></sup> - Hongyu Wang, PhD Student
Purpose : Fragility fractures (FF) reflect systemic decline, yet the interplay of phenotypic aging and genetic susceptibility remains elusive . We decoded FF architecture via an integrative phenomic-genomic paradigm, uncovering novel skeletal aging mechanisms . Methods : We integrated clinical phenomics and genomics . A meta-analysis (88 studies) quantified risk factors . Bone aging profiles from 832 Chinese fragility fracture cohort (CFFC) participants were matched to micro-climate data . Systemic aging (PhenoAge) was validated across cohorts (CFFC, n=7,907; UKB, n=363,637; NHANES, n=27,779) . Eight machine learning algorithms with 44 predictors built a risk framework . Whole-genome sequencing (n=593) drove a GWAS . Causal loci were found via Bayesian fine-mapping and single-cell virtual knockouts . The top target was validated by siRNA knockdown in primary human osteoblasts (hOBs) and osteoclasts (hOCs), assessing differentiation and mineralization . Results : Meta-analysis linked FF to low BMD, high turnover markers, vitamin D deficiency, and sarcopenia . Phenomic analysis correlated FF with mild temperatures, high humidity, and low grip strength . PhenoAge predicted FF risk across cohorts (1.4% - 3.0% FF increase per PhenoAge year) . A LightGBM model achieved optimal performance (AUC=0.928) using 10 core predictors; SHAP revealed non-linear effects . Genomics identified 18 ancestry-specific targets, including EMB and NPTN . Fine-mapping anchored the EMB causal variant to rs1314294945 . Single-cell knockouts mapped targets to immune-stromal signaling and metabolism . Crucially, in vitro EMB knockdown in hOBs impaired osteogenic differentiation and mineralization ( P <0.01) and enhanced osteoclastogenesis in hOCs, confirming its role in the bone microenvironment . Conclusions : Integrating phenomics, machine learning, and genomics establishes a systemic aging framework for FF . The model enables precision risk stratification, while experimental validation of EMB highlights a novel, ancestry-informed therapeutic target for skeletal aging .read more · Original Link ↗
David KarpfStanford University School of Medicine, USA
Hiba Obeid, MDTufts Medical Center, Watertown, MA, US
Claus Christian Glueer, PhDKiel University (Christian Albrechts Universitaet), Kiel, DE
Sung Hye Kong, PhD, MDDepartment of Internal Medicine, Seoul National University Bundang Hospital, Korea, Republic of (South); Seoul National University College Of Medicine, Kyonggi, KR
Nipith Charoenngam, MDEndocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, USA
Martha Isabel Gonzalez RamirezTulane Center for Biomedical Informatics and Genomics, Deming Department of Medicine, School of Medicine, Tulane University, USA
Hongyu Wang, PhDMOE Key Laboratory of Theory and Therapy of Muscles and Bones & Longhua Hospital & Spine Institute, Shanghai Academy of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, China
Built for you by(617)-PATRICK, Champion AI speaker
An industry-supported educational symposium held alongside the main ASBMR program. · Original Link ↗
☆
Sun 10/11 · 12:45 PM - 2:00 PM
Industry-Supported Symposium: Advances in Fibrodysplasia Ossificans Progressiva: Clinical Trials, Emerging Therapies, and Future Directions
● Industry Session
Industry Session
📍 Meeting Room 210
An industry-supported educational symposium held alongside the main ASBMR program. · Original Link ↗
☆
Sun 10/11 · 12:45 PM - 1:30 PM
Industry Expert Session: ReThinking HPP: Insights Beyond Diagnosis
● Industry Session
Industry Session
📍 Meeting Room 304
An industry-sponsored expert session held in the Discovery Hall exhibit area. · Original Link ↗
☆
Sun 10/11 · 12:45 PM - 1:45 PM
Meet the Professor: Biomechanics and Bone Imaging
● Meet the Professor
Meet the Professor
📍 Meeting Room 309
Biomechanics and Bone Imaging - Elizabeth A. Zimmermann, PhD
Biomechanics and Bone Imaging - Saija A. Kontulainen, PhD
Biomechanics and Bone Imaging - Karl J. Lewis, PhD · Original Link ↗
Elizabeth A. Zimmermann, PhDMcgill University, Montreal, QC, CA
Saija A. Kontulainen, PhDUniversity Of Saskatchewan, Saskatoon, SK, CA
Karl J. Lewis, PhDCornell University, Ithaca, NY, US
☆
Sun 10/11 · 12:45 PM - 1:45 PM
Meet the Professor: Pregnancy and Skeletal Health
● Meet the Professor
Meet the Professor
📍 Meeting Room 310
Lactational Bone Turnover with Advanced Maternal Age - Samantha Weaver, PhD
Maternal Exercise as a Regulator of Fetal Skeletal Development - Christopher James Panebianco, PhD
Role of CCN3 in Bone Anabolism in Lactation - Muriel E.Lactational Bone Turnover with Advanced Maternal Age - Samantha Weaver, PhD
Maternal Exercise as a Regulator of Fetal Skeletal Development - Christopher James Panebianco, PhD
Role of CCN3 in Bone Anabolism in Lactation - Muriel E. Babey, MD
Role of Health Disparities in Dental Health - Erin Ealba Bumann, DDS, PhD, MS
Panel Q & Aread more · Original Link ↗
John J. Wysolmerski, MDYale University, USA
Samantha Weaver, PhDUniversity Of Wisconsin-Madison, Madison, WI, US
Christopher James Panebianco, PhDUniversity Of Pennsylvania, Philadelphia, PA, US
Muriel E. Babey, MDStanford University, Stanford, CA, US
Erin Ealba Bumann, DDS, PhD, MSUniversity Of Missouri-Kansas C Ity, Kansas City, MO, USA
☆
Sun 10/11 · 12:45 PM - 1:45 PM
Meet the Professor: Spatial Biology and Multiomics - Mapping the Bone Microenvironment
● Meet the Professor
Meet the Professor
📍 Meeting Room 313
Spatial Biology and Multiomics in Bone and Joints - Chia-Lung Wu, PhD
Spatial transcriptomics of bone in cancer - Conor C Lynch, PhD · Original Link ↗
Chia-Lung Wu, PhDCenter for Musculoskeletal Research, University of Rochester, Rochester, NY, US
Conor C Lynch, PhDH. Lee Moffitt Cancer Center And Research Institute, Tampa, FL, US
Built for you by(617)-PATRICK, Champion AI speaker
Features approximately 98 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Methodological Differences Limit the Feasibility of an Indirect Treatment Comparison Between the Phase III CALYPSO (Eneboparatide) and PaTHway (Palopegteriparatide) Trials in Chronic Hypoparathyroidism";...Features approximately 98 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Methodological Differences Limit the Feasibility of an Indirect Treatment Comparison Between the Phase III CALYPSO (Eneboparatide) and PaTHway (Palopegteriparatide) Trials in Chronic Hypoparathyroidism"; "Long-term follow-up in treatment naïve patients with hypophosphatasia"; "Prospective, Observational Study of a Cohort of Hypophosphatasia Patients' Phenotypes over Time and the Utility of Digital Outcome Measures in this Population"; "EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design"; "Prevalence and Predictors of Poor BMD Gains to Romosozumab: A Real-World Prospective Multicenter Study in Switzerland" and 93 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
☆
Sun 10/11 · 2:00 PM - 3:30 PM
Poster Session II
● Poster Session
Poster Session
📍 Discovery Hall - Exhibit Hall C & D
Features approximately 408 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Chp1 Links NFATc1 Signaling to Serine Metabolism in Osteoclasts"; "Bridging Tissue Architecture and Cellular Organization in Bone Histomorphometry Through AI-Based Spatial Analysis"; "Burosumab...Features approximately 408 poster presentations from ASBMR members and researchers (measured from the official program, 2026-09-29), including "Chp1 Links NFATc1 Signaling to Serine Metabolism in Osteoclasts"; "Bridging Tissue Architecture and Cellular Organization in Bone Histomorphometry Through AI-Based Spatial Analysis"; "Burosumab vs Conventional Therapy in Prepubertal XLH: Catch-Up Growth and Prognostic Value of an Early Response"; "EHR-Generated FRAX Performs Similarly to FRAX Obtained from Direct Questioning of Patients"; "Bone Marrow Adipocytes Mediate a Bone Marrow-Heart Axis in Acute Inflammatory Cardiomyopathy" and 403 others. See Original Link for the complete list and abstracts.read more · Original Link ↗
A short break to stretch, grab a coffee and network with fellow attendees before the next session. · Original Link ↗
☆
Sun 10/11 · 3:45 PM - 4:45 PM
Clinical Symposium: Challenging Subjects in Osteology
● Symposium
Symposium
📍 Ballroom C
The Hidden Skeletal Cost: Bone Health in Eating Disorders - Catherine M. Gordon
Perioperative Management of Bone Health in Orthopedic Patients - Emily Margaret Stein, MD
Early Skeletal Fragility Identifying Genetic Bone Disorders - Ralf Oheim · Original Link ↗
Sabashini Ramchand, MDCleveland Clinic, USA
Maria Belen Zanchetta, MDIdim, Universidad Del Salvador, Buenos Aires, AR
Catherine M. GordonNational Institutes Of Health, Bethesda, MD, US
Emily Margaret Stein, MDHospital for Special Surgery, USA
Ralf OheimDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
☆
Sun 10/11 · 3:45 PM - 4:45 PM
ASBMR/ ORS Basic Debate: The Effect of Mechanical Loading on Bone is Primarily Mediated by Osteocytes - For or Against?
● Symposium
Symposium
📍 General Session - Ballroom A & B
Introductions and Voting
ORS: For the Motion - Matthew J. Silva
ASBMR: Against the Motion - Ryan E Tomlinson, PhD
ORS Rebuttal
ASBMR Rebuttal
Question and Answer
Restatements
Summary and Voting · Original Link ↗
Jennifer J. Westendorf, PhDMayo Clinic, USA
Marjolein C. H. van der MeulenCornell University, Ithaca, NY, US
Matthew J. SilvaDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63110, USA
Ryan E Tomlinson, PhDThomas Jefferson University, Philadelphia, PA, US
Combination Therapy for Gorham-Stout Disease: a Case Report - Fiona Kirkham-Wilson
Background
Gorham-Stout is a rare disorder of lymphatic proliferation causing massive osteolysis of any bone . Patients riskpathological fractures from weakened bones.Combination Therapy for Gorham-Stout Disease: a Case Report - Fiona Kirkham-Wilson
Background
Gorham-Stout is a rare disorder of lymphatic proliferation causing massive osteolysis of any bone . Patients riskpathological fractures from weakened bones. Changes in the lymphatic system can lead to serious respiratory involvement.
WithThere are only 350 reported cases and no standards for management. . Here we discuss, a patient who has been successfully treated despite poor prognostic signs at diagnosis is discussed.
Case
A 45-year-old woman with a 10-year history of shoulder pain presented to the Emergency Department with new shortness of breath. Previous imaging of her spine had shown only disc bulges, and she had beenwhich were managed with analgesia. A CT pulmonary angiogram showed a large right-sided pleural effusion, passive atelectasis in the right lower lobe, small pericardial effusion, and missing second to fifth right ribs (Figure 1).
Pleural biopsies showed non-specific acute and chronic inflammation and exudative pleural effusion with no chylothorax. A repeat MRI of the spine demonstrated new marrow signal in the C2, T1, T2, and T3 vertebrae. Gorham-Stout disease was considered as a differential diagnosis. Avoiding biopsying the sternum and rib, a C4 spinal biopsy stained positive for D2-40 and showed evidence of lymphatic proliferation, confirming the diagnosis.
Monthly intravenous zoledronate was started; the patient relapsed 3 months later with a new large pleural effusion . High dose sirolimus (a non-calcineurin inhibiting immunosuppressant) was then started.
The patient remains stable on combination therapy (bisphosphonate reduced to 3-montly) for four years with occasional therapeutic pleural drains for symptom management.
Discussion
Gorham Stout is a rare bone disease with potentially devastating outcomes, especially in those presenting with effusions at diagnosis. There is no consensus on the treatment duration for Gorham-Stout; this experience indicates that patients can return to good health and quality of life with combination treatments. High doses of sirolimus were needed in this case to achieve trough levels of 8-15ng/mL and treatment has been continued over many years.
Conclusion
Future work should focus on standardising the diagnosis and assessment of Gorham-Stout disease, and testing different dosing regimens of both sirolimus and zoledronate, as well as testing novel therapeutics
Figure 1: CT pulmonary angiogram demonstrating a large right sided pleural effusion with absent ribs at time of diagnosis.
A Case of Severe Recurrent Hypophosphatemia due to Hyperventilation - Iris Hartley
Hyperventilation-induced respiratory alkalosis is known to cause transient hypophosphatemia due to transcellular phosphate shifts. Despite this, it may not be considered during the evaluation of chronic hypophosphatemia. We present a case of prolonged hyperventilation-induced hypophosphatemia that was misidentified and erroneously managed as FGF23-mediated hypophosphatemia.
A 39-year-old woman presented with five years of weakness and dyspnea resulting in >20 emergency room visits where she was frequently found to have profoundly low blood phosphate (Pi). Phosphate repletion was sequentially escalated and, despite chronic IV phosphate 976 mg daily, oral phosphate up to 5000 mg daily, and calcitriol 0.5 mcg daily, she continued to experience recurrent symptomatic hypophosphatemia. Intact FGF23 (iFGF23) was elevated at 109 pg/mL (nl < 59), prompting concern for FGF23-mediated hypophosphatemia and referral to our center.
After phosphate and calcitriol were discontinued on admission, Pi levels were initially normal, followed by recurrent acute episodes of hypophosphatemia, dyspnea, and tachypnea that abated spontaneously or with single doses of phosphate or lorazepam. These episodes coincided with decreased total CO 2 (nadir 13 mmol/L; nl 22-29). Venous blood gas demonstrated respiratory alkalosis with compensatory metabolic acidosis and continuous end-tidal CO₂ monitoring confirmed concurrent hyperventilation. The patient was diagnosed with hyperventilation-induced hypophosphatemia and discharged off phosphate. Cognitive behavioral therapy and long-term anxiolytic treatment were recommended.
Except for fluctuating Pi, initial laboratory assessments were suggestive of PTH- and/or FGF23-mediated hypophosphatemia, including low tubular reabsorption of Pi (TRP), elevated iFGF23, and elevated iPTH. However, these findings likely reflected compensatory PTH and FGF23 responses to excessive chronic phosphate supplementation, as evidenced by biochemical improvement after reduction/discontinuation of phosphate supplementation.
This case demonstrates the importance of supplement withdrawal before laboratory testing when evaluating hypophosphatemia, as chronic exogenous phosphate supplementation can impact TRP, PTH, and FGF23, leading to misdiagnoses and improper management. It also highlights the importance of considering hyperventilation as an etiology of chronic hypophosphatemia, particularly when the presentation is episodic and accompanied by changes in total CO 2 .
A Paradoxical Complication: Calciphylaxis as a Novel Adverse Effect of Asfotase Alfa in Hypophosphatsia - Smriti Madaan, MD
Introduction:
Calciphylaxis is a rare condition characterized by the emergence of non-healing skin ulcers secondary to arterial calcification and thrombosis (1)
Case presentation:
A 73-year-old woman with past medical history of osteoporosis, hypertension, and hypothyroidism, autosomal dominant hypophosphatasia presented with a painful necrotic abdominal lesion. She had recently initiated asfotase alfa therapy about 4 months ago. The lesion started as a bruise, progressed to a nodule and then developed into an excrutiatingly painful ulcer. Interestingly, it did not develop at the injection site but near to it. It was initially misdiagnosed as herpes zoster but the skin swab for HSV was negative. Skin biopsy confirmed calciphylaxis. Laboratory evaluation showed normal renal function tests, serum calcium, serum phosphorus and well as PTH levels were found to be within normal range. Improvement in the lesion was noted with discontinuation of asfotase alfa and no new similar lesions were noted subsequent to that.
Treatment:
Asfotase alfa and calcium supplementation were immediately discontinued. Her wound was managed with wound care with hydrogel dressings and pain was controlled with multimodal analgesia.
Follow up:
Improvement in lesion was noted during the subsequent visits. No new such lesions were reported after discontinuation of asfotase alfa. Patient was asked to avoid taking calcium supplements for some time.
Discussion:
Asfotase alfa is an orphan drug being used for the treatment of hypophosphatasia since 2015. Calciphylaxis has never been reported with this drug. It works by hydrolyzing the pyrophosphate which is an inhibitor of ectopic soft tissue calcification and hence it may predispose to ectopic soft tissue calcification (2). The potential progression to calcific arteriolopathy-like lesions may be the possible mechanism for this adverse effect.
Conclusion:
This case highlights a potentially serious and paradoxical complication of asfotase alfa therapy. It underscores that calciphylaxis should not be considered exclusively a disease of uremia, and clinicians must maintain a high index of suspicion for non-uremic calciphylaxis in patients being treated with asfotase alfa. It emphasizes the need for increased vigilance, post-marketing surveillance, and further research to better characterize the risk, mechanisms, and management strategies for calciphylaxis associated with asfotase alfa.
“Hangry” Bone Syndrome: Novel Management of Refractory Hypocalcemia in Pseudohypoparathyroidism Type 1A - Patrick Cacchio, PA
Pseudohypoparathyroidism type 1A (PHP1A) is a rare disorder caused by end-organ resistance to parathyroid hormone (PTH) due to GNAS mutations. While oral calcium and calcitriol are standard therapy, some patients develop severe, progressive skeletal disease despite optimal management. A 21-year-old African American male with genetically confirmed PHP1A (maternally inherited GNAS mutation), developed profound skeletal involvement progressing from adolescence into adulthood. Despite long-term therapy with calcitriol (up to 2.25 mcg daily), elemental calcium (up to 7,800 mg daily), and ergocalciferol (50,000 units every other day), he sustained multiple pathologic fractures with severe bone pain. Imaging revealed diffuse osteopenia, mixed sclerotic and lytic lesions, and innumerable brown tumors. Biochemically, he exhibited persistently elevated PTH (up to 4,074 pg/mL), severe hypocalcemia (corrected calcium 5.7 mg/dL, ionized calcium 0.66 mmol/L), and markedly elevated bone-specific alkaline phosphatase (BSAP, up to 1,245 U/L). Given recurrent fractures, delayed union, and biochemical instability despite maximum medical therapy, parathyroidectomy was pursued. Imaging identified a dominant left inferior parathyroid gland (4.3 cm, 15.6 g). Left inferior parathyroidectomy of a benign gland was performed, with intraoperative PTH confirming a robust decrease (3,916 to 305 pg/mL). Postoperatively, he required extended ICU monitoring. Suprapharmacologic doses of calcitriol (up to 20 mcg/day) and elemental calcium (up to 7,800 mg daily) were required to prevent symptomatic hypocalcemia. Notably, these doses were tolerated without hypercalciuria (24-hour urine calcium 47 - 52 mg/24h, reference 50 - 300), likely reflecting ongoing skeletal remineralization. BSAP normalization occurred approximately five years postoperatively. This case is unique for the severity of bone disease despite aggressive conventional therapy, the necessity of targeted parathyroidectomy, and extraordinary postoperative calcitriol and calcium requirements without hypercalciuria due to prolonged hungry bone syndrome. The protracted normalization of bone turnover markers is longer than other reported cases of hungry bone syndrome, consistent with known challenges of mineral metabolism in PHP1A. This experience highlights the importance of individualized, multidisciplinary care and the potential role of surgical intervention in select PHP1A patients with refractory bone disease.
Reclassifying a TNFRSF11A Variant: Three-Generation Osteolytic Disease with Zoledronic Acid Response - Kamran Huseynli, MD
Introduction: Pathogenic gain of function mutations in the TNFRSF11A gene, encoding Receptor Activator of Nuclear factor Kappa-B (RANK), the main regulator of osteoclastogenesis, cause ultra rare autosomal dominant osteolytic syndromes including familial expansile osteolysis, expansile skeletal hyperphosphatasia, and early-onset Paget disease of bone, with fewer than 20 families reported worldwide. Variants of uncertain significance in this gene pose a clinical dilemma and may cause aggressive skeletal disease to go unrecognized, as current guidelines recommend against using them to guide management. These cases require clinical correlation and family segregation data for reclassification. We report a three-generation family carrying a heterozygous TNFRSF11A variant of unknown significance with a devastating osteolytic phenotype and therapeutic response to zoledronic acid. Clinical Case: A 54-year-old woman was diagnosed with a bone disorder at age 28 following a low bone density scan. Genetic testing revealed a heterozygous TNFRSF11A variant of uncertain significance. Over the years, she developed slow-healing bilateral ankle fractures with painful masses, acral enlargement, diffuse bone pain, left shoulder malformation with loss of mobility, leg length discrepancy, lifelong tinnitus with recent bilateral hearing loss, and a visual haze. Alkaline phosphatase was elevated only once at 206 U/L (normal: 44-147 U/L), remaining normal thereafter. Five zoledronic acid infusions (2010-2016) produced a 7% bone density improvement and meaningful pain reduction. Family history strongly supports pathogenicity: her mother had brittle bones and died at age 49; her brother had bilateral hip and femur replacements by age 30; her son carries the identical variant with childhood-onset brittle bones. Concurrently, she has Behcet disease with recurrent oral and genital ulcers raising intriguing possibility of shared nuclear factor-kappa B pathway dysregulation. Conclusions: Co-segregation of this TNFRSF11A variant with slow-healing fractures, bony overgrowth, early-onset osteoporosis, and premature death over three generations provides evidence to consider reclassification toward pathogenic. The clinical and radiological response to zoledronic acid adds valuable therapeutic data for these rare syndromes. Additionally, normal alkaline phosphatase despite progressive disease cautions against relying on this biomarker to monitor activity in rare bone diseases.read more · Original Link ↗
Christopher S. Kovacs, MDMemorial University Of Newfoundland, St. John's, NL, CA
Amna N. Khan, MDPerelman School of Medicine at University Of Pennsylvania And Corporal Michael J. Crescenz VA Medical Center, Wynnewood, PA, US
Fiona Kirkham-WilsonUniversity Of Oxford, United Kingdom
Iris HartleyNidcr/Nih, Bethesda, MD, US
Smriti Madaan, MDCanton Medical Education Foundation, Canton, OH, US
Patrick Cacchio, PADuke University, Rougemont, NC, US
Kamran Huseynli, MDCleveland Clinic, Cleveland, OH, US
☆
Sun 10/11 · 5:00 PM - 6:00 PM
Oral Presentations: Cellular and Microenvironmental Drivers of Skeletal Aging
● Oral Abstract Presentations
Oral Abstracts
📍 General Session - Ballroom A & B
Depletion of a detrimental subset of senescent cells by conditional knockout of CXCR2 in p16<sup>INK4a</sup> (p16) expressing senescent cells improves fracture repair - Yiwei Lu, BS
Senescent cells (SCs) accumulate with aging and impair fracture repair.Depletion of a detrimental subset of senescent cells by conditional knockout of CXCR2 in p16<sup>INK4a</sup> (p16) expressing senescent cells improves fracture repair - Yiwei Lu, BS
Senescent cells (SCs) accumulate with aging and impair fracture repair. We previously reported that the senolytic combination Dasatinib (D) + Quercetin (Q) enhanced fracture repair only in aged mice, suggesting that SCs are functionally heterogeneous and that targeting a detrimental SC (dSC) subset could be more effective than broad senolysis. Through single-cell RNA sequencing of callus SCs, we identified a CXCR2 + p16 + dSC subset as the only SC subset that suppressed callus-derived mesenchymal progenitor cell (CaMPC) growth. CXCR2 signaling has been reported to reinforce p53-dependent senescence. Thus, we hypothesized that conditional knockout of CXCR2 in p16-expressing cells improves fracture repair by selectively depleting dSCs in callus. To test this, we performed tibial fracture surgery in young p16-CreERT2; CXCR2 fl/fl (cKO) and CXCR2 fl/fl control mice, with D+Q-treated wild-type mice as a senolytic control. At day 10 post-fracture, cKO mice showed increased woven bone area by ABH staining compared with control and D+Q-treated mice (area mm 2 : 1.53 ± 0.58 vs. 0.84 ± 0.29 vs. 0.86 ± 0.39). Micro-CT further showed increased mineralized bone volume in cKO mice (BV mm 3 : 4.11 ± 0.79 vs. 2.96 ± 0.30 vs. 2.99 ± 0.54). Mechanistically, flow cytometry showed that >75% of SCs (SPiDER-βGal + ) were CD45 - mesenchymal cells. Importantly, cKO selectively reduced CXCR2 + SCs compared with controls to a level comparable to D+Q-treated mice (%, 1.37 ± 0.27 vs. 2.62 ± 0.42 vs. 1.45 ± 0.39), whereas CXCR2 - SCs were not affected by cKO but were reduced by D+Q. Consistently, immunostaining confirmed a marked decrease in CXCR2 + p16 + dSCs in cKO callus. Furthermore, cKO mice showed reduced expression of SASP genes in callus by qPCR, including Tgfb1, Timp2, and IL1a. Immunostaining confirmed decreased TGFb1 + cells along the woven bone surface in cKO, whereas Runx2 + cells were increased, suggesting that CXCR2 cKO suppresses SASP expression and enhances osteogenesis to improve fracture repair. Pharmacologically, AZD5069, a CXCR2 antagonist, enhanced fracture repair in aged mice more effectively than D+Q in vivo by selectively decreasing CXCR2 + dSCs, but not CXCR2 - SCs. Taken together, our study identified a detrimental SC subset and investigated its role in fracture repair using both genetic and pharmacologic approaches. Targeting SC heterogeneity may provide a new therapeutic strategy to improve fracture repair in aging populations.
Low Burdens of Senescent Osteocytes Establish Distance-Dependent Mechano-Inflammatory Niches in 3D Co-Culture - Hossein Shaygani
Senescent osteocytes accumulate with skeletal aging, but the field lacks functional readouts that explain how small senescent burdens remodel the osteocyte niche. We asked whether sparse senescent osteocytes are sufficient to reprogram non-senescent osteocytes and local matrix mechanics in 3D co-cultures. Murine osteocytes (MLO-Y4) were irradiated to induce senescence, fluorescently labeled, and mixed with matched healthy osteocytes to generate 3D bioprinted PEGDA/collagen I/GelMA co-cultures containing 0-15%, or 100% senescent cells. SA-β-gal was assessed on day 7, TUNEL on days 7 and 14, and distance-resolved IL-6, MMP13, YAP1 signaling and matrix micromechanics on days 3 and 7 by immunofluorescence and high-resolution optical fiber-based interferometry nanoindentation. TUNEL signal remained low in 5-15% senescent co-cultures and was comparable to healthy controls, whereas 100% senescent constructs showed the highest DNA fragmentation, indicating that low senescent burdens did not cause overt global apoptosis. In non-senescent osteocytes, IL-6, MMP13, and YAP1 signals varied with senescent burden, time, and 3D distance from the nearest senescent cell. By day 7, IL-6 signal was enriched at intermediate distances of approximately 80-180 µm, while MMP13 signal extended farther, peaking at approximately 180-240 µm. YAP1 was spatially redistributed in co-culture, supporting altered mechanosensitive signaling in non-senescent osteocytes exposed to a senescent niche. Control comparisons showed higher IL-6 and MMP13 and lower YAP1 in fully senescent constructs than in healthy constructs, consistent with an inflammatory, matrix-remodeling, and mechanotransduction-impaired senescent phenotype. Mechanical mapping showed that both cell-free and cell-laden matrices softened over time, but cell encapsulation attenuated this softening and produced senescent burden-dependent stiffness distributions. Low-burden co-cultures, particularly 5-10% senescent constructs, retained greater matrix stiffness than 100% senescent constructs, indicating that sparse senescent osteocytes alter matrix remodeling without widespread apoptosis. These findings show that senescent osteocytes act as spatial organizers of a mechano-inflammatory niche. Mapping distance-dependent signaling with local micromechanics provides a functional framework for defining how senescent osteocyte burden propagates skeletal fragility and for evaluating targeted strategies in aging bone.
MMP12 drives senescence-related bone loss via the cGAS-STING pro-inflammatory pathway - Abhishek Chandra, Ph.D., M.S.
Cellular senescence is a major cause of tissue aging and multiple other acute and chronic conditions, mostly driven by an irreversible, apoptosis-resistant, non-proliferative state, and accompanied by mitochondrial dysfunction and secretion of pro-inflammatory proteins collectively called the senescence-associated secretory phenotype (SASP). One such SASP factor, matrix metalloproteinase 12 ( MMP12 ), has high expression in senescence-related conditions (Fig 1A), but its exact roles in the pathophysiology of osteoporosis are unclear. Here, we characterize the effects of MMP12 abrogation on the regulation of SASP production in vitro and in vivo , and senescence-associated bone loss. Downregulation of MMP12 function, either by a specific pharmacologic MMP12 inhibitor (MMP408) or an siRNA against MMP12 , suppresses the transcription of several SASP genes (Fig 1B), and prevents mitochondrial abnormalities in senescent cells (Fig1 C). Mechanistically, MMP12 inhibition suppresses DNA damage, mitochondrial hypertrophy and activation of the cGAS-STING pathway, which regulates SASP production (Fig 1D). We utilized a mouse model for Mmp12 deletion and demonstrate that both Mmp12+/− and Mmp12−/− mice are protected from the detrimental effects of radiation on bone and exhibit improved bone architecture compared to irradiated wild-type mice (Fig. 1E). Similar patterns were observed in wild-type mice treated with MMP408 (Fig. 1F). Interestingly cellular senescence, the SASP, adipocyte marker genes and osteoclast-associated genes seen in radiated bones of wild-type mice are diminished in radiated bones of Mmp12 -/- mice (data not shown). Furthermore, we demonstrate that pharmacological inhibition of Mmp12 also suppresses aging and radiation-induced bone loss in WT mice (Fig 1G). These data clearly support the hypothesis that Mmp12 is a key factor in senescence-associated bone loss, thus providing a novel therapeutic target.
Aged-related Impairment of Bone Matrix can be Transferred to Young Mice through the Gut Microbiota - Natasha Katharine Hunt, BS, MS
The gut microbiome regulates bone health and matrix quality. Prior work demonstrates that alterations to the gut microbiome reduce bone strength independent of whole-bone geometry. Aging is associated with large compositional shifts in the gut microbiome as well as declines in bone matrix mechanical integrity. The degree to which age-related changes in microbiome contribute to age-related declines in bone matrix strength is not known. We used fecal microbiota transplant (FMT) to directly test whether age-related declines in bone matrix strength could be transferred to a younger individual through the gut microbiome.
Male C57BL/6 mice (4 months, n = 10/group) underwent antibiotic-mediated microbiome depletion followed by FMT from either young or aged donors. Animals were assigned to: (1) young-to-young (control; donor age 4 months) or (2) aged-to-young (heterochronic FMT; donor age 22 months). Transfer was confirmed with 16S rRNA sequencing of fecal samples. At euthanasia (6 months), femurs were analyzed by microCT and mechanical testing, including three-point bending, to assess structural and tissue-level properties.
Aged-to-young mice showed impaired bone matrix strength (p = 0.014) compared to the young-to-young groups. However, the aged-to-young group also displayed increases in whole bone geometry (section modulus, p<0.001), suggesting a response to exposure to the aged microbiota that resulted in increased maximum load (p = 0.033), and stiffness (p = 0.025) at the whole bone level. Engraftment of aged microbial communities into young mice was confirmed by 16S rRNA sequencing and characterized by depletion of Lactobacillaceae, a family involved in calcium absorption and immune regulation, and enrichment of Erysipelotrichaceae, a family associated with metabolic dysregulation and increased inflammation. Spearman correlations linked Lactobacillus abundance to higher tissue strength (ρ = 0.451) and lower section modulus (ρ = −0.522), while Erysipelotrichaceae abundance correlated with reduced tissue strength (ρ = 0.444).
These findings demonstrate that natural changes in the gut microbiome during aging contribute to age-related declines in bone matrix quality, establishing the gut microbiome as a causal link between age-associated shifts in microbial community composition and the structural-material dissociation characteristic of aging bone.
Mechanosensitive Piezo1 - YAP - CCN Signaling in Osteocytes Prevents Skeletal Aging - Yizhong Hu
Mechanical force is critical for bone development, homeostasis, and regeneration. Mechanosensitive osteocytes, the most abundant bone cells, extend long dendritic processes within the bone matrix to coordinate osteoblast and osteoclast activity in response to mechanical cues. Mechanical unloading and aging impair the osteocyte dendritic network, but the molecular mechanisms governing osteocyte dendrite formation, maintenance, and degeneration remain poorly understood. We recently identified the Piezo1 - YAP - CCN signaling axis as a key mechanotransduction pathway controlling osteocyte differentiation and dendrite formation during postnatal bone development. Mechanical loading activates the mechanosensitive ion channel Piezo1, promoting YAP nuclear translocation and induction of the matricellular proteins CCN1/CYR61 and CCN2/CTGF to drive osteocyte maturation and bone accrual. However, whether this pathway regulates osteocyte maintenance and skeletal aging remains unknown.
In this study, we identified Hippo/YAP signaling as a major pathway downregulated in aged bone through unbiased bulk RNA-seq analysis. Key components of the Piezo1 - YAP - CCN signaling axis, including Yap1 , Wwtr1 , and Ccn1 , were also reduced in aged bone, indicating impaired activation of this mechanotransduction pathway during aging. Using a new “knock-in” Dmp1 CreERT2 mouse line we generated, we found that deletion of Piezo1 in adult mice disrupted pre-established osteocyte dendrites and reduced bone mass, recapitulating key degenerative features of skeletal aging. These findings indicate that Piezo1-mediated mechanosensing is required not only for osteocyte development, but also for maintenance of dendritic networks and bone mass in adult bone. Conversely, genetic activation of YAP reversed major aging-associated transcriptional changes in mouse bone. Importantly, intermittent YAP activation or systemic overexpression of CCN1/2 beginning at midlife preserved osteocyte dendritic networks and bone mass in 24-month-old mice, demonstrating that activation of this pathway can prevent age-related skeletal decline. Furthermore, CCN1/2 overexpression reduced marrow adiposity and delayed growth plate fusion in aged bones, suggesting a previously unrecognized non-cell-autonomous role of osteocyte mechanotransduction in the aging bone microenvironment. Ongoing studies will define the molecular and cellular mechanisms by which Piezo1 - YAP - CCN signaling controls skeletal aging.read more · Original Link ↗
Anne Gingery, PhD1
Giovanni Lombardi, PhD2,3
Yiwei Lu, BS4
Hossein Shaygani5
Abhishek Chandra, Ph.D., M.S.1
Natasha Katharine Hunt, BS, MS6,7
Yizhong Hu8, (1)Mayo Clinic, Rochester, MN, US(2)IRCCS Ospedale Galeazzi-Sant'Ambrogio, Laboratory of Experimental Biochemistry and Advanced Diagnostics, Italy(3)Poznan University of Physical Education, Department of Athletics, Strength and Conditioning, Poland(4)University Of Rochester, Rochester, NY, US(5)The University of Texas at Austin, Austin, TX, US(6)University Of California, San Francisco, San Francisco, CA, US(7)Bioengineering and Therapeutic Sciences, University of California, Berkeley, USA(8)Harvard School Of Dental Medicine, Boston, MA, US
☆
Sun 10/11 · 5:00 PM - 6:00 PM
Oral Presentations: Therapeutic Advances Across Rare Bone Diseases
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 302
Efficacy and Safety of Alkaline Phosphatase (ALP) Enzyme Replacement Therapy (ERT) Efzimfotase Alfa in Adolescents and Adults with Hypophosphatasia (HPP): Results of HICKORY as Part of a Three-Trial Phase 3 Clinical Program - Raja Padidela, MD, MBBS Purpose: Phase 3...Efficacy and Safety of Alkaline Phosphatase (ALP) Enzyme Replacement Therapy (ERT) Efzimfotase Alfa in Adolescents and Adults with Hypophosphatasia (HPP): Results of HICKORY as Part of a Three-Trial Phase 3 Clinical Program - Raja Padidela, MD, MBBS
Purpose: Phase 3 studies with efzimfotase alfa (EFZ) in children showed significant, clinically meaningful improvements in bone health, functional, and quality-of-life endpoints vs placebo (PBO) (MULBERRY), and confirmed the safety and maintained benefits for bone health and function after switching from asfotase alfa (CHESTNUT). Here, we report the efficacy and safety of EFZ in adolescents and adults with HPP (HICKORY).
Methods: HICKORY was a double-blind, PBO-controlled study in ERT-naive pts aged ≥12y. EFZ dosing was subcutaneous every 2 wks; endpoints are reported as change from baseline at Wk 25.
Results: In HICKORY (EFZ 84 pts, median age: 45.5y; PBO 40 pts, 43.5y), EFZ showed numerical improvement without statistical significance vs PBO in the primary endpoint of 6-Minute Walk Test (6MWT) distance walked. LSM change from baseline was 40.1m (EFZ) vs 23.1m (PBO); LSM diff: 17.1; 95% CI: - 7.3, 41.4; P =0.1675. Among other secondary endpoints, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) showed nominally significant improvements (LSM diff: 5.7; 95% CI: 2.3, 9.2; nominal P =0.0016) ( Table ).
A combination of prespecified subgroups of pts with pediatric-onset HPP showed nominally statistically significant, clinically meaningful benefits with EFZ vs PBO in mobility by 6MWT (LSM diff: 35.6 m; 95% CI: 1.9, 69.3; P =0.0386), physical function by Sit to Stand repetitions (LSM diff: 1.3; 95% CI: 0.1, 2.5; P =0.0384), and pain by Brief Pain Inventory-Short Form pain severity score (LSM diff: - 1.0; 95% CI: - 1.9, - 0.1; P =0.0260). A post-hoc responder analysis in the overall population showed 2.5-times higher odds of achieving 6MWT improvement ≥MCID with EFZ (45.2% vs 30.0%; OR: 2.5; 95% CI: 1.1, 5.9; nominal P =0.0363).
In an ongoing open-label extension, pts originally randomized to EFZ had continued improvement in primary and all key secondary endpoints at Wk 49. Pts switching from PBO to EFZ had clinically meaningful improvements in efficacy outcomes in the OLE (6MWT mean change at Wk 25 after switch: +43.0 m).
A lower percentage of pts had injection site reactions with EFZ vs registrational asfotase alfa studies.
Conclusions: In HICKORY, the primary endpoint did not meet statistical significance; however, EFZ showed numerical improvements in 6MWT in this broad population of adolescents and adults. In addition, nominally statistically significant improvements were observed for several endpoints. EFZ had a favorable safety profile.
The safety and efficacy of setrusumab in patients <18 years of age with osteogenesis imperfecta: 12-month results of the Phase 3 Orbit and Cosmic trials - Leanne M. Ward
Osteogenesis imperfecta (OI), a rare genetic musculoskeletal disorder, presents with low bone mineral density (BMD), frequent vertebral and non-vertebral fractures, short stature, muscle weakness,and bone pain. Setrusumab (SET) is a fully human, monthly, intravenous (IV) anti-sclerostin mAB being investigated for treating OI.
Two Phase 3 trials investigated treatment with SET in patients (pts) with OI types I, III and IV. Orbit (NCT05125809), a randomized, double-blind, placebo (PBO)-controlled study, enrolled ages 5 to <26 yrs to assess safety and efficacy of SET vs PBO. Cosmic (NCT05768854), a randomized, open-label, active-controlled study, enrolled ages 2 to <7 yrs to compare SET vs IV bisphosphonates (BP). In this 12 month (M) post-hoc analysis of pts <18 yrs of age, we evaluated lumbar spine (LS) BMD z-score (LS-BMDZ), Patient Global Impression of Severity (PGI-S), Pediatric Outcomes Data Collection Instrument (PODCI), Bone Health Index z-score (BHI-Z), and vertebral annualized fracture rate (vAFR). All P- values are nominal.
Neither study achieved its primary endpoint of reduction in AFR; however, in pts <18 years of age, LS-BMDZ, PGI-S, PODCI, and BHI-Z showed significant improvements at M12 in both studies. At M12, least squares mean difference (LSMD) from baseline (SE) in LS-BMDZ was SET 0.70 (0.07) vs PBO −0.26 (0.10, P <0.0001) in Orbit and SET 1.01 (0.22) vs IV-BP 0.32 (0.21, P =0.0116) in Cosmic. At M12, BHI-Z improvements from baseline were statistically significant (LSM [SE] Orbit: SET 0.51 [0.06] vs PBO 0.21 [0.09], P =0.0078; Cosmic: SET 0.43 [0.12] vs IV-BP 0.12 [0.13], P =0.0371). At M12 in Orbit there was statistically significant improvement in PGI-S pain (LSMD −0.37, P =0.0174) and impact on daily activities (LSMD −0.40, P =0.0356); and clinically meaningful improvement in the PODCI sports/physical function domain score vs PBO (LSMD 5.79, P =0.091). Pediatric pts in Orbit (n=135) and Cosmic (n=69) showed numerically lower vAFR of 37% (vAFR, SET 0.21 vs PBO 0.33; P =0.389) and 56% (vAFR, SET 0.14 vs IV-BP 0.33; P =0.083), respectively. Safety data from both studies continued to demonstrate that SET was well-tolerated.
In Orbit and Cosmic, SET was well-tolerated and demonstrated statistically significant improvements in LS-BMDZ and BHI-Z, and numerically lower incident VF rates (by 37 - 56%). In pediatric pts in Orbit, there were statistically significant improvements in daily activities and pain, and meaningful improvements in physical function.
Treatment with high dose sclerostin neutralizing antibody improved mechanoregulation in adults with severe osteogenesis imperfecta - Bettina M. Willie, PhD
Introduction : Osteogenesis imperfecta (OI) is an osteodysplasia leading to bone fragility, and recurrent fractures. Sclerostin antibodies have led to increased bone mass in adults with OI. We assessed the effect of OI severity (type I vs type III/IV) and setrusumab dose (2 or 8 mg/kg vs 20 mg/kg) on bone mechanoregulation over a one-year treatment period.
Methods : Forty-eight adults (34 female, ages 20 - 73) with confirmed COL1A1/COL1A2 mutations (33 OI type I; 15 type III/IV) who received setrusumab (2, 8, or 20 mg/kg) monthly over a year were scanned at the distal tibia using high-resolution peripheral quantitative computed tomography at baseline and 12 months as part of the ASTEROID study (NCT03118570). Volumetric bone formation and resorption were identified through time-lapse analysis (Fig. 1A). Micro-finite element analysis was performed to quantify local bone mechanical stimuli (strain energy density [SED]) (Fig. 1A). Conditional probability (CP) curves and odds ratios were determined to study the bone formation and resorption likelihood with increasing/decreasing SED as markers of bone mechanoregulation. Set point for bone formation was defined as the intersection between formation and quiescent CP curves.
Results : ANOVA showed that sex did not have a significant effect on the volume of formed and resorbed bone, and odds ratio of formation and resorption. Therefore, the male and female data were pooled. We observed for every 1% decrease in strain level, the probability of resorption increased by 1.19 ± 0.16 in OI type III/IV, significantly higher than OI type I (p<0.05) (Fig. 1B). Mechanoregulation CP curves showed that bone is likely to be formed and resorbed, respectively at high and low strain levels, matching the mechanostat theory. Severe OI had a higher bone formation set point than mild OI (41% vs 33%) for low-dose Setrusumab compared to the high-dose. High dose Setrusumab shifted the bone formation set point from 41% to 23% in adults with severe OI, indicating bone formation was initiated at a larger range of strains.
Conclusions : With low dose Setrusumab treatment (2 and 8 mg/kg), people with severe OI were less mechanosensitive compared to mild OI. This was evidenced by bone formation dominating resorption only at higher strain levels in people with severe OI. The limited mechanosensitivity of individuals with severe OI was mitigated at higher doses of Setrusumab (20 mg/kg), where bone formation dominated resorption at lower strain levels.
The Impact of the Inhibition of Activin A by the Neutralizing Antibody Garetosmab for the Resolution of Nascent Heterotopic Bone Lesions in FOP Mice and People with FOP - Dinko Gonzalez Trotter, PhD
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by the accumulation of new heterotopic bone lesions, leading to increasing disability and premature death. FOP is caused by neofunction mutations in the intracellular domain of ACVR1 , a gene encoding a type I bone morphogenic protein receptor. These mutations enable FOP-mutant ACVR1 to uniquely utilize activin A as an agonistic ligand. Using mouse models of FOP, we have shown that inhibition of activin A using an anti-activin monoclonal antibody, garetosmab, inhibits the formation of new heterotopic bone lesions and causes complete regression of nascent lesions. These results led to the clinical exploration of garetosmab as a disease-modifying therapy in FOP. Mirroring the results obtained in FOP mice, the LUMINA-1 and OPTIMA clinical studies demonstrated that garetosmab inhibits the formation of new heterotopic bone lesions by >90%. Here, we report observations of the disappearance of heterotopic bone lesions in participants with FOP treated with garetosmab.
LUMINA-1 and OPTIMA participants were imaged by 18F-NaF positron emission tomography/low-dose computed tomography (CT) and low-dose CT alone, respectively. Baseline, Week 28, and Week 56 images were evaluated by adjudicated blinded independent central review. Six participants out of 62 dosed with garetosmab experienced disappearance of 13 baseline heterotopic bone lesions. No heterotopic bone lesions disappeared in participants treated with placebo (n = 44). These findings demonstrated that, in addition to stopping the formation of new heterotopic bone lesions, garetosmab may also resolve existing (yet nascent) lesions. This observation suggests additional therapeutic potential for garetosmab that should be explored in future clinical studies.
Repurposing Denosumab as Treatment for Adult Langerhans Cell Histiocytosis: Long Term Follow-Up - Polyzois Makras
Purpose: Langerhans cell histiocytosis (LCH) is a rare inflammatory neoplastic disorder characterized by high lesional expression of receptor activator of NF- κ B ligand (RANKL), accompanied by elevated circulating osteoprotegerin, a decoy receptor for RANKL. Based on this pathophysiological mechanism, denosumab, a monoclonal antibody targeting RANKL, represents a rational therapeutic approach in LCH.
Methods: A phase IIb clinical study demonstrated that a regimen of four subcutaneous injections of denosumab 120 mg every 8 weeks achieved an overall response rate of 80% in adult patients with mild symptoms (low-intensity clinical manifestations not requiring hospitalization) and low-risk disease necessitating first-line systemic therapy. We aimed to assess the long-term outcomes of those trial participants, in addition to other patients managed with the same treatment protocol. The primary endpoint was disease activity after administration of denosumab as monotherapy. Secondary endpoints included the proportion of patients requiring further therapeutic interventions, disease activity at the end of the follow-up period, and the occurrence of late skeletal adverse events potentially related to denosumab.
Results: 21 adult patients with LCH were analyzed (11 females; mean age 41.25 ± 14.16 years; range 20 - 66 years), all with active disease requiring first-line systemic treatment. Among them, 4 patients had multifocal single-system disease and 17 had multisystem disease without risk organ involvement. Over a mean follow-up of 42.75 ± 34.9 months (range: 2 - 104 months), 14 patients achieved non-active disease status, 6 demonstrated disease regression, and 1 patient maintained stable disease. During follow-up, 5 patients required additional therapy: 1 declined further treatment, while the remaining patients received either a single intravenous infusion of zoledronate (n=2), intralesional corticosteroids (n=1), or radiotherapy (n=1). After discontinuation of denosumab, no overshoot of bone turnover markers, no reduction in bone mineral density, and no vertebral fractures were observed.
Conclusion: Administration of four subcutaneous doses of denosumab 120 mg at 8-week intervals represents an effective therapeutic option for patients with LCH without risk organ involvement, yielding response rates of up to 80% as monotherapy and up to 95% with minimal sequential treatment. Most patients maintained durable disease control without the need for additional treatment.read more · Original Link ↗
Sudhaker D Rao, MBBSHenry Ford Hospital, Detroit, MI, US
Azarmindokht Khosravi, MDCedars Sinai, los angeles, CA, US
Raja Padidela, MD, MBBSRoyal Manchester Children's Hospital, United Kingdom; Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, United Kingdom
Leanne M. WardChildrens Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Ottawa On K1H, ON, Canada
Bettina M. Willie, PhD., Logan, UT, USA; College of Veterinary Medicine, Utah State University, Logan, USA; Shriners Hospital for Children, Research Center, Montreal, Canada
Dinko Gonzalez Trotter, PhDRegeneron Pharmaceuticals, Inc., USA
Polyzois Makras251 Hellenic Air Force & Va General Hospital, Athens, GR; LCH adult Clinic, Department of Medical Research, 251 Hellenic Air Force and VA General Hospital, Athens, Greece, Greece
☆
Sun 10/11 · 5:00 PM - 6:00 PM
Oral Presentations: New Insights into Bone Development
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 311
APOE regulates lipid droplet metabolism in resting chondrocytes to drive longitudinal bone growth - Kenji Takami
Longitudinal bone growth is driven by growth plate chondrocytes, with resting zone chondrocytes serving as progenitors for columnar-forming cells.APOE regulates lipid droplet metabolism in resting chondrocytes to drive longitudinal bone growth - Kenji Takami
Longitudinal bone growth is driven by growth plate chondrocytes, with resting zone chondrocytes serving as progenitors for columnar-forming cells. We recently demonstrated that resting chondrocytes ubiquitously express Apoe and give rise to proliferative chondrocytes, and further showed that these cells accumulate lipid droplets (LDs) that are utilized to support bone growth. However, whether Apoe functions simply as a marker of resting chondrocytes or plays an intrinsic regulatory role remains unknown.
To address this question, we employed both global and conditional Apoe knockout mouse models to interrogate its role in growth plate biology. Apoe global knockout mice exhibited significantly shortened long bones, accompanied by a marked reduction in proliferating chondrocytes. Notably, these mice displayed aberrant accumulation of LDs throughout the growth plate, in contrast to wild-type mice, where LDs are predominantly restricted to the resting zone. These findings suggest a critical role for Apoe in skeletal growth, but systemic effects of global deletion could not be excluded.
To determine the cell-intrinsic function of Apoe, we generated chondrocyte-specific knockout mice using Acan-CreERT2;Apoe flox/flox . Tamoxifen induction at postnatal days 7 and 14, followed by analysis at 4 weeks of age, revealed phenotypes that closely recapitulated those observed in global knockout mice, including reduced bone length and impaired chondrocyte proliferation. Single-cell RNA sequencing of growth plate chondrocytes demonstrated significantly reduced lipid metabolism module scores and an increased proportion of cells in the G0/G1 phase in conditional knockout mice, indicating impaired lipid metabolic activity and cell cycle progression.
Mechanistically, we found that APOE physically contacts LDs in chondrocytes. Lipidomic analyses revealed that Apoe-deficient chondrocytes accumulate triglycerides (TGs) and diacylglycerols (DGs), with a concomitant reduction in phosphatidylcholines (PCs), suggesting impaired LD hydrolysis and lipid remodeling.
Collectively, these findings demonstrate that Apoe is not only a marker of resting chondrocytes but also plays a critical cell-intrinsic role in regulating LD metabolism in resting chondrocytes. This function is essential for maintaining proper chondrocyte proliferation and normal longitudinal bone growth.
Cellular-resolution spatial transcriptomics reveals an orthogonal PTHrP-GDF5 signaling axis in early endochondral bone development - Shion Orikasa
Objectives: Endochondral bone development requires tightly coordinated chondrocyte proliferation, differentiation, and spatially regulated cell migration. Parathyroid hormone-related protein (PTHrP) is a key regulator that maintains proliferating chondrocytes and prevents premature hypertrophy; however, how PTHrP orchestrates cell-cell communications and downstream cell fate decisions remains unclear. Here, we aim to elucidate the novel mechanisms of PTHrP-directed bone development by utilizing cellular-resolution spatial transcriptomics and lineage tracing.
Methods: We employed a sequencing-based cellular-resolution spatial transcriptomics, CurioSeeker (v1.1), using 10 µm barcoded beads to analyze fetal femurs from Pthrp mCherry/+ (Control) and Pthrp mCherry/mCherry (PTHrP-KO) mice at embryonic day (E) 14.5 and 16.5. We performed topological velocity inference (TopoVelo) and CytoSignal, novel algorithms for inferring cell dynamics and ligand-receptor cell-cell communications in space. To validate these computational predictions, we generated Pthrp mCherry/+ ;Fgfr3-creER;R26R ZsGreen and Pthrp mCherry/mCherry ;Fgfr3-creER;R26R ZsGreen mice to label E14.5 cartilage template cells by tamoxifen injection at E12.5. We also injected BMP inhibitor (LDN193189) from E12.5 and tissues were harvested at E16.5 and 18.5.
Results: Spatial transcriptomics successfully captured the cellular architecture of the E14.5 cartilage template and perichondrium, including hypertrophic chondrocytes. TopoVelo analysis predicted inward migration of fetal perichondrial cells toward the cartilage template in Control mice. However, PTHrP-deficiency disrupted this cell migration, with some cartilage template cells predicted to migrate outward. Consistent with these predictions, lineage tracing revealed that the number of ZsGreen-labeled cartilage lineage cells in bone collar was increased at E16.5 in PTHrP-KO mice. CytoSignal analysis further demonstrated aberrant activation of GDF5 signaling in hypertrophic zone in PTHrP-KO mice. Additionally, inhibition of BMP signaling partially rescued PTHrP-KO-induced abnormalities, reducing ectopic cell migration, normalizing the femur width, and restoring growth plate structure.
Conclusion: Our findings demonstrate that PTHrP restricts BMP signaling spatially to maintain proper cell fate trajectories and tissue architecture during early bone development. Loss of PTHrP alters the spatial domain of GDF5 action through growth plate disorganization.
Spatiotemporal Dynamics of An Endochondral Skeletal Stem Cell Subtype Governs Skeletal Morphogenesis and Regenerative Potential - Yuting Wang, PhD, MD
Skeletal stem cells (SSCs) play a crucial role in the maintenance and repair of the skeletal system, including cartilage, bone and bone marrow. A thorough understanding of the regulatory logic governing SSC niches during development, injury and aging under robust methods and lineage-tracing tools is essential for developing efficient and targeted strategies that harness the power of stem cell-mediated musculoskeletal regeneration. We constructed a new 3D, live cell based, single cell spatial transcriptomic platform (TESSERACT) to map in situ cellular crosstalk within SSC niches across long bone development, fracture repair and articular cartilage formation. SSC lineage dynamics during embryonic and postnatal skeletal and marrow development, as well as skeletal regeneration following fracture injury, were traced and verified with our newly generated SSC-specific reporter mouse strain. Niche-associated regulatory networks identified by TESSERACT were functionally interrogated using defined combinations of recombinant signaling factors in both in vitro and in vivo systems. Based on TESSERACT, we identified a novo osteochondral-SSC (ocSSC) marker that defines a niche-dependent SSC population essential for skeletal regeneration and revealed a coordinated network of niche-derived signals that govern ocSSC fate decisions and orchestrate long bone growth, soft callus formation and articular cartilage regeneration. Functional perturbation of these signaling axes demonstrated that combinatorial modulation of defined pathways is sufficient to enhance regenerative outcomes. Notably, targeted delivery of niche factor combinations enabled robust regeneration of hyaline cartilage at joint microfracture sites in both young, aged and osteoarthritic mice, indicating that aged niches retain responsiveness to stem cell instructive signals. Our study advances the understanding of SSC biology and sets the stage for targeted therapeutic strategies to enhance bone and cartilage healing for the treatment of conditions like osteoporosis and osteoarthritis. The TESSERACT platform offers a powerful tool to investigate similar regulatory processes in other tissues, potentially leading to novel regenerative treatments beyond musculoskeletal disorders.
Identification of the METTL16-m⁶A-YTHDC1 Axis as an Epitranscriptomic Regulator of Limb and Craniofacial Development via Chromatin Regulation - Zhong Zhang
N 6 -methyladenosine (m 6 A) is a vital regulator of RNA metabolism, yet the functional specificity between various m 6 A "writers" and "readers" in complex developmental contexts remain poorly defined. Taking limb and craniofacial organogenesis as development models, we uncover a critical and specific functional axis between the m 6 A reader YTHDC1 and writer METTL16. Limb-specific (by crossing Prrx1-Cre mice) or neural crest-specific (by crossing Wnt1-Cre mice) conditional knock-out of either YTHDC1 or METTL16-but not METTL3-cause severe limb or craniofacial malformations, revealing unexpected functional selectivity. Specifically, massive progenitor cell death and decreased proliferation could be seen at E10.5~E12.5 embryonic limb buds or craniofacial mesenchyme, while significantly decreased bone mass and shortened limbs appear at later developmental stages. In vitro cellular assays demonstrated disruption of METTL16-m 6 A-YTHDC1 axis inhibits chondrogenesis, accumulates R-loops and arrests transcription in osteo-chondroprogenitors, causing transcription-replication conflicts. Mechanistically, METTL16 and METTL3 insert distinct sets of m 6 A on chromatin-associated RNAs (caRNAs). More abundant intronic m 6 A sites inserted by METTL16 was also identified. YTHDC1 preferentially recognizes METTL16-deposited m 6 A marks on caRNAs, facilitating chromatin state tuning, guarding enhancer-dependent cis -regulation and orchestrating co-transcriptional splicing of genes vital for development. Importantly, chromatin-bound YTHDC1 brings splicing factors, such as SRSF3 and SRSF7, and transcriptional complex into proximity in a liquid-liquid phase separation (LLPS)-dependent manner, with alkalic arginine residues in its C-terminal region being molecular determinants. In conclusion, our findings identify a selective and specific METTL16-m 6 A-YTHDC1 axis that couples RNA modification with chromatin regulation and co-transcriptional splicing during mammalian organogenesis, providing molecular insights into how epi-transcriptomic regulation governs developmental decisions.
Loss of PRDM16 Drives Nasal Septal Deviation via Dysregulated TGFβ2 Signaling - Eliya Tazreena Tashbib, PhD
Nasal septal deviation is among the most common craniofacial disorders, affecting ~20% of newborns globally and ~2.2 million individuals in the US. Genome-wide association studies linked PRDM16 (a histone methyltransferase) to craniofacial abnormalities, but its role in nasal septum development remains unclear. Global Prdm16 knockout (gKO) mice exhibit severe craniofacial defects, including shortened Meckel’s cartilage, mandibular hypoplasia, and airway obstruction resembling Pierre Robin syndrome in humans. However, Prdm16 gKO mice are neonatally lethal, limiting postnatal study. To address this knowledge gap, we generated an osteochondral lineage-specific, conditional Prdm16 knockout (Col2a1-Cre; Prdm16 fl/fl ; cKO) mouse. We found that both sexes of cKO mice display significantly shorter nasal bone length, with a sex-dependent increase in nasal bone volume fraction in 12-wk-old cKO males (only males shown due to space; Fig. A). Moreover, cKO shows nasal septal deviation as early as postnatal day 15, progressing with age (Fig. B). scRNA seq of 4-wk-old nasal septal cartilage showed that cKO mice had decreased Mgp + chondrocytes (WT: 71% vs. cKO: 33%) and increased Col10a1 + /Serpina3n + hypertrophic chondrocytes (WT: 3% vs. cKO: 41%), suggesting PRDM16 regulates chondrocyte phenotypes (Fig. C). Spatial transcriptomic analysis revealed that Mgp + chondrocytes and Col1a1 high /Col3a1 + fibrotic cells are located at the septal cartilage-bone interface (i.e., deviation site in cKO mice; Fig. D). Intercellular communication analysis between Mgp + chondrocytes and fibrotic cells reveals a switch in sender cells from fibrotic cells in WT to Mgp + chondrocytes in cKO (Fig. E). MultiNichenet identified increased TGFβ2 signaling in the deviation site (Fig. F). Particularly, in cKO mice, TGFβ2 signaling from Mgp + chondrocytes to fibrotic cells drives Col1a1/Col1a2 upregulation, fibrotic ECM deposition, and osteogenesis, consistent with high RUNX2 level in cKO mice (RUNX2 IHC not shown due to space). IHC further validates increased TGFβ2 + cells in fibrous ECM of internasal tissue (orange arrows) and in the apical region of nasal cartilage in cKO (green arrows) mice but not in WT (Fig. G). Additionally, loss of PRDM16 increases apoptosis (cleaved CASP3) in 4- and 12-wk cKO septal cartilage (CASP3 IHC not shown due to space). Collectively, our data indicate that loss of PRDM16 drives hypertrophic and fibrotic remodeling of nasal septal cartilage via dysregulated TGFβ2 signaling.read more · Original Link ↗
Diana L. Carlone, PhDBoston Children's Hospital, Boston, MA, US
Koji Ishikawa, PhDDuke University, Chapel Hill, NC, US
Kenji TakamiUniversity Of Maryland, Baltimore, MD, US
Shion OrikasaUniversity of Texas Health Science Center at Houston School of Dentistry, Houston, TX, US
Yuting Wang, PhD, MDucdavis, sacramento, CA, US
Zhong ZhangState Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China, China
Eliya Tazreena Tashbib, PhDUniversity of Rochester, Rochester, NY, US; Department of Orthopaedic Surgery and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, USA; Department of Chemical and Sustainability Engineering, University of Rochester, USA
☆
Sun 10/11 · 5:00 PM - 6:00 PM
Oral Presentations: Multi-Omics and Regulatory Genomics in Skeletal Biology
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 312
Decoding Skeletal Genetics with a Bone Atlas of Genetic Regulatory Effects - Kristyna Kupkova, PhD
Background: Bone mineral density (BMD) is highly heritable and a major predictor of osteoporotic fracture.Decoding Skeletal Genetics with a Bone Atlas of Genetic Regulatory Effects - Kristyna Kupkova, PhD
Background: Bone mineral density (BMD) is highly heritable and a major predictor of osteoporotic fracture. Genome-wide association studies (GWAS) have identified >1,200 independent associations with BMD, providing a strong foundation for gene and therapeutic target discovery. However, the identification of causal effector genes has been slow because ~90% of associations map to non-coding regions. Colocalization with expression quantitative trait loci (eQTL) can address this gap, but the absence of a bone-specific eQTL reference remains a major limitation.
Aims: To generate the first human bone eQTL atlas and integrate it with BMD GWAS to identify effector genes, prioritizing those with roles in osteoblast function and relevance to osteoanabolic therapies.
Methods: We collected acetabular reamings from 193 hip arthroplasty patients, isolated purified bone, and generated bulk RNA-seq datasets. We also performed low-pass whole-genome sequencing on matched DNA samples to call genotypes. Using the Pantry pipeline, we mapped cis-eQTLs in bone and performed colocalization with 1,294 estimated BMD (eBMD) GWAS loci using coloc. Integration of complementary datasets (RNA-seq, ATAC-seq, single-cell RNA-seq) prioritized genes likely to exert their effect on bone through osteoblasts. We used CRISPR interference/activation (CRISPRi/a) in the human fetal osteoblast (hFOB) cell line to test the effects of gene perturbation on mineralization.
Results: We identified cis-eQTLs for 4,182 protein-coding and 1,805 lncRNA genes in human bone. Colocalization with eBMD GWAS prioritized 67 protein-coding and 19 lncRNA effector genes. Multiomic integration highlighted candidates with evidence of activity in osteoblasts for functional follow-up. Among these, FHL3 (Fig. 1A), previously implicated in SMAD signaling and muscle biology but not bone, emerged as a novel candidate. CRISPRi/a perturbation showed that FHL3 negatively regulates osteoblast mineralization (Fig. 1 B,C), consistent with GWAS - eQTL predictions.
Conclusions: We present the first bone eQTL atlas, providing a critical resource for skeletal research. This framework enables functional interpretation of BMD loci in a disease-relevant tissue, improves prioritization of effector genes, and supports translation of genetic discoveries into therapeutic targets. FHL3 is a negative regulator of osteoblast-mediated mineralization and a candidate target for osteoanabolic strategies.
Multi-Omics Integration Reveals Regulatory Biomarkers Associated with Bone Mineral Density Variation in Men - Boluwatife Lawrence Afolabi, BTech., MSc.
Bone mineral density (BMD) is a key clinical indicator of bone health, yet the multilayer molecular regulatory mechanisms underlying BMD variation, particularly in men, remain poorly understood. To address this gap, we integrated DNA methylation, miRNA, mRNA, and proteomic profiles with BMD phenotypes to identify regulatory molecular features associated with BMD variation. We analyzed multi-omics data and BMD phenotypes across 13 skeletal sites from 1,055 men (mean age 36.88 ± 8.65 years) in the Louisiana Osteoporosis Study. We applied IntegrAO, a multi-omics integration framework that learns unified latent representations across molecular layers, to identify phenotype-associated molecular candidates. These candidates were further interpreted using regulatory network-based functional enrichment analysis. To assess external support and translational potential, we mapped the discovery features to gene-level candidates and evaluated them using UK Biobank datasets, GTEx eQTL evidence from bone-related proxy tissues, and drug-target annotation. IntegrAO identified 263 unique BMD-associated molecular features (FDR < 0.05), comprising 4 miRNAs, 13 mRNAs, 233 DNA methylation features, and 13 proteins. Among these, 69 features were associated with BMD at two or more skeletal sites, suggesting shared molecular regulation across skeletal regions. Functional enrichment analyses highlighted biological processes related to osteoclast differentiation and skeletal development. After mapping the discovery features to gene-level candidates, 40 genes were validated in UK Biobank datasets, including 5 protein- layer candidates (GFRAL, SOST, BGLAP, MYBPH, and MYOM3), 3 transcriptomic-layer candidates (C4A, C4B, and GLRB), and 4 CpG-associated genes (CISD2, KCNH7, FKBP1C, and PPIP5K2). By applying GTEx eQTL datasets, we identified 6 phenotype-gene associations with regulatory support across bone-related proxy tissues. Drug-target annotations further highlighted potentially tractable candidates across omics layers, including GLRB from transcriptomic layer, GFRAL and SOST from proteomic layer, and CISD2, KCNH7, and PPIP5K2 from DNA methylation layer. Together, these findings define a multi-omics regulatory landscape of BMD variation in men and identify genetically supported biomarkers with potential relevance for skeletal-risk stratification, mechanistic investigation, and therapeutic target discovery.
High-Definition Spatial Transcriptomics of Mouse Femoral Head Integrated with GWAS Reveals Bone-Muscle Crosstalks and Genetic Risk for Osteoporosis - Yuwei Hou, MPH
Understanding the complex cellular architecture and signaling networks of the bone niche is essential for addressing metabolic bone diseases like osteoporosis. Single-cell transcriptomics provided comprehensive bone cell atlases, characterizing the transcriptional states across diverse skeletal populations. However, these dissociated approaches lack the preserved tissue architecture necessary to define niche-specific signaling environments and cannot resolve where genetic risk for osteoporosis is executed. In this study, we performed high-definition spatial transcriptomics profiling of the mouse femoral head to characterize the spatial architecture of the bone niche and the signaling networks coordinated between bone and muscle cell groups. for osteoporosis. The mouse femoral head was harvested from a 25-week-old C57BL/6 mouse. Tissue processing and spatial transcriptomic profiling were performed using the 10x Genomics Visium HD platform with optimized cell-segmentation methods. Through refined clustering analysis, we successfully identified critical cell populations, including skeletal lineage cells and muscle lineage myofibers, organized into key regions for niche-specific analysis, including trabecular marrow, endosteal surface, articular cartilage, periosteum, and the myotendinous junction (MTJ). Cell-cell communication analysis revealed a robust signaling network among bone and muscle cell groups coordinating bone homeostasis. For instance, we identified putative muscle-to-bone support via Vegfa-Itgb1 signaling to mesenchymal progenitors and reciprocal bone-to-muscle feedback through Col1a1-Cd36 interactions. Niche-level pathway enrichment confirmed biological coherence: bone niches were enriched for Bone Morphogenetic Proteins (BMPs) binding and collagen fibril organization, while muscle niches were enriched for sarcomere organization and oxidative phosphorylation. Integration with eBMD GWAS using the gsMap framework revealed significant spatial heritability enrichment at the periosteum and MTJ. Within these niches, Sparc and Fgfr1 co-occur as top contributing genes based on their Gene Specificity Score, nominating a niche-resolved Sparc/Fgfr1 program as a candidate mechanism. Overall, this project provides an advanced spatial atlas of the bone niche, reveals candidate integrated bone-muscle communication, and links genetic susceptibility for osteoporosis to specific cellular microenvironments necessary for musculoskeletal health.
Identification of a<em> </em>skeleton specific <em>DLX5</em> distal enhancer and involvement of the enhancer in bone homeostasis - Shinse Fujita, M.D., Ph.D.
Enhancers are located in non-coding region of the genome and regulate gene expression programs that are crucial to maintain cellular function and tissue homeostasis, including bone metabolism. Genome-wide association studies (GWAS) have shown that numerous variants associated with bone mineral density (BMD) also reside in non-coding regions. However, the enhancers through which these variants act remain poorly understood.
We previously identified a human DLX5 (h DLX5 ) distal enhancer (DE) through open chromatin analysis in human osteoblasts derived from hPSC-based bone tissue ( Development, Growth & Differentiation , 2025). Integration with GWAS data further revealed that a single nucleotide polymorphism (SNP) associated with BMD was located within this enhancer. In this study, we examined the skeletal-specific activity of the h DLX5 DE and the functional significance of the SNP.
Single-cell multiome analysis (ATAC-seq and gene expression) with the hPSC-based bone tissue highlighted h DLX5 DE as an osteoblast-specific open chromatin region. Histological analysis of 10-week-old h DLX5 DE lacZ reporter mice revealed reporter activity in osteoblasts, osteocytes, and growth plate chondrocytes. In-vitro luciferase reporter assay revealed that introducing the same variant of the BMD associated SNP in the h DLX5 DE decreased the reporter activity in osteogenic differentiated MC3T3-E1. Integrative analysis of motif enrichments and gene expression identified a candidate transcription factor (TF); its overexpression enhanced h DLX5 DE activity. Lastly, to investigate the contribution of this enhancer to bone mineral density (BMD), we generated Dlx5 DE knockout mice. The 10-week-old Dlx5 DE homologous KO mice had no obvious difference in body weight and skeletal structure compared with wild-type mice. However, mild increases in Tb.Th and BMD, as well as prolonged osteoid maturation time were observed in the lumbar vertebrae of female Dlx5 DE homologous KO mice.
Not only the redundant roles of Dlx5 / 6 , but also enhancer redundancy probably contributed to this mild phenotype in Dlx5 DE homologous KO mice. These unexpected sex-dependent findings also suggest that DLX5 DE may contribute to adult bone homeostasis in a context dependent manner, possibly through gene regulatory mechanisms in osteoblasts. These results potentially help elucidate the pathogenesis of osteoporosis and discover therapeutic targets.
<em>SERPINA1</em>-Associated Alpha-1 Antitrypsin Deficiency Reduced Vertebral Bone Structure and Mediated Bone Cells Toward Osteoporosis - Neharika Bhadouria
Severe alpha-1 antitrypsin (AAT) deficiency from homozygous variants in SERPINA1 is a well-known cause of chronic obstructive pulmonary disease (COPD); however, its contribution to osteoporosis is less well characterized. By contrast, heterozygous carriers of SERPINA1 variants who develop mild-to-moderate AAT deficiency are largely protected from COPD and therefore are not treated with augmentation therapy to protect lung degradation. Whether this partial deficiency adversely affects vertebral bone structure remains unknown because the cellular mechanism of bone loss is unclear. We hypothesized that (i) hetero- and homozygosity for SERPINA1 variants is associated with reduced vertebral bone mineral density (BMD) in a human cohort, (ii) in vivo deletion of murine serpinA1a/c leads to impaired vertebral bone structure and (iii) augmentation therapy with human AAT does not restore vertebral bone structure from deletion of serpinA1a/c in mice. Thoracic vertebral bone structure (T2-T11) was analyzed from clinical computed tomography scans from men (n=1,091) and women (n=1,077) with and without defective SERPINA1 variants. In vitro cell differentiation of pre-osteoclasts, -osteoblasts and -osteocytes was used to evaluate serpinA1 paralogs. Vertebral bone structure was assessed in 4-month male and 4- and 13-month female serpinA1a/c KO and wild-type (WT) mice (n=4-5/sex/genotype). A separate set of mice received subcutaneous human AAT (50 mg/kg, 5×/wk, 4 wk). Heterozygosity for S- and Z-type SERPINA1 alleles was associated with lower vertebral BMD in most male vertebrae and T11 in women. Similarly, deletion of serpinA1a/c reduced vertebral bone volume fraction in young-adult male mice, with a greater number of TRAP+ osteoclasts and sclerostin+ osteocytes, fewer cuboidal osteoblasts and a delayed phenotype in female mice. Pre-osteoclast and - osteocyte differentiation was associated with downregulation of SerpinA1a expression and pre-osteoblast differentiation was associated with upregulation of SerpinA1a expression. AAT augmentation did not increase vertebral bone structure in WT or S erpinA1a/c KO mice. These data suggest that SERPINA1 heterozygosity is associated with reduced vertebral bone density from regulation of osteoclasts, osteoblasts, and osteocytes toward bone loss. Augmentation therapy in people with severe AAT may not normalize bone loss, and people with any SERPINA1 variant may require bone cell-targeted approaches to reduce skeletal fragility.read more · Original Link ↗
Ling Qin, PhDUniversity Of Pennsylvania, Philadelphia, PA, US
David Karasik, PhDHebrew Seniorlife; Bar Ilan University, newton, MA, US
Kristyna Kupkova, PhDDepartment of Genome Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA
Boluwatife Lawrence Afolabi, BTech., MSc.Tulane Center for Biomedical Informatics and Genomics, Deming Department of Medicine, School of Medicine, Tulane University, USA
Yuwei Hou, MPHTulane University, New Orleans, LA, US
Shinse Fujita, M.D., Ph.D.Clinical Biotechnology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Japan; Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Japan; Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Japan
Neharika BhadouriaIcahn School of Medicine at Mount Sinai, New York, NY, US
Plenary Symposium: International Perspectives on Bone Health & Highlights of the Year in Skeletal Biology
● Symposium
Plenary
📍 General Session - Ballroom A & B
ASBMR News Esteemed Awards Presentations Reimagining Routine Health Information Systems to Detect Fracture Risk and Osteoporosis: A Technical Report Prepared for the World Health Organization (WHO) - Marc Sim, PhD Disparities in Fragility Fracture and Osteoporosis Care in Africa -...ASBMR News
Esteemed Awards Presentations
Reimagining Routine Health Information Systems to Detect Fracture Risk and Osteoporosis: A Technical Report Prepared for the World Health Organization (WHO) - Marc Sim, PhD
Disparities in Fragility Fracture and Osteoporosis Care in Africa - Kate A. Ward, PhD
I will discuss the need to consider musculoskeletal health as an important challenge to adults in Africa. Taking evidence from across the life course, I will discuss barriers and potential implementable solutions for better bone and muscle health to address the inevitable increase in fragility fractures and sarcopenia over coming decades
Epidemiology of Osteoporosis in Asia: Regional Disparities and Global Impact - Ching-Lung Cheung, PhD
Asia is undergoing the world’s most rapid demographic transition, making it the primary epicentre of the global osteoporosis crisis. Driven by unprecedented population aging, over half of all osteoporotic hip fractures worldwide are projected to occur in Asian populations by 2050. However, the continent’s vast economic and healthcare heterogeneity masks critical regional disparities. High-income hubs demonstrate plateauing or declining age-standardized fracture rates, yet their sheer volume of elderly citizens keeps absolute fracture counts climbing. Conversely, rapidly developing and low-to-middle-income Asian nations face a dual burden of rising age-adjusted incidence alongside explosive demographic expansion.
Compounding this crisis is a widespread post-fracture care gap across the region. Severe under-treatment following index fragility fractures remains pervasive, contributing to elevated long-term disability and post-fracture mortality - with older Asian men bearing a disproportionately high mortality burden. Addressing this trajectory demands a shift from traditional Western-centric frameworks toward Asia-specific risk stratification, scalable secondary prevention models, and data-driven public health policies. This plenary session outlines the evolving epidemiological landscape across Asia and examines actionable solutions to avert a looming global healthcare challenge.
Year in Review: Basic & Clinical - Michael Mannstadt, MD
This presentation will review selected landmark papers in bone research published over the past year. Given the wealth of outstanding studies, the presenter apologizes in advance that time constraints allow only a small fraction of them to be discussed.read more · Original Link ↗
Sang Wan Kim, MDSeoul National University College of Medicine, Korea, Republic of (South)
Maria Belen Zanchetta, MDIdim, Universidad Del Salvador, Buenos Aires, AR
Marc Sim, PhDEdith Cowan University, Kardinya, WA, AU
Kate A. Ward, PhDUniversity Of Southampton, Southampton, GB
Ching-Lung Cheung, PhDThe University Of Hong Kong, Hong Kong, HK
Michael Mannstadt, MDMassachusetts General Hospital Harvard Medical School, Boston, MA, US
Introductory Remarks
JBMR: The Fourth Decade (Part 1) - Roberto Civitelli, MD
JBMR: The Fourth Decade (Part 2) - Rajesh V. Thakker, MD · Original Link ↗
Marja Marie HurleyUConn Health School Of Medicine, Farmington, CT, US
Roberto Civitelli, MDDepartment of Medicine, Division of Bone and Mineral Diseases. Musculoskeletal Research Center. Washington University School of Medicine, St. Louis, MO USA, USA
Rajesh V. Thakker, MDUniversity of Oxford, United Kingdom
☆
Mon 10/12 · 9:45 AM - 10:00 AM
Networking/Coffee Break
● General
📍 Ballroom AB Foyer
Coffee and light refreshments in the Discovery Hall, with time to network between sessions. · Original Link ↗
Bench to Bedside Symposium: Translating Genomics Discoveries into Meaningful Clinical Outcomes
● Symposium
Symposium
📍 Ballroom C
Polygenic Risk Scores and Clinical Fragility - Carolina Medina-Gomez, PhD
From Beside Back to Bench: How Genetics Are Reshaping Drug Development - Lon R Cardon, PhD
Over the past two decades, genetics has transformed our understanding of disease.Polygenic Risk Scores and Clinical Fragility - Carolina Medina-Gomez, PhD
From Beside Back to Bench: How Genetics Are Reshaping Drug Development - Lon R Cardon, PhD
Over the past two decades, genetics has transformed our understanding of disease. Hundreds of thousands of variants have been associated with common diseases, and four to five new rare disease gene associations are discovered every week. Yet only a small fraction of these discoveries has led to new therapies. Rare diseases are increasingly demonstrating to be an exception, showing even greater impact in human translation. In this presentation, Dr. Cardon will explore why so many promising insights stall in the chasm between basic research and the clinic and how new approaches in rare disease can bridge the gap. He will introduce the ‘Power of Three’, the integration of animal models, cellular models, and AI, to improve prediction and accelerate the development of new therapies.
Translating Genomics into Clinically Meaningful Outcomes: Pharmacogenomics and Clinically Actionable Results - Yvonne Bombard, PhDread more · Original Link ↗
Matthew A BrownDepartment of Medical and Molecular Genetics, King’s College London, London, United Kingdom
J Brent Richards, MD, MScDepartment of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
Carolina Medina-Gomez, PhDDepartment of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Netherlands
Lon R Cardon, PhDThe Jackson Laboratory, Bar Harbor, ME, US
Yvonne Bombard, PhDUniversity of Toronto, Unity Health Toronto, Toronto, ON, CA; Genetics Adviser, Canada
☆
Mon 10/12 · 10:00 AM - 11:15 AM
ASBMR/BMAS Symposium: BMAT
● Symposium
Symposium
📍 Meeting Room 302
Mechanisms of BMAT Expansion During CR Including Novel Mouse Models and Diets - Isabel Dorothy Kane Hermsmeyer, PhD, MPH Site-specific metabolic profiles of BMAT - Drenka Trivanovic, PhD Genetic architecture and clinical implications of bone marrow adiposity in the UK...Mechanisms of BMAT Expansion During CR Including Novel Mouse Models and Diets - Isabel Dorothy Kane Hermsmeyer, PhD, MPH
Site-specific metabolic profiles of BMAT - Drenka Trivanovic, PhD
Genetic architecture and clinical implications of bone marrow adiposity in the UK Biobank: a meta-GWAS and MR-PheWAS study - Wei Xu
Aim: Bone marrow adipose tissue (BMAT) comprises >10% of total adipose mass in healthy adults, which contributes to skeletal fragility, metabolic dysfunction, and immune senescence. Advancements in imaging (MRI) and deep learning technologies, have enabled non-invasive measurement of BMAT as the bone marrow fat fraction (BMFF), facilitating large-scale studies in populations. In this study, we aimed to investigate genetic variants and disease outcomes associated with BMFF.
Methods: We applied deep learning to measure BMFF of the femoral head, total hip, diaphysis, and spine from MRI of >48,000 participants in the UK Biobank. We conducted the genome-wide association study (GWAS) meta-analysis to investigate the overall as well as ancestry- and sex-specific genetic architecture of BMFF in the four bone sites. We then established BMFF polygenic risk scores and conducted phenome-wide association studies (PheWAS) and Mendelian randomization (MR) to identify BMFF-associated diseases, including potential causal associations between BMFF and risk of musculoskeletal and cardiometabolic diseases [osteoporosis, fractures, T2D].
Results: Our meta-GWAS study identified hundreds of bone site-specific genetic associations for BMFF. The mapped genes are of clear relevance to bone marrow adiposity, including TIMP4 , LEPR , LEPROT , PPARG, TERT , CCDC170 , and TNFRSF11 , implicating pathways in fat metabolism, bone remodelling, estrogen signalling, and inflammation. PheWAS demonstrated that BMFF is associated with 47 incident diseases across 12 disease categories. Musculoskeletal diseases were among the strongest associations. Higher BMFF is associated with increased risk of osteoporosis and fractures. MR analyses validated a causal role of BMFF in osteoporosis.
Conclusion: This is the first large-scale meta-GWAS and MR-PheWAS that identifies genetic variants influencing marrow adiposity at multiple bone sites and establishes BMFF associations with skeletal and cardiometabolic diseases. The findings expand BMFF’s clinical relevance and open the possibility of leveraging BMFF as a novel biomarker with translational applications.read more · Original Link ↗
Andre J. van WijnenUniversity of Vermont, USA
Serge Livio Ferrari, MDGeneva University Hospitals And Faculty Of Medicine, Geneva, Switzerland, Geneva, CH
Isabel Dorothy Kane Hermsmeyer, PhD, MPHUniversity Of Michigan, Ypsilanti, MI, US
Drenka Trivanovic, PhDUniversity Of Belgrade, Serbia
Oral Presentations: Pathway Therapeutics in Rare and Genetic Bone Disease
● Oral Abstract Presentations
Oral Abstracts
📍 Ballroom C
C-type natriuretic peptide (CNP) agonist CNP38 promotes longitudinal bone growth by growth plate expansion in the Hyp mouse model of XLH - Clemens Bergwitz, MD Background: X‑Linked Hypophosphatemia (XLH) is caused by PHEX mutations leading to elevated FGF23, renal phosphate...C-type natriuretic peptide (CNP) agonist CNP38 promotes longitudinal bone growth by growth plate expansion in the Hyp mouse model of XLH - Clemens Bergwitz, MD
Background: X‑Linked Hypophosphatemia (XLH) is caused by PHEX mutations leading to elevated FGF23, renal phosphate wasting, and impaired bone mineralization, resulting in persistent skeletal abnormalities despite current therapies. We hypothesized that the C-type natriuretic peptide (CNP) agonist CNP38 may improve growth plate morphology in Hyp mice by binding NPR‑B, attenuating FGF23/FGFR3 signaling
Methods: We treated female Hyp mice, a model of XLH, with vehicle and a 0.3% phosphate diet (NPD), vehicle and a 1.2% phosphate diet (HPD) and 175 ng/kg calcitriol subcutaneously (SC) three times weekly, CNP38 (800 µg/kg/day) and a NPD, and CNP38(800 µg/kg/day) with a HPD/calcitriol SC, starting on weaning day 21 (P21) until P60 with daily weight and weekly length measurements. On day 60, fasting blood and urine, and tissues were collected to evaluate phosphate homeostasis, histology of entheses, growth plates, static histomorphometry, micro-CT analysis, and biomechanics.
Results: By P60, total body length in Hyp mice treated with CNP38 and a HPD/calcitriol SC (161.4±1.73 mm; p=ns vs. WT ) approached that of WT on a NPD (160.9±1.03 mm) and was greater than that in Hyp treated with vehicle and NPD (136.5±1.66 mm; p=0.0001 vs. WT); Hyp treated with HPD/calcitriol SC (145.6±1.61 mm; p<0.0001 vs. WT); and Hyp receiving only CNP38 and a NPD (150.3±2.29 mm; p<0.0037 vs. WT). Histology revealed growth plate expansion in the CNP38-treated Hyp mice on NPD (Figure 1A), which may promote longitudinal bone growth (Figure 1B), and this expansion was replaced by well-organized primary spongiosa when co-treated with a HPD/calcitriol SC. There was no effect of CNP38 on phosphate homeostasis, although plasma Pi in all Hyp groups was lower than in WT, and phosphate excretion indices (PEI) and iFGF23 levels in Hyp mice receiving a HPD/calcitriol SC were significantly higher when compared to Hyp mice receiving vehicle or CNP38. Likewise, HPD/calcitriol SC improved femoral micro-CT and histomorphometry and tibial biomechanical parameters, whereas no additional effect was seen with CNP38. CNP38 had no effect on entheses or skull length measured by micro-CT.
Conclusion: The C-type natriuretic peptide (CNP) agonist CNP38 promotes longitudinal bone growth in concert with enhancing growth plate expansion. CNP treatment, when supplemented with a HPD/calcitriol SC, improved multiple growth parameters in the Hyp mouse model of XLH.
ENPP1 Inhibition Improves the Bone Phenotype, Mobility, Muscle Strength and Endurance in Later-Onset HPP Mice - Valeria Guglielmi
Hypophosphatasia (HPP) is an inherited metabolic disease characterized by skeletal and dental hypomineralization, caused by loss of function mutations in the gene (ALPL) encoding tissue-nonspecific alkaline phosphatase (TNAP) that catalyzes the hydrolysis of inorganic pyrophosphate (PP i ), a potent inhibitor of mineralization. In addition to the skeletal symptoms, HPP patients experience muscle weakness, cramps, and fatigue, suggesting that TNAP deficiency might affect muscular function, either directly or indirectly. The currently approved enzyme replacement with bone-targeted TNAP (asfotase alfa) improves both the skeletal and muscle phenotypes. However, the frequent injections and high cost of the medication represent a burden for the patients, highlighting the need of an alternative treatment. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) catalyzes the hydrolysis of ATP to produce PP i . Therefore, inhibition of ENPP1 activity is a potential alternative strategy to sink pathologically elevated levels of PP i and help resolve musculoskeletal deficits in HPP. In this study, we tested the efficacy of the ENPP1 inhibitor ALE1 in improving bone mineralization and motor function deficits in Alpl Prx1/- mice, a model of later-onset HPP. We administered ALE1 via the diet at doses of 0, 50, and 100 mg/kg body weight to Alpl Prx1/- mice for four months. To evaluate their muscle strength and endurance we performed grip strength test, wire hang test, graded exercise test on a treadmill, and weight holding capacity. We also assessed their physical activity using voluntary wheel running. We found that treatment with 100 mg/kg ALE1 increases muscle strength, restores weight holding ability of Alpl Prx1/- to levels of wild type mice, and increases the energy produced during the voluntary wheel running as well as running bout duration in Alpl Prx1/- mice. X-ray analysis of tibia and femur of ALE1-treated Alpl Prx1/- mice showed improved bone mineralization in patella, cortical bone in diaphysis and normalized epiphysis shape. Length of tibia and femur increased but did not reach the levels of wild type mice. In agreement with these skeletal improvements, a significant increase in P i /PP i ratio was detected in Alpl Prx1/- mice after ALE1 treatment. In conclusion, we demonstrate that ENPP1 inhibition improves bone mineralization and muscle performance in the later-onset HPP model and, therefore, could be translated into an effective treatment for HPP patients.
Autophagy Stimulation Improves Bone Formation and Restores Cortical Thickness of a Murine Model of Osteogenesis Imperfecta - Alicen James
Osteogenesis imperfecta (OI) is a genetic disorder characterized by low bone mass and increased fragility. In OI, mutations in type I collagen or collagen-modifying proteins often result in misfolding and aggregation of procollagen in the endoplasmic reticulum (ER). This leads to enlarged ER cisternae and elevated ER stress and is thought to impair osteoblast function. Misfolded procollagen in the ER is degraded by autophagy. Previous ex vivo studies have shown that elevating autophagy in OI osteoblasts helps clear misfolded proteins, decreases ER stress, and increases mineral deposition in culture. Therefore, we sought to determine whether stimulating autophagy increases bone formation and improves the skeletal pathology of OI. To stimulate autophagy, we used in vivo CRISPR activation and elevated expression of Tfeb , the major transcriptional regulator of genes involved in autophagy and lysosomal biogenesis, in the entire osteoblast lineage (Osx1-Cre; CRa; sgRNA Tfeb or Tfeb CRa mice). Under physiological conditions, this genetic maneuver increases bone formation, bone mass, and strength. To test if autophagy stimulation would improve OI pathology, we crossed Tfeb CRa mice with a murine model of severe recessive OI, namely Crtap null mice. Crtap null mice lack an important collagen-modifying protein and have enlarged ER. Autophagy stimulation starting at 3 weeks of age caused a progressive increase in bone mineral density of Crtap null mice at 3, 4, and 5 months of age. μCT analysis performed at 5 months of age revealed that lack of CRTAP causes a significant decrease in femoral and vertebral cortical thickness which was restored to control levels after autophagy stimulation. Lack of CRTAP also causes a dramatic decrease in femoral cancellous bone volume, which is improved by autophagy stimulation. Circulating markers of bone formation (P1NP) and bone resorption (CTX) suggested that elevated bone mass of Crtap -/- ; Tfeb CRa is due to an increase in bone formation. Moreover, dynamic histomorphometry indicated that the increase in femoral cortical thickness of Crtap -/- ; Tfeb CRa mice is due to increased bone formation at the femur periosteal surface. Overall, these studies provide proof of principle that autophagy stimulation is a meaningful therapeutic strategy for improving low bone mass in OI. Further studies are needed to address whether these improvements are sufficient to increase the strength of OI bones.
Romosozumab Improves Bone Material Quality in Osteogenesis Imperfecta - Bowen Wang
Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility throughout the lifespan. Low bone mineral density (BMD) and hypermineralization of the bone matrix (high mineral-to-matrix ratio (MMR) due to collagen deficiency) are the hallmarks of bone pathology in OI. Currently, there is no effective treatment for OI. Bisphosphonates (BPs) are considered the gold standard for managing fracture risk in OI. However, BP use in OI remains challenging as BPs do not correct poor material quality. A recent study of an OI mouse model suggested that long-term BP use does not improve bone fracture resistance in OI. This highlights the importance of improving bone material quality in OI. Anabolic therapies, such as Romosozumab (ROMO), may enhance bone formation and improve bone quality in OI. We previously reported bone histomorphometry data in OI following 12 months of ROMO treatment. Here, we evaluated cortical bone compositional quality in the transiliac bone biopsies pre- and post-treatment using Raman spectroscopy and X-ray diffraction (XRD). The patient, a 47-year-old male with skeletal deformities and a history of multiple fractures since childhood, is a carrier of a pathogenic variant in the COL1A1 gene (c.2089C>T; p.Arg697). The lumbar spine (LS) areal BMD was very low (Z-score -3.7). Following 12 months of ROMO (210 mg/month), the biopsy showed pronounced improvement in cortical remodeling and trabecular parameters. In parallel, bone formation increased, and the LS BMD was increased by 13%. The patient did not have further fractures. Evaluation of bone compositional quality revealed that the mineral crystallinity (pre: 0.055±0.0005 vs post: 0.055±0.0003) and carbonate substitution (pre: 0.174±0.008 vs post: 0.179±0.004) remained unchanged with treatment. The MMR was markedly reduced by 43% (pre: 1.37±0.22 vs post: 0.96±0.13), indicating that ROMO treatment may improve collagen content in the bone matrix. The XRD peak linked to the mineral crystal c-axis was sharpened (peak width pre: 0.33±0.04 vs post: 0.31±0.03), while the lattice spacing was slightly reduced (pre: 3.45±0.005 vs post: 3.44±0.006). Thus, ROMO could promote the formation of larger bone mineral crystals (known to be abnormally small in OI) with tighter lattice packing. This is the first report on the improvement in bone material quality in OI bone biopsy following anabolic treatment, suggesting that ROMO treatment may help reduce bone fragility in individuals with OI.
Romosozumab is associated with large BMD increases in premenopausal osteoporosis with and without osteoporosis-related genetic findings - Lauren Kelly Lynch, PhD, MD
We previously reported that 12M of romosozumab (ROMO) was associated with large BMD increases at spine (+15%) and hip (+5%) sites in premenopausal women with idiopathic osteoporosis (PremenIOP).
Several characteristics of PremenIOP, including early onset, disease severity, and lack of secondary causes have led to the hypothesis that PremenIOP may have genetic underpinnings. In prior exome sequencing (ES) studies of PremenIOP (n=75) and pregnancy/lactation osteoporosis (n=110), we identified heterozygous, rare (<1% in gnomAD), predicted deleterious variants (RPDV; ACMG III-V) in genes related to bone in 10-30%. Although multiple potential osteoporosis mechanisms were identified, the most common findings involved RPDV in genes related to the WNT pathway ( LRP5, LRP6, WNT1 ). ROMO, an antisclerostin antibody, acts via this pathway. Effects of genotype on ROMO response are not yet known.
Therefore, as an ancillary study to our single-arm study of ROMO (210mg SQ monthly for 12M) in PremenIOP, we enrolled 27 women (mean±SD: age 38±7 yrs, BMI 23±4 kg/m 2 , 4±2 adult fractures (Fx); 56% with vertebral Fx; PLO presentation in 50%) in ES studies to investigate relationships between genetic findings (RPDV) and ROMO DXA BMD response. Analyses of ES data identified 9 RPDV in 8/27 participants: LRP5 (n=3), LRP6 (n=2), PLS3 (n=1), COL5A1 (n=1), LRP6 & SMAD6 (n=1). We compared clinical characteristics and BMD response between those with RPDV (n=8) and those without RPDV (n=19). Baseline clinical characteristics (age, BMI, # of Fx, vertebral Fx, childhood Fx, family osteoporosis history, PLO presentation and BMD) did not differ between the groups. BMD increased at the lumbar spine (LS) and total hip in each group (p<0.01). However, those with RPDV had attenuated responses to ROMO at LS vs those without RPDV (10.0±3.8% vs 14.6±5.5%, p=0.04; FIGURE). A similar trend at LS (p=0.10) was seen when analyses were limited to WNT pathway RPDV (n=6) vs no RPDV.
In summary, this ancillary study identified a potential monogenic etiology of PremenIOP in 30%, most commonly in LRP5/LRP6 , similar to our prior studies. Those with RPDV had attenuated responses to ROMO at LS. However, substantial BMD response to ROMO was documented in both groups: those with and without potential monogenetic etiologies of osteoporosis, many related to the WNT bone formation pathway. These findings suggest that ROMO can have clinical utility for various forms of primary or idiopathic osteoporosis.
Plasma Proteomics Distinguishes Clinical Expression in ADO and Highlights Differential Inflammatory and Matrix Remodeling Pathways - Jeffrey Mital, PhD
Purpose : Autosomal dominant osteopetrosis (ADO) is a rare bone disease usually caused by mutations in the CLCN7 gene that impair osteoclast resorption. ADO shows variable penetrance from asymptomatic carriers to severe symptomatic disease with fractures and hematological complications. Circulating plasma biomarkers that capture this heterogeneity and reflect disease mechanisms are limited. We aimed to define proteomic signatures that distinguish symptomatic from asymptomatic ADO and identify pathways relevant to disease biology.
Methods : Plasma from symptomatic ADO (n=12), asymptomatic ADO (n=6), and age/sex/menopause-matched healthy controls (n=10) was profiled using high-throughput proteomics covering >5,440 proteins. We confirmed technical consistency via normalized protein expression distributions. Differential expression contrasts compared symptomatic/asymptomatic vs. healthy and symptomatic vs. asymptomatic, ranked by log fold change and FDR; targeted analyses focused on bone turnover markers and known ADO biomarkers. Pathway and protein-protein interaction enrichment used curated databases.
Results : Overall, 129 upregulated proteins were identified in symptomatic vs. healthy, 182 proteins upregulated in asymptomatic vs. healthy, and 883 proteins upregulated in both symptomatic and asymptomatic vs. healthy. Tartrate-resistant acid phosphatase 5b (TRAP5b), a known ADO biomarker, was significantly elevated in symptomatic subjects, supporting the biological and technical validity of these analyses. Pathway enrichment analyses highlighted upregulated extracellular matrix organization (MMP12 and MMP13) and cytokine signaling (TNFRSF9) as well as downregulated heme metabolism (CA1) in symptomatic ADO patients. Symptomatic and asymptomatic ADO patients both exhibited increased markers of membrane trafficking (IFI30) and apoptosis (CASP3).
Conclusions : Circulating proteomic differential expression analyses distinguish symptomatic ADO patients, asymptomatic ADO patients, and healthy controls. The data reveal biological patterns of extracellular matrix remodeling and inflammation, alongside cellular responses that are consistent with dysregulation of lysosomal acidification and bone resorption. These findings identify potential biomarkers that could help explain ADO pathophysiology, monitor disease activity, and support therapeutic target validation studies. Larger patient datasets are needed to validate and strengthen these promising initial findings.read more · Original Link ↗
Elisabeth M.W. Eekhoff, Professor, PhD, MD, Amsterdam Umc, Location Vu University Medical Center, Amsterdam, The Netherlands, Amsterdam, NL
Rodis D. Paparodis, MDHellenic Endocrine Network, PATRA, GR
Clemens Bergwitz, MDYale School Of Medicine, New Haven, CT, US
Valeria GuglielmiSanford Burnham Prebys Medical Discovery Institute, San Diego, CA, US
Alicen JamesUniversity Of Arkansas For Medical Sciences, Little Rock, AR, US
Bowen WangRensselaer Polytechnic Institute, ALBANY, NY, US; Rensselaer - Icahn School of Medicine at Mount Sinai Center for Engineering and Precision Medicine, New York, NY, USA
Lauren Kelly Lynch, PhD, MDDivision of Endocrinology, Department of Medicine, Columbia University, New York, USA
Jeffrey Mital, PhDNew Haven, CT, US
☆
Mon 10/12 · 11:30 AM - 12:45 PM
Oral Presentations: Bone at the Interface of Interorgan Communication
● Oral Abstract Presentations
Oral Abstracts
📍 General Session - Ballroom A & B
Bone-derived PDGF-BB Impairs Amyloid-β Clearance in the Brain - Jiekang Wang, MS
Alzheimer’s disease (AD) is the most common cause of dementia, and its clinical association with osteoporosis suggests a potential link between skeleton and AD.Bone-derived PDGF-BB Impairs Amyloid-β Clearance in the Brain - Jiekang Wang, MS
Alzheimer’s disease (AD) is the most common cause of dementia, and its clinical association with osteoporosis suggests a potential link between skeleton and AD. Bone may contribute to this link by secreting endocrine factors that regulate distant tissues, including the brain. Pre-osteoclast (PreOC) secreted platelet-derived growth factor-BB (PDGF-BB) has been linked to blood-brain barrier (BBB) dysfunction and cognitive decline. In this study, we aimed to determine whether bone-derived PDGF-BB contributes to AD progression. We first measured circulating PDGF-BB levels and found circulating PDGF-BB levels were significantly higher in plasma from patients with mild cognitive impairment than in normal controls. Similarly, serum PDGF-BB levels were elevated in two AD mouse models, APP/PS1 and 5XFAD , compared with WT control mice. Parabiosis surgery to expose AD mice to the circulation of PreOC-specific Pdgfb-overexpressing mice ( Pdgfb cTG ), in which serum PDGF-BB levels are approximately threefold higher than those in WT controls. Notably, AD mice paired with Pdgfb cTG mice showed significantly increased cortical amyloid-β (Aβ) plaque burden compared with those paired with WT control mice, suggesting that high level PreOC-derived PDGF-BB promotes Aβ plaque formation. Impaired Aβ clearance, including disrupted BBB-mediated Aβ efflux into the circulation, is a major driver of AD progression. To determine whether PDGF-BB-induced Aβ plaque accumulation results from impaired Aβ clearance, Aβ42 was directly injected into the cerebral cortex of Pdgfb cTG mice. Pdgfb cTG mice showed circulating Aβ42 levels below 50% of control levels and approximately two-fold higher brain Aβ42 levels, supporting impaired Aβ42 clearance from the brain into the circulation. A newly established BBB-on-a-chip model containing astrocytes, pericytes, and endothelial cells was used to examine PDGF-BB-dependent changes in barrier permeability and Aβ42 transport. Consistent with the in vivo results, prolonged PDGF-BB exposure impaired BBB integrity and reduced BBB-mediated Aβ42 efflux in the system. Finally, AD mice were treated with our produced PDGF-BB-neutralizing antibody to evaluate its therapeutic effect. Together, these findings identify bone-derived PDGF-BB as an important contributor to BBB dysfunction, defective Aβ clearance, and increased Aβ plaque burden. The results suggest that targeting skeletal PreOCs or reducing circulating PDGF-BB may be a new way to slow AD progression.
Preclinical Evaluation of an FSH-Blocking Therapeutic Antibody for the Treatment of Osteoporosis, Obesity, and Alzheimer’s Disease - Satish Rojekar, PhD
Background: Follicle-stimulating hormone (FSH) directly regulates bone, adipose tissue, and brain function. Blocking FSH action with antibodies prevents osteoporosis, obesity, and Alzheimer's disease (AD) in mouse models. Clinical translation via subcutaneous delivery requires a stable, high-concentration antibody formulation. We describe the formulation development, biophysical evaluation, and preclinical validation of our humanized FSH-blocking monoclonal antibody (MS-Hu6) and its murine surrogate (Hf2) in animal models of osteoprosis, obesity, and AD.
Methods: We determined the atomic-resolution crystal structure of MS-Hu6. MS-Hu6 and Hf2 were formulated at 100 mg/mL using FDA-approved excipients under GLP-compliant (21 CFR 58) conditions and characterized by protein thermal shift assay, SEC, and DLS. Pharmacokinetics and biodistribution of ⁸⁹Zr-labeled MS-Hu6 were evaluated in C57BL/6 mice. Skeletal effects were assessed in ovariectomized C57BL/6 and C3H/HeJ mice using DXA, μCT, and histomorphometry. Metabolic efficacy of Hf2 was examined in ovariectomized C57BL/6 mice fed a high-fat diet, while cognitive outcomes were evaluated in OVX 3xTg and APP/PS1 Alzheimer’s disease mouse models. Safety was assessed in African green monkeys administered MS-Hu6 (8 mg/kg, i.v. or s.c.) monthly for 5 months.
Results: MS-Hu6 binds FSH with high precision, as confirmed by crystallographic and docking analyses. Formulated antibodies showed excellent thermal and colloidal stability. Monomer purity exceeded 99.6%, and retention was over 98% after four freeze - thaw cycles and storage for 90 days at 4°C or 25°C. ⁸⁹Zr-MS-Hu6 had a β-phase serum half-life up to 132 hours in Tg32 FcRn-humanized mice. In ovariectomized mice, MS-Hu6 significantly improved bone mineral density and microarchitecture by blocking FSH - FSHR signaling. In high-fat-fed ovariectomized mice, Hf2 reduced body weight by 13.2% and fat mass by 24% by week 5. These effects were sustained for 20 weeks post-treatment, including a 35% decline in mesenteric WAT. Lean mass and food intake remained unchanged. Hf2 improved recognition and spatial memory in 3xTg and APP/PS1 mice. MS-Hu6 was well tolerated in monkeys, with normal vital and biochemical indices throughout.
Conclusions: MS-Hu6 is a GLP-compliant, structurally defined FSH-blocking antibody with durable metabolic, anabolic, and cognitive efficacy and favorable safety in nonhuman primates, supporting IND-enabling advancement to first-in-human studies.
Conditional Osteoblast D2 Receptor Deletion Rescues Diabetic Bone Disease in Mice - Yaser Peymanfar, PhD
Diabetic bone disease is a major skeletal complication of diabetes mellitus characterized by impaired bone formation, microarchitecture deterioration, and increased fracture risk. Although peripheral dopamine levels are metabolically modulated, and dopamine receptors regulate opposing G protein signaling pathways, the roles for peripheral dopamine in skeletal homeostasis and diabetic bone disease remain unknown. We hypothesized that elevated circulating dopamine observed in mouse models of diabetes, and humans contribute to diabetic bone disease through osteoblast dopamine receptor D2 (D2r) signaling through a D2r/Gαi/o initiated pathway.
To test this hypothesis, we generated conditional osteoblast-specific heterozygous D2r knockout mice ( D2r wt/fl , Col1-2.3 cre+/- (obKO)) and induced type 1 diabetes using streptozotocin. Skeletal phenotyping was performed using μCT, histomorphometry, dynamic bone formation analyses, serum biomarker assessment, and biomechanical testing.
Circulating dopamine levels were significantly elevated in diabetic mice, and in human subjects with type 1 and type 2 diabetes, compared to non-diabetic controls. Diabetic control mice exhibited marked trabecular bone deterioration, including reduced bone volume fraction, trabecular number, and connectivity density together with increased trabecular spacing. In contrast, conditional osteoblast D2r deletion significantly attenuated diabetic skeletal deterioration and restored trabecular microarchitecture. Histological analyses demonstrated rescue of trabecular organization and osteoblast number in diabetic knockout mice. Diabetes-induced disruption of growth plate chondrocyte organization was similarly restored following osteoblast D2r deletion. Dynamic histomorphometry demonstrated rescue of suppressed mineral apposition rate in diabetic knockout mice. Importantly, biomechanical analyses revealed significant improvements in ultimate force, stiffness, and work to fracture following osteoblast-specific D2r deletion under diabetic conditions.
These findings identify osteoblast dopamine D2 receptor signaling as a previously unrecognized regulator of diabetic skeletal pathology. Elevated peripheral dopamine may directly impair bone formation and skeletal integrity in diabetes through osteoblast D2r signaling, highlighting this pathway as a potential therapeutic target for diabetic bone disease.
Disrupted lipid homeostasis underlies bone fragility in diabetes, which is corrected by pharmacological activation of the transcription factor LXR - Nisreen Akel, BS
Diabetes (DM) disrupts lipid homeostasis inducing ectopic lipid accumulation in tissues including bone. Cholesterol and phospholipid efflux from cells to bind apoproteins for excretion is mediated by the membrane transporter ATP-binding cassette subfamily A member 1 (ABCA1). Abca1 is upregulated by the transcription factor liver-X-receptor (LXR), which in turn is regulated by cAMP/CREB. ABCA1 mutations are associated with DM in humans. Yet, the role of ABCA1 and LXR in DM-bone disease and the protection by anabolic PTH receptor (PTHR) signaling is unknown. We report that bones from male C57Bl/6 DM mice exhibit accumulation of phospholipids known to be effluxed by ABCA1, quantified by untargeted lipidomics. Also, Abca1 expression is decreased in DM bones and increased by PTHR activation with teriparatide or abaloparatide, assessed by bulk RNAseq analysis and validated by scRNAseq in preosteoblast and osteoblast clusters. ChIP-X enrichment analysis of bulk RNAseq, validated by scRNAseq in preosteoblast/osteoblast clusters, demonstrated that DM downregulated and, conversely, PTHR activation upregulated Abca1 and other LXR target genes. We next examined the effects of the LXR agonist GW3965 (GW, oral gavage, 10mg/kg/d, 28d) on DM bone disease. Serum cholesterol was elevated in DM mice and further increased by GW. GW increased the expression of LXR target genes in bone including Abca1 , by qPCR. Moreover, GW reversed the increase in Sost expression and partially corrected the DM-induced reduction in the bone formation marker P1NP. In contrast, GW had no effect on DXA BMD (total, spine, femur), which remained low in DM mice treated with GW. However, the decreased femoral cancellous BV/TV and trabecular number, and the reduced cortical area/thickness, as well as polar moment of inertia induced by DM were abrogated by GW. GW-treated DM mice were also protected from bone material deterioration, quantified by cyclic reference point indentation. Thus, DM increased Total Indentation Distance, Indentation Distance Increase, and Average Creep Indentation Distance, and GW reversed these indices of bone fragility. We conclude that disrupted lipid homeostasis underlies DM-induced structural/extrinsic and material/intrinsic deterioration of bone, and that LXR activity is sufficient to alleviate DM induced bone fragility independently of BMD. Thus, at least part of the restoration of bone health in DM by PTHR signaling could be accounted for by stimulation of LXR activity.
Osteocytic ENPP1 Mediates Bone - Liver Crosstalk and Induces Fatty Liver Disease by Promoting Lysosomal Secretion of Spermine Synthase - Chang Liu, PhD, MD
Objective: Osteoporosis and nonalcoholic fatty liver disease (NAFLD) are prevalent clinical comorbidities, yet the underlying mechanisms linking them remain poorly understood. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is highly expressed in bone tissue, and its mutations are associated with early-onset osteoporosis and obesity. This study aimed to determine whether ENPP1 in osteocytes is involved in bone - liver crosstalk and mediates the comorbidity of bone and liver disorders.
Methods: Metabolic phenotypes were evaluated in osteocyte-specific ENPP1 knockout mice, as well as in ovariectomized (OVX) and high-fat diet (HFD)-fed mouse models. In vitro co-culture systems, combined with integrated proteomic, transcriptomic, and metabolomic analyses, were employed to explore the effects of osteocytic ENPP1 on other tissues and systemic glucose-lipid metabolism, and to elucidate the underlying molecular mechanisms.
Results: ENPP1 expression was markedly downregulated in the bone tissues of OVX and HFD‑fed mice. Loss of osteocytic ENPP1 disrupted hepatic lipid metabolism, ultimately leading to spontaneous fatty liver disease. Integrated multi‑omics analyses revealed that ENPP1 downregulation increased the secretion of spermine synthase (SMS) from osteocytes. Serum SMS levels were elevated in both OVX‑induced osteoporotic mice and HFD‑fed mice. Overexpression or addition of recombinant SMS protein upregulated the expression of lipogenic genes in hepatocytes. Furthermore, SMS knockdown relieved the dysregulation of lipid metabolism induced by ENPP1 deficiency in a co‑culture model using ENPP1 knockout MLO-Y4 osteocytes and AML12 hepatocytes, indicating that SMS is a novel bone‑derived osteokine that mediates bone - liver crosstalk. Mechanistically, osteocytic ENPP1 deficiency enhanced calcium influx and upregulated the expression of phospholipase A2 group IVA (PLA2G4A), a key enzyme in glycerophospholipid metabolism. PLA2G4A induced plasma membrane damage and facilitated lysosomal exocytosis of SMS.
Conclusion: Osteocytic ENPP1 acts as a key mediator of bone - liver crosstalk and its deficiency induces fatty liver disease by promoting the lysosomal secretion of SMS. SMS not only functions as a potential biomarker for the comorbidity of osteoporosis and fatty liver disease but also holds promise as a novel therapeutic target for the simultaneous management of these two conditions.
Lymphatic VEGFD Signaling Orchestrates T Cell-Dependent Bone Remodeling after Injury - Neda Vishlaghi, PhD
Heterotopic ossification (HO) is a pathologic process of ectopic bone formation following trauma in which mechanisms regulating inflammatory resolution and bone remodeling remain poorly defined. Lymphatic vessels are emerging regulators of immune coordination during tissue repair. Here, we identify VEGFD as a central regulator of injury-dependent lymphatic-immune signaling that promotes osteoclast-mediated bone resorption. Using a trauma-induced HO model, we show that VEGFD overexpression reduces HO and enhances remodeling of adjacent bone. scRNA sequencing of injured tissue revealed that VEGFD reshapes the transcriptional landscape of the HO microenvironment by expanding myeloid and lymphoid compartments. These changes were accompanied by activation of inflammatory remodeling pathways, including MAPK, PI3K-Akt, TNF, and osteoclast differentiation signaling (Fig1A). Moreover, osteoclast-lineage genes including Tnfrsf11a , Fcgr3 , Csf1 , and Aif1 were increased within HO lesions. Bone marrow analysis demonstrated expansion of osteoclast precursor-associated myeloid populations without enrichment of terminal differentiation signatures, indicating systemic priming of precursor reservoirs. Circulating immune profiling revealed increased T-cell and interferon-responsive populations with reduced macrophages, consistent with coordinated systemic immune remodeling downstream of VEGFD signaling. Subclustering of LECs identified VEGFD-driven expansion of proliferating and activated capillary LEC states accompanied by induction of interferon-associated signaling components including Ifnar1 , Ifnar2 , Stat2 (Fig1B) . Proteomic profiling of injured tissue at later timepoints confirmed sustained lymphatic activation together with enrichment of chemokines CCL21a/b and osteoclast remodeling proteins including SPP1, ACP5. Parallel transcriptional analyses demonstrated interferon-associated activation and phenotypic remodeling of lesion-resident T cells. Functionally, depletion of CD4⁺ T cells abolished VEGFD-mediated suppression of HO and reversed VEGFD-dependent bone resorption (Fig.1C-D), establishing adaptive immune signaling as a required downstream mediator of VEGFD activity. Together, these findings define an injury-dependent VEGFD-lymphatic-T cell regulatory axis that promotes osteoclastogenesis and coordinates pathological bone remodeling following trauma. Targeting lymphatic signaling pathways may provide a therapeutic strategy for controlling heterotopic ossification.read more · Original Link ↗
Lorenz C. Hofbauer, MDDivision of Endocinology, Diabetes, and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany, Germany
Christopher J. Hernandez, PhDUniversity Of California, San Francisco, San Francisco, CA, US
Jiekang Wang, MSJohns Hopkins University, Baltimore, MD, US
Satish Rojekar, PhDInstitute for Translational Medicine and Pharmacology, USA; Icahn School Of Medicine At Mount Sinai, Jersey City, NJ, US
Yaser Peymanfar, PhDHarvard School of Dental Medicine, USA; ADA Forsyth Institute, USA
Nisreen Akel, BSUniversity Of Arkansas For Medical Sciences, Little Rock, AR, US; Central Arkansas Veterans Healthcare System, John L. McClellan, Little Rock, AR, USA
Chang Liu, PhD, MDThe Second Affiliated Hospital of Zhejiang University School of Medicine, China
Neda Vishlaghi, PhDUtsw, Dallas, Texas, TX, US; UT Southwestern Medical Center, USA
☆
Mon 10/12 · 11:30 AM - 12:45 PM
Oral Presentations: The Aging Skeleton in High Resolution
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 302
Deterioration of Bone Microarchitecture Across the Menopause Transition Assessed by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) - Alyssa B.Deterioration of Bone Microarchitecture Across the Menopause Transition Assessed by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) - Alyssa B. Dufour, PhD
Background : Accelerated bone loss during the menopause transition is well established by dual-energy X-ray absorptiometry (DXA), yet its impact on bone microarchitecture remains incompletely characterized. HR-pQCT enables assessment of trabecular and cortical compartments, offering insight into structural mechanisms underlying skeletal fragility. Methods : We conducted a longitudinal study of 1274 women in the Framingham Heart Study, acquiring HR-pQCT scans (XtremeCT2) of the distal radius and tibia ~6 yrs apart, using 3D registration to align scan regions. The baseline endocortical boundary was used on the follow-up scans. Women self-identified as pre- or postmenopausal (no menstrual cycles for >1 yr) at each visit. Changes were evaluated using linear regression models to estimate LSMeans, with adjustment for age, BMI, race, physical activity and estrogen or osteoporosis medication use. Results : At the baseline scan, women (92% White) had a mean age of 53.9±8.8 yrs and BMI of 27.7±6.2 kg/m 2 . 250 women were premenopausal at both visits (PRE); 798 postmenopausal at both visits (POST) and 226 reported going through the menopause transition (MT). In general, deterioration was greater at the radius than the tibia, greater in cortical than trabecular bone; and greater in MT and POST groups than PRE (Table). Specifically, at the radius Ct.BMD declined ~2.5-fold more in MT (-6.82%) and POST (-6.7%) than PRE (-2.74%), while Ct.Por increased 2-fold more in MT and POST compared to PRE. In contrast, Tb.BMD increased in PRE (7.77%), and was maintained in MT and POST groups. Tibia Ct.BMD declined and Ct.Por increased significantly more in MT than POST, with both groups showing greater changes than PRE. Tibial Tb.BMD increased in PRE and was maintained in MT and POST. Conclusion : In sum, the menopause transition was associated with marked and compartment-specific deterioration in bone microarchitecture. Cortical deterioration was pronounced, with significant increases in cortical porosity and reductions in Ct.BMD, suggesting a critical role for cortical degradation in early postmenopausal bone fragility. Changes were more pronounced at the distal radius compared to the weight-bearing tibia. These findings extend beyond areal BMD measurements and highlight structural pathways that may underlie increased fracture risk for women in midlife. HR-pQCT-derived measures may improve identification of women at highest risk and inform timing and selection of interventions.
Time-lapse HR-pQCT Reveals Rapid Cortical Bone Loss With Localized Periosteal Apposition and Subperiosteal Circumferential Pore Formation in Older Men - Minhao Zhou, Ph.D.
Osteoporotic fractures are a major problem in older men. Nevertheless, skeletal pathophysiology in older men is not well understood, and the spatial organization of bone remodeling has not been examined. Time-lapse high-resolution peripheral quantitative CT (TL HR-pQCT) accurately captures spatial mapping of bone gain and loss over time. Thus, this study aims to apply TL HR-pQCT in the MrOS cohort to assess localized bone remodeling patterns in older men.
In 110 men (mean age 84 yrs), we analyzed paired distal tibia HR-pQCT scans obtained ~6 yrs apart; any scans with motion or poor registration were excluded. A customized TL HR-pQCT pipeline previously optimized for XtremeCT II scans was applied. 1 Volumetric bone gain/loss was evaluated within trabecular and cortical compartments, and expressed as a fraction of respective baseline bone volumes. Within the cortical bone, additional sub-regions were analyzed: subperiosteal (only tissue within 0.5 mm below the periosteal surface) and extra-osseal (only tissue within 0.5 mm above the periosteal surface).
Over 6 years, time-lapse HR-pQCT revealed consistent net bone loss in both cortical (-6.91% [IQR: -9.75, -5.02]) and trabecular bone (-3.65% [IQR: -5.38, -2.25]%), with significantly greater loss in cortical bone (p<0.001). Net subperiosteal bone loss was observed in 107/110 subjects. In contrast, the extra-osseal layer showed net bone gain (0.73% [IQR: 0.31, 1.29]%) in 105/110 subjects. Localized periosteal apposition was identified in conjunction with subperiosteal circumferential pores that were observed beneath or adjacent to periosteal apposition sites (Fig A).
The study demonstrates the feasibility of time-lapse HR-pQCT to evaluate localized, compartment-specific bone remodeling patterns in vivo. Older men exhibited substantial net bone loss, primarily attributed to cortical bone loss. Extra-osseal bone gain and the presence of localized periosteal apposition may represent a compensatory adaptive response to bone loss, analogous to periosteal adaptations observed following exposure to microgravity. 2 However, the formation of connected periosteal circumferential pores beneath and adjacent to these apposition sites suggests impaired cortical structural integrity and potentially elevated local fracture risk. Future work will explore the mechanisms underlying the localized periosteal apposition and pore formation.
Zhou+, JBMR 2025, 40: p738-752
Lang+, JBMR 2006, 21(8): p1224-30
Longitudinal Changes in Bone Microarchitecture According to Age, Sex, and Diabetes Status Using High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) - Chandler Da Cruz, BS
Changes in bone microarchitecture in population-based samples remain incompletely characterized. We examined longitudinal HR-pQCT in the Framingham Heart Study Gen 3 cohort to characterize bone changes by age, sex, glycemic status and diabetes duration. Participants included 1,278 women and 1,075 men with HR-pQCT scans at baseline and follow-up. Distal radius and tibia HR-pQCT (XtremeCT2) used a relative-offset (4.0% radius, 7.3% tibia) and 3D registration, with the baseline endosteal contour propagated to follow-up. Glycemic status was classified as normoglycemia, prediabetes, or T2D, and T2D was categorized by duration >10 years. We calculated 6-year percent change in CtBMD, CtPo, TbBMD, TbTh, TbN, and TtBMD. We calculated sex-specific mean (SD) bone changes by age group and estimated LSMeans (age, sex, weight, and height) for the association between glycemic status and diabetes duration with changes in bone measures. In 2,353 participants (mean age 54±9 yrs, 54% women), mean 6-year decline in radius CtBMD increased across age groups from -2.8% to -6.9% in men and -2.9% to -10.4% in women. Mean decline in tibia CtBMD increased from -1.9% to -4.4% in men and -2.6% to -8.7% in women. Radius CtPo increased across age groups from 36% to 81% in men and 43% to 125% in women, while tibia CtPo increased from 15% to 37% in men and 24% to 84% in women (Figure 1). Changes in TbBMD were smaller across age groups at both skeletal sites. In adjusted analyses, change in most bone measures were similar by glycemic status. Prediabetes was associated with less decline in radius TbBMD vs normoglycemia (LSMeans: -0.4% vs -1.3%; P=0.03), while T2D did not differ from normoglycemia. T2D duration >10 yrs was associated with greater decline in tibia CtBMD vs no diabetes (LSMeans: -6.2% vs -4.5%; P=0.01), but not radial CtBMD. Skeletal changes were characterized by age and sex-related cortical deterioration, with larger deficits in women, suggesting that cortical bone loss may dominate age-related skeletal change. Although diabetes status was generally not associated with changes in bone measures, longer duration diabetes was significantly associated with CtBMD loss. In conclusion, the observed bone loss patterns parallel the increases in fragility fractures that are more common with aging and in women. Cortical bone loss in the lower but not upper extremity in longstanding diabetes may explain the increased risk of lower extremity fractures that occur in patients with diabetes.
Patient-Specific Probability of Hip Fracture as Assessed by BCT to Identify Women and Men Age 65 and Older Who are at High and Very High Risk of Hip Fracture - Tony M. Keaveny, PhD
Introduction: AACE practice guidelines recommend use of FRAX or “other validated fracture risk algorithms” to identify patients at high or very high risk of hip fracture for possible treatment. Here we report performance of the new individualized fracture probability output of biomechanical computed tomography (BCT) for such purposes.
Methods: VirtuOst BCT+ uses the patient’s age, a finite element analysis-derived femoral strength, and AI-assisted measurements of bone size, pelvic size, soft tissue thickness, a trabecular-to-cortical density ratio, muscle fat content, and muscle size to compute a patient-specific probability of hip fracture within the next five years, conditional on survival for five years. All input for BCT+ can be obtained from a routine abdominal-pelvic CT from clinical care. Here, we assess hip fracture prediction for the BCT+ probability output, with pre-specified cut points for “high risk” (probability ≥ 4.8%) and “very high risk” (probability ≥ 9.6%) classifications. We sampled from a population of 271,389 patients age ≥ 65 in a large integrated healthcare system who had a hip-containing CT scan (start of observation) during their clinical care. Our independent validation analysis cohort (63% non-White, median age 72 years) comprised of all 837 women and 456 men who had a first incident hip fracture within 5 years of the CT, and a random sample containing no-fracture patients who either survived observation without hip fracture or died first. Using weighted logistic regression, we estimated sensitivity, specificity, PPV, NPV, FPR, FNR, and an odds ratio for hip fracture for the full underlying population. Any patient with ≥ 100 days of osteoporosis treatment during observation was excluded. Results were compared against FRAX (hip, w/BMD), as a clinical reference, without hypothesis testing.
Results: For women, all performance metrics were higher for BCT+ than FRAX. For men, sensitivity was higher for BCT+ than FRAX; specificity was lower for BCT+ but still higher than for the women. For both tests, the ratio of PPV (risk of fracture if test positive) to population fracture risk was confirmed higher for the “very high risk” than “high risk” classification.
Conclusions: In this real-world clinical cohort, fracture probability from BCT+ performed similarly to FRAX for identifying patients at clinically significant high risk and very high risk of hip fracture within five years, thus validating this new algorithm for such purposes.
Magnetic Resonance Imaging-derived novel vertebra-disc-scores (VDS) for assessing osteoporosis and vertebral fracture risk - Rahman Ud Din, Ph.D.
Disc degeneration may increase vertebral fracture risk but disc status has not been considered during clinical assessment of osteoporosis or vertebral fracture. Routine magnetic resonance imaging (MRI) offers a unique opportunity to evaluate both disc and bone quality simultaneously. In this study, we developed novel vertebra-to-disc scores (VDS) based on T1 and T2 MRI sequences, i.e., the ratio of the median L1‒L5 vertebral signal intensity to that of the adjacent discs, and examined their diagnostic performances with multi-cohorts. Cohort-1 included 400 patients with both lumbar MRI and quantitative CT; Cohort-2 enrolled 38 female subjects who underwent MRI and DXA. The reproducibility and generalizability of VDS were assessed in two additional cohorts, and the intraclass correlation coefficient (ICC) reported as the reliability metric. Diagnostic performances of the VDS in osteoporosis and vertebral fracture were evaluated using the receiver operating characteristic (ROC) and area under the curve (AUC) was reported. Furthermore, QCT-based finite element analysis was conducted to examine the effects of disc degeneration on vertebral strength. Overall, 4663 lumbar vertebrae and adjacent discs were assessed. The osteoporotic patients had higher T1-VDS (2.12 vs. 1.72, p< 0.001; ICC=0.90) and T2-VDS (3.20 vs. 1.87, p<0.001; ICC=0.96) than non-osteoporotic subjects; T1-VDS had a greater AUC of 0.85 (p< 0.001) than VBQ (0.74; p< 0.001). In assessing vertebral fractures, the T1-VDS had an AUC of 0.75 comparable to QCT-vBMD (AUC: 0.78). Additionally, T1/T2-VDS outperformed DXA-aBMD in differentiating vertebral fractures, both with AUCs of 0.95 vs. 0.72. Finite element analysis of 47 subjects’ subgroup revealed 11% reduction in vertebral strength in degenerated disc-osteoporotic vertebra model (vs. 7% with healthy disc) and 7% reduction in degenerated disc-healthy vertebra (vs. 6% with healthy disc-vertebra model). The VDS demonstrated moderate-to-strong negative correlation with vertebral strength (r = -0.60, p < 0.001), whereas no correlation found between vertebral signal intensity and vertebral strength. These results together suggest that integration of vertebrae and discs in MRI improves osteoporosis and vertebral fracture assessment, likely due to the consideration of their biomechanical interactions. The novel vertebra-to-disc scores derived from routine MRI may serve as new index for opportunistic assessment of osteoporosis and vertebral fracture risk.
Bone Strength Assessment Using Magnetic Resonance Imaging (MRI) Compared to High-resolution Peripheral QCT (HR-pQCT) - Chamith S. Rajapakse, PhD
Purpose: Accelerated bone strength loss is a hallmark of postmenopausal osteoporosis, spaceflight exposure, and disuse in conditions such as spinal cord injury (SCI). Three-dimensional imaging enables high-resolution characterization of bone microarchitecture, which can be used to construct finite element (FE) models for estimating mechanical strength and for monitoring disease progression and treatment response. The objective of this study was to evaluate the accuracy of MRI-based FE analysis relative to HR-pQCT. Methods: Twenty-two subjects, including individuals with recent SCI (n=11) and abled-bodied controls (n=11), were recruited. Each subject underwent MRI on a Siemens MAGNETOM Vida system and SCANCO HR-pQCT scanning of the left distal tibia. MRI parameters included 0.242 mm in-plane resolution, 1.5 mm slice thickness, TE/TR = 4.92/37 ms, field of view (FOV) = 124 mm, 18-channel body coil, and flip angle = 25° using a spoiled gradient echo (SPGR) sequence. HR-pQCT images were acquired using a standard 0.061 mm isotropic voxel size protocol. Both MRI and HR-pQCT datasets were converted into voxel-based FE meshes, and simulated compression was performed using a custom-built solver to estimate bone stiffness. Results: Distal tibia bone stiffness derived from MRI showed strong correlation with HR-pQCT-derived stiffness (R = 0.80). Conclusion: Despite substantial differences in imaging modality, spatial resolution, field of view, and contrast, MRI-derived bone stiffness demonstrated strong agreement with HR-pQCT estimates, even without image registration. MRI captured a broad spectrum of bone health (Figure 1). Given its ability to be performed on clinical MRI scanners using standard hardware and software at virtually any anatomical site and without ionizing radiation, MRI-based FE analysis offers a promising approach for assessing bone deterioration and monitoring treatment response at clinically critical fracture sites, such as the hip and spine. This is valuable in populations including persons with SCI, astronauts, and patients with chronic kidney disease (CKD) and chronic steroid use in whom DXA utility remains limited or not well established. Reference: Rajapakse et al., Bone 2010. Figure 1: Representative MR and HR-pQCT images of the distal tibia from subjects with (A) intact trabecular microarchitecture and (B) marked loss of trabecular microarchitecture. These images were used to generate FE models for estimating bone stiffness.read more · Original Link ↗
Cesar Libanati, MDConsultant, Fort Lauderdale, FL, US
Douglas P. Kiel, MD, MPHHebrew Seniorlife, Roslindale, MA, US; Broad Institute of MIT & Harvard, USA
Alyssa B. Dufour, PhDHinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA
Minhao Zhou, Ph.D.Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
Chandler Da Cruz, BSMarcus Institute for Aging Research, Boston, MA, US
Tony M. Keaveny, PhDUC Berkeley, USA
Haisheng Yang, PhDBeijing University of Technology, China
Chamith S. Rajapakse, PhDDepartments of Radiology and Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA
Abaloparatide with Continued Denosumab Versus Continued Denosumab Alone (ACTED Study) - Felicia Cosman, MD
Purpose: For women on denosumab (Dmab) who remain at high fracture risk, there are limited options.Abaloparatide with Continued Denosumab Versus Continued Denosumab Alone (ACTED Study) - Felicia Cosman, MD
Purpose: For women on denosumab (Dmab) who remain at high fracture risk, there are limited options. This randomized trial evaluated 18 months of continued Dmab alone versus continued Dmab with abaloparatide (ABL) added concomitantly.
Methods: 70 postmenopausal women with osteoporosis were recruited from Crozer Osteoporosis Clinic, PA (n=19) or Hospital for Special Surgery, NY (n=51). Participants had > 3 prior Dmab treatments; were within 7 months from their last Dmab treatment; and had a T-Score < -2.5 in the lumbar spine (LS), total hip (TH) or femoral neck (FN), or T-Score < -1.5 at LS, TH or FN and a fracture within the last 5 years. The primary outcome was group difference in % change in LS BMD at 18 months. Secondary outcomes included group differences in 18-month TH BMD change, BMD changes at FN and 1/3 radius, and changes in serum levels of PINP and CTX at 3 months. Participants were randomized to: continued Dmab 60mg every 6 months ( Dmab-Only ) or continued Dmab every 6 months plus daily subcutaneous ABL 80mcg ( ABL+Dmab ) for 18 months. BMD was measured by DXA every 6 months and fasting AM blood obtained for PINP and CTX levels at 3, 6, 12 and 18 months. Analyses were performed using modified intention to treat, where all participants had > 1 postbaseline BMD. Group differences in BMD % change were analyzed by ANCOVA and linear mixed models for repeated measures, both adjusted for baseline BMD.
Results: At baseline, groups were well matched with no significant differences (mean age 72; mean T-score at LS -1.8, TH -2.1, and FN -2.6; mean Dmab doses 5.6; median serum PINP=13 and CTX=66). 89% of participants completed the trial. At 18 months, comparing ABL+Dmab vs Dmab-Only groups, mean BMD change in the LS was 6.4% vs 2.7%, p=0.008; TH was 2.6% vs 1.0%, p=0.057; FN was 3.4% vs 1.5%, p=0.21; and 1/3 radius was 0.7% vs 0.1%, p=0.4 (after adjustment for baseline BMD). There were no major differences after adjustment for other baseline covariates. Similar results were seen with mixed models (Figure). At 3 months, serum PINP increased by 101% with ABL+Dmab (p=0. 02) vs no change with Dmab-Only . Serum CTX did not change significantly in either group. There were 3 serious AEs and none was related to study medication.
Conclusion: We conclude that for patients on prior Dmab, adding ABL to ongoing Dmab for 18 months might be a viable therapeutic strategy to stimulate bone formation and improve BMD.
Zoledronate to Reduce Fractures in People with Parkinson’s Disease or Atypical Parkinsonism. A Home-based Randomized Trial - Steven R. Cummings, MD
People with Parkinson’s disease and atypical parkinsonism (PD/AP) have a high risk of fractures with more severe complications, but only a small proportion receive appropriate treatment to prevent fractures. Previous rials found that one infusion of zoledronate reduces clinical fracture risk and zoledronate also reduced the risk of clinical fracture in people with BMD T-scores above -2.5. We conducted a randomized trial of a pragmatic approach of giving one infusion of zoledronate at home to reduce clinical fracture risk in people with PD/AP ≥ 60 years old.
Methods: The trial was conducted from participant’s homes. They were referred from diverse sources, e.g. neurology practices and outreach form PD/AP patient organizations, to enroll and consent via a study website. The diagnosis and stage of PD/AP was confirmed by the participant’s neurologist or video assessment by an expert neurologist. Participants received 2,000 IU /d for 7 days before a nurses visited home, screened for exclusions and infused 5 mg of zoledronate or placebo over 45 min along with acetaminophen for 3 days. Clinical fracture was a primary, hip fracture secondary, and vertebral fracture post hoc outcomes In a Bayesian approach, treatment effects were estimated as probabilities of risk reductions. We also analyzed risks of fracture after a first one.
Results: We randomized 2719 participants with PD/AP ≥60 years old in 49 US states. Over a median of 2.3 years, the hazard ratio (HR) for clinical fracture was 1.0 with 68.7% probability of no effect - an HR between 0.9 and 1.1). Zoledronate reduced hip fracture risk 20% (HR 0.80; 84.0% probability the HR was <1.0) and vertebral fracture by 20% (HR = 0,8; 79.7% probability of a HR <1.0). In the prespecified subgroup with severe disease (Hohn and Yahr stage 4 and 5) zoledronate reduced clinical fracture risk 50% (HR = 0.5; 96.8% probability of HR <1.0), Occurrence of a fracture carried a 16.4% risk of another one within 12 months.
Conclusion: The pragmatic strategy of one infusion of zoledronate for unselected older people with PD/AP did not reduce overall clinical fracture risk but probably provides at least some reduction in hip and vertebral fracture risk. It reduced clinical fractures in those with severe PD/AP. While all older people with PD/AP should be clinically assessed for potential treatments that have established efficacy, a recent fracture warrants expeditious assessment and treatment to rapidly reduce that very high risk.
Circulating Cellular Communication Network Factor 3 Predicts Maternal Skeletal Recovery During Lactation - Muriel E. Babey, MD
Lactation is characterized by increased bone turnover, transient bone mineral density (BMD) loss, and recovery after weaning. Mammary-derived parathyroid hormone-related peptide (PTHrP) drives lactation-induced bone resorption, yet endocrine signals coordinating skeletal recovery remain incompletely defined. In preclinical models, Cellular Communication Network Factor 3 (CCN3) promotes bone formation and mediates physiological skeletal adaptation during lactation. Whether circulating CCN3 exhibits distinct postpartum trajectories in breastfeeding (BF) versus nonBF women, associates with biochemical markers of bone formation, and prospectively predicts maternal skeletal recovery remains unknown.
We performed a post hoc analysis of a longitudinal postpartum cohort of 25 women (14 BF, 11 nonBF) followed for 18 months (M) postpartum. Circulating CCN3, fasting bone turnover markers, and areal bone mineral density (BMD) by DXA were measured at baseline (36±15 days postpartum) and 6, 12, and 18M. Longitudinal associations were evaluated using linear mixed-effects models.
Baseline CCN3 concentrations were similar across groups. Over follow-up, trajectories diverged: CCN3 declined in nonBF participants at 12 and 18M (adjusted p =0.002 and 0.0003) but remained stable in BF participants, resulting in a significant time-by-group interaction ( p =0.038). Among BF participants, circulating CCN3 was positively associated with procollagen type 1 N-terminal propeptide (P1NP), osteocalcin, and bone-specific alkaline phosphatase. BF participants exhibited lumbar spine and total hip BMD loss at 6M postpartum followed by recovery between 12 and 18M. Higher CCN3 AUC₀ - ₆ predicted higher lumbar spine ( p =0.0373) (Figure A) and total hip (Figure B) BMD ( p =0.0126) during the subsequent 12 - 18M recovery period (BMD AUC₁₂ - ₁₈), adjusted for baseline BMD. Similar associations were observed for CCN3 AUC₀ - ₁₂. Circulating CCN3 was not associated with concurrent BMD, suggesting it reflects skeletal remodeling rather than static bone mass. No associations were observed in nonBF participants.
Distinct postpartum CCN3 trajectories, associations with bone formation, and prediction of maternal skeletal recovery support a role for CCN3 in postpartum skeletal regeneration. These findings provide the first human evidence linking circulating CCN3 to physiological bone formation and maternal skeletal recovery, supporting CCN3 as a promising therapeutic target for osteoporosis and low bone mass disorders.
The Long-Term Safety and Efficacy of Garetosmab in Adults with Fibrodysplasia Ossificans Progressiva: Week 84 Results From the Phase 3 OPTIMA Study - Richard W. Keen, MD PhD
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder caused by variants in ACVR1 . OPTIMA assessed the safety and efficacy of garetosmab (GAR), a human monoclonal anti ‑ activin A antibody, in adults with FOP.
OPTIMA was a phase 3, double-blind (DB), placebo (PBO)-controlled study (NCT05394116) with a 56-week (W) DB treatment period (DBTP), an optional extended DBTP (ETP) or observation period (OP; ≥28W), and a 30W follow-up safety period. Participants (pts) were randomized 1:1:1 to receive IV PBO, GAR 3 mg/kg, or GAR 10 mg/kg every 4W. At W56, GAR was generally well tolerated and significantly reduced new heterotopic bone lesions vs PBO (by low-dose CT).
Pts who entered the ETP and elected to stay in the study continued their blinded treatment until the last pt completed W84; those who did not elect to stay entered an off-drug unblinded OP. Safety was assessed via incidence and severity of adverse events (AEs) through the W84 database lock (DBL; Feb 26, 2026 cutoff). Efficacy endpoints assessed at W84 included the number and total volume of new heterotopic bone lesions, the proportion of pts with new lesions, the total number of clinician-assessed flare-ups, and the proportion of pts with clinician-assessed flare-ups.
Overall, 58/62 pts ( PBO: n=19, GAR 3 mg/kg: n=19, GAR 10 mg/kg: n=20) completed the ETP. Through the W84 DBL, all pts had ≥ 1 treatment-emergent AE. Skin and soft tissue infections occurred in 33% of pts on PBO, 53% on GAR 3 mg/kg, and 78% on GAR 10 mg/kg. Bleeding events (all non-serious) occurred in 62% of pts on PBO, 58% on GAR 3 mg/kg, and 26% on GAR 10 mg/kg. Epistaxis occurred in 33% of pts on PBO, 58% on GAR mg/kg, and 22% on GAR 10 mg/kg. No deaths were reported. At W84, there were 28 new lesions with PBO, 0 with GAR 3 mg/kg, and 1 with GAR 10 mg/kg. From W56 - 84, 9 new lesions occurred in pts on PBO and none were reported with GAR. At W84, the proportion of pts with new lesions was 33% with PBO, 0% with GAR 3 mg/kg, and 4% with GAR 10 mg/kg. The mean total volume of new lesions at W84 was 16.9 cm 3 with PBO and 0 cm 3 with both GAR doses. Through W84, the total number of clinician-assessed flare-ups was 83 for PBO, 67 for GAR 3 mg/kg, and 10 for GAR 10 mg/kg. The proportion of pts with clinician-assessed flare-ups was 71% for PBO, 58% with GAR 3 mg/kg, and 22% with GAR 10 mg/kg.
These data show that GAR is generally well tolerated beyond 18 months with robust sustained long-term efficacy in pts with FOP.
Finding the Optimal Resistance Training Intensity for Your Bones (FORTIFY Bones): A Randomized Controlled Trial - Lora M. Giangregorio, PhD
Objective: There is evidence that resistance training may improve bone mineral density, but many exercise trials combine it with impact exercise or other types of exercise, making it difficult to discern the efficacy of resistance training as a single intervention. The purpose of the FORTIFY Bones trial was to evaluate the effect of twice-weekly, moderate-to-high intensity progressive resistance training (PRT) for 1 year on lumbar spine bone mineral density (BMD) in individuals with low BMD, compared to attention control. Secondary analyses will examine if resistance training improves other health outcomes or if high intensity is more effective than moderate intensity resistance training.
Methods: We recruited males and postmenopausal females aged ≥50 years with low femoral neck, total hip, or lumbar spine BMD (T-score of ≤-1) or increased risk of fracture to participate in a randomized controlled trial with 1:1:1 randomization. Participants were stratified by site (3 sites) to twice-weekly, supervised PRT at moderate intensity (about 10 repetitions maximum), high intensity PRT (≤6 repetitions maximum), or a home posture and balance exercise program (attention control) for 1 year (resistance training to comparator allocation ratio of 2:1). The primary outcome was lumbar spine BMD via dual-energy X-ray absorptiometry. Secondary outcomes include proximal femur and total hip BMD, and bone-free and appendicular lean mass, physical functioning, falls, fractures and adverse events. Between-group differences were tested in intention-to-treat analyses using analysis of covariance, chi-square tests, or negative binomial or logistic regression, adjusting for site and baseline values.
Results: Between September 2022 and February 2025, 699 were assessed for eligibility, and 324 were randomized (108 per group): retention at 1-year follow-up was 92%. The mean age of participants was 67.1 years (SD 6.6), and 302 (93%) were female. 39 and 25 participants reported 44 and 30 non-serious possibly related or related adverse events, respectively (e.g., injuries, pain), and there were 2 and 0 possibly related and related serious adverse events, respectively. Between group differences in bone mineral density and other outcomes will be reported at the conference.
Conclusions: The results of the FORTIFY Bones trial will support decision making on resistance training for people at risk of fracture.
Effects of Limited versus Standard Dose Romosozumab followed by Denosumab on Peripheral Bone Density and Microarchitecture: The LIDA-HRpQCT Extension study - Joy Tsai, MD
Background: In the Limited Duration Anabolic (LIDA) study, 3 months of romosozumab (ROMO) followed by 9 months of denosumab (DMAB) produced 12-month total hip bone mineral density (BMD) gains that were non-inferior to those achieved with 12 months of ROMO in postmenopausal women. During the 12-month extension phase, all participants received denosumab for an additional 12-months. The effect of these sequences on peripheral cortical and trabecular bone density and microarchitecture is unknown.
Methods: We randomized 50 postmenopausal women with osteoporosis (mean age 70yo) to receive ROMO 210-mg SC monthly for 3 months followed by DMAB 60-mg SC every 6 months for 9 months (3-MO ROMO) or ROMO 210-mg SC monthly for 12 months (12-MO ROMO). 41 women who continued in the one-year extension then switched or continued DMAB 60-mg SC every 6 months (3-MO ROMO, extension N=22; 12-MO ROMO, extension N=19). Total, trabecular and cortical volumetric BMD (Tot.vBMD, Tb.vBMD, Ct.vBMD), microarchitectural parameters including estimated strength were measured by high-resolution peripheral QCT (and finite element analysis) of the distal radius and tibia at 0, 12, and 24 months.
Results (Fig): At the tibia, Tot.vBMD, Tb.vBMD, and Ct.vBMD increased at 24-months in both groups. At the radius, Tot.vBMD, Tb.vBMD, and Ct.vBMD increased at 24-months only in the 3-MO ROMO group. Cortical thickness increased at 24-months in both groups at the tibia and increased at 24-months at the radius in the 3-MO ROMO group. There were no significant within-group changes in cortical porosity in either group at month 24. Failure load and stiffness increased at the tibia in both groups and increased at the radius in the 3-MO ROMO group by 24-months. There were no significant changes in trabecular microarchitectural parameters in either group. Nor were there significant between group differences at either the tibia or radius in vBMD, cortical microarchitecture, or estimated bone strength at the 24-month time point.
Conclusions: A limited 3-month course of ROMO followed by DMAB resulted in changes in peripheral bone density and microarchitecture that were generally comparable to those achieved with the standard 12-month course of ROMO followed by DMAB over a 2-year treatment sequence. These findings continue to support the utilization of this shorter romosozumab regimen within shared decision making framework for patients who wish to limit use of ROMO.read more · Original Link ↗
Matthew T. Drake, PhD, MDHospital for Special Surgery, USA
Huy Gia Nguyen, PhDGarvan Institute of Medical Research, Marrickville, NSW, AU
Felicia Cosman, MDHospital for Special Surgery, NY, USA; Columbia University, Vagelos College of Physicians and Surgeons, USA
Steven R. Cummings, MDSan Francisco Coordinating Center, Mill Valley, CA, US
Muriel E. Babey, MDStanford University, Stanford, CA, US
Richard W. Keen, MD PhDCentre for Metabolic Bone Disease, Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom
Lora M. Giangregorio, PhDUniversity Of Waterloo, Waterloo, ON, CA
Joy Tsai, MDMassachusetts General Hospital, Boston, MA, US
☆
Mon 10/12 · 11:30 AM - 12:45 PM
Late-Breaking Oral Presentations: Basic Science
● Oral Abstract Presentations
Oral Abstracts
📍 Meeting Room 312
Senescent Osteocyte-Derived CXCL2 Drives Age-Related Osteoporosis via FOXO3/SLC7A11-Dependent Ferroptosis in Osteoclast Precursors - Qiangqiang Li
Purpose: Senescent osteocytes contribute to age-related osteoporosis by secreting senescence-associated secretory phenotypes (SASPs). However, the key osteocyte-derived SASP factors driving bone loss remain unclear.Senescent Osteocyte-Derived CXCL2 Drives Age-Related Osteoporosis via FOXO3/SLC7A11-Dependent Ferroptosis in Osteoclast Precursors - Qiangqiang Li
Purpose: Senescent osteocytes contribute to age-related osteoporosis by secreting senescence-associated secretory phenotypes (SASPs). However, the key osteocyte-derived SASP factors driving bone loss remain unclear. This study aimed to identify critical SASP mediators from senescent osteocytes and define their roles in osteoclastogenesis. Methods: A natural aging mouse model (3-, 6-, 12-, and 24-month-old male C57BL/6 mice) was used to assess osteocyte senescence and bone loss. Osteocyte-enriched bone from young and aged mice was co-cultured with osteoblast and osteoclast precursors to evaluate the effects of senescent osteocytes on bone remodeling. Transcriptomic profiling identified dysregulated SASP factors, and CXCL2 expression was validated both in mice and human. Recombinant CXCL2 and osteocyte-specific CXCL2 overexpression mice were used to investigate its role in osteoclast differentiation, bone resorption, and skeletal phenotypes. Finally, a tetracycline-modified macrophage membrane nanoplatform was used to deliver a bone-targeted CXCL2-neutralizing antibody to evaluate the therapeutic effects of CXCL2 inhibition in aged mice. Two-tailed Student’s t test, one- or two-way ANOVA tests following post hoc Bonferroni’s correction test were used for statistical analysis. Results: Age-related bone loss was accompanied by progressive osteocyte senescence. Senescent osteocytes promoted osteoclast differentiation while suppressing osteoblast differentiation in co-culture assays. Transcriptomic analysis identified CXCL2 as one of the most significantly upregulated SASP factors in aged osteocytes, which was further confirmed by qPCR, Western blotting, immunohistochemistry, and ELISA both in human and mice. Mechanistically, CXCL2 enhanced osteoclastogenesis by suppressing the FOXO3/SLC7A11 signaling axis, thereby promoting ferroptosis in osteoclast precursors. Systemic CXCL2 administration or osteocyte-specific CXCL2 overexpression increased osteoclast activity and accelerated bone loss in mice. Conversely, bone-targeted delivery of a CXCL2-neutralizing antibody using a tetracycline-modified macrophage membrane nanoplatform attenuated bone loss in aged mice by suppressing osteoclastogenesis and bone resorption. Conclusion: Senescent osteocyte-derived CXCL2 drives age-related osteoporosis by promoting osteoclastogenesis through FOXO3/SLC7A11-mediated ferroptosis. Targeting the CXCL2 - ferroptosis axis may offer a therapeutic strategy for skeletal aging.
Reduced PDGF-BB/PDGFRβ Signaling in LEPR+ Osteoprogenitors Contributes to Skeletal Fragility in Experimental Type 2 Diabetes - Cyril Thouverey, PhD
Patients with type 2 diabetes (T2D) exhibit increased fracture risk despite preserved bone mass, owing in part to altered bone material properties and cortical deficits. Long-standing T2D has been associated with osteoprogenitor dysfunction. PDGF-BB/PDGFRβ signaling regulates the mobilization and function of LEPR+ osteoprogenitors within the bone marrow niche. We hypothesized that disruption of this pathway contributes to skeletal fragility in T2D. Three-month-old male B6;129S/SvJae Lepr-Cre control and Lepr-Cre;Pdgfrbf/f ( Pdgfrb cKO) mice lacking PDGFRβ in LEPR+ osteoprogenitors were subjected to a high-fat diet combined with a single low dose of streptozotocin (HFD+STZ) for 4.5 months to induce T2D (n=7/group). Metabolic parameters, circulating PDGF-BB, bone marrow Pdgfb expression, bone microarchitecture (micro-CT), and biomechanical properties (3-point bending) were assessed. Pdgfrb cKO mice under the control regimen did not show significant alterations in bone microarchitecture or biomechanical properties. Both control and Pdgfrb cKO mice exposed to HFD+STZ exhibited reduced circulating PDGF-BB levels and an approximately 30% reduction in bone marrow Pdgfb expression (main effect of T2D), together with obesity, hyperglycemia, glucose intolerance and insulin resistance. Diabetic control mice exhibited preserved trabecular and cortical bone mass but impaired bone material properties, with a reduced yield point (-18.8%, p=0.0122) and a trend toward lower bone strength (-13.1%, p=0.1511). In contrast, diabetic Pdgfrb cKO mice displayed a more severe skeletal phenotype than diabetic control mice, characterized by reduced trabecular thickness (-14.5%, p=0.0329) and cortical thickness (-8.4%, p=0.0605), together with impaired bone quality, including reduced yield point (-18.6%, p=0.0119) and work to fracture (-27.7%, p=0.0367). These alterations culminated in a marked reduction in whole-bone strength (-24.5%, p=0.0009). In summary, experimental T2D is associated with reduced bone marrow Pdgfb expression and impaired bone mechanical competence despite preserved bone mass. Loss of PDGFRβ signaling in LEPR+ osteoprogenitors, which does not affect skeletal homeostasis under control conditions, markedly aggravates the diabetic skeletal phenotype. These findings suggest that the T2D-associated reduction in PDGF-BB/PDGFRβ signaling contributes to diabetic skeletal fragility by impairing the maintenance of bone microarchitecture and mechanical competence.
PTH receptor activation restores pro-osteogenic transcriptional program and Wnt signaling in diabetic bone and stimulates osteocyte-to-preosteoblast communication through Wnt5b-Fzd5 ligand-receptor interactions. - Sudipta Baroi, PhD, BS, MS
Parathyroid hormone receptor ligands teriparatide (PTH) and abaloparatide (ABL) correct the decrease in bone formation and Wnt signaling induced by diabetes (DM). However, the cellular targets and underlying mechanisms remain unknown. Here, we mapped transcriptional programs, lineage dynamics, and intercellular Wnt communication using single-cell RNA sequencing (seq) of 23,759 mesenchymal lineage cells of bones from control and type 2 DM mice (high fat diet + STZ) treated with PTH or ABL. DM expanded preosteoblast/osteoCARs (preOb, +50%), and PTH/ABL expanded osteoblasts (Ob, +50-160%) and osteocytes (Ot, +65-380%) in both control and DM conditions at the expense of adipoCARs (-50%) and chondrocytes (-60%). Cell fate analysis by CellRank predicted that DM decreases OsteoX-to-Ob and Ob-to-Ot transitions; whereas PTH/ABL increase preOB-, adipoCAR, Chondrocyte- and OsteoX-to-Ob and Ob-to-Ot transitions. Differential gene expression analysis revealed that, indeed, DM decreased preOb, Ob and Ot markers, except for Sost which was increased; and PTH/ABL restored cluster marker expression and suppressed Sost . Further, DM suppressed Wnt-related gene components and gene ontology terms (GOs) in preOb and Ob, which were restored more strongly by PTH whereas ABL was more potent than PTH in control conditions, revealing context-dependent PTH receptor ligand pharmacology. RNA velocity analysis of preOb, Ob and Ot revealed that DM downregulated RNA splicing genes and GOs and increased unspliced RNAs, and that these changes were reversed by PTH/ABL, supporting a halt in cell differentiation by DM restored by PTH/ABL. These effects were validated by bulk RNAseq and RNA hybridization. CellChat analysis showed that DM decreased incoming and outgoing Wnt signals in preOb (-35%) and Ob (-71%), which were restored by PTH/ABL. Ot outgoing Wnt signaling was the most affected, and it was reduced by DM and strongly restored by PTH (+185%). Non-canonical Wnt5b-Fzd5 was the major ligand-receptor pair mediating Ot-to-preOb communication, validated by CellChat analysis of human scRNAseq public datasets comprising 23,798 mesenchymal cells. Moreover, Wnt5b-Fzd5 interaction was disrupted by DM and rescued by PTH/ABL. These findings demonstrate that DM suppresses and PTH/ABL restore RNA processing, transcriptomic programming and intercellular Wnt signaling among osteoblastic cells and identify Ot-to-preOb communication through Wnt5b-Fzd5 as a therapeutic target in DM bone disease.
Pentose Phosphate Pathway-Rewired Neutrophils Sabotage Diabetic Bone Healing via LCN2-Mediated Osteogenic Suppression - Ruiying Chen, PhD, DDS
Clinical evidence indicates that diabetic patients suffer from sever and poorly managed bone complications, including significantly elevated fracture risk and profoundly delayed healing. However, the underlying mechanisms in this context remain incompletely understood, limiting opportunities to develop therapeutic treatments. Bone marrow neutrophils demonstrate remarkable functional plasticity and subset heterogeneity, and serving as pivotal effectors that translate systemic pathological signals into skeletal pathology. Here, we identified a subset of immature neutrophils with high expression of lipocalin-2 (LCN2) that was aberrantly expanded in diabetic patients. This subset exerted potent osteoinhibitory functions through LCN2 mediated disrupting of Wnt/β-catenin signaling in osteoprogenitor cells, contrasting with a mature neutrophil subset that engaged in macrophage crosstalk to support bone regeneration. Hyperglycemia was found to specifically activate the pentose phosphate pathway (PPP) in this immature neutrophil subset, promoting its expansion, LCN2 overexpression and driving bone healing defects. Mechanistically, the PPP-derived metabolite D-Ribose-5-phosphate initiated a signaling axis wherein YAP inactivation relieved repression of MAFG, resulting in transcriptional activation and subsequent secretion of LCN2. Treatment with Lurasidone, an FDA-approved agent that targets PPP induced LCN2 overexpression, significantly restored bone healing in diabetic models. Our findings unveil a metabolic-transcriptional axis that reprograms neutrophils to disrupt skeletal repair in diabetes, identifying Lurasidone as a promising pharmacological approach to treat diabetic osteopathy.
ANK and ABCC6 Cooperatively Regulate Extracellular Pyrophosphate and Citrate Homeostasis to Control Soft Tissue Calcification and Bone Quality - Koen Van De Wetering, PhD, DVM
Extracellular pyrophosphate (PPi) is a critical inhibitor of pathological mineralization and is generated through ATP release mediated by ABCC6 and ANK. While ABCC6 is the major source of circulating PPi, ANK additionally mediates citrate export. We investigated how ABCC6 and ANK regulate extracellular PPi and citrate, ectopic calcification, and skeletal integrity using single and compound mutant mouse models.
Plasma PPi concentrations were reduced by 35% in Ank mutant mice and 60% in Abcc6-deficient mice. In contrast, plasma citrate depended predominantly on ANK, with a 75% reduction in Ank mutants and no change in Abcc6-deficient animals. Ank deficiency was associated with hypophosphatemia and increased serum alkaline phosphatase activity. Compound Abcc6-/-;Ankank/ank mice developed severe ectopic calcification that greatly exceeded either single mutant, demonstrating complementary roles of ABCC6 and ANK in preventing pathological mineralization.
To determine whether citrate contributes to inhibition of ectopic calcification, we evaluated oral citrate supplementation in Abcc6-/- mice, a model of pseudoxanthoma elasticum (PXE), an inherited disorder characterized by ectopic calcification of skin, eyes, and blood vessels. Citrate was bioavailable after oral administration and dose-dependently reduced connective tissue calcification, with high-dose treatment nearly completely preventing mineral deposition.
Analysis of bone revealed distinct roles for ABCC6 and ANK. ANK accounted for the majority of PPi and citrate incorporated into bone mineral, whereas ABCC6 made a smaller contribution to bone PPi accumulation. Loss of ANK reduced trabecular bone volume, cortical thickness, tissue mineral density, and mechanical strength. These skeletal abnormalities were accompanied by marked reductions in PPi and citrate content of bone.
These findings establish ANK as a central regulator of extracellular PPi and citrate homeostasis and demonstrate critical roles for both ANK and ABCC6 in protecting against ectopic calcification and maintaining skeletal quality. Furthermore, the ability of oral citrate to prevent ectopic calcification identifies citrate-based approaches as promising therapeutic strategies for PXE and related mineralization disorders.
Metformin alleviates osteoarthritis and chondrocytes senescence by HDAC5/mTOR/autophagy regulatory axis - Xiaoling Zhang, PhD
Purpose : Osteoarthritis (OA) is a disabling degenerative joint disease prevalent among middle-aged and elderly populations. To date, no first-line oral drugs are available to slow or reverse cartilage degeneration. Metformin has been proven to exert therapeutic effects against OA, yet its precise molecular regulatory mechanisms remain unelucidated. In this study, we identified histone deacetylase 5 (HDAC5) as a pivotal molecule mediating the chondroprotective effects of metformin, and clarified its functional mechanisms in maintaining chondrocyte homeostasis and regulating cartilage degeneration.
Methods: In vivo osteoarthritis models were established in mice, followed by daily oral metformin administration (100 mg/kg) or intra-articular injection for HDAC5 overexpression (HDAC5-OE). In vitro, cellular senescence was induced in chondrocytes using H 2 O 2 treatment. To elucidate the underlying molecular targets, we integrated transcriptomic analysis of GEO datasets with unbiased proteomic screening. The expression levels, subcellular localization, and regulatory relationships of HDAC5, mTOR, autophagy-related proteins (LC3, ATG5), and senescence markers (P16, P21, SA-β-gal) were systematically evaluated utilizing Western blotting, immunofluorescence, and small interfering RNA (si-HDAC5) knockdown assays.
Results: During the progression of osteoarthritis lesions, the expression of HDAC5 is specifically downregulated in chondrocytes, and metformin can effectively reverse this altered expression. Furthermore, unbiased proteomic analysis identified the mTOR signaling pathway as a key downstream target negatively regulated by HDAC5. Mechanistically, metformin promotes HDAC5 accumulation, which directly suppresses mTOR activation and restores protective autophagic flux. Crucially, knocking down HDAC5 abolished metformin's ability to inhibit mTOR and activate autophagy, demonstrating a strictly HDAC5-dependent mechanism. Finally, intra-articular overexpression of HDAC5 significantly ameliorated OA lesions and preserved extracellular matrix synthesis in vivo.
Conclusion: This study identifies HDAC5 as a critical molecule mediating the chondroprotective effects of metformin. It uncovers a novel regulatory cascade, metformin - HDAC5 - mTOR - autophagy, responsible for cartilage protection. These findings deepen our understanding of OA pathogenesis, provide an innovative therapeutic target for osteoarthritis treatment, and broaden avenues for new drug development.read more · Original Link ↗
Matt Prideaux, PhDAugusta University, Augusta, GA, US
Vicki Rosen, PhDHarvard School Of Dental Medicine, Boston, MA, US
Qiangqiang LiDivision of Sports Medicine and Adult Reconstructive Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China
Cyril Thouverey, PhDUniversity Hospitals Of Geneva, Geneva, CH
Sudipta Baroi, PhD, BS, MSDepartment of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Central Arkansas Veterans Healthcare System, John L. McClellan, Little Rock, AR, USA
Ruiying Chen, PhD, DDSShanghai Jiaotong University, Huang Pu Qu, Shang Hai Shi, CN
Koen Van De Wetering, PhD, DVMThomas Jefferson University, Philadelphia, PA, US
Paste one into your AI after the list, or create your own.
Pick the 3 best sessions for me and say why.
ROLE: Expert conference advisor for ASBMR 2026 Annual Meeting attendees
CONTEXT: I'm pasting over 100 sessions for the ASBMR 2026 Annual Meeting. I am a bone and mineral researcher or clinician. I want the oral abstract and symposium sessions on bone quality, osteoporosis and skeletal biology, Meet the Professor sessions with senior researchers, and good networking opportunities.
GOAL: Pick the top 3 sessions for me.
OUTPUT FORMAT: List in chronological order. Label each with its relevance rank (e.g. the third one listed might be Rank #1 of over 100). Include day, time, and session title. Write 2-3 sentences on why each fits my goals.
VERIFICATION: Before answering, confirm how many sessions you received. You should have at least 100. If you received significantly fewer, tell me immediately - my paste was probably truncated.
Which sessions are right for you?
Describe yourself and what you want from ASBMR 2026 Annual Meeting. The more specific you are, the better this works.
You can also say how many you want or when you're free - “give me 10”, “give me 20”, “only Friday afternoon”. You get 3 unless you ask for more.
There is a daily limit on the phone version
so it can stay free for everyone at the event.
However, you can run it as many times as you want using your own AI account at home:
go to the bottom of the page
download the session list, then tap Click for sample prompts
paste the list, then a prompt, into Claude, ChatGPT, or Gemini.
Powered by Claude. Your text is sent to Anthropic to generate the ranking, and is logged on this site so the feature can be improved. Please don't type anything confidential.